var images_info;if (!images_info) images_info =[]; images_info["113"]={"113001":{"type":"graphic_picture","displayName":"Sting reaction from Megalopyge opercularis caterpillar","title":"Sting reaction from <EM>Megalopyge opercularis</EM> caterpillar (puss caterpillar)","html":"<div class=\"graphic\"><div style=\"width: 758px\" class=\"figure\"><div class=\"ttl\">Sting reaction from <EM>Megalopyge opercularis</EM> caterpillar (puss caterpillar)</div><div class=\"cntnt\"><img style=\"width:738px; height:458px;\" src=\"images/DERM/113001_Rctn_Mglpyg_oprclrs_ctrpllr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classic \"tram-track\" pattern of hemorrhagic papules secondary to contact with a <EM>Megalopyge opercularis</EM> caterpillar (puss caterpillar).</div><div class=\"graphic_reference\">Courtesy of Ted Rosen, MD.</div><div id=\"graphicVersion\">Graphic 113001 Version 1.0</div></div></div>"},"113002":{"type":"graphic_table","displayName":"Kato-Katz technique","title":"Kato-Katz technique for quantification of helminth eggs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Kato-Katz technique for quantification of helminth eggs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ol class=\"numbers_to_nine\"> <li>Place fresh stool on scrap paper or impervious tile. </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"2\"> <li>Press mesh screen over stool to filter large particles. </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"3\"> <li>Collect filtered stool using a small spatula and fill template (1.5 mm thick with hole 6 mm in diameter) resting on a glass slide. </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"4\"> <li>Remove the template (leaving a 1.5 mm by 6 mm sample of stool). </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"5\"> <li>Place a piece of cellophane (soaked in glycerol-malachite green or glycerol-methylene) over the stool sample as a cover slip. </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"6\"> <li>Invert the slide and press down until the stool spreads evenly. </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"7\"> <li>Place the slide in a rack for 30 minutes. </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"8\"> <li>Count the number of eggs on the slide and multiply by 24 to determine total eggs per gram of stool. </li> </ol> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 113002 Version 1.0</div></div></div>"},"113004":{"type":"graphic_figure","displayName":"Baseball stitch","title":"Baseball stitch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Baseball stitch</div><div class=\"cntnt\"><img style=\"width:421px; height:524px;\" src=\"images/OBGYN/113004_Baseball_stitch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The baseball stitch is a continuous, unlocked stitch in which the needle is driven through the cut edge of the myometrium to exit the serosa a few millimeters from the incision for each needle bite. This brings the serosal surfaces together to cover the infolded edges of the incision. </div><div id=\"graphicVersion\">Graphic 113004 Version 1.0</div></div></div>"},"113019":{"type":"graphic_figure","displayName":"Trap door incisions","title":"Trap door incisions","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Trap door incisions</div><div class=\"cntnt\"><img style=\"width:526px; height:720px;\" src=\"images/SURG/113019_Trapdoorincisions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left-sided trap door (A)&nbsp;is the classic approach to the&nbsp;left subclavian&nbsp;region. To provide exposure of the right subclavian region, an upper sternotomy with a right supraclavicular extension (B) can be used, particularly in the setting of&nbsp;trauma. For the innominate artery, a full sternotomy provides more reliable exposure. A right-sided trap door (C)&nbsp;is useful in elective surgery, providing optimal exposure&nbsp;of the right upper&nbsp;chest&nbsp;(eg, Pancoast tumor resection).</div><div id=\"graphicVersion\">Graphic 113019 Version 1.0</div></div></div>"},"113026":{"type":"graphic_figure","displayName":"Ever-use of e-cigarettes among US youth","title":"Trends in ever e-cigarette use among US middle and high school students; National Youth Tobacco Survey (NYTS) 2011–2015","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Trends in ever e-cigarette use among US middle and high school students; National Youth Tobacco Survey (NYTS) 2011–2015</div><div class=\"cntnt\"><img style=\"width:724px; height:436px;\" src=\"images/PEDS/113026_E-cigarette_use_US_youth.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>These data reflect students&nbsp;who responded “yes” to the following question: “Have you ever used an electronic cigarette or e-cigarette, even once or twice?”</LI>&#xD;&#xA;<LI>In 2014, modifications were made to the e-cigarette measure to enhance its accuracy, which may limit the comparability of this estimate to those collected in previous years. The dotted lines from 2013 to 2015 represent these differences.</LI></UL></div><div class=\"graphic_reference\">Reproduced from: US Department of Health and Human Services. E-Cigarette Use Among Youth and Young Adults: A Report of the Surgeon General—Executive Summary. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2016.</div><div id=\"graphicVersion\">Graphic 113026 Version 3.0</div></div></div>"},"113030":{"type":"graphic_algorithm","displayName":"Management of laryngospasm in children","title":"Management of laryngospasm in children","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Management of laryngospasm in children</div><div class=\"cntnt\"><img style=\"width:468px; height:732px;\" src=\"images/ANEST/113030_Mgmt_laryngospasm_children.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CPAP: continuous positive airway pressure; IV: intravenous; IM: intramuscular.<br />* If succinylcholine is contraindicated, administer rocuronium 1.2 mg/kg IV, or if no IV access, 1 mg/kg IM in children &lt;1 yr of age, 1.8 mg/kg IM in children &gt;1 year of age; expect prolonged duration of paralysis.</div><div class=\"graphic_reference\">Adapted from: Orliaguet GA, Gall O, Savoldelli GL, Couloigner V. Case scenario: perianesthetic management of laryngospasm in children. Anesthesiology 2012; 116:458.</div><div id=\"graphicVersion\">Graphic 113030 Version 1.0</div></div></div>"},"113031":{"type":"graphic_table","displayName":"Local anesthetic agents dosing for epidural anesthesia","title":"Local anesthetic agents dosing for epidural anesthesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Local anesthetic agents dosing for epidural anesthesia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Local anesthetic</td> <td class=\"subtitle1\">Dose (mg)</td> <td class=\"subtitle1\">Peak cephalad block height</td> <td class=\"subtitle1\">Time to two-segment regression<br /> (1 SD or range) (minutes)*</td> <td class=\"subtitle1\">Recommended time interval for top-up dose (minutes)<sup>&#182;</sup></td> </tr> <tr> <td>Chloroprocaine 2 to 3% plus<br /> 1:200,000 epinephrine<sup>[1,2]</sup></td> <td class=\"centered\">600</td> <td class=\"centered\">T5</td> <td class=\"centered\">80 (15)</td> <td class=\"centered\">45</td> </tr> <tr> <td>Lidocaine 1.5 to 2% plus<br /> 1:200,000 epinephrine<sup>[2,3]</sup></td> <td class=\"centered\">300 to 400</td> <td class=\"centered\">T4</td> <td class=\"centered\">100 (50 to 60)</td> <td class=\"centered\">60</td> </tr> <tr> <td>Bupivacaine 0.5 to 0.75% (plain)<sup>[4,5]</sup></td> <td class=\"centered\">100 to 150</td> <td class=\"centered\">T5</td> <td class=\"centered\">150 to 190 (60 to 80)</td> <td class=\"centered\">120</td> </tr> <tr> <td>Ropivacaine 1% (plain)<sup>[6]</sup><br /> Age 30 (18 to 40)<sup>&#916;</sup></td> <td class=\"centered\">150</td> <td class=\"centered\">T8<sup>&#9674;</sup></td> <td class=\"centered\">143 (45 to 298)</td> <td class=\"centered\">120</td> </tr> <tr> <td>Ropivacaine 1% (plain)<sup>[6]</sup><br /> Age 51 (41 to 59)<sup>&#916;</sup></td> <td class=\"centered\">150</td> <td class=\"centered\">T6</td> <td class=\"centered\">190 (100 to 340)</td> <td class=\"centered\">120</td> </tr> <tr> <td>Ropivacaine 1% (plain)<sup>[6]</sup><br /> Age 71 (61 to 82)<sup>&#916;</sup></td> <td class=\"centered\">150</td> <td class=\"centered\">T4<sup>&#9674;</sup></td> <td class=\"centered\">203 (105 to 378)</td> <td class=\"centered\">120</td> </tr> <tr> <td>Levobupivacaine 0.75% (plain)<sup>[7]</sup><br /> Age 32 (18 to 44)<sup>&#916;</sup></td> <td class=\"centered\">125</td> <td class=\"centered\">T8<sup>&#9674;</sup></td> <td class=\"centered\">166 (51)</td> <td class=\"centered\">120</td> </tr> <tr> <td>Levobupivacaine 0.75% (plain)<sup>[7]</sup><br /> Age 57 (47 to 69)<sup>&#916;</sup></td> <td class=\"centered\">125</td> <td class=\"centered\">T5</td> <td class=\"centered\">158 (59)</td> <td class=\"centered\">120</td> </tr> <tr> <td>Levobupivacaine 0.75% (plain)<sup>[7]</sup><br /> Age 78 (72 to 85)<sup>&#916;</sup></td> <td class=\"centered\">125</td> <td class=\"centered\">T5<sup>&#9674;</sup></td> <td class=\"centered\">174 (61)</td> <td class=\"centered\">120</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Mean (1 SD or range).<br />¶ Dosing intervals are approximate guidelines. In awake and cooperative patients, clinical monitoring for signs and symptoms (increase in blood pressure and heart rate or objective evaluation of dermatomal level of block) of dermatomal regression will indicate the need for a top-up dose.<br />Δ Ages expressed as mean (range).<br /><FONT class=lozenge>◊</FONT> Note for ropivacaine and levobupivacaine the significant difference in peak block height between the youngest and oldest age groups.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Liu SS, Ware PD, Rajendran S. Effects of concentration and volume of 2-chloroprocaine on epidural anesthesia in volunteers. Anesthesiology 1997; 86:1288.</LI>&#xD;&#xA;<LI>Kopacz DJ, Mulroy MF. Chloroprocaine and lidocaine decrease hospital stay and admission rate after outpatient epidural anesthesia. Reg Anesth 1990; 15:19.</LI>&#xD;&#xA;<LI>Terai T, Yukioka H, Fujimori M. A double-blind comparison of lidocaine and mepivacaine during epidural anesthesia. Acta Anaesthesiol 1993; 37:607.</LI>&#xD;&#xA;<LI>Kopacz DJ, Allen HW, Thompson GT. A comparison of epidural levobupivacaine 0.75% with racemic bupivacaine for lower abdominal surgery. Anesth analg 2000; 90:642.</LI>&#xD;&#xA;<LI>Veering BT, Burm AGL, Van Kleef JW, et al. Epidural anesthesia with bupivacaine: Effects of age on neural blockage and pharmacokinetics. Anesth analg 1987; 66:589.</LI>&#xD;&#xA;<LI>Simon MJG, Veering BT, Stienstra R, et al. The effects of age on neural blockade and hemodynamic changes after epidural anesthesia with ropivacaine. Anesth analg 2002; 94:1325.</LI>&#xD;&#xA;<LI>Simon MJG, Veering BT, Stienstra R, et al. Effect of age on the clinical profile and systemic absorption and disposition of levobupivacaine after epidural administration. Br J Anaesth 2004; 93:512.</LI></OL>Adapted with permission from: Salinas FV. Pharmacology of drugs used for spinal and epidural anesthesia and analgesia. In: Spinal and epidural anesthesia, Wong C (Ed), McGraw-Hill Education 2007. Copyright © 2017 McGraw-Hill Education. McGraw-Hill Education makes no representations or warranties as to the accuracy of any information contained in the McGraw-Hill Education Material, including any warranties of merchantability or fitness for a particular purpose. In no event shall McGraw-Hill Education have any liability to any party for special, incidental, tort, or consequential damages arising out of or in connection with the McGraw-Hill Education Material, even if McGraw-Hill Education has been advised of the possibility of such damages.</div><div id=\"graphicVersion\">Graphic 113031 Version 3.0</div></div></div>"},"113032":{"type":"graphic_figure","displayName":"Epidural needle insertion paramedian","title":"Epidural needle insertion paramedian approach","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epidural needle insertion paramedian approach</div><div class=\"cntnt\"><img style=\"width:317px; height:937px;\" src=\"images/ANEST/113032_Epidural_needle_insertion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic of thoracic epidural catheter placement using transverse and posterior views of drawings of the thoracic spine.<br />(A) The epidural needle is inserted 1 cm lateral to the spinous process of the targeted segment and advanced until the lamina is contacted. If lamina is not contacted, avoid advancing the needle laterally, which will place the needle in the paravertebral space. Note the needle depth to the lamina.<br />(B) Withdraw the needle slightly, and redirect approximately 15 degrees medially and 45 degrees cephalad.<br />(C) Advance the needle, walking the tip off the lamina. Stop needle advancement as soon as the ligamentum flavum is felt. <br /></div><div class=\"graphic_reference\">From: Manion SC, Brennan TJ. Thoracic epidural analgesia and acute pain management. Anesthesiology 2011; 115:181. DOI: <A href=\"http://anesthesiology.pubs.asahq.org/article.aspx?articleid=1933866\" target=_blank>10.1097/ALN.0b013e318220847c</A>. Copyright © 2011 American Society of Anesthesiologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113032 Version 1.0</div></div></div>"},"113034":{"type":"graphic_table","displayName":"Mgmt options after inadvertent dural puncture","title":"Advantages and disadvantages of management options after inadvertent dural puncture during attempted epidural anesthesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of management options after inadvertent dural puncture during attempted epidural anesthesia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Option</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr class=\"divider_bottom\"> <td>Continuous spinal analgesia</td> <td> <ol class=\"numbers_to_nine\"> <li>Avoid risk of second dural puncture </li> <li>Reliable continuous anesthesia </li> <li>Possible decreased risk of PDPH </li> </ol> </td> <td> <ol class=\"numbers_to_nine\"> <li>Risk of total spinal if an \"epidural\" dose is inadvertently injected into the catheter </li> <li>Possible increased risk of infection </li> </ol> </td> </tr> <tr> <td>Place/replace catheter at different interspace</td> <td> <ol class=\"numbers_to_nine\"> <li>May use for a prophylactic blood patch </li> <li>Higher margin of safety relative to local anesthetic injection </li> </ol> </td> <td> <ol class=\"numbers_to_nine\"> <li>Risk of second dural puncture </li> <li>Risk of high spinal anesthesia with epidural bolus injection of local anesthetic </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PDPH: post dural puncture headache.</div><div class=\"graphic_reference\">Reproduced with permission from: Yilmax M, Wong CA. Technique of neuraxial anesthesia. In: Spinal and epidural anesthesia, Wong C (Ed), McGraw-Hill Education 2007. Copyright © 2017 McGraw-Hill Education. McGraw-Hill Education makes no representations or warranties as to the accuracy of any information contained in the McGraw-Hill Education Material, including any warranties of merchantability or fitness for a particular purpose. In no event shall McGraw-Hill Education have any liability to any party for special, incidental, tort, or consequential damages arising out of or in connection with the McGraw-Hill Education Material, even if McGraw-Hill Education has been advised of the possibility of such damages.</div><div id=\"graphicVersion\">Graphic 113034 Version 3.0</div></div></div>"},"113036":{"type":"graphic_picture","displayName":"Pyogenic granuloma nail","title":"Pyogenic granuloma of the nail unit","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Pyogenic granuloma of the nail unit</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/113036_Pyogenic_granuloma_nail.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pyogenic granuloma of the nail bed presenting as a red, multilobular, friable nodule after the removal of the nail plate.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 113036 Version 1.0</div></div></div>"},"113037":{"type":"graphic_algorithm","displayName":"Management of pregnant women with or at risk for hypothyroidism","title":"Management of pregnant women with or at risk for hypothyroidism","html":"<div class=\"graphic\"><div style=\"width: 1019px\" class=\"figure\"><div class=\"ttl\">Management of pregnant women with or at risk for hypothyroidism</div><div class=\"cntnt\"><img style=\"width:999px; height:421px;\" src=\"images/ENDO/113037_Mgmt_prgnnt_wmn_hypothyrdsm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended to use in conjunction with additional UpToDate content on thyroid disease in pregnancy. Refer to UpToDate topics on the management of pregnant women with or at risk for hypothyroidism for additional details.</div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone; TPO: thyroid peroxidase antibodies; T4: thyroxine.<br />* An increased risk of adverse pregnancy outcomes has been reported in euthyroid women with elevated TPO antibodies. Since carefully monitored T4 treatment is safe, some experts offer T4 to TPO-positive, euthyroid women without a prior history of miscarriage. Most pregnant women without prior history of recurrent miscarriage are unlikely to know their antibody status.<br />¶ Measure TSH approximately every four weeks during the first trimester, then once in each of the second and third trimesters to monitor for the development of hypothyroidism. TPO-negative women may require less frequent assessment (eg, at least once more during the first trimester and again mid pregnancy). Treat with levothyroxine if TSH rises above 4 mU/L.<br />Δ 4 mU/L or population and trimester-specific upper limit of normal, if available.<br /><FONT class=lozenge>◊</FONT> The presence of TPO antibodies guides management of patients with TSH &gt;2.5 but &lt;10 mU/L. It informs the extent of autoimmunity, the risk of pregnancy loss, and the risk of postpartum thyroid dysfunction.<br />§ Some experts begin levothyroxine, 50 mcg daily. Others base the treatment decision on patient values and preferences. In this setting, measurement of free T4 may aid in decision making. A free T4 in the lower end of the assay and trimester-specific reference range argues more for treatment.<br />¥ Free T4 should be interpreted using assay method and trimester-specific reference ranges.</div><div id=\"graphicVersion\">Graphic 113037 Version 1.0</div></div></div>"},"113038":{"type":"graphic_figure","displayName":"Hand position for epidural anesthesia technique","title":"Hand position for epidural anesthesia technique","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hand position for epidural anesthesia technique</div><div class=\"cntnt\"><img style=\"width:422px; height:710px;\" src=\"images/ANEST/113038_Hand_position_for_epidural_anesthesia_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graphic shows several possible hand positions for advancement of an epidural needle. <br /><br />&nbsp;A. The thumb and index finger of the non-dominant hand are used to grasp the shaft of the epidural needle near the patient's back, and are used to advance the needle incrementally or continuously. The thumb of the dominant hand is used to apply intermittent or continuous pressure&nbsp;on the syringe barrel to&nbsp;assess for&nbsp;loss of resistance.<br /><br />B.&nbsp;The non-dominant hand stabilizes the needle and syringe against the patient's back, while the thumb and index finger are used to grasp the hub of the needle. The needle is advanced continuously or incrementally, while the thumb of the dominant hand is used to apply intermittent or continuous pressure&nbsp;on the syringe barrel to&nbsp;assess for&nbsp;loss of resistance.<br /><br />C. The third through fifth fingers of both hands are used to stabilize&nbsp;the needle relative to the patient's back, while the&nbsp;epidural needle wings are grasped with the thumbs and forefingers. The needle is advance incrementally. Between advancements, the thumb of the dominant hand is used to apply pressure&nbsp;on the needle barrel to assess for loss of resistance.<br /><br />For further information, refer to UpToDate content on epidural and combined spinal epidural technique.&nbsp;</div><div class=\"graphic_reference\">Redrawn from: Yilmax M, Wong CA. Technique of neuraxial anesthesia. In: Spinal and epidural anesthesia, Wong C (Ed), McGraw-Hill Education 2007.</div><div id=\"graphicVersion\">Graphic 113038 Version 1.0</div></div></div>"},"113039":{"type":"graphic_table","displayName":"ASRA preprocedure checklist","title":"ASRA preprocedure checklist","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ASRA preprocedure checklist</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ol> <li>Patient is identified, two criteria. </li> <li>Allergies and anticoagulation status are reviewed. </li> <li>Surgical procedure/consent is confirmed. </li> <li>Block plan is confirmed, site is marked. </li> <li>Necessary equipment is present, drugs/solutions are labeled. </li> <li>Resuscitation equipment is immediately available: Airway devices, suction, vasoactive drugs, lipid emulsion. </li> <li>Appropriate ASA* monitors are applied; intravenous access, sedation, and supplemental oxygen are provided, if indicated. </li> <li>Aseptic technique is used: Hand cleansing is performed, mask and sterile gloves are used. </li> <li>\"Time out\" is performed before needle insertion for each new block site if the position is changed or separated in time or performed by another team. </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Corrected based on erratum.<SUP>[1]</SUP></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>A checklist for performing regional nerve blocks: Erratum. Reg Anesth Pain Med 2014; 39:357.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Mulroy MF, Weller RS, Liguori GA. A checklist for performing regional nerve blocks. Reg Anesth Pain Med 2014; 39:195. DOI: <a href=\"http://journals.lww.com/rapm/Abstract/2014/05000/A_Checklist_for_Performing_Regional_Nerve_Blocks.7.aspx\" target=\"_blank\">10.1097/AOG.0000000000000971</a>. Copyright &copy; 2014 European Society of Regional Anaesthesia and Pain Therapy (ESRA), Asian and Oceanic Society of Regional Anesthesia (AOSRA), and Latin American Society of Regional Anesthesia (LASRA). Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113039 Version 1.0</div></div></div>"},"113044":{"type":"graphic_picture","displayName":"Pill box PI","title":"Pill box","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Pill box</div><div class=\"cntnt\"><img style=\"width:756px; height:539px;\" src=\"images/PI/113044_Pill_box_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A pill box has a section for each day of the week. It can help you avoid taking too much or too little of your medicines.</div><div class=\"graphic_reference\">Reproduced from: Prescribing patterns change following direct marketing restrictions. News Release, May 2, 2017. National Institutes of Health. Available at: <A href=\"https://www.nih.gov/news-events/news-releases/prescribing-patterns-change-following-direct-marketing-restrictions\" target=_blank>https://www.nih.gov/news-events/news-releases/prescribing-patterns-change-following-direct-marketing-restrictions</A> (Accessed on May 9, 2017).</div><div id=\"graphicVersion\">Graphic 113044 Version 1.0</div></div></div>"},"113048":{"type":"graphic_table","displayName":"Parenteral and oral opioid analgesics for acute periop pain","title":"Parenteral and oral opioid analgesics for acute perioperative pain in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral and oral opioid analgesics for acute perioperative pain in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug (United States brand name)</td> <td class=\"subtitle1\">Approximate equianalgesic doses*</td> <td class=\"subtitle1\">Sample initial dose for opioid-na&#239;ve adult<sup>&#182;</sup></td> <td class=\"subtitle1\">Serum half-life (in hours)</td> <td class=\"subtitle1\">Duration of analgesic effect (in hours)</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Parenteral opioids</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fentanyl (Sublimaze)</td> <td>100 micrograms IV</td> <td>25 to 50 micrograms for moderate pain or 50 to 100 micrograms for more severe pain IV/SQ; repeat every two to five minutes as needed until adequate pain relief</td> <td>7 to 12</td> <td>0.5 to 1 (IV)<br /> 1 to 2 (SQ)</td> <td> <ul> <li>Fentanyl does not release histamine and may therefore be preferred in the presence of hemodynamic instability or bronchospasm. </li> <li>Potential for drug interactions as it is hepatically metabolized by CYP3A4.<sup>&#916;</sup> </li> <li>Duration of effect increases after repeated use. </li> <li>May be used for PCA, less commonly than hydromorphone and morphine. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hydromorphone (Dilaudid)</td> <td>1.5 mg IV</td> <td>0.2 to 0.5 mg IV; repeat every five minutes as needed until adequate pain relief, then 0.2 to 0.5 mg IV three to four hours as needed</td> <td>2 to 3</td> <td>3 to 4</td> <td> <ul> <li>High potency (small volume) useful for SQ administration which is about 80% bioavailable. </li> <li>Lower potential for drug interactions as it is hepatically metabolized primarily by glucuronidation. </li> <li>Use reduced dose in renal and/or hepatic impairment. </li> <li>May be used for PCA. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Morphine (Infumorph, others)</td> <td>10 mg IV</td> <td>1 to 3 mg IV; repeat every five minutes as needed until adequate pain relief; then 1 to 3 mg IV every three to four hours as needed</td> <td>2 to 3</td> <td>4 to 5</td> <td> <ul> <li>Lower potential for drug interactions as it is hepatically metabolized primarily by glucuronidation. </li> <li>In patients with renal impairment, clearance of active metabolites that contribute to hyperalgesia and neuroexcitation is decreased; hydromorphone or fentanyl may be preferred. </li> <li>Histamine release and vagally mediated venodilation, hypotension, and bradycardia can be significant. </li> <li>May be used for PCA. </li> <li>SQ not recommended due to local tissue irritation. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Oral immediate-release opioids</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Codeine</td> <td>200 mg orally</td> <td>15 to 60 mg orally every four to six hours as needed</td> <td>2 to 4</td> <td>4 to 6</td> <td> <ul> <li>Potential for drug interactions as it is hepatically metabolized by CYP2D6 to active metabolite (ie, morphine). </li> <li>Analgesic and adverse effects are unpredictable because rate of conversion to morphine is genetically determined by polymorphic CYP2D6 enzyme. Generally not recommended for this reason. </li> <li>Oral immediate-release preparations are also available in combinations with acetaminophen (eg, Tylenol #3); acetaminophen component dose limits apply to combinations. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hydrocodone (immediate-release only available in US in combination products, eg, Vicodin, Lorcet, others)</td> <td>30 mg orally</td> <td>5 to 10 mg orally every six hours as needed</td> <td>3 to 4</td> <td>4 to 8</td> <td> <ul> <li>Hepatically metabolized by CYP2D6 and 3A4 to active (ie, hydromorphone) and inactive metabolites. </li> <li>Oral immediate-release preparations are only available in United States in combinations with acetaminophen or ibuprofen; nonopioid component dose limits apply. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hydromorphone (Dilaudid)</td> <td>7.5 mg orally</td> <td>2 to 4 mg orally every four hours as needed</td> <td>2 to 3</td> <td>3 to 6</td> <td> <ul> <li>Refer to comments for parenteral hydromorphone above. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Morphine</td> <td>30 mg orally</td> <td>15 to 30 mg orally every four hours as needed</td> <td>2 to 3</td> <td>3 to 6</td> <td> <ul> <li>Refer to comments for parenteral morphine above. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Oxycodone (Oxy-IR, Roxicodone, others)</td> <td>20 mg orally</td> <td>5 to 30 mg orally every four to six hours as needed</td> <td>2 to 3</td> <td>3 to 6</td> <td> <ul> <li>Hepatically metabolized by CYP2D6 and 3A4 to active and inactive metabolites. </li> <li>Oral immediate-release preparations are also available in combinations with acetaminophen, aspirin, or ibuprofen; non-opioid component dose limits apply to combinations. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Oxymorphone (Opana)</td> <td>10 to 15 mg orally</td> <td>5 to 10 mg orally every four to six hours as needed</td> <td>7 to 9</td> <td>3 to 6</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Tramadol (Ultram, others)</td> <td>Not established</td> <td>50 to 100 mg every four to six hours as needed</td> <td>6 to 9 (includes active metabolite)</td> <td>4 to 6</td> <td> <ul> <li>Multiple mechanisms of action: Weak mu-opioid agonist and reuptake inhibitor of norepinephrine and serotonin. </li> <li>Risk of drug interactions. </li> <li>Use reduced dose for moderate renal or hepatic impairment. </li> <li>Not recommended in severe organ impairment or if risk for seizures. </li> <li>Effects not fully reversed by naloxone. </li> <li>Also available in combinations with acetaminophen; dose limits apply. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Initial IV titration and continuous infusion of opioids for acute perioperative pain should only be administered in a closely monitored setting with pulse oximetry and end-tidal carbon dioxide monitoring capabilities. For dosing of continuous infusion delivery, refer to UpToDate content on pain control in critically ill patients.<br />Oral opioids should be prescribed starting with the minimum dose needed to alleviate pain and after maximizing nonopioid analgesic options. Extended-release preparations of oral opioids are generally not recommended for acute pain.<br />For PCA doses, refer to UpToDate content on management of acute perioperative pain.</div><div class=\"graphic_footnotes\">IV: intravenous; SQ: subcutaneous; CYP: cytochrome P-450 metabolism; PCA: patient controlled analgesia; US: United States.<br />* Equianalgesic conversions serve only as a general guide to estimate opioid dose equivalents.<br />&para; A dose reduction of approximately 50% and a reduced frequency is warranted for older or debilitated adults or patients with impaired liver or kidney functioning, low cardiac output, or respiratory compromise.<br />&Delta; A list of inhibitors and inducers of CYP3A4 metabolism is available as a separate table in UpToDate.</div><div class=\"graphic_reference\">Courtesy of Edward Mariano, MD.<br />Additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved</LI></OL></div><div id=\"graphicVersion\">Graphic 113048 Version 2.0</div></div></div>"},"113050":{"type":"graphic_algorithm","displayName":"Treatment of HCV in children and adolescents","title":"Treatment of hepatitis C virus infection in children and adolescents","html":"<div class=\"graphic\"><div style=\"width: 844px\" class=\"figure\"><div class=\"ttl\">Treatment of hepatitis C virus infection in children and adolescents</div><div class=\"cntnt\"><img style=\"width:824px; height:330px;\" src=\"images/PEDS/113050_Trtmnt_HCV_child_adoles.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HCV: hepatitis C virus; HBV: hepatitis B virus; DAA: direct acting antiviral agent for HCV.<br />* The goal of deferring treatment is to wait until the patient has access to an effective regimen of direct acting antiviral agents (DAAs). These may become available by waiting until the patient reaches the age in which the regimen is approved (eg, after the patient's 12th or 18th birthday), or until new regimens are approved for the patient's age group, or until the patient is eligible to enroll in a clinical trial. Deferring treatment for even several years is often appropriate because most pediatric patients have mild HCV liver disease that progresses slowly.<br />¶ Velpatasvir is not yet approved for adolescents in the United States. An alternative option is the combination of sofosbuvir with ribavirin, but this regimen has potential adverse effects of ribavirin.</div><div id=\"graphicVersion\">Graphic 113050 Version 1.0</div></div></div>"},"113066":{"type":"graphic_figure","displayName":"Skin incisions for cesarean delivery","title":"Skin incisions for cesarean delivery","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Skin incisions for cesarean delivery</div><div class=\"cntnt\"><img style=\"width:453px; height:460px;\" src=\"images/OBGYN/113066_Skin_incisions_for_cesarean_delivery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Pfannenstiel skin incision is slightly curved, 2 to 3 cm above the symphysis pubis, with the midportion of the incision within the clipped area of the pubic hair.&nbsp;The Joel-Cohen type incision is straight, 3 cm below the line that joins the anterior superior iliac spines, and slightly more cephalad than Pfannenstiel.</div><div id=\"graphicVersion\">Graphic 113066 Version 1.0</div></div></div>"},"113076":{"type":"graphic_algorithm","displayName":"CAP site of care","title":"Community-acquired pneumonia: Determining the appropriate site of treatment in adults","html":"<div class=\"graphic\"><div style=\"width: 1046px\" class=\"figure\"><div class=\"ttl\">Community-acquired pneumonia: Determining the appropriate site of treatment in adults</div><div class=\"cntnt\"><img style=\"width:1026px; height:834px;\" src=\"images/ID/113076_Algo_CAP_site_of_care.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ICU: intensive care unit; ED: emergency department; PSI: pneumonia severity index.<br />​* Although a definitive etiologic diagnosis is often not established until after the site of treatment decision has been made, clinical or epidemiologic evidence favoring a pathogen associated with rapidly progressive pneumonia (eg, post-influenza bacterial pneumonia, severe acute respiratory syndrome, Middle East respiratory syndrome, avian influenza [eg, H5N1, H7N9], <EM>Legionella</EM> pneumonia) should be considered and, if deemed likely, warrant hospital admission.<br />¶ Among the available scoring systems for determining the need for admission in patients with community-acquired pneumonia (CAP), we prefer the PSI because it the best studied and validated. If a less complex scoring system is desired, the CURB-65 score is a reasonable alternative, although its effectiveness and safety in guiding the initial site of treatment have not been empirically assessed. Refer to the UpToDate topic on assessing severity and determining the appropriate site of care in patients with CAP for additional details and to access PSI and CURB-65 calculators.<br />Δ Scoring systems, such as the PSI and CURB-65, and clinical criteria are intended to supplement rather than override the judgment of the physician. Factors other than the predictors included in the rules and the clinical criteria may be important when making an admission decision or selecting the site of inpatient care.<br /><FONT class=lozenge>◊</FONT> Using the CURB-65 score, if the patient has a score of 1 because he or she is ≥65 years of age and he or she has no major comorbidities, hospital admission is not necessarily indicated.<br />§ Some PSI class II and III patients may benefit from in-home healthcare support, also termed \"hospital-at-home,\" (eg, a visiting nurse, intravenous fluids, intravenous antibiotics).</div><div id=\"graphicVersion\">Graphic 113076 Version 2.0</div></div></div>"},"113078":{"type":"graphic_figure","displayName":"Microscopic TWA","title":"Examples of microscopic T-wave alternans (TWA)","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Examples of microscopic T-wave alternans (TWA)</div><div class=\"cntnt\"><img style=\"width:528px; height:506px;\" src=\"images/CARD/113078_MicroscopicTWA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Visually inapparent microvolt-level TWA, uncovered by digital signal processing.</div><div class=\"graphic_footnotes\">TWA: T-wave alternans.<br />* The more positive T-wave of each alternating pair.</div><div class=\"graphic_reference\">Reproduced from: Narayan SM. T-wave alternans and the susceptibility to ventricular arrhythmias. J Am Coll Cardiol 2006; 47:269. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113078 Version 1.0</div></div></div>"},"113079":{"type":"graphic_table","displayName":"Complications of open ventral hernia repair by mesh location","title":"Complications of open ventral incisional hernia repair by mesh location","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of open ventral incisional hernia repair by mesh location</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Onlay mesh&nbsp;(%)</td> <td class=\"subtitle1\">Inlay mesh&nbsp;(%)</td> <td class=\"subtitle1\">Sublay mesh&nbsp;(%)</td> <td class=\"subtitle1\">Underlay mesh&nbsp;(%)</td> </tr> <tr> <td><strong>Overall complications</strong></td> <td class=\"centered\">21</td> <td class=\"centered\">26</td> <td class=\"centered\">17</td> <td class=\"centered\">7</td> </tr> <tr> <td><strong>Wound infection</strong></td> <td class=\"centered\">4</td> <td class=\"centered\">25</td> <td class=\"centered\">4</td> <td class=\"centered\">7</td> </tr> <tr> <td><strong>Seroma</strong></td> <td class=\"centered\">12</td> <td class=\"centered\">12</td> <td class=\"centered\">3</td> <td class=\"centered\">10</td> </tr> <tr> <td><strong>Mesh explantation</strong></td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">0.5</td> <td class=\"centered\">3</td> </tr> <tr> <td><strong>Hernia recurrence</strong></td> <td class=\"centered\">17</td> <td class=\"centered\">17</td> <td class=\"centered\">5</td> <td class=\"centered\">7</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Albino FP, Patel KM, Nahabedian MY, et al. Does mesh location matter in abdominal wall reconstruction? A systematic review of the literature and a summary of recommendations. Plast Reconstr Surg 2013; 132:1295. DOI: <A href=\"http://journals.lww.com/plasreconsurg/pages/articleviewer.aspx?year=2013&amp;issue=11000&amp;article=00047&amp;type=abstract\" target=_blank>10.1097/PRS.0b013e3182a4c393</A>. Copyright © 2013 American Society of Plastic Surgeons, Inc. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113079 Version 1.0</div></div></div>"},"113080":{"type":"graphic_table","displayName":"Recommendations for resuming driving after syncope","title":"Recommendations for resuming driving after syncope","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for resuming driving after syncope</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Symptom-free waiting time*</td> </tr> <tr> <td>OH</td> <td>One month</td> </tr> <tr> <td>VVS, no syncope in prior year<sup>[1]</sup></td> <td>No restriction</td> </tr> <tr> <td>VVS, one to six syncope per year<sup>[2]</sup></td> <td>One month</td> </tr> <tr> <td>VVS, &#62;6 syncope per year<sup>[2,1]</sup></td> <td>Not fit to drive until symptoms resolved</td> </tr> <tr> <td>Situational syncope other than cough syncope</td> <td>One month</td> </tr> <tr> <td>Cough syncope, untreated</td> <td>Not fit to drive</td> </tr> <tr> <td>Cough syncope, treated with cough suppression</td> <td>One month</td> </tr> <tr> <td>Carotid sinus syncope, untreated<sup>[1]</sup></td> <td>Not fit to drive</td> </tr> <tr> <td>Carotid sinus syncope, treated with permanent pacemaker<sup>[1]</sup></td> <td>One week</td> </tr> <tr> <td>Syncope due to nonreflex bradycardia, untreated<sup>[1]</sup></td> <td>Not fit to drive</td> </tr> <tr> <td>Syncope due to nonreflex bradycardia, treated with permanent pacemaker<sup>[1,3]</sup></td> <td>One week</td> </tr> <tr> <td>Syncope due to SVT, untreated<sup>[1]</sup></td> <td>Not fit to drive</td> </tr> <tr> <td>Syncope due to SVT, pharmacologically suppressed<sup>[1]</sup></td> <td>One month</td> </tr> <tr> <td>Syncope due to SVT, treated with ablation<sup>[1]</sup></td> <td>One week</td> </tr> <tr> <td>Syncope with LVEF &#60;35% and a presumed arrhythmic etiology without an ICD<sup>[4,5]</sup></td> <td>Not fit to drive</td> </tr> <tr> <td>Syncope with LVEF &#60;35% and presumed arrhythmic etiology with an ICD<sup>[6,7]</sup></td> <td>Three months</td> </tr> <tr> <td>Syncope presumed due to VT/VF, structural heart disease, and LVEF &#8805;35%, untreated</td> <td>Not fit to drive</td> </tr> <tr> <td>Syncope presumed due to VT/VF, structural heart disease, and LVEF &#8805;35%, treated with an ICD and guideline-directed drug therapy<sup>[6,7]</sup></td> <td>Three months</td> </tr> <tr> <td>Syncope presumed due to VT with a genetic cause, untreated</td> <td>Not fit to drive</td> </tr> <tr> <td>Syncope presumed due to VT with a genetic cause, treated with an ICD or guideline-directed drug therapy</td> <td>Three months</td> </tr> <tr> <td>Syncope presumed due to a nonstructural heart disease VT, such as RVOT or LVOT, untreated</td> <td>Not fit to drive</td> </tr> <tr> <td>Syncope presumed due to a nonstructural heart disease VT, such as RVOT or LVOT, treated successfully with ablation or suppressed pharmacologically<sup>[1]</sup></td> <td>Three months</td> </tr> <tr> <td>Syncope of undetermined etiology</td> <td>One month</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OH: orthostatic hypotension; VVS: vasovagal syncope; SVT: supraventricular tachycardia; LVEF: left ventricular ejection fraction; ICD: implantable cardioverter-defibrillator; VT: ventricular tachycardia; VF: ventricular fibrillation; RVOT: right ventricular outflow tract; LVOT: left ventricular outflow tract.<br />* It may be prudent to wait and observe for this time without a syncope spell before resuming driving.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Epstein AE, Miles WM, Benditt DG, et al. Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations. A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology. Circulation 1996; 94:1147-66.</li>&#xD;&#xA;    <li>Tan VH, Ritchie D, Maxey C, et al. Prospective assessment of the risk of vasovagal syncope during driving. JACC Clin Electrophysiol 2016; 2:203.</li>&#xD;&#xA;    <li>Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2013; 61:e6.</li>&#xD;&#xA;    <li>B&auml;nsch D, Brunn J, Castrucci M, et al. Syncope in patients with an implantable cardioverter-defibrillator: incidence, prediction and implications for driving restrictions. J Am Coll Cardiol 1998; 31:608.</li>&#xD;&#xA;    <li>Antonelli D, Peres D, Freedberg NA, et al. Incidence of postdischarge symptomatic paroxysmal atrial fibrillation in patients who underwent coronary artery bypass graft: long-term follow-up. Pacing Clin Electrophysiol 2004; 27:365.</li>&#xD;&#xA;    <li>Thijssen J, Borleffs CJ, van Rees JB, et al. Driving restrictions after implantable cardioverter defibrillator implantation: an evidence-based approach. Eur Heart J 2011; 32:2678.</li>&#xD;&#xA;    <li>Vijgen J, Botto G, Camm J, et al. Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators. Europace 2009; 11:1097.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Shen W-K, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope. J Am Coll Cardiol 2017. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113080 Version 1.0</div></div></div>"},"113085":{"type":"graphic_picture","displayName":"Facial nerve anatomy 2","title":"Facial nerve anatomy","html":"<div class=\"graphic\"><div style=\"width: 645px\" class=\"figure\"><div class=\"ttl\">Facial nerve anatomy</div><div class=\"cntnt\"><img style=\"width:625px; height:464px;\" src=\"images/DERM/113085_Facial_nerve_anatomy_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intermingling of buccal branches of the facial nerve (held with Adson forceps) with sensory infraorbital nerve branches (held with fine forceps).</div><div class=\"graphic_reference\">From: Tzafetta K, Terzis JK. Essays on the Facial Nerve: Part I. Microanatomy. Plast Reconstr Sur 2010; 125:879. DOI: <a href=\"http://journals.lww.com/plasreconsurg/Abstract/2010/03000/Essays_on_the_Facial_Nerve__Part_I__Microanatomy.14.aspx\" target=\"_blank\">10.1097/PRS.0b013e3181ccdc78</a>. Copyright &copy; 2010 American Society of Plastic Surgeons, Inc. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113085 Version 1.0</div></div></div>"},"113086":{"type":"graphic_figure","displayName":"Temporal branch of facial nerve distribution","title":"Distribution of the temporal branch of the facial nerve","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Distribution of the temporal branch of the facial nerve</div><div class=\"cntnt\"><img style=\"width:712px; height:496px;\" src=\"images/DERM/113086_Tmprl_brch_facial_nrve_dist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic showing the course and distribution of the temporal branch of the facial nerve. The range of distance from the root of helix to the temporal nerve at the zygomatic arch&nbsp;is&nbsp;21.5 to 35.4 mm. The distance from the bony supraorbital ridge to the temporal branch ranges from 2.8 to 25 mm at 10 mm lateral to the supraorbital notch.</div><div class=\"graphic_footnotes\">SON: supraorbital notch.</div><div class=\"graphic_reference\">From: Hwang K, Kim YJ, Chung IH. Innervation of the Corrugator Supercilii Muscle. Ann Plast Surg 2004; 52:140. Copyright © 2004. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113086 Version 1.0</div></div></div>"},"113099":{"type":"graphic_table","displayName":"Previous transfusion alternatives","title":"Products formerly under development in the United States as supplements or pharmaceutical bridging agents to allogeneic red blood cell transfusion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Products formerly under development in the United States as supplements or pharmaceutical bridging agents to allogeneic red blood cell transfusion</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Perfluorochemicals</td> <td class=\"subtitle1\">Hemoglobin-based products*</td> </tr> <tr> <td>Hemolink (Hemosol, Inc)</td> <td>HemAssist (Baxter Healthcare Corporation)</td> </tr> <tr> <td>Oxycyte (Oxygen Biotherapeutics)</td> <td>Hemospan (MP4OX; Sangart)</td> </tr> <tr> <td>Oxygent (Alliance Pharmaceutical)</td> <td>rHb1.1 (Optro) and rHb2.0 (Baxter Healthcare Corporation)</td> </tr> <tr> <td>&nbsp;</td> <td>Polyheme (Northfield Laboratories)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Products are listed according to mechanism of action, with the manufacturer in parentheses. Refer to UpToDate for additional discussion of oxygen carriers and other products to use when blood transfusion is not available.</div><div class=\"graphic_footnotes\">* Hemoglobin-based products were derived from human red blood cells, with the exception of rHb1.1 and rHb2.0, which were produced recombinantly.</div><div id=\"graphicVersion\">Graphic 113099 Version 1.0</div></div></div>"},"113100":{"type":"graphic_figure","displayName":"Mesh locations in ventral hernia repair","title":"Mesh locations in ventral hernia repair","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Mesh locations in ventral hernia repair</div><div class=\"cntnt\"><img style=\"width:481px; height:664px;\" src=\"images/SURG/113100_Mesh_locations.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mesh locations: (A) onlay, (B) sublay, (C) underlay, and (D) inlay.<br />The blue line depicts mesh location.</div><div class=\"graphic_reference\">Modified from: Holihan JL, Alawadi ZM, Harris JW, et al. Ventral hernia: Patient selection, treatment, and management. Curr Probl Surg 2016; 53:307.</div><div id=\"graphicVersion\">Graphic 113100 Version 1.0</div></div></div>"},"113116":{"type":"graphic_picture","displayName":"Prone gel head support","title":"Prone gel head support","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Prone gel head support</div><div class=\"cntnt\"><img style=\"width:756px; height:667px;\" src=\"images/ANEST/113116_Prone_gel_head_support.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright © 2017 Action Products, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113116 Version 1.0</div></div></div>"},"113123":{"type":"graphic_table","displayName":"Definitions for postpartum hemorrhage","title":"Examples of definitions for postpartum hemorrhage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of definitions for postpartum hemorrhage</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organization</td> <td class=\"subtitle1\">Definition of PPH</td> </tr> <tr> <td>World Health Organization<sup>[1]</sup></td> <td> <ul> <li>Blood loss &#8805;500 mL within 24 hours after birth. </li> <li>Severe PPH: Blood loss &#8805;1000 mL within the same time frame. </li> </ul> </td> </tr> <tr> <td>American College of Obstetricians and Gynecologists<sup>[2]</sup></td> <td> <ul> <li>Cumulative blood loss &#8805;1000 mL or blood loss accompanied by signs or symptoms of hypovolemia within 24 hours after the birth process (includes intrapartum loss) regardless of route of delivery.</li> </ul> </td> </tr> <tr> <td>Royal College of Obstetricians and Gynaecologists<sup>[3]</sup></td> <td> <ul> <li>Minor PPH (500 to 1000 mL) and major PPH (&#62;1000 mL). Subdivisions of major PPH include moderate (1001 to 2000 mL) or severe (&#62;2000 mL). </li> </ul> </td> </tr> <tr> <td>International expert panel<sup>[4]</sup></td> <td> <ul> <li>Active bleeding &#62;1000 mL within the 24 hours following birth that continues despite the use of initial measures, including first-line uterotonic agents and uterine massage. </li> </ul> </td> </tr> <tr> <td>Society of Obstetricians and Gynaecologists of Canada<sup>[5]</sup></td> <td> <ul> <li>Any amount of bleeding that threatens the patient's hemodynamic stability. </li> </ul> </td> </tr> <tr> <td>California Maternal Quality Care Collaborative<sup>[6]</sup></td> <td> <ul> <li>Stage 0: All women in labor or recently delivered. </li> <li>Stage 1: Blood loss &#62;500 mL after vaginal or &#62;1000 mL after cesarean delivery; or vital sign changes &#62;15%; or heart rate &#8805;110 beats/minute, blood pressure &#8804;85/45 mmHg, O<sub>2</sub> saturation &#60;95%. </li> <li>Stage 2: Continued bleeding with total blood loss &#60;1500 mL. </li> <li>Stage 3: Total blood loss &#62;1500 mL or &#62;2 units packed red cells&nbsp;trasfused or unstable vital signs or suspicion of disseminated intravascular coagulation. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPH: postpartum hemorrhage.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. Geneva: World Health Organization; 2012.</LI>&#xD;&#xA;<LI>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin Number 183, October 2017: Postpartum hemorrhage. Obstet Gynecol 2017; 130:e168. </LI>&#xD;&#xA;<LI>Prevention and management of postpartum haemorrhage: Green-top guideline No. 52. BJOG 2017; 124:e106.</LI>&#xD;&#xA;<LI>Abdul-Kadir R, McLintock C, Ducloy AS, et al. Evaluation and management of postpartum hemorrhage: Cnsensus from an international expert panel. Transfusion 2014; 54:1756.</LI>&#xD;&#xA;<LI>Leduc D, Senikas V, Lalonde AB, et al. Active management of the third stage of labour: Pevention and treatment of postpartum hemorrhage. J Obstet Gynaecol Can 2009; 31:980.</LI>&#xD;&#xA;<LI>CMQCC. <A href=\"http://www.cmqcc.org/resources-tool-kits/toolkits/ob-hemorrhage-toolkit\" target=_blank>www.cmqcc.org/resources-tool-kits/toolkits/ob-hemorrhage-toolkit</A> (Accessed on May 17, 2017).</LI></OL></div><div id=\"graphicVersion\">Graphic 113123 Version 2.0</div></div></div>"},"113134":{"type":"graphic_picture","displayName":"Chronic plaque psoriasis on knees","title":"Chronic plaque psoriasis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Chronic plaque psoriasis</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/DERM/113134_Chron_plaque_psoriasis_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clusters of small plaques on the knees.</div><div id=\"graphicVersion\">Graphic 113134 Version 1.0</div></div></div>"},"113135":{"type":"graphic_picture","displayName":"Chronic plaque psoriasis on extremity","title":"Chronic plaque psoriasis","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Chronic plaque psoriasis</div><div class=\"cntnt\"><img style=\"width:498px; height:750px;\" src=\"images/DERM/113135_Chrnc_plaque_psorss_extrmty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thick, well-demarcated plaques of psoriasis on the lower legs of an obese adolescent girl.</div><div id=\"graphicVersion\">Graphic 113135 Version 1.0</div></div></div>"},"113136":{"type":"graphic_picture","displayName":"Guttate psoriasis on back","title":"Guttate psoriasis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Guttate psoriasis</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/113136_Guttate_psoriasis_back.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Drop-like guttate psoriasis on the lower back. Some lesions have cleared, leaving postinflammatory hypopigmentation.</div><div id=\"graphicVersion\">Graphic 113136 Version 1.0</div></div></div>"},"113137":{"type":"graphic_picture","displayName":"Generalized pustular psoriasis with annular configuration","title":"Generalized pustular psoriasis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Generalized pustular psoriasis</div><div class=\"cntnt\"><img style=\"width:756px; height:506px;\" src=\"images/DERM/113137_Pstlr_psoriass_annlr_config.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tiny pustules with surrounding erythema studding the back, some in an annular configuration.</div><div id=\"graphicVersion\">Graphic 113137 Version 1.0</div></div></div>"},"113138":{"type":"graphic_picture","displayName":"Scalp psoriasis on temporal scalp","title":"Chronic plaque psoriasis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Chronic plaque psoriasis</div><div class=\"cntnt\"><img style=\"width:756px; height:506px;\" src=\"images/DERM/113138_Scalp_psoriasis_temprl_sclp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thick scale on the temporal scalp.</div><div id=\"graphicVersion\">Graphic 113138 Version 1.0</div></div></div>"},"113139":{"type":"graphic_picture","displayName":"Psoriasis on scalp and neck","title":"Chronic plaque psoriasis","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Chronic plaque psoriasis</div><div class=\"cntnt\"><img style=\"width:516px; height:708px;\" src=\"images/DERM/113139_Psoriasis_scalp_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic areas of psoriasis involvement on the periphery of the scalp, postauricular area, conchal area of the ear, and neck.</div><div id=\"graphicVersion\">Graphic 113139 Version 1.0</div></div></div>"},"113140":{"type":"graphic_picture","displayName":"Nail psoriasis in child","title":"Nail psoriasis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Nail psoriasis</div><div class=\"cntnt\"><img style=\"width:756px; height:608px;\" src=\"images/DERM/113140_Nail_psoriasis_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple dystrophic fingernails and toenails.</div><div id=\"graphicVersion\">Graphic 113140 Version 1.0</div></div></div>"},"113141":{"type":"graphic_picture","displayName":"Nail psoriasis in a child close view","title":"Nail psoriasis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Nail psoriasis</div><div class=\"cntnt\"><img style=\"width:756px; height:530px;\" src=\"images/DERM/113141_Nail_psoriasis_child_close.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pitting, ridging, and discoloration of the nail.</div><div id=\"graphicVersion\">Graphic 113141 Version 1.0</div></div></div>"},"113142":{"type":"graphic_picture","displayName":"Chronic plaque psoriasis annular plaque","title":"Chronic plaque psoriasis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Chronic plaque psoriasis</div><div class=\"cntnt\"><img style=\"width:756px; height:550px;\" src=\"images/DERM/113142_Chron_plaque_psoriass_annlr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular psoriasis plaque.</div><div id=\"graphicVersion\">Graphic 113142 Version 1.0</div></div></div>"},"113143":{"type":"graphic_picture","displayName":"Pityriasis rubra pilaris palms","title":"Pityriasis rubra pilaris","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Pityriasis rubra pilaris</div><div class=\"cntnt\"><img style=\"width:756px; height:487px;\" src=\"images/DERM/113143_Pityriasis_rubra_pilars_plm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Salmon-colored palmoplantar keratoderma.</div><div id=\"graphicVersion\">Graphic 113143 Version 1.0</div></div></div>"},"113144":{"type":"graphic_figure","displayName":"TAA endovascular repair PI","title":"Thoracic aortic aneurysm – Endovascular repair","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracic aortic aneurysm – Endovascular repair</div><div class=\"cntnt\"><img style=\"width:441px; height:617px;\" src=\"images/PI/113144_TAA_endovascular_repair_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows an aneurysm in the descending thoracic aorta. The doctor makes a cut in a blood vessel at the top of the thigh and inserts a folded graft. Then he or she threads the graft up to the bulging part of the aorta and unfolds it. This type of graft does not need to be sewn into place. Blood flows through the graft.</div><div id=\"graphicVersion\">Graphic 113144 Version 1.0</div></div></div>"},"113145":{"type":"graphic_figure","displayName":"TAA open surgery PI","title":"Thoracic aortic aneurysm – Open surgery repair","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Thoracic aortic aneurysm – Open surgery repair</div><div class=\"cntnt\"><img style=\"width:526px; height:454px;\" src=\"images/PI/113145_TAA_open_surgery_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A: This drawing shows an aneurysm in the ascending thoracic aorta. <br />B: This type of aneurysm is repaired with open surgery. To do this, the doctor cuts open your chest to get to your heart. Then he or she replaces the bulging part of the aorta with a tube called a \"graft.\" The graft is sewn into place. Blood can flow normally through it. </div><div id=\"graphicVersion\">Graphic 113145 Version 1.0</div></div></div>"},"113146":{"type":"graphic_picture","displayName":"Endoscopic view of an obstructing colon cancer","title":"Endoscopic view of an obstructing colon cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic&nbsp;view of an obstructing colon cancer</div><div class=\"cntnt\"><img style=\"width:372px; height:362px;\" src=\"images/GAST/113146_Endoscpc_obstrctng_colon_ca.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient presented with an obstructing colon cancer and was evaluated for palliative stent placement. The endoscope was passed to the level of the obstructing lesion.</div><div id=\"graphicVersion\">Graphic 113146 Version 1.0</div></div></div>"},"113147":{"type":"graphic_diagnosticimage","displayName":"Fluoroscopic image of obstructing colon cancer","title":"Fluoroscopic image of obstructing colon cancer","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Fluoroscopic image of obstructing colon cancer</div><div class=\"cntnt\"><img style=\"width:756px; height:756px;\" src=\"images/GAST/113147_Fluoroscpc_obstrct_colon_ca.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 'apple-core' lesion is best seen with fluoroscopic imaging after injection of contrast.</div><div id=\"graphicVersion\">Graphic 113147 Version 1.0</div></div></div>"},"113148":{"type":"graphic_picture","displayName":"Endoscopic view of stent","title":"Endoscopic view of stent following placement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic view of stent following placement</div><div class=\"cntnt\"><img style=\"width:372px; height:363px;\" src=\"images/GAST/113148_Endoscopic_view_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A self-expanding metal stent (Wallflex, Boston Scientific) is used as palliative treatment for an obstructing colon cancer. The position of the stent was assessed by endoscopic visualization, and colonic decompression was accomplished following stent placement.</div><div id=\"graphicVersion\">Graphic 113148 Version 1.0</div></div></div>"},"113149":{"type":"graphic_diagnosticimage","displayName":"Fluoroscopic image following stent placement","title":"Fluoroscopic image following colonic stent placement","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Fluoroscopic image following colonic stent placement</div><div class=\"cntnt\"><img style=\"width:756px; height:756px;\" src=\"images/GAST/113149_Fluoroscpc_img_stent_plcmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After the colonic self-expanding metal stent is deployed, placement is assessed by fluoroscopic imaging.</div><div id=\"graphicVersion\">Graphic 113149 Version 1.0</div></div></div>"},"113159":{"type":"graphic_table","displayName":"Short mood and feelings questionnaire - Self-report","title":"Short mood and feelings questionnaire - Self-report","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Short mood and feelings questionnaire - Self-report</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup span=\"3\" width=\"10%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <p>This form is about how you might have been feeling or acting <strong>recently</strong>.</p> <br /> <p>For each question, please check (✓) how you have been feeling or acting <em><strong>in the past two weeks</strong></em>.</p> <br /> <p>If a sentence was not true about you, check NOT TRUE.<br /> If a sentence was only sometimes true, check SOMETIMES.<br /> If a sentence was true about you most of the time, check TRUE.</p> <br /> <p><strong>Score the MFQ as follows:</strong><br /> NOT TRUE = 0<br /> SOMETIMES = 1<br /> TRUE = 2</p> </td> </tr> <tr> <td class=\"subtitle1\">To code, please use a checkmark (✓) for each statement.</td> <td class=\"subtitle1\">NOT<br /> TRUE</td> <td class=\"subtitle1\">SOME<br /> TIMES</td> <td class=\"subtitle1\">TRUE</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\"> <li>I felt miserable or unhappy. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"2\"> <li>I didn't enjoy anything at all. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"3\"> <li>I felt so tired I just sat around and did nothing. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"4\"> <li>I was very restless. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"5\"> <li>I felt I was no good anymore. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"6\"> <li>I cried a lot. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"7\"> <li>I found it hard to think properly or concentrate. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"8\"> <li>I hated myself. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"9\"> <li>I was a bad person. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"10\"> <li>I felt lonely. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"11\"> <li>I thought nobody really loved me. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"12\"> <li>I thought I could never be as good as other kids. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td> <ol class=\"numbers_no_heading\" start=\"13\"> <li>I did everything wrong. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Copyright &copy; 1987 Adrian Angold and Elizabeth J. Costello; Developmental Epidemiology Program, Duke University. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 113159 Version 1.0</div></div></div>"},"113160":{"type":"graphic_table","displayName":"Short mood and feelings questionnaire - Parent report","title":"Short mood and feelings questionnaire - Parent report","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Short mood and feelings questionnaire - Parent report</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup span=\"3\" width=\"10%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <p>This form is about how your child might have been feeling or acting <strong>recently</strong>.</p> <br /> <p>For each question, please check (✓) how s/he has been feeling or acting <em><strong>in the past two weeks</strong></em>.</p> <br /> <p>If a sentence was not true about your child, check NOT TRUE.<br /> If a sentence was only sometimes true, check SOMETIMES.<br /> If a sentence was true about your child most of the time, check TRUE.</p> <br /> <p><strong>Score the MFQ as follows:</strong><br /> NOT TRUE = 0<br /> SOMETIMES = 1<br /> TRUE = 2</p> </td> </tr> <tr> <td class=\"subtitle1\">To code, please use a checkmark (✓) for each statement.</td> <td class=\"subtitle1\">NOT<br /> TRUE</td> <td class=\"subtitle1\">SOME<br /> TIMES</td> <td class=\"subtitle1\">TRUE</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\"> <li>S/he felt miserable or unhappy. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"2\"> <li>S/he didn't enjoy anything at all. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"3\"> <li>S/he felt so tired that s/he just sat around and did nothing. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"4\"> <li>S/he was very restless. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"5\"> <li>S/he felt s/he was no good anymore. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"6\"> <li>S/he cried a lot. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"7\"> <li>S/he found it hard to think properly or concentrate. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"8\"> <li>S/he hated him/herself. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"9\"> <li>S/he felt s/he was a bad person. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"10\"> <li>S/he felt lonely. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"11\"> <li>S/he thought nobody really loved him/her. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td> <ol class=\"numbers_no_heading\" start=\"12\"> <li>S/he thought s/he could never be as good as other kids. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td> <ol class=\"numbers_no_heading\" start=\"13\"> <li>S/he felt s/he did everything wrong. </li> </ol> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Copyright &copy; 1987 Adrian Angold and Elizabeth J. Costello; Developmental Epidemiology Program, Duke University. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 113160 Version 1.0</div></div></div>"},"113168":{"type":"graphic_table","displayName":"Countries with tuberculosis incidence ≥40 per 100,000","title":"Countries with tuberculosis incidence ≥40 per 100,000","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Countries with tuberculosis incidence ≥40 per 100,000</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Countries A - L</td> </tr> <tr> <td class=\"indent1\">Afghanistan</td> </tr> <tr> <td class=\"indent1\">Algeria</td> </tr> <tr> <td class=\"indent1\">Angola</td> </tr> <tr> <td class=\"indent1\">Armenia</td> </tr> <tr> <td class=\"indent1\">Azerbaijan</td> </tr> <tr> <td class=\"indent1\">Bangladesh</td> </tr> <tr> <td class=\"indent1\">Belarus</td> </tr> <tr> <td class=\"indent1\">Benin</td> </tr> <tr> <td class=\"indent1\">Bhutan</td> </tr> <tr> <td class=\"indent1\">Bolivia (Plurinational State of)</td> </tr> <tr> <td class=\"indent1\">Botswana</td> </tr> <tr> <td class=\"indent1\">Brazil</td> </tr> <tr> <td class=\"indent1\">Brunei Darussalam</td> </tr> <tr> <td class=\"indent1\">Burkina Faso</td> </tr> <tr> <td class=\"indent1\">Burundi</td> </tr> <tr> <td class=\"indent1\">Cabo Verde</td> </tr> <tr> <td class=\"indent1\">Cambodia</td> </tr> <tr> <td class=\"indent1\">Cameroon</td> </tr> <tr> <td class=\"indent1\">Central African Republic</td> </tr> <tr> <td class=\"indent1\">Chad</td> </tr> <tr> <td class=\"indent1\">China</td> </tr> <tr> <td class=\"indent1\">China, Hong Kong SAR</td> </tr> <tr> <td class=\"indent1\">China, Macao SAR</td> </tr> <tr> <td class=\"indent1\">C&#244;te d'Ivoire</td> </tr> <tr> <td class=\"indent1\">Congo</td> </tr> <tr> <td class=\"indent1\">Democratic People's Republic of Korea</td> </tr> <tr> <td class=\"indent1\">Democratic Republic of the Congo</td> </tr> <tr> <td class=\"indent1\">Djibouti</td> </tr> <tr> <td class=\"indent1\">Dominican Republic</td> </tr> <tr> <td class=\"indent1\">Ecuador</td> </tr> <tr> <td class=\"indent1\">El Salvador</td> </tr> <tr> <td class=\"indent1\">Equatorial Guinea</td> </tr> <tr> <td class=\"indent1\">Eritrea</td> </tr> <tr> <td class=\"indent1\">Ethiopia</td> </tr> <tr> <td class=\"indent1\">Fiji</td> </tr> <tr> <td class=\"indent1\">Gabon</td> </tr> <tr> <td class=\"indent1\">Gambia</td> </tr> <tr> <td class=\"indent1\">Georgia</td> </tr> <tr> <td class=\"indent1\">Ghana</td> </tr> <tr> <td class=\"indent1\">Greenland</td> </tr> <tr> <td class=\"indent1\">Guam</td> </tr> <tr> <td class=\"indent1\">Guinea</td> </tr> <tr> <td class=\"indent1\">Guinea-Bissau</td> </tr> <tr> <td class=\"indent1\">Guyana</td> </tr> <tr> <td class=\"indent1\">Haiti</td> </tr> <tr> <td class=\"indent1\">Honduras</td> </tr> <tr> <td class=\"indent1\">India</td> </tr> <tr> <td class=\"indent1\">Indonesia</td> </tr> <tr> <td class=\"indent1\">Iraq</td> </tr> <tr> <td class=\"indent1\">Kazakhstan</td> </tr> <tr> <td class=\"indent1\">Kenya</td> </tr> <tr> <td class=\"indent1\">Kiribati</td> </tr> <tr> <td class=\"indent1\">Kyrgyzstan</td> </tr> <tr> <td class=\"indent1\">Lao People's Democratic Republic</td> </tr> <tr> <td class=\"indent1\">Latvia</td> </tr> <tr> <td class=\"indent1\">Lesotho</td> </tr> <tr> <td class=\"indent1\">Liberia</td> </tr> <tr> <td class=\"indent1\">Libya</td> </tr> <tr> <td class=\"indent1\">Lithuania</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Countries M - Z</td> </tr> <tr> <td class=\"indent1\">Madagascar</td> </tr> <tr> <td class=\"indent1\">Malawi</td> </tr> <tr> <td class=\"indent1\">Malaysia</td> </tr> <tr> <td class=\"indent1\">Maldives</td> </tr> <tr> <td class=\"indent1\">Mali</td> </tr> <tr> <td class=\"indent1\">Marshall Islands</td> </tr> <tr> <td class=\"indent1\">Mauritania</td> </tr> <tr> <td class=\"indent1\">Micronesia (Federated States of)</td> </tr> <tr> <td class=\"indent1\">Mongolia</td> </tr> <tr> <td class=\"indent1\">Morocco</td> </tr> <tr> <td class=\"indent1\">Mozambique</td> </tr> <tr> <td class=\"indent1\">Myanmar</td> </tr> <tr> <td class=\"indent1\">Namibia</td> </tr> <tr> <td class=\"indent1\">Nauru</td> </tr> <tr> <td class=\"indent1\">Nepal</td> </tr> <tr> <td class=\"indent1\">Nicaragua</td> </tr> <tr> <td class=\"indent1\">Niger</td> </tr> <tr> <td class=\"indent1\">Nigeria</td> </tr> <tr> <td class=\"indent1\">Northern Mariana Islands</td> </tr> <tr> <td class=\"indent1\">Pakistan</td> </tr> <tr> <td class=\"indent1\">Palau</td> </tr> <tr> <td class=\"indent1\">Panama</td> </tr> <tr> <td class=\"indent1\">Papua New Guinea</td> </tr> <tr> <td class=\"indent1\">Paraguay</td> </tr> <tr> <td class=\"indent1\">Peru</td> </tr> <tr> <td class=\"indent1\">Philippines</td> </tr> <tr> <td class=\"indent1\">Republic of Korea</td> </tr> <tr> <td class=\"indent1\">Republic of Moldova</td> </tr> <tr> <td class=\"indent1\">Romania</td> </tr> <tr> <td class=\"indent1\">Russian Federation</td> </tr> <tr> <td class=\"indent1\">Rwanda</td> </tr> <tr> <td class=\"indent1\">Sao Tome and Principe</td> </tr> <tr> <td class=\"indent1\">Senegal</td> </tr> <tr> <td class=\"indent1\">Sierra Leone</td> </tr> <tr> <td class=\"indent1\">Singapore</td> </tr> <tr> <td class=\"indent1\">Solomon Islands</td> </tr> <tr> <td class=\"indent1\">Somalia</td> </tr> <tr> <td class=\"indent1\">South Africa</td> </tr> <tr> <td class=\"indent1\">South Sudan</td> </tr> <tr> <td class=\"indent1\">Sri Lanka</td> </tr> <tr> <td class=\"indent1\">Sudan</td> </tr> <tr> <td class=\"indent1\">Swaziland</td> </tr> <tr> <td class=\"indent1\">Tajikistan</td> </tr> <tr> <td class=\"indent1\">Thailand</td> </tr> <tr> <td class=\"indent1\">Timor-Leste</td> </tr> <tr> <td class=\"indent1\">Togo</td> </tr> <tr> <td class=\"indent1\">Turkmenistan</td> </tr> <tr> <td class=\"indent1\">Tuvalu</td> </tr> <tr> <td class=\"indent1\">Uganda</td> </tr> <tr> <td class=\"indent1\">Ukraine</td> </tr> <tr> <td class=\"indent1\">United Republic of Tanzania</td> </tr> <tr> <td class=\"indent1\">Uzbekistan</td> </tr> <tr> <td class=\"indent1\">Vanuatu</td> </tr> <tr> <td class=\"indent1\">Vietnam</td> </tr> <tr> <td class=\"indent1\">Yemen</td> </tr> <tr> <td class=\"indent1\">Zambia</td> </tr> <tr> <td class=\"indent1\">Zimbabwe</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">There is no consensus regarding the appropriate threshold for&nbsp;tuberculosis screening. Guidelines are developed for public health goals and therefore may not represent the best clinical choice for individual patients. Decisions regarding&nbsp;tuberculosis screening should be based on risk, and local or regional&nbsp;tuberculosis incidence data should be used to help define such risk. </div><div class=\"graphic_reference\">Data from: World Health Organization. 2015 WHO data. Available from: <a href=\"https://extranet.who.int/tme/generateCSV.asp?ds=estimates\" spellcheck=\"true\" target=\"_blank\">https://extranet.who.int/tme/generateCSV.asp?ds=estimates</a> (Accessed on May 15, 2017).</div><div id=\"graphicVersion\">Graphic 113168 Version 1.0</div></div></div>"},"113169":{"type":"graphic_figure","displayName":"Classification femoral artery aneurysm","title":"Classification femoral artery aneurysm<sup>[1]</sup>","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Classification femoral artery aneurysm<sup>[1]</sup></div><div class=\"cntnt\"><img style=\"width:494px; height:679px;\" src=\"images/SURG/113169_Classification_femoral_artery_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classification femoral artery aneurysm<sup>[1]</sup>&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>Type I: Limited to the common femoral artery</li>&#xD;&#xA;    <li>Type II: Involves the common femoral artery but extends into the origin of the superficial femoral or deep femoral artery</li>&#xD;&#xA;    <li>Type III: Limited to the superficial femoral artery</li>&#xD;&#xA;    <li>Type IV: Limited to the deep femoral artery</li>&#xD;&#xA;</ul>&#xD;&#xA;The original classification by Cutler included only type I and type II femoral artery aneurysm. The inclusion of isolated superficial and deep femoral aneurysm is advocated by some vascular surgeons, as given above.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>​Amer N, Grocott E, Shami S. Time for a new classification of femoral artery aneurysm? Vasa 2004; 33:170.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 113169 Version 1.0</div></div></div>"},"113182":{"type":"graphic_table","displayName":"Aplasia cutis congenita classification","title":"Classification of aplasia cutis congenita","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of aplasia cutis congenita</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Body area affected</td> <td class=\"subtitle1\">Associated abnormalities</td> <td class=\"subtitle1\">Inheritance</td> </tr> <tr> <td colspan=\"4\"><strong>Group 1:</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Scalp ACC without multiple anomalies</td> <td>Scalp, usually vertex</td> <td>Cleft lip and palate; tracheoesophageal fistula; double cervix and uterus; patent ductus arteriosus; omphalocele; polycystic kidney; mental retardation; cutis marmorata telangiectatica congenita</td> <td>Autosomal dominant or sporadic</td> </tr> <tr> <td colspan=\"4\"><strong>Group 2:</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Scalp ACC with associated limb abnormalities</td> <td>Midline scalp</td> <td>Limb reduction abnormalities; two to three syndactyly; clubfoot; nail absence or dystrophy; skin tags on toes; persistent cutis marmorata; encephalocele; woolly hair; hemangioma; heart disease; cryptorchidism; postaxial polydactyly (one family)</td> <td>Autosomal dominant</td> </tr> <tr> <td colspan=\"4\"><strong>Group 3:</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Scalp ACC with associated epidermal and organoid nevi</td> <td>Scalp, may be asymmetric</td> <td>Corneal opacities; scleral dermoids; eyelid colobomas; psychomotor retardation; seizures</td> <td>Sporadic</td> </tr> <tr> <td colspan=\"4\"><strong>Group 4:</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">ACC overlying embryologic malformations</td> <td>Abdomen, lumbar skin, scalp; any site</td> <td>Meningomyeloceles; spinal dysraphia; cranial stenosis; congenital midline porencephaly; leptomeningeal angiomatosis; ectopia of ear; omphalocele; gastroschisis</td> <td>Depends on underlying condition</td> </tr> <tr> <td colspan=\"4\"><strong>Group 5:</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">ACC with associated fetus papyraceus or placental infarcts</td> <td>Multiple, symmetric areas, often stellate or linear, on scalp, chest, flanks, axillae, and extremities</td> <td>Single umbilical artery; developmental delay; spastic paralysis; nail dystrophy; clubbed hands and feet; amniotic bands</td> <td>Sporadic</td> </tr> <tr> <td colspan=\"4\"><strong>Group 6:</strong> ACC associated with EB:</td> </tr> <tr> <td class=\"indent1\">Blistering, usually localized, without multiple congenital anomalies</td> <td>Extremities</td> <td>Blistering of skin and/or mucous membranes; absent or deformed nails; metatarsus varus; congenital absence of kidney (seen in cases of recessive, dystrophic EB; dominant, dystrophic EB; and EB simplex)</td> <td>Depends on EB type: may be autosomal dominant or recessive</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Widespread skin fragility with congenital anomalies</td> <td>Large areas on extremities and torso</td> <td>Pyloric or duodenal atresia; abnormal ears and nose; ureteral stenosis; renal abnormalities; arthrogryposis; amniotic bands; nail dystrophy</td> <td>Autosomal recessive</td> </tr> <tr> <td colspan=\"4\"><strong>Group 7:</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">ACC localized to extremities without blistering</td> <td>Pretibial areas; dorsal aspects of hands and feet; extensor areas of wrists</td> <td>None</td> <td>Autosomal dominant or recessive</td> </tr> <tr> <td colspan=\"4\"><strong>Group 8:</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">ACC caused by specific teratogens</td> <td>Scalp (with methimazole); any area (with varicella and herpes simplex infections)</td> <td>Imperforate anus (methimazole); signs of intrauterine infection with varicella and herpes simplex infections</td> <td>Not inherited</td> </tr> <tr> <td colspan=\"4\"><strong>Group 9:</strong></td> </tr> <tr> <td class=\"indent1\">ACC associated with malformation syndromes</td> <td>Scalp; any location</td> <td>Trisomy 13; 4p&nbsp;deletion syndrome; many ectodermal dysplasias; Johanson-Blizzard syndrome; focal dermal hypoplasia; amniotic band disruption complex; XY gonadal dysgenesis</td> <td>Varies, depending on specific syndrome</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACC: aplasia cutis congenita; EB: epidermolysis bullosa.</div><div class=\"graphic_reference\">Reproduced from: Frieden IJ. Aplasia cutis congenital: A clinical review and proposal for classification. J Am Acad Dermatol 1986; 14:646. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113182 Version 1.0</div></div></div>"},"113183":{"type":"graphic_algorithm","displayName":"Management of HCT-eligible first relapse or refractory cHL","title":"Management of HCT-eligible first relapse or refractory classical Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Management of HCT-eligible first relapse or refractory classical Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:595px; height:831px;\" src=\"images/HEME/113183_Mgmt_HCT_elgb_rlp_rfcty_cHL.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm describes our approach to the management of first relapse of classical Hodgkin lymphoma (cHL) or primary refractory cHL. All suspected relapses should be confirmed by biopsy. Care of these patients should be coordinated between the primary hematologist/medical oncologist and a hematopoietic cell transplantation specialist. Select patients who have asymptomatic relapse &gt;2 years after initial therapy may be candidates for chemotherapy (with or without radiation) without subsequent autologous HCT. Further details are presented in UpToDate content on the treatment of relapsed or refractory Hodgkin lymphoma.</div><div class=\"graphic_footnotes\">cHL: classical Hodgkin lymphoma; CR: complete response, Deauville 1-3; PR: partial response, Deauville 4-5; PD: progressive disease, by PET/CT or clinical evaluation; ICE: ifosfamide, carboplatin, etoposide; GVD: gemcitabine, vinorelbine, pegylated liposomal doxorubicin; DHAP: dexamethasone, cytarabine, cisplatin; HCT: hematopoietic cell transplantation; BV: brentuximab vedotin; RT: radiation therapy.<br />* Experts differ regarding preferred salvage chemotherapy and number of treatment cycles. The most common options include ICE, GVD, and DHAP. We prefer two cycles of ICE as our initial salvage chemotherapy. We offer GVD as a second-line salvage regimen for those who require additional chemotherapy treatment.<br />¶ Options include targeted chemotherapy (eg, brentuximab vedotin) or immune checkpoint blockade.<br />Δ Involved site RT (preferred) or involved field RT; second-line salvage chemotherapy or brentuximab vedotin are acceptable alternatives in this setting, especially if radiation therapy is expected to result in significant short-term or long-term toxicity.<br /><FONT class=lozenge>◊</FONT> PET/CT is performed to exclude PD (ie, new activity outside of the radiation port), but PET may remain positive within the port due to inflammation-associated activity.<br />§ Involved site radiation therapy may be administered prior to HCT, after achieving CR with alternative salvage chemotherapy.<br />¥ BV improves progression free survival (but not overall survival) in patients with primary refractory disease, early relapse (ie, &lt;12 months after initial treatment), or extranodal involvement in patients who did not previously receive BV; a decision to treat must also consider the high incidence of neuropathy associated with BV.</div><div id=\"graphicVersion\">Graphic 113183 Version 1.0</div></div></div>"},"113184":{"type":"graphic_diagnosticimage","displayName":"Main MRI changes in CADASIL","title":"Main MRI changes in CADASIL","html":"<div class=\"graphic\"><div style=\"width: 775px\" class=\"figure\"><div class=\"ttl\">Main MRI changes in CADASIL</div><div class=\"cntnt\"><img style=\"width:755px; height:614px;\" src=\"images/NEURO/113184_Main_MRI_changes_CADASIL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lacunar infarcts shown on T1-weighted imaging are mainly located in the brainstem (pons), thalamus, and lentiform nuclei in a 61-year-old man with a history of stroke, gait difficulties, and executive dysfunction with memory deficits.<br />(B) Small deep infarcts are shown on fluid-attenuated inversion recovery images in association with diffuse and confluent white-matter hyperintensities involving the anterior part of the temporal lobes.<br />(C) Microbleeds are visible on T2 or gradient-echo images as small hypointense foci in the thalamus and brainstem.</div><div class=\"graphic_footnotes\">CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.</div><div class=\"graphic_reference\">Reproduced from: Chabriat H, Joutel A, Dichgans M, et al. Cadasil. Lancet Neurol 2009; 8:643. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113184 Version 1.0</div></div></div>"},"113185":{"type":"graphic_table","displayName":"Management of severe traumatic brain injury","title":"Summary of anesthetic considerations based on the 2016 Brain Trauma Foundation Guidelines for the Management of Severe Traumatic Brain Injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of anesthetic considerations based on the 2016 Brain&nbsp;Trauma Foundation Guidelines for the Management of Severe Traumatic Brain Injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Parameter/modality</td> <td class=\"subtitle1\">Recommendation/comment</td> <td class=\"subtitle1\">Anesthetic consideration</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Treatment phase</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hyperosmolar therapy</td> <td> <ul> <li>Hyperosmolar therapy with mannitol or hypertonic saline may lower intracranial pressure, but there is insufficient evidence to support the use of one rather than the other. </li> </ul> </td> <td>Hyperosmolar agents are often required preoperatively and intraoperatively. When using mannitol, the anesthetist must be aware of fluid shifts; hypovolemia in a patient with concurrent hemorrhagic shock can be exacerbated.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cerebrospinal fluid drainage</td> <td> <ul> <li>An EVD zeroed at the midbrain with continuous drainage of CSF may be considered to lower ICP; this may be more effective than intermittent use. </li> <li>The use of an EVD to lower ICP in patients with an initial GCS &#60;6 during the first 12 hours of injury may be considered. </li> </ul> </td> <td>Continuous monitoring requires constant intraoperative vigilance; excessive drainage can lead to brain herniation.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ventilation therapies</td> <td> <ul> <li>Hyperventilation is recommended as a temporizing measure for the reduction of elevated ICP. </li> <li>Hyperventilation should be avoided during the first 24 hours after injury when CBF is often critically reduced. </li> <li>Prolonged hyperventilation with a PaCO<sub>2</sub> of 25 mmHg or less is not recommended. </li> </ul> </td> <td>The target PaCO<sub>2</sub> is 35 to 45 mmHg; PaCO<sub>2</sub> is a powerful determinant of CBF. Low PaCO<sub>2</sub> levels result in low CBF and cerebral ischemia whereas high PaCO<sub>2</sub> levels can result in cerebral hyperemia and high ICP.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Anesthetics, analgesics, sedatives</td> <td> <ul> <li>The use of barbiturates to induce burst suppression as measured by EEG as prophylaxis against an elevated ICP is not recommended. </li> <li>High dose barbiturate administration is recommended to control elevated ICP refractory to maximum standard medical and surgical treatment. </li> <li>Propofol is recommended to help control ICP, but caution is required as high-dose propofol is associated with significant morbidity. </li> </ul> </td> <td> <p>Patients with ICP elevation refractory to standard medical treatment may present to the operating room on a barbiturate infusion.</p> High dose propofol should be avoided.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Steroids</td> <td> <ul> <li>The use of steroids is not recommended. High-dose methylprednisolone is associated with increased mortality. </li> </ul> </td> <td>Steroids are contraindicated and should not be administered in the OR.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Infection prophylaxis</td> <td> <ul> <li>General critical care protocols and practices should be followed to prevent ventilator-associated pneumonia; periprocedural antibiotics for intubation are no longer recommended. </li> </ul> </td> <td>Antibiotics before intubation are not required (a change from the previous 3rd edition guidelines).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Seizure prophylaxis</td> <td> <ul> <li>Early (within seven days of injury) administration of phenytoin is recommended to decrease the incidence of post-traumatic seizures. </li> <li>There is insufficient evidence to recommend levitiracetam (Keppra) over phenytoin regarding efficacy in preventing post-traumatic seizures. </li> </ul> </td> <td> <p>Seizure prophylaxis with phenytoin is often initiated in the operating room. Intravenous fosphenytoin or levetiracetam should be considered instead of phenytoin due to risks associated with extravasation of phenytoin.</p> Active seizures should be treated according to the standard of care (ie, midazolam or lorazepam).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Prophylactic hypothermia</td> <td> <ul> <li>Not recommended to improve outcomes in patients with diffuse injury. </li> </ul> </td> <td>Temperature monitoring for TBI patients is mandatory; normothermia should be maintained.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Monitoring phase</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Intracranial pressure monitoring</td> <td> <ul> <li>Management of severe TBI patients using information from ICP monitoring is recommended to reduce post-injury mortality. </li> </ul> </td> <td>Although not supported by evidence meeting current standards, ICP should be measured in TBI patients with a GCS of 3 to 8 and an abnormal CT scan (ie, a scan that reveals hematomas, contusions, swelling, herniation, or compressed basal cisterns). ICP monitoring may also be indicated in severe TBI patients with a normal CT scan who are older than 40 years of age, have hypotension (SBP &#60;90 mmHg), or exhibit unilateral or bilateral motor posturing.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cerebral perfusion pressure monitoring</td> <td> <ul> <li>CPP monitoring is recommended to decrease mortality. </li> </ul> </td> <td>CPP is proportional to the gradient between MAP and mean ICP; MAP can be modulated directly by the anesthetist (ie, with vasopressors, fluids) and requires close monitoring (ie, with arterial catheter) and treatment in the operating room.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Advanced cerebral monitoring</td> <td> <ul> <li>Jugular bulb monitoring of arteriovenous oxygen content difference may be considered. </li> <li>Brain tissue oxygen monitoring is no longer recommended due to insufficient evidence. </li> </ul> </td> <td>Anesthetists should be aware of the presence of jugular bulb monitors, and how to correctly interpret the information provided by these devices.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Thresholds</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Blood pressure</td> <td> <ul> <li>Maintaining SBP &#8805;100 mmHg for patients 50 to 69 years old or at &#8805;110 mmHg for patients 15 to 49 or &#62;70 years old may be considered to decrease mortality and improve outcomes. </li> </ul> </td> <td>Monitoring blood pressure (ie, arterial catheter) and avoiding hypotension in patients with severe TBI is a major perioperative goal.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Intracranial pressure</td> <td> <ul> <li>Treatment for ICP greater than 22 mmHg is recommended because values above this level are associated with increased mortality. </li> </ul> </td> <td>In practice, a combination of ICP values, clinical exam, and brain CT findings are required to make management decisions.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cerebral perfusion pressure</td> <td> <ul> <li>The recommended CPP value is 60 to 70 mmHg. </li> </ul> </td> <td>The exact threshold for CPP is unclear, and depends on the patient's autoregulatory status.</td> </tr> <tr> <td class=\"indent1\">Advanced monitoring</td> <td> <ul> <li>A jugular venous saturation &#60;50% may be a threshold to avoid in order to reduce mortality and improve outcomes. </li> </ul> </td> <td>Anesthetists should be aware of the presence of jugular bulb monitors, and how to correctly interpret the information provided by these devices.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EVD: external ventricular device; CSF: cerebrospinal fluid; ICP: intracranial pressure; GCS: Glascow coma scale; CBF: cerebral blood flow; EEG: electroencephalogram; OR: operating room; TBI: traumatic brain injury; CT: computerized tomography; SBP: systolic blood pressure; CPP: cerebral perfusion pressure; MAP: mean arterial pressure.</div><div class=\"graphic_reference\">Adapted from: Carney N, Totten AM, O'Reilly C, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery 2017; 80:6.</div><div id=\"graphicVersion\">Graphic 113185 Version 3.0</div></div></div>"},"113189":{"type":"graphic_algorithm","displayName":"Testing vitamin B12 and folate","title":"Diagnostic testing for suspected vitamin B12 or folate deficiency","html":"<div class=\"graphic\"><div style=\"width: 722px\" class=\"figure\"><div class=\"ttl\">Diagnostic testing for suspected vitamin B12 or folate deficiency</div><div class=\"cntnt\"><img style=\"width:702px; height:336px;\" src=\"images/HEME/113189_Testing_vitamin_B12_folate.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">UpToDate topics on vitamin B12 and folate deficiency discuss the presenting findings, diagnostic approach, differential diagnosis, and treatment in more detail, as well as additional post-diagnostic testing for the underlying causes of these deficiencies. This algorithm should not substitute for clinical judgment. Refer to laboratory-specific lower limits of normal. &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Typical values for vitamin B12 are as follows: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Deficient: &lt;200 pg/mL</LI>&#xD;&#xA;<LI>Borderline: 200 to 300 pg/mL</LI>&#xD;&#xA;<LI>Normal: &gt;300 pg/mL</LI></UL></LI>&#xD;&#xA;<LI>Typical values for folate are as follows: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Deficient: &lt;2 ng/mL</LI>&#xD;&#xA;<LI>Borderline:&nbsp;2 to&nbsp;4 ng/mL</LI>&#xD;&#xA;<LI>Normal: &gt;4 ng/mL</LI></UL></LI></UL></div><div class=\"graphic_footnotes\">MMA: methylmalonic acid; RBC: red blood cell.<br />​* Folate testing may be omitted if diet and gastrointestinal anatomy and function are normal. If dietary folate deficiency is suspected in a patient who has recently received a normal meal, RBC folate should be measured instead of serum folate. If one level is deficient and the other is borderline, then it may be necessary to follow more than one diagnostic path (eg, if folate is deficient and vitamin B12 is borderline, then folate deficiency may be confirmed but MMA and homocysteine testing may be required to determine vitamin B12 status). Another alternative in this setting would be to administer both vitamins.<br />¶ Additional testing may be appropriate. Examples include testing of MMA and homocysteine levels to further support a diagnosis of vitamin B12 deficiency; testing for autoantibodies to intrinsic factor if there is vitamin B12 deficiency not attributable to a known gastrointestinal condition; or screening endoscopy for malignancy in individuals with newly diagnosed pernicious anemia.</div><div id=\"graphicVersion\">Graphic 113189 Version 2.0</div></div></div>"},"113191":{"type":"graphic_table","displayName":"Safe prescribing for hypnotic medications in pts with insomnia","title":"Safe prescribing practices for hypnotic medications in patients with insomnia*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Safe prescribing practices for hypnotic medications in patients with insomnia*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Prescribe the lowest possible effective dose</li> </ul> </td> </tr> <tr> <td> <ul> <li>Avoid prescribing a dose greater than the maximum recommended dose</li> </ul> </td> </tr> <tr> <td> <ul> <li>Avoid combining with alcohol or other sedatives, including opioids </li> </ul> </td> </tr> <tr> <td> <ul> <li>Use increased caution in older adults and patients with renal and liver dysfunction </li> </ul> </td> </tr> <tr> <td> <ul> <li>In patients with comorbid depression, assess for suicidal ideation before prescribing and if present, monitor closely while considering other treatment options </li> </ul> </td> </tr> <tr> <td> <ul> <li>Instruct patients on proper timing of the drug in relation to desired sleep onset </li> </ul> </td> </tr> <tr> <td> <ul> <li>Instruct patients on drug half-life and expected duration of effect </li> </ul> </td> </tr> <tr> <td> <ul> <li>Advise against use if there is insufficient time for drug elimination between planned bedtime and rise time </li> </ul> </td> </tr> <tr> <td> <ul> <li>Discuss risk of next-day impairment in alertness, memory, coordination, and driving </li> </ul> </td> </tr> <tr> <td> <ul> <li>Discuss risk of complex sleep-related behaviors such as sleep walking, eating, and driving </li> </ul> </td> </tr> <tr> <td> <ul> <li>Schedule regular follow-up to review efficacy, side effects, non-pharmacologic options, and assess ongoing need for medication </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For detailed prescribing information, clinicians should refer to the individual drug information topics within UpToDate. Comprehensive information on drug-drug interactions can be determined using the drug interactions tool (Lexi-Interact online). This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.</div><div class=\"graphic_reference\">Adapted from: McCall WV, Benca RM, Rosenquist PB, et al. Hypnotic medications and suicide: Risk, mechanisms, mitigation, and the FDA. Am J Psychiatry 2017; 174:18.</div><div id=\"graphicVersion\">Graphic 113191 Version 1.0</div></div></div>"},"113193":{"type":"graphic_table","displayName":"Medical treatment for heavy bleeding in copper IUD users","title":"Medical treatment for heavy bleeding in copper IUD users","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical treatment for heavy bleeding in copper IUD users</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Timing</td> <td class=\"subtitle1\">Medication class</td> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Oral dose</td> <td class=\"subtitle1\">Frequency</td> <td class=\"subtitle1\">Length of time</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Prophylaxis of postinsertion bleeding*</td> <td>NSAID</td> <td>Ibuprofen</td> <td>400 mg</td> <td>3 times daily</td> <td>10 days</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Antifibrinolytic</td> <td>Tranexamic acid</td> <td>650 mg<sup>&#182;</sup> (US available prescription)</td> <td>2 times daily</td> <td>5 days</td> </tr> <tr class=\"divider_bottom\"> <td>Tranexamic acid</td> <td>500 mg<sup>&#182;</sup> (preparation is not available in US)</td> <td>2 times daily</td> <td>5 days</td> </tr> <tr> <td rowspan=\"10\">Treatment of heavy bleeding &#62;3 months postinsertion</td> <td rowspan=\"7\">NSAID</td> <td>Ibuprofen</td> <td>400 mg</td> <td>4 times daily</td> <td>7 days</td> </tr> <tr> <td>Indomethacin</td> <td>25 mg</td> <td>2 times daily</td> <td>7 days</td> </tr> <tr> <td>Indomethacin</td> <td>25 mg</td> <td>4 times daily</td> <td>3 days</td> </tr> <tr> <td>Mefenamic acid</td> <td>100 mg (preparation is not available in US)</td> <td>3 times daily</td> <td>3 days</td> </tr> <tr> <td>Mefenamic acid</td> <td>500 mg (US available preparation)</td> <td>3 times daily</td> <td>5 days</td> </tr> <tr> <td rowspan=\"2\">Diclofenac</td> <td>50 mg</td> <td>3 times daily</td> <td>1 day, then</td> </tr> <tr> <td>25 mg</td> <td>3 times daily</td> <td>4 days</td> </tr> <tr> <td rowspan=\"2\">Antifibrinolytic</td> <td>Tranexamic acid</td> <td>1300 mg<sup>&#182;</sup> (US available preparation)</td> <td>3 times daily</td> <td>5 days</td> </tr> <tr> <td>Tranexamic acid</td> <td>1500 mg<sup>&#182;</sup> (preparation is not available in US)</td> <td>3 times daily</td> <td>5 days</td> </tr> <tr> <td>Antidiuretic</td> <td>Desmopressin</td> <td>300 mcg intranasally</td> <td>Intranasal daily</td> <td>5 days</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Treatment is initiated on the first day of menses, or alternatively several days before expected menstruation, to reduce bleeding and cramping. Aspirin is not recommended.<br />NSAIDs are generally avoided in patients with renal impairment, reduced cardiac output, difficult to control hypertension and some other comorbidities; refer to UpToDate clinical reviews of NSAID safety and individual Lexicomp drug monograph for detail. </div><div class=\"graphic_footnotes\">NSAID: nonsteroidal anti-inflammatory drug; US: United States.<br />* UpToDate contributors generally do not use prophylactic medication as the abnormal bleeding typically resolves quickly and most women do well with advance education.<br />¶ Dose adjustment needed in setting of renal impairment.</div><div class=\"graphic_reference\">Reproduced from: Friedlander E, Kaneshiro B. Therapeutic options for unscheduled bleeding associated with long-acting reversible contraception. Obstet Gynecol Clin North Am 2015; 42:593. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113193 Version 1.0</div></div></div>"},"113194":{"type":"graphic_figure","displayName":"Cough arc pathway","title":"Simplified schematic pathway of the cough arc","html":"<div class=\"graphic\"><div style=\"width: 870px\" class=\"figure\"><div class=\"ttl\">Simplified schematic pathway of the cough arc</div><div class=\"cntnt\"><img style=\"width:850px; height:472px;\" src=\"images/PEDS/113194_Cough_arc_pathway.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stimuli that trigger cough can be broadly divided into mechanical, inflammation and infection, and chemical categories. Examples of each of these are listed in the box. These triggers stimulate the various airway receptors, all of which are vagal airway afferents. The triggers can also sensitize and alter the receptor phenotype. All signals end at the nucleus tractus solitaries, from which second order neurons project into the brainstem respiratory network, which is also responsible for regulating respiration. The cerebral cortex and subcortex can modulate these networks that have plasticity. Neurons from the brainstem network project onto the larynx and spinal motor neurons (respiratory muscles and sphincter) that are activated during cough.<SUP>[1-4]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Canning BJ, Chang AB, Bolser DC, Smith JA, Mazzone SB, McGarvey L. Anatomy and neurophysiology of cough: CHEST Guideline and Expert Panel report. Chest 2014; 146:1633.</LI>&#xD;&#xA;<LI>Mazzone SB, Undem BJ. Vagal Afferent Innervation of the Airways in Health and Disease. Physiol Rev 2016; 96:975.</LI>&#xD;&#xA;<LI>Canning BJ. Afferent nerves regulating the cough reflex: Mechanisms and Mediators of Cough in Disease. Otolaryngol Clin North Am 2010; 43:15-vii.&nbsp;&nbsp;&nbsp;&nbsp; </LI>&#xD;&#xA;<LI>Canning BJ. Functional implications of the multiple afferent pathways regulating cough. Pulm Pharmacol Ther 2011; 24:295.</LI></OL></div><div id=\"graphicVersion\">Graphic 113194 Version 1.0</div></div></div>"},"113195":{"type":"graphic_figure","displayName":"Overlap between nonspecific and specific cough","title":"Schematic diagram of the overlap between nonspecific and specific cough in children","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Schematic diagram of the overlap between nonspecific and specific cough in children</div><div class=\"cntnt\"><img style=\"width:628px; height:432px;\" src=\"images/PEDS/113195_Ovrlp_nonspecf_specf_cough.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The presence of signs and symptoms of specific causes of cough (specific cough \"pointers\") are used to distinguish specific cough from non-specific cough during the initial evaluation; refer to UpToDate table on specific cough for details. The size of the circles reflect that non-specific cough is likely more common than specific cough in the community. In referral populations (pulmonary clinics), specific cough is more common than nonspecific cough. The overlap between these circles indicates that some children who are initially categorized as having specific cough (due to the presence of specific cough pointers) ultimately prove to have nonspecific cause, and vice-versa.</div><div id=\"graphicVersion\">Graphic 113195 Version 1.0</div></div></div>"},"113197":{"type":"graphic_table","displayName":"Medical interventions for unscheduled bleeding in LNg users","title":"Medical interventions for unscheduled and/or heavy bleeding in levenorgestrel users","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical interventions for unscheduled and/or heavy bleeding in levenorgestrel users</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication class</td> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Oral dose (mg)</td> <td class=\"subtitle1\">Frequency</td> <td class=\"subtitle1\">Length of time</td> </tr> <tr> <td>Nonsteroidal anti-inflammatory drug (NSAID)</td> <td>Naproxen</td> <td>500*</td> <td>Two times daily</td> <td>Five days</td> </tr> <tr> <td>Antifibrinolytic</td> <td>Tranexamic acid</td> <td>500 to 650<sup>&#182;</sup><sup>&#916;</sup></td> <td>Three times daily</td> <td>Until bleeding stops (typically four days)</td> </tr> <tr> <td>Antiprogestin</td> <td>Mifepristone</td> <td>100</td> <td>Once</td> <td>Monthly</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Naproxen base.<br />¶ Dose adjustment may be needed in setting of renal impairment.<br />Δ In the United States, tranexamic acid is available as a 650 mg tablet. A 500 mg tablet is available elsewhere.</div><div class=\"graphic_reference\">Adapted from: Friedlander E, Kaneshiro B. Therapeutic options for unscheduled bleeding associated with long-acting reversible contraception. Obstet Gynecol Clin North Am 2015; 42:593.</div><div id=\"graphicVersion\">Graphic 113197 Version 1.0</div></div></div>"},"113198":{"type":"graphic_diagnosticimage","displayName":"Airway foreign body","title":"Airway foreign body","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Airway foreign body</div><div class=\"cntnt\"><img style=\"width:756px; height:551px;\" src=\"images/PEDS/113198_Airway_foreign_body.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An expiratory chest radiograph showing unilateral lung hyperinflation, suggestive of the presence of foreign body aspiration. This child's bronchoscopy revealed a nut in the right main bronchus.</div><div id=\"graphicVersion\">Graphic 113198 Version 1.0</div></div></div>"},"113199":{"type":"graphic_diagnosticimage","displayName":"Primary ciliary dyskinesia in a child","title":"Primary ciliary dyskinesia in a child","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Primary ciliary dyskinesia in a child</div><div class=\"cntnt\"><img style=\"width:756px; height:714px;\" src=\"images/PEDS/113199_Prmry_ciliary_dysknsa_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph at the first presentation of a child known to have left atrial isomerism. He was first referred at four years of age with&nbsp;a history of chronic wet cough for more than two years. He never had a prior chest radiograph. The chest radiograph shows collapse of the right lower lobe, which re-expanded after bronchoscopy and intravenous antibiotics. The bronchoscopy showed left pulmonary isomerism and endobronchial secretions. The ciliary biopsy showed immotile cilia, confirming the diagnosis of primary ciliary dyskinesia (PCD). The child also had heterotaxy syndrome, which is commonly associated with PCD.</div><div id=\"graphicVersion\">Graphic 113199 Version 1.0</div></div></div>"},"113200":{"type":"graphic_diagnosticimage","displayName":"Right middle lobe changes","title":"Right middle lobe atelectasis in a child with chronic cough","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Right middle lobe atelectasis in a child with chronic cough</div><div class=\"cntnt\"><img style=\"width:756px; height:669px;\" src=\"images/PEDS/113200_Right_middle_lobe_changes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph showing right middle lobe changes reflecting atelectasis. This child presented with chronic cough and exertional dyspnea. The child was treated with asthma medication and the radiographic changes resolved.</div><div id=\"graphicVersion\">Graphic 113200 Version 1.0</div></div></div>"},"113201":{"type":"graphic_diagnosticimage","displayName":"Normal perihilar thickening in chronic cough","title":"Normal chest x-ray in a child with chronic cough","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Normal chest x-ray in a child with chronic cough</div><div class=\"cntnt\"><img style=\"width:756px; height:730px;\" src=\"images/PEDS/113201_Perihlr_thcknng_chron_cough.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph showing perihilar bronchial thickening only. This common finding in healthy children and also in children&nbsp;with protracted bacterial bronchitis.</div><div id=\"graphicVersion\">Graphic 113201 Version 1.0</div></div></div>"},"113202":{"type":"graphic_diagnosticimage","displayName":"Bronchiectasis in a child","title":"Radiographic features of bronchiectasis in a child with chronic cough","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Radiographic features of bronchiectasis in a child with chronic cough</div><div class=\"cntnt\"><img style=\"width:756px; height:750px;\" src=\"images/PEDS/113202_Bronchiectasis_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of a child showing ring shadows (dashed arrows) and tram-tracking (double arrow) evident within both lower zones; these are radiographic features of bronchiectasis. There is opacification in the right lower zone, obscuring the right cardiac margin and medial aspect of the right hemidiaphragm, consistent with consolidation (thick arrow) in the medial right lower lobe and medial aspect of the right middle lobe. The radiograph also shows hyperinflation and ill-defined consolidation present within the retrocardiac left lower zone. Note that chest radiographs have very poor sensitivity for diagnosing bronchiectasis. </div><div id=\"graphicVersion\">Graphic 113202 Version 1.0</div></div></div>"},"113204":{"type":"graphic_diagnosticimage","displayName":"Right-sided aortic arch","title":"Right-sided aortic arch","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Right-sided aortic arch</div><div class=\"cntnt\"><img style=\"width:756px; height:514px;\" src=\"images/PEDS/113204_Right-sided_aortic_arch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph showing right-sided arch suggested by the absence of the left aortic contour. The arrow points to the area where the left aortic contour would be seen in a normal radiograph.<br />A right-sided arch is associated with vascular sling or ring and tracheomalacia. While tracheomalacia does not cause cough, it results in reduced cough efficiency, and hence predisposes the child to prolonged coughing episodes and endobronchial infections such as protracted bacterial bronchitis.</div><div id=\"graphicVersion\">Graphic 113204 Version 1.0</div></div></div>"},"113206":{"type":"graphic_table","displayName":"Causes of chronic cough in children","title":"Causes of chronic cough in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of chronic cough in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">May be isolated, but more likely if other tics are present. Primary cause</td> <td class=\"subtitle1\">Risk factors or mechanisms</td> <td class=\"subtitle1\">Major evaluation method (in addition to clinical findings)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Pulmonary causes</td> </tr> <tr> <td class=\"indent1\">Aspiration* (recurrent small volume)</td> <td> <ul> <li>Primary swallowing dysfunction or laryngeal disorders (eg, laryngeal cleft, trachea-esophageal fistula), gastroesophageal reflux, achalasia </li> </ul> </td> <td> <ul> <li>Swallowing assessment (eg, videofluoroscopic), and other evaluation as indicated<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Asthma, cough-dominant asthma*</td> <td> <ul> <li>Genetics, environment, atopy, post-acute respiratory infections </li> </ul> </td> <td> <ul> <li>Lung function, airway hyperresponsiveness </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Chronic endobronchial suppurative disease* (protracted bacterial bronchitis, chronic suppurative lung disease, bronchiectasis)&nbsp;</td> <td> <ul> <li>Cystic fibrosis </li> <li>Immunodeficiency (primary or secondary) </li> <li>Primary ciliary dyskinesia </li> <li>Aspiration </li> </ul> </td> <td> <ul> <li>Sweat test, genetic screening </li> <li>Evaluation of immune function </li> <li>Cilia biopsy, genetic testing </li> <li>Refer to \"Aspiration\" above </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Chronic pneumonia*</td> <td> <ul> <li>Chronic atelectasis, mucous plugging, plastic bronchitis </li> <li>Pathogens include tuberculosis, nontuberculosis mycobacteria, mycoplasma, fungi, and chlamydia </li> </ul> </td> <td> <ul> <li>Chest CT, bronchoscopy </li> <li>Relevant microbial assessment (eg, QuantiFERON gold and Gene Xpert for tuberculosis) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Eosinophilic lung disease*</td> <td> <ul> <li>Primary or secondary (ie, related to parasitic disease) </li> </ul> </td> <td> <ul> <li>Bloods and bronchoalveolar lavage </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Inhaled retained foreign body*</td> <td> <ul> <li>Young child; history of choking (even if days or weeks before cough onset) </li> </ul> </td> <td> <ul> <li>Bronchoscopy </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Interstitial lung disease*</td> <td> <ul> <li>Primary genetic abnormality, post-severe infection bronchiolitis obliterans, autoimmune disease, radiation, drugs </li> </ul> </td> <td> <ul> <li>Relevant genetic or autoimmune test, &#177; lung biopsy </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Mechanical inefficiency&nbsp;&nbsp;</td> <td> <ul> <li>Tracheobronchomalacia and other airway anomalies</li> <li>Vascular rings or other anomalies that cause tracheal&nbsp;narrowing </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Dynamic bronchoscopy</li> <li>Chest CT with contrast</li> <li>Chest MRI&nbsp;(if vascular cause suspected) ​&nbsp;&nbsp;</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Noninfective bronchitis*</td> <td> <ul> <li>Exposure to environmental pollutants (eg, tobacco smoke, fungi, traffic) </li> </ul> </td> <td> <ul> <li>History and removal of trigger </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Post-infection (self-resolving)</td> <td> <ul> <li>Viral infections, pertussis, parapertussis </li> </ul> </td> <td> <ul> <li>PCR and/or serology </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Space-occupying lesions*</td> <td> <ul> <li>Cysts and tumors </li> </ul> </td> <td> <ul> <li>Chest CT or MRI scan </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Extrapulmonary causes</td> </tr> <tr> <td class=\"indent1\">Cardiac*&nbsp;</td> <td> <ul> <li>May cause cough&nbsp;due to&nbsp;airway compression, pulmonary edema, or arrhythmia&nbsp; </li> </ul> </td> <td> <ul> <li>ECG and other evaluation as indicated </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Ear disease*&nbsp;</td> <td> <ul> <li>Oto-respiratory reflex (Arnold's reflex), in which stimulation of the auricular branch of the vagus nerve triggers cough </li> </ul> </td> <td> <ul> <li>Examination of the ear canal, and removal of the object or treatment of disease that is triggering the cough </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Esophageal disorders&nbsp;</td> <td> <ul> <li>Gastroesophageal reflux (acid and non-acid) </li> </ul> </td> <td> <ul> <li>Esophageal pH monitoring or impedance monitoring, &#177; endoscopy </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Medications*</td> <td> <ul> <li>ACE inhibitors (common). Any inhaled medication, proton pump inhibitors,&nbsp;other drugs (uncommon).&nbsp; </li> <li>Certain other medications (eg, cytotoxic drugs) may be associated with interstitial lung disease </li> </ul> </td> <td> <ul> <li>Discontinuation of medication </li> <li>Evaluation for interstitial lung disease (eg, HRCT) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Tic cough (habit cough)*</td> <td> <ul> <li>May be isolated, but more likely if other tics are present. </li> </ul> </td> <td> <ul> <li>Suppressibility, distractibility, suggestibility, variability, and the presence of a premonitory sensation. </li> <li>Response to behavioral therapy (eg, suggestion therapy)&nbsp;&nbsp; </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Somatic cough disorder (psychogenic cough)*&nbsp;&nbsp;</td> <td> <ul id=\"_telerik_insertedList_id\"> <li>More likely in individuals with generalized anxiety or other somatic symptom disorders. </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Disproportionate&nbsp;thoughts and anxiety&nbsp;about the seriousness of symptoms. </li> <li>Response to reassurance, counseling, or psychotherapy &nbsp; </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Upper airway pathology</td> <td> <ul> <li>Chronic sinusitis, obstructive sleep disorders<sup>&#916;</sup> </li> </ul> </td> <td> <ul> <li>Evaluation guided by suspected disorder (CT, polysomnography) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; PCR: polymerase chain reaction; MRI: magnetic resonance imaging; ACE: angiotensin converting enzyme; HRCT: high-resolution computerized tomography; ECG: echocardiogram.<br />* Children with these disorders typically have specific signs and symptoms that are clues to the underlying disease, sometimes known as specific cough \"pointers.\"<br />¶ Evaluation for suspected aspiration may include bronchoscopy, esophageal pH monitoring or impedance monitoring, endoscopy, nuclear medicine scans. Refer to UpToDate topic on evaluation of children with suspected swallowing dysfunction.<br />Δ Possibly related to aspiration of secretions rather than primary pathology.</div><div id=\"graphicVersion\">Graphic 113206 Version 5.0</div></div></div>"},"113207":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image of malpositioned IUDs","title":"Comparison of ultrasound images of malpositioned IUDs for 2D and 3D imaging","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Comparison of ultrasound images of malpositioned IUDs for 2D and 3D imaging</div><div class=\"cntnt\"><img style=\"width:763px; height:582px;\" src=\"images/OBGYN/113207_Ultrsnd_img_malpositnd_IUDs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Two-dimensional normal position.<br />(B) Two-dimensional rotated position.<br />(C) Three-dimensional rotated position.<br />(D) Illustration of rotated position.</div><div class=\"graphic_footnotes\">2D: two-dimensional; 3D: three-dimensional.</div><div class=\"graphic_reference\">(A) Courtesy of Deborah Levine, MD.<br />(B and C) Reproduced with permission from: Goldstein SR, Fujimoto C. STOP relying on 2D ultrasound for IUD localization. OBG Manag 2014; 26:39. Copyrighted 2017. Frontline Medical Communication. 130392: 0717CH.<br />(D) Reproduced with permission from: Braaten KP, Goldberg AB. Malpositioned IUDs: When you should intervene (and when you should not). OBG Manag 2012; 24:38. Copyrighted 2017. Frontline Medical Communication. 130392: 0717CH.</div><div id=\"graphicVersion\">Graphic 113207 Version 1.0</div></div></div>"},"113208":{"type":"graphic_table","displayName":"Specific cough pointers","title":"Signs and symptoms suggesting a specific cause of cough in children (specific cough \"pointers\")","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms suggesting a specific cause of cough in children (specific cough \"pointers\")</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Specific chronic cough \"pointer\"</td> <td class=\"subtitle1\">Possible major underlying etiology</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">History</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Pulmonary symptoms</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Chronic wet or productive cough* </li> </ul> </td> <td>Suppurative lung diseases (protracted bacterial bronchitis, chronic suppurative lung disease, bronchiectasis), aspiration, abscess, cavitations</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Hemoptysis </li> </ul> </td> <td>Infection (eg, tuberculosis), interstitial lung disease, bronchiectasis, autoimmune lung disease</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Wheeze (at rest or on exertion) </li> </ul> </td> <td>Asthma (if no other specific cough pointer present other than spirometry, and dyspnea that responds to bronchodilators); <br /> Bronchiectasis, eosinophilic disorders (if other specific cough pointer(s) present)</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Dyspnea (at rest or on exertion) </li> </ul> </td> <td>Asthma or any severe lung disease</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Classically recognizable cough sounds<sup>&#182;</sup> </li> </ul> </td> <td>These cough characteristics (eg, barking, honking, whooping) often suggest a specific cause of cough<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Recurrent pneumonia </li> </ul> </td> <td>Immunodeficiency, obstructed airways or any conditions causing bronchiectasis</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Timing and triggers</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Symptoms from neonatal period </li> </ul> </td> <td>Congenital abnormality related to airways, immune function, or causes with predisposition to bronchiectasis (eg, primary ciliary dyskinesia)</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Onset after an episode of choking </li> </ul> </td> <td>Inhaled retained foreign body</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Cough worsens when child is anxious or attention is focused; improves with distraction or suggestion; can be voluntarily suppressed </li> </ul> </td> <td>Tic cough (habit cough)</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Child has disproportionate thoughts and anxiety about the seriousness of symptoms </li> </ul> </td> <td>Somatic cough disorder (psychogenic cough)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Associated symptoms or conditions</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Cardiac disease </li> </ul> </td> <td>Primary cardiac disease causing cough, tracheomalacia or primary ciliary dyskinesia</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Neurologic and developmental abnormalities </li> </ul> </td> <td>Aspiration</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Feeding difficulties </li> </ul> </td> <td>Laryngeal or trachea disorders, aspiration</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Failure to thrive </li> </ul> </td> <td>Any severe lung disease, cystic fibrosis, immunodeficiency, indolent infections (eg, tuberculosis)</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Exposure to tuberculosis, pertussis, and/or sick animals and travel history </li> </ul> </td> <td>Tuberculosis and other mycobacterium, pertussis, parasites (eg, toxocara) and/or zoonoses (eg, Trematodes, strongyloides, Q Fever)</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>History of deep infections &#177; immunodeficiency (primary or secondary to cancer treatment or medications) </li> </ul> </td> <td>Opportunistic infections (eg, fungal)</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Autoimmune disease </li> </ul> </td> <td>Interstitial lung disease</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Angiotensin converting enzyme inhibitor use </li> </ul> </td> <td>Known adverse effect of angiotensin-converting enzyme inhibitor</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Chronic fever </li> </ul> </td> <td>Indolent infection with or without immunodeficiency</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Examination</td> </tr> <tr> <td class=\"indent1\">Digital clubbing</td> <td>Bronchiectasis or interstitial lung disease</td> </tr> <tr> <td class=\"indent1\">Chest wall abnormality</td> <td>Any lung disease, neuromuscular disease</td> </tr> <tr> <td class=\"indent1\">Wheezing or crepitations</td> <td>Any lung disease; in particular asthma, bronchiolitis obliterans, bronchiectasis (from any cause), bronchopulmonary dysplasia, heart failure, immunodeficiency and aspiration</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hypoxia</td> <td>Any lung disease</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Routine investigations/tests</td> </tr> <tr> <td class=\"indent1\">Abnormal chest radiography</td> <td>Any lung disease</td> </tr> <tr> <td class=\"indent1\">Abnormal spirometry</td> <td>Obstructive or restrictive lung/chest wall diseases</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In young children, wet cough is substituted for productive cough.<br />&para; Classically recognized characteristics are a cough that sounds barking/brassy, honking, paroxysmal/whooping or staccato, or that produces casts. Refer to separate table on classically recognizable cough sounds for details.</div><div class=\"graphic_reference\">Adapted from: Chang AB, Oppenheimer JJ, Weinberger MM, Weir KA, Rubin BK, Irwin RS. Use of management pathways or algorithms in children with chronic cough: CHEST Guideline and Expert Panel Report. Chest 2017;151:884-890.</div><div id=\"graphicVersion\">Graphic 113208 Version 1.0</div></div></div>"},"113212":{"type":"graphic_table","displayName":"CAA classification in KD","title":"Classification of coronary artery abnormalities in children with Kawasaki disease<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of coronary artery abnormalities in children with Kawasaki disease<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Classification</td> <td class=\"subtitle1\">Size of coronary artery abnormality*</td> </tr> <tr> <td>No coronary involvement</td> <td>Z-score always &#60;2 <strong>and </strong>no more than a 0.9 decrease in Z-score during follow-up</td> </tr> <tr> <td>Dilation only</td> <td>Z-score 2 to &#60;2.5 <strong>or </strong>if initially &#60;2, a &#8805;1 decrease in Z-score during follow-up<sup>&#182;</sup></td> </tr> <tr> <td>Small aneurysm</td> <td>Z-score &#8805;2.5 to &#60;5</td> </tr> <tr> <td>Medium aneurysm</td> <td>Z-score of &#8805;5 to &#60;10 <strong>and</strong> absolute dimension &#60;8 mm</td> </tr> <tr> <td>Large aneurysm or giant aneurysm</td> <td>Z-score &#8805;10 <strong>or </strong>absolute dimension &#8805;8 mm</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Size is classified according to internal lumen diameter, normalized for body surface area as Z-scores or standard deviation units.<br />¶ Some children who have coronary artery dimensions within the normal range (ie, Z-score &lt;2) have substantial reduction in coronary artery dimension over time, suggesting that the coronary artery was initially dilated. Such patients are categorized as \"dilation only\" despite always having coronary artery dimensions within the normal range.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017; 135:e927.</li>&#xD;&#xA;    <li>Manlhiot C, Millar K, Golding F, McCrindle BW. Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease. Pediatr Cardiol 2010; 31:242.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 113212 Version 1.0</div></div></div>"},"113215":{"type":"graphic_picture","displayName":"Tinea capitis PI","title":"Tinea capitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tinea capitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PI/113215_Tinea_capitis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows tinea capitis, a fungal infection of the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 113215 Version 1.0</div></div></div>"},"113216":{"type":"graphic_algorithm","displayName":"Algorithm for growth hormone therapy in children","title":"Algorithm for growth hormone therapy in children","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Algorithm for growth hormone therapy in children</div><div class=\"cntnt\"><img style=\"width:762px; height:534px;\" src=\"images/PEDS/113216_Algo_GH_therapy_child.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm describes the author's approach to adjusting GH dosing for patients with GH deficiency. The optimal protocol for IGF-I-based GH dosing has not been established, and various protocols are used. Guidelines from the Pediatric Endocrine Society (PES) suggest dose adjustment for patients with high IGF-I levels but do not specify the other dose adjustments outlined above for GH deficiency because data on adult height outcomes after IGF-I-based dosing are not available.<SUP>[1]</SUP></div><div class=\"graphic_footnotes\">GH: growth hormone; IGF-I: insulin-like growth factor-I; SD: standard deviations from the mean.<br />* For most patients, we start at the higher end of this range, at approximately 35 micrograms/kg/day (0.24 mg/kg/week). For patients with severe GH deficiency, we use a lower starting dose of about 20 micrograms/kg/day because these individuals are more sensitive to the drug.<br />¶ For monitoring GH therapy, target range for IGF-I is the upper half of the normal range (ie, IGF-I 0 to +2 SD). IGF-I levels below this target range are associated with subnormal growth response to therapy; IGF-I levels above this target range (ie, &gt;+2 SD) may be associated with possible adverse effects of GH.<br />Δ If GH is increased to &gt;0.3 mg/kg/week but IGF-I levels remain low (&lt;–1 SD) despite good adherence to therapy, the patient may have GH insensitivity. If such patients also fail to have an appropriate growth response to GH therapy, the possibility of a GH insensitivity syndrome should be explored (refer to relevant UpToDate topic review).<br /><FONT class=lozenge>◊</FONT> The growth response is typically considered adequate if the height velocity increases to above the 75th percentile for the child's age and gender during the period of \"catch-up\" growth. Refer to UpToDate topic text for details.<br />§ In patients with a comorbid disease that contributes to or causes the short stature, IGF-I levels vary depending on the nutritional status, but are typically below the normal range, or in the low end of the normal range.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Horm Res Paediatr 2016; 86:361.</LI></OL></div><div id=\"graphicVersion\">Graphic 113216 Version 1.0</div></div></div>"},"113217":{"type":"graphic_figure","displayName":"Change in IUD-related bleeding with time","title":"Change in IUD-related bleeding by IUD type with time","html":"<div class=\"graphic\"><div style=\"width: 781px\" class=\"figure\"><div class=\"ttl\">Change in IUD-related bleeding by IUD type with time</div><div class=\"cntnt\"><img style=\"width:761px; height:849px;\" src=\"images/OBGYN/113217_Chng_IUD-reld_bleeding_time.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Number of days of bleeding per month in each group. The continuous line denotes the median, the broken lines denote the 25<SUP>th</SUP> and 27<SUP>th</SUP> percentiles, and the dotted lines denote the 5<SUP>th</SUP> and 95<SUP>th</SUP> percentiles.</div><div class=\"graphic_footnotes\">Cu IUD: copper IUD; LNg IUS: levonorgestrel intrauterine system.</div><div class=\"graphic_reference\">Reproduced from: Suvisaari J, Lahteenmaki P. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system. Contraception 1996; 54:201. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113217 Version 1.0</div></div></div>"},"113218":{"type":"graphic_picture","displayName":"Repetitive transcranial magnetic stimulation treatment suite","title":"Repetitive transcranial magnetic stimulation treatment suite","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Repetitive transcranial magnetic stimulation treatment suite</div><div class=\"cntnt\"><img style=\"width:756px; height:582px;\" src=\"images/PSYCH/113218_Trnscrnlmagstimtrtmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The elements of a repetitive transcranial magnetic stimulation (rTMS) treatment suite include (1) the stimulator, (20 cooling system, (3) treatment chair, (4) induction coil and, in some cases, (5) a magnetic resonance imaging (MRI)–guided navigation system that incorporates (6) a three-dimensional frameless stereotactic navigation camera. An rTMS technician or nurse typically performs the treatments. Cooling systems are not universally employed, but can allow for higher volumes of treatments per day; MRI-guided navigation systems are also not universally employed, but can offer greater accuracy for some applications of rTMS.</div><div class=\"graphic_reference\">From: Downar J, Blumberger DM, Daskalakis ZJ. Repetitive transcranial magnetic stimulation: an emerging treatment for medication-resistant depression. CMAJ 2016; 188:1175. Copyright © 2016 Canadian Medical Association. Copied under license from Access Copyright. Further reproduction, distribution or transmission is prohibited except as otherwise permitted by law.</div><div id=\"graphicVersion\">Graphic 113218 Version 2.0</div></div></div>"},"113220":{"type":"graphic_algorithm","displayName":"Lab testing for Zika virus in symptomatic pregnant women","title":"Updated testing recommendations*<SUP>¶</SUP><SUP>Δ</SUP><SUP>◊</SUP><SUP>§</SUP><SUP>¥</SUP><SUP>‡</SUP> and interpretation of results<SUP>†</SUP> for symptomatic pregnant women with possible Zika virus exposure**<SUP>,</SUP><SUP>¶¶</SUP> – US","html":"<div class=\"graphic\"><div style=\"width: 1131px\" class=\"figure\"><div class=\"ttl\">Updated testing recommendations*<SUP>¶</SUP><SUP>Δ</SUP><SUP>◊</SUP><SUP>§</SUP><SUP>¥</SUP><SUP>‡</SUP> and interpretation of results<SUP>†</SUP> for symptomatic pregnant women with possible Zika virus exposure**<SUP>,</SUP><SUP>¶¶</SUP>&nbsp;– US</div><div class=\"cntnt\"><img style=\"width:1111px; height:625px;\" src=\"images/OBGYN/113220_Lab_test_Zika_sympt_preg.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">US: United States; NAT: nucleic acid testing; IgM: immunoglobulin M; PRNT: plaque reduction neutralization test.<br />* Ask about type and duration of Zika virus exposure before and during current pregnancy. Exposure before the current pregnancy might limit interpretation of Zika virus IgM results; pretest counseling can help inform testing decisions. Some patients may choose not to receive Zika virus IgM testing.<br />¶ Zika virus testing is not routinely recommended for pregnant women with a previous diagnosis of laboratory-confirmed Zika virus infection by either NAT or serology (positive/equivocal Zika virus or dengue virus IgM and Zika virus PRNT ≥10 and dengue virus PRNT &lt;10 results).<br />Δ This algorithm also applies to pregnant women with possible Zika virus exposure who have a fetus with prenatal ultrasound findings consistent with congenital Zika virus syndrome.<br /><FONT class=lozenge>◊</FONT> The duration of detectable Zika virus RNA in pregnant women following infection is not known. Preliminary data suggest that NAT might remain positive for several weeks after symptom onset in some pregnant women. Zika virus IgM antibodies are most likely to be detected within 12 weeks after infection; however, IgM antibodies might be detected for months after infection, limiting the ability to determine whether infection occurred before or during the current pregnancy.<br />§ Dengue virus IgM antibody testing is recommended for symptomatic pregnant women. For laboratory interpretation in the presence of dengue virus IgM results, refer to <A href=\"https://www.cdc.gov/dengue/clinicallab/laboratory.html\" target=_blank>https://www.cdc.gov/dengue/clinicallab/laboratory.html</A>.<br />¥ Non-negative results include \"positive,\" \"equivocal,\" \"presumptive positive,\" or \"possible positive.\" These are examples of assay interpretation that might accompany test results; nonnegative serology terminology varies by assay. For explanation of a specific interpretation, refer to the instructions for use for the specific assay performed. Information on each assay can be found at <A href=\"https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika\" target=_blank>https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika</A> under the \"Labeling\" tab for the specific assay.<br />‡ Currently, PRNT confirmation is not routinely recommended for persons living in Puerto Rico. For laboratory interpretation in the absence of PRNT testing, refer to <A href=\"https://www.cdc.gov/zika/pdfs/lab-table.pdf\" target=_blank>https://www.cdc.gov/zika/pdfs/lab-table.pdf</A>.<br />† Despite the high specificity of NAT, false-positive NAT results have been reported. <STRONG>If both serum and urine specimens are NAT-positive, regardless of IgM antibody results, results should be interpreted as evidence of acute Zika virus infection. If either serum or urine specimen is NAT-positive in conjunction with a positive Zika virus IgM, results should be interpreted as evidence of acute Zika virus infection.</STRONG> If NAT is only positive on serum or urine and IgM testing is negative, repeat testing on the original NAT-positive specimen. <STRONG>If repeat NAT is positive, results should be interpreted as evidence of acute Zika virus infection.</STRONG> If repeat NAT testing is negative, results are indeterminate and health care providers should repeat Zika virus IgM antibody testing on a serum specimen collected ≥2 weeks after symptom onset. <STRONG>If subsequent IgM antibody test is positive, interpret as evidence of acute Zika virus infection</STRONG>, but if negative, interpret as no evidence of Zika virus infection.<br />​** Possible Zika virus exposure includes travel to or residence in an area with risk for Zika virus transmission (<A href=\"https://wwwnc.cdc.gov/travel/page/zika-travel-information\" target=_blank>https://wwwnc.cdc.gov/travel/page/zika-travel-information</A>) during pregnancy or the periconceptional period (8 weeks before conception [6 weeks before the last menstrual period]), or sex without a condom during pregnancy or the periconceptional period, with a partner who traveled to, or resides in an area with risk for Zika virus transmission.<br />¶¶ For the purposes of this guidance, recent possible Zika virus exposure or Zika virus/flavivirus infection is defined as a possible exposure or infection during the current pregnancy or periconceptional period.</div><div class=\"graphic_reference\">From: Oduyebo T, Polen KD, Walke HT, et al. Update: Interim guidance for health care providers caring for pregnant women with possible Zika virus exposure — United States (including U.S. territories), July 2017. MMWR 2017; 66:1.</div><div id=\"graphicVersion\">Graphic 113220 Version 4.0</div></div></div>"},"113221":{"type":"graphic_figure","displayName":"Dengue diagnostic tests","title":"Laboratory tests for diagnosis of dengue virus infection","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Laboratory tests for diagnosis of dengue virus infection</div><div class=\"cntnt\"><img style=\"width:720px; height:347px;\" src=\"images/ID/113221_Dengue_diagnostic_tests.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparative merits of laboratory methods for diagnosis of dengue infection.</div><div class=\"graphic_footnotes\">Ig: immunoglobulin.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Microbiology. Peeling RW, Artsob H, Pelegrino JL, et al. Evaluation of diagnostic tests: Dengue. Nat Rev Microbiol 2010; 8:S30. Copyright &copy; 2010. <a href=\"http://www.nature.com/nrmicro\" target=\"_blank\">www.nature.com/nrmicro</a>.</div><div id=\"graphicVersion\">Graphic 113221 Version 1.0</div></div></div>"},"113222":{"type":"graphic_figure","displayName":"Dengue antibody kinetics","title":"Dengue antibody response in primary and secondary infection","html":"<div class=\"graphic\"><div style=\"width: 771px\" class=\"figure\"><div class=\"ttl\">Dengue antibody response in primary and secondary infection</div><div class=\"cntnt\"><img style=\"width:751px; height:481px;\" src=\"images/ID/113222_Dengue_antibody_kinetics.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RNA: ribonucleic acid; NS1: nonstructural protein 1; Ig: immunoglobulin.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Microbiology. Peeling RW, Artsob H, Pelegrino JL, et al. Evaluation of diagnostic tests: Dengue. Nat Rev Microbiol 2010; 8:S30. Copyright © 2010. <A href=\"http://www.nature.com/nrmicro\" target=_blank>www.nature.com/nrmicro</A>.</div><div id=\"graphicVersion\">Graphic 113222 Version 1.0</div></div></div>"},"113227":{"type":"graphic_picture","displayName":"Tinea capitis black dots PI","title":"Tinea capitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tinea capitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PI/113227_Tinea_capitis_black_dot_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tinea capitis can lead to bald patches on the scalp, with black dots where the hairs have broken off.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 113227 Version 1.0</div></div></div>"},"113232":{"type":"graphic_algorithm","displayName":"Contrast administration for CT: Concern for acute reaction","title":"Patient evaluation for contrast administration for computed tomography: Concern for acute contrast reaction","html":"<div class=\"graphic\"><div style=\"width: 1187px\" class=\"figure\"><div class=\"ttl\">Patient evaluation for contrast administration for computed tomography: Concern for acute contrast reaction</div><div class=\"cntnt\"><img style=\"width:1167px; height:787px;\" src=\"images/PC/113232_ContrastadminCTacutrctn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standards for patient preparation and indications for contrast vary somewhat with each practice. Referring provider should refer to institutional policies for detailed guidelines in patients with a history of an acute reaction to iodinated contrast.</div><div class=\"graphic_footnotes\">CT: computed tomography.<br />* Refer to UpToDate topics or the American College of Radiology (ACR) Appropriateness Criteria for CT contrast recommendations based on a specific exam indication.<br />¶ Acute reaction to contrast can occur after oral, intracavitary, or intravascular administration. Verify that the reaction was to iodinated contrast (used for CT, radiography, fluoroscopy, or angiography) rather than to noniodinated contrast used for other imaging modalities (eg, gadolinium, used for magnetic resonance imaging), as there is no cross-reactivity between the two classes. If the reaction was delayed (&gt;20 minutes) it is not considered an acute reaction.<br />Δ Refer to the inset box titled \"Clinical manifestations of acute contrast reaction\" to classify reaction.<br /><FONT class=lozenge>◊</FONT> Refer to UpToDate topic for commonly used premedication prophylaxis regimens. For outpatients, one option is three doses of 50 mg oral prednisone administered 13, 7, and 1 hour prior to contrast administration; and 50 mg oral diphenhydramine administered one hour prior to contrast administration.<br />§ Imaging alternatives are CT without contrast, ultrasound, magnetic resonance imaging, or nuclear scintigraphy. Discuss with a radiologist whether any of these are likely to provide a diagnosis.<br />¥ Examples of such scenarios are extremely rare and may include CT angiography for diagnosis of acute aortic injury or dissection.</div><div id=\"graphicVersion\">Graphic 113232 Version 1.0</div></div></div>"},"113233":{"type":"graphic_algorithm","displayName":"Contrast administration for CT: Concern for CIN","title":"Patient evaluation for contrast administration for computed tomography: Concern for contrast induced nephropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patient evaluation for contrast administration for computed tomography: Concern for contrast induced nephropathy</div><div class=\"cntnt\"><img style=\"width:413px; height:926px;\" src=\"images/PC/113233_ContrastadminCTCIN.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standards for patient preparation and indications for contrast vary somewhat with each practice. Provider should refer to institutional policies for detailed guidelines in patients likely to require an intervention.</div><div class=\"graphic_footnotes\">CT: computed tomography; eGFR: estimated glomerular filtration rate.<br />* Refer to UpToDate topics or the American College of Radiology (ACR) Appropriateness Criteria for CT contrast recommendations based on a specific exam indication. Enteric (oral or rectal) contrast is not associated with renal injury.<br />¶ Medical judgment should be used to determine whether baseline renal function is likely stable. In general, eGFR within 30 days in an outpatient and two days in an inpatient is likely to reflect baseline renal function if the medical condition and treatments have not been changing in the interim.<br />Δ Examples are patients with sepsis, myocardial infarction, or large volume hemorrhage.<br /><FONT class=lozenge>◊</FONT> Imaging alternatives are CT without contrast, ultrasound, magnetic resonance imaging, or nuclear scintigraphy. Discuss with a radiologist whether any of these are likely to provide a diagnosis.<br />§ No standard regimen has been described. Examples are 100 cc/hour, beginning 6 to 12 hours before and continuing 4 to 12 hours after the exam in inpatients, and 500 cc bolus over 30 minutes to one hour before and during the exam in outpatients.</div><div id=\"graphicVersion\">Graphic 113233 Version 1.0</div></div></div>"},"113238":{"type":"graphic_algorithm","displayName":"Approach to the diagnosis of cystic lung disease","title":"Approach to the diagnosis of cystic lung disease","html":"<div class=\"graphic\"><div style=\"width: 1614px\" class=\"figure\"><div class=\"ttl\">Approach to the diagnosis of cystic lung disease</div><div class=\"cntnt\"><img style=\"width:1594px; height:965px;\" src=\"images/PULM/113238_Aprch_diagn_cystic_lung_ds.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ANA: antinuclear antibody; BAL: bronchoalveolar lavage; BHD: Birt-Hogg-Dubé; CD1a: CD1 antigen; CVID: common variable immunodeficiency; FLCN: folliculin; GGO: ground glass opacities; HRCT: high resolution computed tomography; LAM: lymphangioleiomyomatosis; LIP: lymphoid interstitial pneumonia; PLCH: pulmonary Langerhans cell histiocytosis; RF: rheumatoid factor; SSA: anti-Ro/SSA antibodies; SSB: anti-La/SSb antiboides; TSC: tuberous sclerosis complex.<br />* This is a suggested approach to the diagnosis of cystic lung disease identified on HRCT; not all patients with cystic lung disease will fit these categories. Refer to the UpToDate review on the diagnosis of cystic lung disease.<br />¶ In addition to the typical HRCT features of LAM cysts, pleural fluid is more likely to be associated with LAM than other causes of cystic lung disease and occurs in about 10% of patients. MMPH nodules 2 to 14 mm are seen in up to two-thirds of patients with TSC-LAM, and much less commonly in LAM.<br />Δ Features of TSC include family history of TSC, facial angiofibromas, hypomelanotic macules, confetti lesions, Shagreen patches, seizures, cognitive impairment. Diagnosis requires review by TSC specialist. Refer to UpToDate reviews on diagnosis of TSC.<br /><FONT class=lozenge>◊</FONT> Refer to the UpToDate review on diagnosis of LAM.<br />§ Immunodeficiencies associated with LIP are largely HIV infection and CVID. Refer to UpToDate topic reviews.<br />¥ Lung biopsy is NOT helpful to confirm BHD, as histologic changes are nonspecific.<br />‡ The systemic rheumatic diseases most commonly associated with LIP are Sjögren syndrome and rheumatoid arthritis.</div><div id=\"graphicVersion\">Graphic 113238 Version 1.0</div></div></div>"},"113240":{"type":"graphic_algorithm","displayName":"2014 ACCM treatment of septic shock in children","title":"American College of Critical Care Medicine algorithm for time-sensitive, goal-directed stepwise management of hemodynamic support in infants and children*","html":"<div class=\"graphic\"><div style=\"width: 791px\" class=\"figure\"><div class=\"ttl\">American College of Critical Care Medicine algorithm for time-sensitive, goal-directed stepwise management of hemodynamic support in infants and children*</div><div class=\"cntnt\"><img style=\"width:771px; height:919px;\" src=\"images/EM/113240_ACCM_trtmnt_sptc_shck_child.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">American College of Critical Care Medicine algorithm for time-sensitive, goal-directed stepwise management of hemodynamic support in infants and children. Proceed to next step if shock persists: &#xD;&#xA;<OL class=decimal_heading>&#xD;&#xA;<LI>First hour goals—restore and maintain heart rate thresholds, capillary refill ​≤2 seconds, and normal blood pressure in the first​​​ hour/emergency department.</LI>&#xD;&#xA;<LI>​Subsequent ICU goals—as above and warm extremities, urine output &gt;1 mL/kg/hour; normal mental status; and normalization of serum lactate, anion gap, and INR. If shock not reversed proceed to invasive monitoring and restore and maintain normal perfusion pressure (MAP – CVP) for age, Sc​​​​​vO<SUB>2</SUB> &gt;70%, and cardiac index 3.3 to 6.0 L/minute/m<SUP>2</SUP> in PICU.​​​​​​​​​​​</LI></OL></div><div class=\"graphic_footnotes\">IV: intravenous; IO: intraosseous; IM: intramuscular; PALS: Pediatric Advanced Life Support; US: ultrasound; PICCO: pulse index contour; FATD: femoral artery thermodilution; PAC: pulmonary artery catheter; MAP: mean arterial pressure; CVP: central venous pressure; Sc​​​​​vO<SUB>2</SUB>: central venous oxygen saturation; CI: cardiac index; IAP: intraabdominal pressure; ECMO: extracorporeal membrane oxygenation.<br />* This algorithm represents the approach to septic shock contained in the text and figures presented by the American College of Critical Care Medicine. The timeframes reflect optimal care. However, these timeframes are not always feasible depending upon resources available. For further guidance, refer to UpToDate topics on septic shock in children.<br />¶ The ScVO<SUB>2</SUB> target does not apply to congenital heart patients with mixing​​ lesions. Central venous access for invasive monitoring is indicated for patients with catecholamine-resistant septic shock. Central venous access is also appropriate in patients who have reversal of shock after initiation of vasoactive drugs, although patients who rapidly improve after receiving vasoactive medications and in whom a rapid weaning of support is expected, may not require central venous line placement.<br />Δ Enoximone and levosimendan may have limited availability in many institutions and evidence is lacking to show improved outcomes during combination vasoactive therapy compared to medications such as milrinone and dobutamine.</div><div class=\"graphic_reference\">From: Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine Clinical Practice Parameters for hemodynamic support of pediatric and neonatal septic shock. Crit Care Med 2017; 45:1061. DOI: <A href=\"http://journals.lww.com/ccmjournal/fulltext/2017/06000/American_College_of_Critical_Care_Medicine.18.aspx\" target=_blank>10.1097/CCM.0000000000002425</A>. Copyright © 2017 Society of Critical Care Medicine. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113240 Version 4.0</div></div></div>"},"113241":{"type":"graphic_algorithm","displayName":"Management algorithm for femoral artery aneurysm","title":"Management algorithm for femoral artery aneurysm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management algorithm for femoral artery aneurysm</div><div class=\"cntnt\"><img style=\"width:417px; height:315px;\" src=\"images/SURG/113241_Algo_mgmt_femoral_aneurysm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on the management of femoral artery aneurysm for additional details of our approach to treatment and the overall efficacy of these treatments.</div><div class=\"graphic_footnotes\">FAA: femoral artery aneurysm; CFA: common femoral artery; SFA: superficial femoral artery; DFA: deep femoral artery.<br />* More than 0.5 cm/year.<br />¶ For isolated CFA aneurysm, open repair is performed using an interposition graft.<br />Δ Infected FAA requires complete resection of affected vessel and reconstruction, ideally with autogenous conduit (typically contralateral saphenous vein). May require a two-stage procedure for severe systemic manifestations.<br /><FONT class=lozenge>◊</FONT> For CFA aneurysm extending to the SFA or DFA, replantation of SFA or DFA may suffice, or a bypass procedure may be necessary.<br />§ Most isolated SFA aneurysms are located in the mid to distal SFA, and endovascular repair is generally preferred.<br />¥ Ligation of the aneurysm may be an option (without repair or bypass) in the absence of lower extremity ischemia.<br />‡ Imaging, typically using ultrasound, every six months after diagnosis, then, if no change with successive ultrasounds, annual surveillance.<br />† If during a period of observation, the FAA diameter is &gt;3.0 cm, or there is evidence for rapid expansion (&gt;0.5 cm/year), development of intraluminal thrombus, or saccular morphology, repair is indicated (refer to \"Repair FAA\" node).</div><div id=\"graphicVersion\">Graphic 113241 Version 1.0</div></div></div>"},"113242":{"type":"graphic_algorithm","displayName":"Algorithm diagnosis and treatment of May-Thurner syndrome","title":"Algorithm diagnosis and treatment of May-Thurner syndrome","html":"<div class=\"graphic\"><div style=\"width: 657px\" class=\"figure\"><div class=\"ttl\">Algorithm diagnosis and treatment of May-Thurner syndrome</div><div class=\"cntnt\"><img style=\"width:637px; height:813px;\" src=\"images/SURG/113242_Alg_dig_tmt_My_Thrnr_syndm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MTS: May-Thurner syndrome; DVT: deep vein thrombosis; MR: magnetic resonance; CT: computed tomography; IVUS: intravascular ultrasound.<br />* Typically between 20 and 40 years of age.<br />&para; Following stent placement, antiplatelet therapy includes clopidrogel for eight weeks, and then aspirin indefinitely.</div><div id=\"graphicVersion\">Graphic 113242 Version 1.0</div></div></div>"},"113245":{"type":"graphic_figure","displayName":"Variability of saphenofemoral junction","title":"Variability of saphenofemoral junction","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Variability of saphenofemoral junction</div><div class=\"cntnt\"><img style=\"width:523px; height:511px;\" src=\"images/SURG/113245_Variability_of_saphenofemoral_junction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure shows the anatomic configuration of the saphenofemoral junction and its most common variations.</div><div class=\"graphic_reference\">Modified from: Souroullas P, Barnes R, Smith G, et al. The classic saphenofemoral junction and its anatomical variations. Phlebology 2017; 32:172.</div><div id=\"graphicVersion\">Graphic 113245 Version 1.0</div></div></div>"},"113247":{"type":"graphic_table","displayName":"Airway management airway disruption","title":"Airway management for patients with airway disruption","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Airway management for patients with airway disruption</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Perform awake intubation if major laryngeal or tracheal/bronchial tear, provided the patient is awake, cooperative, hemodynamically stable, and able to maintain adequate O<sub>2</sub> saturation. </li> </ul> </td> </tr> <tr> <td> <ul> <li>If patient is uncooperative and DA is not otherwise suspected, consider rapid sequence intubation (RSI) using VAL and FIS. </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Consider intubation and airway evaluation with VAL if a supralaryngeal defect is present. VAL has the added benefit of allowing multiple viewers, aiding in examination and surgical planning. </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>For infralaryngeal and tracheal injury, consider RSI followed by DL and insertion of an FIS (with appropriately sized endotracheal tube [ETT] already loaded over it) through the larynx to rapidly evaluate for possible airway injury. The ETT is then introduced over the FIS and the cuff positioned below the level of injury.<sup>[1,2]</sup> </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Avoid positive pressure ventilation and transtracheal jet ventilation proximal to tear. </li> </ul> </td> </tr> <tr> <td> <ul> <li>If bronchial disruption is suspected, consider lung separation via placement of a double lumen tube or bronchial blocker. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Consider cardiopulmonary bypass. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">O<SUB>2</SUB>: oxygen; DA: difficult airway; VAL: video-assisted laryngoscopy; FIS: flexible intubation scope; DL: direct laryngoscopy.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Diez C, Varon AJ. Airway management. In: Essentials of Trauma Anesthesia, Varon AJ, Smith CE (Eds), Cambridge University Press 2012.</LI>&#xD;&#xA;<LI>Desjardins G, Varon AJ. Airway management for penetrating neck injuries. The Miami experience. Resuscitation 2001; 48:71.</LI></OL>Reproduced with permission from: Hagberg CA, Kaslow O. Difficult airway management algorithm in trauma: Updated by COTEP. ASA Monitor 2014; 78:56. Copyright © 2014 American Society of Anesthesiologists. Excerpted from ASA Monitor (2014) of the American Society of Anesthesiologists. A copy of the full text can be obtained from ASA, 1061 American Lane, Schaumburg, IL, 60173-4973 or online at <A href=\"http://www.asahq.org/\" target=_blank>www.asahq.org</A>.</div><div id=\"graphicVersion\">Graphic 113247 Version 2.0</div></div></div>"},"113248":{"type":"graphic_table","displayName":"Airway management oral and maxillofacial trauma ","title":"Airway management for patients with oral and maxillofacial trauma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Airway management for patients with oral and maxillofacial trauma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Radiologic results are crucial to discern anatomic distortion and airway integrity. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Limited mouth opening and accumulated blood, secretions, and foreign bodies can all obscure visualization and compromise DL, VAL, and FSI. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Perform awake intubation if patient is cooperative, stable, and able to clear airway; this will maintain both spontaneous ventilation and O<sub>2</sub> saturation. </li> </ul> </td> </tr> <tr> <td> <ul> <li>If awake, intubation fails, airway compromise occurs or the patient is agitated, an awake tracheostomy may be the best approach. </li> </ul> </td> </tr> <tr> <td> <ul> <li>BVM ventilation may be difficult and result in displacement of facial fractures or even airway compromise. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Blind intubation (oral and nasal) is discouraged: It may dislodge foreign bodies (teeth, bony fragments, blood clot) into the airway or create a false passage. Blind nasal attempts in the setting of midface fracture may lead to violation of the cranial vault. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Nasal intubation is not contraindicated in a patient with lateral or posterior skull base fractures; FSI could be safely performed even if the fracture occurred in the central anterior skull base. Risk versus benefit discussion for choosing nasal route for intubation should be documented in a patient's record. </li> </ul> </td> </tr> <tr> <td> <ul> <li>If initial oral intubation interferes with the surgical approach, it can be converted later to submental or nasal intubation. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DL: direct laryngoscopy; VAL: video-assisted laryngoscopy; FSI: flexible scope intubation; O<SUB>2</SUB>: oxygen; BVM: bag-valve mask.</div><div class=\"graphic_reference\">Reproduced with permission from: Hagberg CA, Kaslow O. Difficult airway management algorithm in trauma: Updated by COTEP. ASA Monitor 2014; 78:56. Copyright &copy; 2014 American Society of Anesthesiologists. Excerpted from ASA Monitor (2014) of the American Society of Anesthesiologists. A copy of the full text can be obtained from ASA, 1061 American Lane, Schaumburg, IL, 60173-4973 or online at <a href=\"http://www.asahq.org/\" target=\"_blank\">www.asahq.org</a>.</div><div id=\"graphicVersion\">Graphic 113248 Version 2.0</div></div></div>"},"113250":{"type":"graphic_table","displayName":"Airway management neck hematoma","title":"Airway management for the patient with a neck hematoma causing airway compression","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Airway management for the patient with a neck hematoma causing airway compression</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Awake intubation is recommended if the patient is cooperative, stable, and can maintain spontaneous ventilation, airway patency, and adequate O<sub>2</sub> saturation. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Personnel able to perform a surgical airway should be prepared to immediately intervene should life-threatening airway obstruction occur. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Consider opening the wound if an expanding postoperative neck hematoma is suspected. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Maintain spontaneous ventilation with induction of GA. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Position tracheal tube below level of obstruction. Fiberoptic confirmation may be required. </li> </ul> </td> </tr> <tr> <td> <ul> <li>SGA is <strong>not</strong> recommended. </li> </ul> </td> </tr> <tr> <td> <ul> <li>VAL and FSI are good choices as long as they allow visualizing airway. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">O<SUB>2</SUB>: oxygen; GA: general anesthesia; SGA: supraglottic airway devices; VAL: video-assisted laryngoscopy; FSI: flexible scope intubation.</div><div class=\"graphic_reference\">Reproduced with permission from: Hagberg CA, Kaslow O. Difficult airway management algorithm in trauma: Updated by COTEP. ASA Monitor 2014; 78:56. Copyright © 2014 American Society of Anesthesiologists. Excerpted from ASA Monitor (2014) of the American Society of Anesthesiologists. A copy of the full text can be obtained from ASA, 1061 American Lane, Schaumburg, IL, 60173-4973 or online at <A href=\"http://www.asahq.org/\" target=_blank>www.asahq.org</A>.</div><div id=\"graphicVersion\">Graphic 113250 Version 3.0</div></div></div>"},"113253":{"type":"graphic_figure","displayName":"Fluid movement in the human gastrointestinal tract","title":"Fluid movement in the human gastrointestinal tract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fluid movement in the human gastrointestinal tract</div><div class=\"cntnt\"><img style=\"width:449px; height:721px;\" src=\"images/PEDS/113253_Fluid_movement_in_the_human_gastrointestinal_tract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram of the&nbsp;GI tract showing daily volumes (in liters) of fluid secretion and absorption.</div><div class=\"graphic_footnotes\">GI: gastrointestinal.</div><div class=\"graphic_reference\">Modified from: Thiagarajah JR, Verkman AS. Water transport in the gastrointestinal tract. In: Physiology of the gastrointestinal tract, 5th ed, Johnson LR (Ed), Elsevier Inc, New York 2012. p. 1757.</div><div id=\"graphicVersion\">Graphic 113253 Version 1.0</div></div></div>"},"113254":{"type":"graphic_figure","displayName":"Overview of diarrhea mechanisms","title":"Overview of the mechanisms causing diarrhea","html":"<div class=\"graphic\"><div style=\"width: 792px\" class=\"figure\"><div class=\"ttl\">Overview of the mechanisms causing diarrhea</div><div class=\"cntnt\"><img style=\"width:772px; height:543px;\" src=\"images/PEDS/113254_Ovrview_diarrhea_mchnsm_Ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) <STRONG>Normal</STRONG> — During normal function, sodium (Na<SUP>+</SUP>) and nutrient absorption drives fluid absorption, with a small basal amount of electrolyte- (Cl<SUP>–</SUP>) driven fluid secretion, allowing efficient reabsorption of fluid leading to minimal fluid loss via feces.<br />(Panel B) <STRONG>Loss of nutrient absorption, or the presence of non-absorbable solutes</STRONG> (diet-induced or \"osmotic\" diarrhea) — Loss of nutrient absorption because of damage or loss of the required transporter, or the presence of un-absorbable osmoles in the lumen (eg, polyethylene glycol), prevents fluid absorption and promotes fluid secretion into the intestinal lumen, leading to diarrhea.<br />(Panel C) <STRONG>Increased secretion or reduced absorption of electrolytes</STRONG> (electrolyte transport-related or \"secretory\" diarrhea) — Excessive anion-driven fluid secretion and reduced electrolyte-driven fluid absorption, as occurs in certain infections such as cholera, leads to accumulation of fluid in the intestinal lumen and diarrhea.<br />(Panel D) <STRONG>Rapid intestinal transit</STRONG> (motility-related diarrhea) — Increased intestinal motility results in reduced time to absorb electrolytes and nutrients, leading to excessive unabsorbed substrates in the intestine and reduced fluid absorption, leading to diarrhea.</div><div id=\"graphicVersion\">Graphic 113254 Version 2.0</div></div></div>"},"113255":{"type":"graphic_figure","displayName":"Intestinal transport mechanisms","title":"Intestinal transport mechanisms","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Intestinal transport mechanisms</div><div class=\"cntnt\"><img style=\"width:728px; height:898px;\" src=\"images/PEDS/113255_Intestinal_trnsprt_mchansms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><STRONG>Small intestine:</STRONG> &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>(Panel A) Fluid absorption in primarily villus epithelial cells showing active transepithelial transport of sodium via apical membrane transporters (sodium-glucose cotransporter [SGLT1], sodium-hydrogen exchanger [NHE3] and the chloride/bicarbonate exchanger [DRA]), and the basolateral Na<SUP>+</SUP>/K<SUP>+</SUP> ATPase with corresponding passive chloride and water flux.</LI>&#xD;&#xA;<LI>(Panel B) Fluid secretion in primarily crypt epithelial cells showing active transport of chloride from the basolateral side via the sodium-chloride transporter (NKCC) and apical chloride channels (cystic fibrosis transmembrane regulator [CFTR], calcium-activated chloride channels [CaCC]) with corresponding passive sodium and water flux.</LI></UL><STRONG>Colon:</STRONG> &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>(Panel C) Fluid absorption in both surface and crypt epithelial cells showing active transepithelial transport of sodium, via apical membrane transporters and channels (epithelial sodium channel [eNaC], sodium-hydrogen exchanger [NHE3], and the sodium-driven short-chain fatty acid transporter [SMCT]).</LI>&#xD;&#xA;<LI>(Panel D) Fluid secretion in primarily crypt epithelial cells showing active transport of chloride from the basolateral side, via the sodium-chloride transporter (NKCC) and apical chloride channels (cystic fibrosis transmembrane regulator [CFTR], calcium-activated chloride channels [CaCC]) with corresponding passive sodium and water flux.</LI></UL></div><div class=\"graphic_footnotes\">SGLT1: sodium-glucose cotransporter 1 (SLC5A1); DRA: downregulated in adenoma chloride/bicarbonate exchanger&nbsp;(SLC26A3); NHE3: sodium-hydrogen exchanger 3; CFTR: cystic fibrosis transmembrane regulator; CaCC: calcium-activated chloride channels; NKCC: Na<SUP>+</SUP>/K<SUP>+</SUP>/Cl<SUP>-</SUP> symporter 1 (SLC12A2); SCFA: short chain fatty acids; SMCT: sodium-coupled monocarboxylate transporter (SLC5A8); eNaC: epithelial sodium channel. &nbsp;</div><div id=\"graphicVersion\">Graphic 113255 Version 3.0</div></div></div>"},"113256":{"type":"graphic_figure","displayName":"Abnormal electrolyte transport in bacterial and viral diarrheas","title":"Pathophysiology of abnormal electrolyte transport in bacterial and viral diarrheas","html":"<div class=\"graphic\"><div style=\"width: 797px\" class=\"figure\"><div class=\"ttl\">Pathophysiology of abnormal electrolyte transport in bacterial and viral diarrheas</div><div class=\"cntnt\"><img style=\"width:777px; height:342px;\" src=\"images/PEDS/113256_Abnrm_elctrlyt_trns_diarrh.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) <STRONG>Bacterial diarrheas:</STRONG> Some bacteria secrete enterotoxins that increase intracellular cyclic nucleotides, resulting in chloride ion (Cl<SUP>–</SUP>) secretion and inhibition of the sodium-hydrogen exchanger (NHE3) and sodium ion (Na<SUP>+</SUP>) absorption. Invasive bacteria cause a tissue inflammatory response involving recruitment of immune cells and release of cytokines, resulting in intracellular calcium ion (Ca<SUP>2+</SUP>) signaling.<br />(Panel B) <STRONG>Viral diarrheas:</STRONG> The rotaviral protein NSP4 causes elevation of cytoplasmic Ca<SUP>2​+</SUP> concentration by binding to integrin-alpha(1)beta(2), galanin, and/or by activation of enteric nerves. Rotaviral NSP4 also inhibits NHE3 and SGLT1.</div><div class=\"graphic_footnotes\"><EM>E.coli</EM>: Escherichia coli; CFTR: cystic fibrosis transmembrane conductance regulator; DRA: downregulated in adenoma Cl<SUP>–</SUP>/HCO<SUB>3</SUB> exchanger (SLC26A3); NHE3: sodium-hydrogen exchanger 3; CaCC: calcium-activated chloride channel; ENaC: epithelial Na<SUP>+</SUP> channel; CT: cholera toxin; STa: heat-stable toxin; EC cells: enterochromaffin cells; cGMP: cyclic guanine monophosphate; cAMP: cyclic adenosine monophosphate; 5-HT: 5-hydroxytryptamine; VIP: vasoactive intestinal peptide; ENS: enteric nervous system; NKCC: Na<SUP>+</SUP>/K<SUP>+</SUP>/Cl<SUP>–</SUP> symporter; IL-6: interleukin-6; IL-8: interleukin-8; TNF: tumor necrosis factor; SGLT1: sodium/glucose co-transporter (SLC5A1); NSP4: nonstructural protein 4; Gal: galanin; GALR1: galanin receptor 1.</div><div class=\"graphic_reference\">Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Gastroenterology &amp; Hepatology. Thiagarajah JR, Donowitz M, Verkman AS. Secretory diarrhoea: mechanisms and emerging therapies. Nat Rev Gastroenterol Hepatol 2015; 12:446. Copyright © 2015. <A href=\"http://www.nature.com/nrgastro\" target=_blank>www.nature.com/nrgastro</A>.</div><div id=\"graphicVersion\">Graphic 113256 Version 1.0</div></div></div>"},"113257":{"type":"graphic_table","displayName":"Mechanism and uses of antidiarrheal therapies","title":"Mechanism and uses of antidiarrheal therapies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mechanism and uses of antidiarrheal therapies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"30%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Therapy&nbsp;<br /> [brand names]<br /> Adult dose, administration</td> <td class=\"subtitle1\">Mechanism of action</td> <td class=\"subtitle1\">Indications</td> <td class=\"subtitle1\">Notes and adverse effects</td> <td class=\"subtitle1\">References</td> </tr> <tr> <td> <p><strong>Alosetron</strong><br /> [Lotronex]</p> <p>Adults: 1 to 2 mg daily, in divided doses, oral</p> </td> <td>5-hydroxytryptamine<sub>3</sub> receptor antagonist; antimotility, antisecretory.</td> <td>Refractory diarrhea-predominant irritable bowel syndrome in women.</td> <td> <p>Contraindicated for patients with constipation; intestinal ileus, obstruction, perforation, impaction, toxic megacolon, or ischemic colitis.</p> Efficacy in men has not been established.</td> <td>Koch et al. (2004)<sup>[1]</sup></td> </tr> <tr> <td> <p><strong>Cholestyramine resin </strong><br /> [Prevalite; Questran]</p> <p>Adults: 4 to 24 g daily, in divided doses, oral&nbsp;&nbsp;</p> <p><strong>&nbsp;</strong></p> <p><strong>Colesevelam </strong><br /> [Welchol; Lodalis; Cholestagel]</p> <p>Adults: 3.75 g daily, oral</p> </td> <td>Binds with bile acids in the intestine to form an insoluble complex that is fecally excreted; antisecretory, promotes absorption.</td> <td>Bile acid malabsorption diarrhea; ileal resection.</td> <td> <p>Unlabeled indication.</p> Adverse effects include impaired absorption of other drugs; malabsorption of fat-soluble vitamins; nausea, bloating, cramping, constipation, impaction, and elevated aminotransferases.</td> <td>Koch et al. (2004)<sup>[1]</sup></td> </tr> <tr> <td> <p><strong>Crofelemer</strong><br /> [Fulyzaq; Mytesi]</p> <p>Adults: 250 mg daily, in divided doses, oral </p> </td> <td>Botanical that blocks chloride secretion and accompanying water loss in diarrhea; CFTR and CaCC channel inhibitor; antisecretory.</td> <td>Alternative agent for diarrhea associated with antiretroviral therapy for HIV/AIDS.</td> <td>Not approved for infectious or other diarrheas. Experience with this agent is limited.</td> <td>Macarthur et al. (2013)<sup>[2]</sup></td> </tr> <tr> <td> <p><strong>Diphenoxylate and atropine<br /> </strong>[Lomotil]</p> <p>Adults: 5 to 20 mg daily, in divided doses, oral </p> </td> <td> <p>Synthetic mu-opioid receptor agonist within the intestinal wall; antimotility.</p> Atropine ingredient is at subtherapeutic doses, and is intended to discourage abuse.</td> <td>Acute nonspecific diarrhea; chronic diarrhea; reduction of stool fluidity and volume in patients with colostomies or ileostomies.</td> <td> <p>Contraindicated in diarrhea associated with enterotoxigenic bacteria, pseudomembranous colitis, and ulcerative colitis.</p> Adverse effects include CNS depression, dizziness, paralytic ileus, anorexia, nausea, vomiting, abdominal discomfort.</td> <td>Karim et al. (1972)<sup>[3]</sup></td> </tr> <tr> <td> <p><strong>Loperamide </strong><br /> [Imodium; Diamode]</p> <p>Adults: 4 to 16 mg daily, in divided doses, oral </p> </td> <td>Synthetic mu-opioid receptor agonist within the intestinal wall, with minimal systemic exposure when given at recommended doses; antimotility.</td> <td>Acute nonspecific diarrhea; chronic diarrhea; chemotherapy-associated diarrhea; reduction of stool fluidity and volume in patients with colostomies or ileostomies.</td> <td> <p>Contraindicated in bacterial enterocolitis, pseudomembranous colitis, and ulcerative colitis.</p> Adverse effects include constipation, nausea, urinary retention, and paralytic ileus. Overdose may cause CNS depression and QT prolongation.</td> <td>Koch et al. (2004)<sup>[1]</sup>;<br /> DuPont et al. (1990)<sup>[4]</sup>;<br /> Ericsson et al. (1990)<sup>[5]</sup></td> </tr> <tr> <td> <p><strong>Racecadotril </strong><br /> [Hidrasec, Tiorfan]</p> <p>Adults: 100 to 300 mg daily, in divided doses, oral</p> </td> <td>Enkephalinase inhibitor that inhibits breakdown of endogenous opioids; antisecretory.</td> <td>Acute nonspecific diarrhea.</td> <td>Not approved in the United States. Adverse effects include headache.</td> <td>Hamza et al. (1999)<sup>[6]</sup></td> </tr> <tr> <td> <p><strong>Bismuth subsalicylate</strong>*<br /> [Pepto-Bismol; Bismatrol; many others]</p> <p>Adults: approximately 0.5 to 4 g daily, oral</p> </td> <td>Antisecretory; antimicrobial; may provide some antiinflammatory action.</td> <td>Acute mild nonspecific diarrhea.</td> <td> <p>Fecal discoloration, tongue discoloration, tinnitus, CNS depression, dizziness, Reye syndrome in children (related to salicylate content).</p> Bismuth toxicity with long-term use (bone/joint toxicity; encephalopathy).</td> <td>DuPont et al. (1990)<sup>[4]</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CFTR: cystic fibrosis transmembrane conductance regulator; CaCC: calcium-activated chloride channel; HIV: human immunodeficiency virus; AIDS: acquired immune deficiency syndrome; CNS: central nervous system.<br />* Other bismuth salts and compounds are available for treatment of acute diarrhea and other gastrointestinal disorders. Refer to individual product information.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Koch KM, Corrigan BW, Manzo J, et al. Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors. Aliment Pharmacol Ther 2004; 20:223.</LI>&#xD;&#xA;<LI>Macarthur RD, Hawkins TN2, Brown SJ, et al. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study. HIV Clin Trials 2013; 14:261.</LI>&#xD;&#xA;<LI>Karim A, Ranney RE, Evensen KL, Clark ML. Pharmacokinetics and metabolism of diphenoxylate in man. Clin Pharmacol Ther 1972; 13:407.</LI>&#xD;&#xA;<LI>DuPont HL, Flores Sanchez J, Ericsson CD, et al. Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea. Am J Med 1990; 88:15S.</LI>&#xD;&#xA;<LI>Ericsson CD, Johnson PC. Safety and efficacy of loperamide. Am J Med 1990; 88:10S.</LI>&#xD;&#xA;<LI>Hamza H, Ben Khalifa H, Baumer P, et al. Racecadotril versus placebo in the treatment of acute diarrhoea in adults. Aliment Pharmacol Ther 1999; 13(Suppl 6):15.</LI></OL>Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Gastroenterology &amp; Hepatology. Thiagarajah JR, Donowitz M, Verkman AS. Secretory diarrhoea: mechanisms and emerging therapies. Nat Rev Gastroenterol Hepatol 2015; 12:446. Copyright © 2015. <A href=\"http://www.nature.com/nrgastro\" target=_blank>www.nature.com/nrgastro</A>.</div><div id=\"graphicVersion\">Graphic 113257 Version 1.0</div></div></div>"},"113261":{"type":"graphic_figure","displayName":"Intermalleolar distance measurement","title":"Measurement of intermalleolar distance in the evaluation of knock-knees","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Measurement of intermalleolar distance in the evaluation of knock-knees</div><div class=\"cntnt\"><img style=\"width:384px; height:608px;\" src=\"images/PEDS/113261_Intermalleolar_distance_measurement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intermalleolar distance is measured with the patellas facing straight ahead and the femoral condyles touching. Intermalleolar distance &gt;8 cm (approximately 3 inches) is a clue to a pathologic cause of knock-knees. </div><div id=\"graphicVersion\">Graphic 113261 Version 1.0</div></div></div>"},"113263":{"type":"graphic_picture","displayName":"Bladder exstrophy: Protective transparent adhesive","title":"Bladder exstrophy with protective transparent adhesive dressing","html":"<div class=\"graphic\"><div style=\"width: 780px\" class=\"figure\"><div class=\"ttl\">Bladder exstrophy with protective transparent adhesive dressing</div><div class=\"cntnt\"><img style=\"width:760px; height:277px;\" src=\"images/PEDS/113263_Bldr_extrphy_Prt_trspnt_adh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lateral view of bladder exstrophy in a newborn boy with small bladder.<br />(B) Protective transparent adhesive covering bladder exstrophy at one month of age.</div><div id=\"graphicVersion\">Graphic 113263 Version 1.0</div></div></div>"},"113265":{"type":"graphic_table","displayName":"Classically recognizable cough sounds","title":"Classically recognizable cough sounds in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classically recognizable cough sounds in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cough characteristic</td> <td class=\"subtitle1\">Suggested underlying pathology</td> </tr> <tr> <td>Barking or brassy cough</td> <td>Tracheomalacia, tic cough (if acute: Croup)</td> </tr> <tr> <td>Honking or 'goose-like' cough</td> <td>Tracheomalacia, tic cough (habit cough), somatic cough disorder (psychogenic cough)</td> </tr> <tr> <td>Paroxysmal cough (with or without inspiratory whoop)</td> <td>Pertussis and parapertussis</td> </tr> <tr> <td>Staccato cough</td> <td>Chlamydia in infants</td> </tr> <tr> <td>Cough productive of casts</td> <td>Plastic bronchitis and conditions associated with mucous plugs such as ABPA (refer to UpToDate topic)</td> </tr> <tr> <td>Chronic wet or productive cough only in the mornings</td> <td>Suppurative lung diseases (eg, bronchiectasis, cystic fibrosis)</td> </tr> <tr> <td>Wet or productive cough</td> <td>Presence of endobronchial secretions</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ABPA: allergic bronchopulmonary aspergillosis.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Chang AB, Glomb WB. Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:260S.</li>&#xD;&#xA;    <li>Chang AB, Landau LI, Van Asperen PP, et al. Cough in children: Definitions and clinical evaluation. Position statement of the Thoracic Society of Australia and New Zealand. Med J Australia 2006; 184:398.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 113265 Version 1.0</div></div></div>"},"113268":{"type":"graphic_picture","displayName":"Oxygen hood","title":"Oxygen hood use for a newborn infant","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Oxygen hood use for a newborn infant</div><div class=\"cntnt\"><img style=\"width:762px; height:370px;\" src=\"images/PEDS/113268_Oxygen_hood.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Images courtesy of Natus Medical Incorporated.</div><div id=\"graphicVersion\">Graphic 113268 Version 1.0</div></div></div>"},"113273":{"type":"graphic_picture","displayName":"Nasal cannula neonate","title":"Use of a nasal cannula in a neonate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Use of a nasal cannula in a neonate</div><div class=\"cntnt\"><img style=\"width:216px; height:177px;\" src=\"images/PEDS/113273_Nasal_cannula_neonate.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Copyright &copy; 2017 Salter Labs. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 113273 Version 1.0</div></div></div>"},"113276":{"type":"graphic_picture","displayName":"CPAP neonate","title":"Continuous positive airway pressure (CPAP) for a newborn infant","html":"<div class=\"graphic\"><div style=\"width: 773px\" class=\"figure\"><div class=\"ttl\">Continuous positive airway pressure (CPAP) for a newborn infant</div><div class=\"cntnt\"><img style=\"width:753px; height:502px;\" src=\"images/PEDS/113276_CPAP_neonate.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Dr. Tanzeema Hossain, MD.</div><div id=\"graphicVersion\">Graphic 113276 Version 1.0</div></div></div>"},"113281":{"type":"graphic_table","displayName":"Open fractures: Gustilo classification","title":"Open fractures: Gustilo classification<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Open fractures: Gustilo classification<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Type I</td> </tr> <tr> <td class=\"indent1 divider_bottom\" colspan=\"2\">Open fracture with a skin wound &#60;1 cm in length and clean.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Type II</td> </tr> <tr> <td class=\"indent1 divider_bottom\" colspan=\"2\">Open fracture with a laceration &#62;1 cm in length without extensive soft tissue damage, flaps, or avulsions.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Type III</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Open segmental fracture wound with extensive soft tissue injury.</td> </tr> <tr> <td class=\"indent1\"><strong>III<sub>A</sub></strong></td> <td>Adequate soft tissue coverage.</td> </tr> <tr> <td class=\"indent1\"><strong>III<sub>B</sub></strong></td> <td>Significant soft tissue loss with exposed bone that requires soft tissue transfer to achieve coverage.</td> </tr> <tr> <td class=\"indent1\"><strong>III<sub>C</sub></strong></td> <td>Associated vascular injury that requires repair for limb preservation.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Gustilo RB, Anderson JT. Prevention of infection in the treatment of 1025 open fractures of long bones: retrospective and prospective analyses. J Bone Joint Surg Am 1976; 58:453.</LI>&#xD;&#xA;<LI>Gustilo RB, Mendoza RM, Williams DN. Problems in the management of type III (severe) open fractures: a new classification of type III open fractures. J Trauma 1984; 24:742.</LI></OL>From: Hoff WS, Bonadies JA, Cachecho R, Dorlac WC. East Practice Management Guidelines Work Group: Update to practice management guidelines for prophylactic antibiotic use in open fractures. J Trauma 2011; 70:751. DOI: <A href=\"http://journals.lww.com/jtrauma/fulltext/2011/03000/East_Practice_Management_Guidelines_Work_Group_.32.aspx\" target=_blank>10.1097/TA.0b013e31820930e5</A>. Copyright © 2011 American Association for the Surgery of Trauma. Adapted with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113281 Version 2.0</div></div></div>"},"113282":{"type":"graphic_table","displayName":"Resp distress observation scale","title":"Respiratory Distress Observation Scale (RDOS) for patients unable to self-report dyspnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Respiratory Distress Observation Scale (RDOS) for patients unable to self-report dyspnea</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"35%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">0 points</td> <td class=\"subtitle1\">1 point</td> <td class=\"subtitle1\">2 points</td> <td class=\"subtitle1\">Total</td> </tr> <tr> <td>Heart rate per minute</td> <td>&#60;90 beats</td> <td>90 to 109 beats</td> <td>&#8805;110 beats</td> <td>&nbsp;</td> </tr> <tr> <td>Respiratory rate per minute</td> <td>&#8804;18 breaths</td> <td>19 to 30 breaths</td> <td>&#62;30 breaths</td> <td>&nbsp;</td> </tr> <tr> <td>Restlessness: Nonpurposeful movements</td> <td>None</td> <td>Occasional, slight movements</td> <td>Frequent movements</td> <td>&nbsp;</td> </tr> <tr> <td>Paradoxical breathing pattern: Abdomen moves in on inspiration</td> <td>None</td> <td>&nbsp;</td> <td>Present</td> <td>&nbsp;</td> </tr> <tr> <td>Accessory muscle use: Rise in clavicle during inspiration</td> <td>None</td> <td>Slight rise</td> <td>Pronounced rise</td> <td>&nbsp;</td> </tr> <tr> <td>Grunting at end-expiration: Guttural sound</td> <td>None</td> <td>&nbsp;</td> <td>Present</td> <td>&nbsp;</td> </tr> <tr> <td>Nasal flaring: Involuntary movement of nares</td> <td>None</td> <td>&nbsp;</td> <td>Present</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Look of fear</td> <td>None</td> <td>&nbsp;</td> <td>Eyes wide open, facial muscles tense, brow furrowed, mouth open, teeth together</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"4\"><strong>Total</strong></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Instructions for use: &#xD;&#xA;<OL>&#xD;&#xA;<LI>RDOS is not a substitute for patient self-report if able.</LI>&#xD;&#xA;<LI>RDOS is an adult assessment tool.</LI>&#xD;&#xA;<LI>RDOS cannot be used when the patient is paralyzed with a neuromuscular blocking agent.</LI>&#xD;&#xA;<LI>Count respiratory and heart rates for 1 minute; auscultate if necessary.</LI>&#xD;&#xA;<LI>Grunting may be audible with intubated patients on auscultation.</LI></OL>​</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Campbell ML, Templin TN. Intensity cut-points for the Respiratory Distress Observation Scale. Palliat Med 2015; 29:436.</LI>&#xD;&#xA;<LI>Campbell ML, Kero KK, Templin TN.&nbsp;Mild, moderate, and severe intensity cut-points for the Respiratory Distress Observation Scale. Heart Lung 2017; 46:14.</LI></OL>Reproduced with permission from Margaret L. Campbell, PhD, RN. Originally published in: Campbell ML, Templin T, Walch J. A Respiratory Distress Observation Scale for Patients Unable To Self-Report Dyspnea. J Palliat Med 2010; 13:285.</div><div id=\"graphicVersion\">Graphic 113282 Version 1.0</div></div></div>"},"113283":{"type":"graphic_table","displayName":"Aplasia cutis classification 2","title":"Classification and management of aplasia cutis congenita","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification and management of aplasia cutis congenita</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Type</td> <td class=\"subtitle1\" rowspan=\"2\">Size of defect</td> <td class=\"subtitle1\" rowspan=\"2\">Layers involved</td> <td class=\"subtitle1\" rowspan=\"2\">Involvement of veins</td> <td class=\"subtitle1\" colspan=\"2\">Treatment</td> </tr> <tr> <td class=\"subtitle2\">Immediate</td> <td class=\"subtitle2\">Late</td> </tr> <tr> <td class=\"centered\">0</td> <td>Any</td> <td>Intact epidermis without skin appendages (scarred, hairless area on the scalp)</td> <td>No</td> <td>None</td> <td>&nbsp;</td> </tr> <tr> <td class=\"centered\">I</td> <td>&#60;15 cm<sup>2</sup></td> <td>Skin defect, no skull bone defect</td> <td>No</td> <td>Conservative treatment until complete epithelialization</td> <td rowspan=\"4\">Hair transplantation, serial excision, or tissue expansion and flap reconstruction, according to final defect size</td> </tr> <tr> <td class=\"centered\">II</td> <td>&#62;15 cm<sup>2</sup></td> <td>Skull bone defect, exposed dura</td> <td>No</td> <td>Conservative treatment until complete epithelialization; emergency coverage may be considered</td> </tr> <tr> <td class=\"centered\">III</td> <td>Any, usually large</td> <td>Skin and skull defect with exposed dura and sagittal sinus</td> <td>Enlarged exposed veins</td> <td>Emergency coverage with allograft, skin substitute, or autologous skin graft</td> </tr> <tr> <td class=\"centered\">IV</td> <td>Any, usually large</td> <td>Skin, skull, and dura defect with brain exposure</td> <td>Any, usually with enlarged exposed veins</td> <td>Flap reconstruction</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Silberstein E, Pagkalos VA, Landau D, et al. Aplasia Cutis Congenita: Clinical Management and a New Classification System. Plast Reconstr Surg 2014; 134:766e. DOI: <A href=\"http://journals.lww.com/plasreconsurg/Abstract/2014/11000/Aplasia_Cutis_Congenita___Clinical_Management_and.30.aspx\" target=_blank>10.1097/PRS.0000000000000638</A>. Copyright © 2014 American Society of Plastic Surgeons, Inc. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113283 Version 1.0</div></div></div>"},"113285":{"type":"graphic_algorithm","displayName":"Initial antibiotics for staph and strep SSTI in neonates","title":"Suggested approach to initial antimicrobial therapy for suspected <EM>Staphylococcus aureus</EM> or streptococcal skin and soft tissue infections in infants ≤28 days of age","html":"<div class=\"graphic\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">Suggested approach to initial antimicrobial therapy for suspected <EM>Staphylococcus aureus</EM> or streptococcal skin and soft tissue infections in infants ≤28 days of age</div><div class=\"cntnt\"><img style=\"width:688px; height:736px;\" src=\"images/PEDS/113285_AntibistphstrpSSTIneont.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is meant to be used in conjunction with UpToDate content on <EM>S. aureus</EM> and streptococcal skin and soft tissue infections in neonates.</div><div class=\"graphic_footnotes\">SSTI: skin and soft tissue infection; T: temperature; MRSA: methicillin-resistant <EM>S. aureus</EM>; GBS: group B <EM>Streptococcus</EM>; MSSA: methicillin-susceptible <EM>S. aureus</EM>.<br />* These regimens provide adequate empiric therapy for group B streptococcal cellulitis but are not appropriate for neonatal sepsis or meningitis. Refer to UpToDate content on treatment of neonatal sepsis and meningitis.<br />¶ Refer to UpToDate topics on SSTI in neonates for additional details, including duration of therapy.<br />Δ We consider the local prevalence of MRSA to be high if &gt;10 to 15% of <EM>S. aureus</EM> isolates are MRSA. Other experts may use a different threshold for increased prevalence of MRSA.<br /><FONT class=lozenge>◊</FONT> We do not use clindamycin if the local prevalence of clindamycin-resistant <EM>S. aureus</EM> is &gt;10 to 15%. Other experts may have a different threshold for avoidance of clindamycin.<br />§ Parenteral coverage should be broadened to include coverage for MRSA, GBS, and enteric gram-negative pathogens if the infant develops systemic findings and to include coverage for MRSA, GBS, and other beta-hemolytic streptococci if the infant develops cellulitis.</div><div class=\"graphic_reference\">Prepared with data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>American Academy of Pediatrics Committee on Infectious Diseases. Staphylococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, 2015. p.715.</LI>&#xD;&#xA;<LI>American Academy of Pediatrics Committee on Infectious Diseases. Antimicrobial agents and related therapy. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.881.</LI>&#xD;&#xA;<LI>Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</LI>&#xD;&#xA;<LI>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:147.</LI></OL></div><div id=\"graphicVersion\">Graphic 113285 Version 2.0</div></div></div>"},"113286":{"type":"graphic_picture","displayName":"Endoscopic submucosal dissection technique","title":"Endoscopic submucosal dissection technique","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Endoscopic submucosal dissection technique</div><div class=\"cntnt\"><img style=\"width:570px; height:514px;\" src=\"images/GAST/113286_Endscpc_sbmcsl_dssctn_tchnq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows careful endoscopic assessment of the focally ulcerated neoplastic lesion located in the mid gastric antrum. Narrow band imaging was also used but is not shown.<br />Panel B shows circumferential cautery marking at 5 mm from the margin of the lesion.<br />Panel C shows submucosal incision around the lifted lesion following the submucosal injection with methylene blue containing solution.<br />Panel D shows successful en bloc dissection of the lesion. Pathologic specimen revealed intramucosal cancer with no involvement of the lateral and vertical margins.</div><div class=\"graphic_reference\">Courtesy of Eugene Zolotarevsky, MD.</div><div id=\"graphicVersion\">Graphic 113286 Version 1.0</div></div></div>"},"113287":{"type":"graphic_algorithm","displayName":"Evaluation and differential diagnosis of glomerular disease","title":"Overview of the evaluation and differential diagnosis of glomerular disease","html":"<div class=\"graphic\"><div style=\"width: 1672px\" class=\"figure\"><div class=\"ttl\">Overview of the evaluation and differential diagnosis of glomerular disease</div><div class=\"cntnt\"><img style=\"width:1652px; height:1544px;\" src=\"images/NEPH/113287_Eval_DDx_glomerular_disease.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kidney biopsy specimens should always be analyzed with light microscopy and immunofluorescence. In some cases, electron microscopy is also necessary. Because electron microscopy is not available at some institutions, the biopsy should be analyzed at a different institution (ie, should be sent to a hospital with electron microscopy capabilities) if the clinical scenario, light microscopy, and/or immunofluorescence suggest that the following disorders may be present: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Minimal change disease.</LI>&#xD;&#xA;<LI>FSGS.</LI>&#xD;&#xA;<LI>C3 glomerulopathy (C3 glomerulonephritis or dense deposit disease).</LI>&#xD;&#xA;<LI>Thin basement membrane nephropathy.</LI>&#xD;&#xA;<LI>Alport syndrome.</LI>&#xD;&#xA;<LI>Fabry disease.</LI>&#xD;&#xA;<LI>Fibrillary glomerulonephritis.</LI>&#xD;&#xA;<LI>Immunotactoid glomerulonephritis.</LI>&#xD;&#xA;<LI>Monoclonal immunoglobulin deposition disease.</LI>&#xD;&#xA;<LI>Amyloidosis.</LI></UL></div><div class=\"graphic_footnotes\">C3: complement component 3; C4: complement component 4; ANA: antinuclear antibody; anti-dsDNA: anti-double-stranded DNA; ANCA: antineutrophil cytoplasmic antibody; ELISA: enzyme-linked immunoassay; PR3: proteinase 3; MPO: myeloperoxidase; GBM: glomerular basement membrane; HIV: human immunodeficiency virus; HBV: hepatitis B virus; HCV: hepatitis C virus; IgA: immunoglobulin A; HbA1c: hemoglobin A1C; NSAIDs: nonsteroidal antiinflammatory drugs; anti-PLA2R: anti-phospholipase-A2-receptor; FSGS: focal segmental glomerulosclerosis; AL amyloidosis: amyloid light-chain amyloidosis; AA amyloidosis: amyloid A amyloidosis; immunotactoid GN: immunotactoid glomerulopathy; APOL1: apolipoprotein L1; eGFR: estimated glomerular filtration rate; RBC: red blood cell.<br />* Glomerular hematuria and proteinuria are defined as follows: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Glomerular hematuria is established by the presence of urinary RBC casts (of any number) or hematuria in which more than 5% of RBCs are acanthocytes or dysmorphic.</LI>&#xD;&#xA;<LI>Proteinuria is typically defined as a 24-hour urine protein excretion of ≥150 mg (or a corresponding value using the spot urine protein, spot urine creatinine, and the protein excretion rate equation).</LI>&#xD;&#xA;<LI>Albuminuria (albumin is a component of urinary protein, is the major component in glomerular disease, and is the protein that is detected by the urine dipstick) is typically defined as a 24-hour urine albumin excretion of ≥30 mg (or a corresponding value using the spot urine albumin, spot urine creatinine, and the albumin excretion rate equation).</LI></UL>¶ A systemic disorder that also involves the kidney should be suspected if there is evidence for inflammation of other organ systems, such as the skin (eg, purpura, rash), joints (eg, arthritis), eye (eg, retinitis, uveitis), nose (eg, epistaxis), mouth (eg, ulcers), lungs (eg, hemoptysis, infiltrates), nervous system (eg, seizures, neuropathy), extremities (eg, digital ischemia or infarction), or abdomen (eg, enteritis, colitis), or if there is an infection (particularly with <EM>Staphylococcus</EM>, <EM>Streptococcus</EM>, hepatitis virus, or HIV).<br />Δ Orthostatic proteinuria is characterized by increased protein excretion while in the upright posture but normal protein excretion when recumbent; it is typically found in adolescents and young adults but not in older adults. The diagnosis is made by establishing that urine protein excretion is normal when the patient is supine, either with an overnight urine collection or a first-morning voided urine specimen.<br /><FONT class=lozenge>◊</FONT> Some patients with FSGS will have a genetic mutation that results in a defect of podocyte or slit diaphragm function; the most commonly involved genes include nephrin, podocin, alpha-actinin-4, <EM>TRPC6</EM>, <EM>INF2</EM>, and <EM>MYO1E</EM>.</div><div id=\"graphicVersion\">Graphic 113287 Version 3.0</div></div></div>"},"113296":{"type":"graphic_algorithm","displayName":"Management of the patient with external otitis","title":"Management of the patient with external otitis","html":"<div class=\"graphic\"><div style=\"width: 753px\" class=\"figure\"><div class=\"ttl\">Management of the patient with external otitis</div><div class=\"cntnt\"><img style=\"width:733px; height:503px;\" src=\"images/PC/113296_Mgmt_patient_extrnl_otitis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">All patients with suspected external otitis should have their canals cleaned prior to initiating antiinflammatory/antibiotic therapies and be provided with appropriate analgesia.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.<br />* For example, poorly controlled diabetes mellitus, chemotherapy, chronic high-dose corticosteroid therapy, use of other immunosuppressive drugs, neutropenia, advanced HIV infection.<br />&para; We generally prefer Cipro HC (ciprofloxacin 0.2% and hydrocortisone 1% opic suspension) because of fewer side effects than Cortisporin (neomycin 0.35%, polymyxin B 10,000 units/mL, and hydrocortisone 0.5% otic solution), but it is more costly. Refer to UpToDate content for additional options.<br />&Delta; In patients who do not respond to treatment, culture of the ear canal and/or referral to an otolaryngologist is appropriate. Patients should be evaluated for other conditions that may mimic or complicate external otitis. Refer to UpToDate content for more information.</div><div id=\"graphicVersion\">Graphic 113296 Version 2.0</div></div></div>"},"113299":{"type":"graphic_table","displayName":"Dose of antibiotics for S. aureus/streptococcal SSTI in children","title":"Doses of antibiotics for the treatment of suspected <EM>Staphylococcus aureus</EM> or streptococcal skin and soft tissue infections in children<SUP>[1-</SUP><SUP>3]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doses of antibiotics for the treatment of suspected <EM>Staphylococcus aureus</EM> or streptococcal skin and soft tissue infections in children<SUP>[1-</SUP><SUP>3]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antimicrobial agent</td> <td class=\"subtitle1\">Regimen</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Parenteral therapy</td> </tr> <tr> <td class=\"indent1\">Cefazolin</td> <td> <ul> <li>50 to 100 mg/kg per day IV in 3 doses (maximum daily dose 3 g) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Ceftaroline</td> <td> <ul> <li>2 months to &#60;2 years: 24 mg/kg per day IV in 3 doses </li> <li>&#8805;2 years to &#60;18 years: <ul> <li>&#8804;33 kg: 36 mg/kg per day IV in 3 doses </li> <li>&#62;33 kg: 400 mg every 8 hours IV or 600 mg every 12 hours IV </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Ceftriaxone</td> <td> <ul> <li>75 to 100 mg/kg per day IV in 1 or 2 doses (maximum daily dose 4 g) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Clindamycin</td> <td> <ul> <li>30 to 40 mg/kg per day IV in 3 to 4 doses (maximum daily dose 2.7 g) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Daptomycin</td> <td> <ul> <li>12 through 23 months: 10 mg/kg once per day IV </li> <li>2 through 6 years: 9 mg/kg once per day IV </li> <li>7 through 11 years: 7 mg/kg once per day IV </li> <li>12 through 17 years: 5 mg/kg once per day IV </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Linezolid</td> <td> <ul> <li>&#60;12 years: 30 mg/kg per day IV in 3 doses </li> <li>&#8805;12 years: 600 mg twice per day IV </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Nafcillin</td> <td> <ul> <li>150 to 200 mg/kg per day IV in 4 to 6 doses (maximum daily dose 12 g) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Oxacillin</td> <td> <ul> <li>150 to 200 mg/kg per day IV in 4 to 6 doses (maximum daily dose 12 g) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vancomycin</td> <td> <ul> <li>40 mg/kg per day IV in 4 doses, or </li> <li>45 mg/kg per day IV in 3 doses, or </li> <li>60 mg/kg per day IV in 4 doses (if the child is seriously ill* or hemodynamically unstable) </li> </ul> <br /> Maximum daily dose 4 g/day unless levels are inappropriately low</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Oral therapy</td> </tr> <tr> <td class=\"indent1\">Amoxicillin</td> <td> <ul> <li>25 to 50 mg/kg per day orally in 3 doses (maximum daily dose 1.5 g) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Cefadroxil</td> <td> <ul> <li>30 mg/kg per day orally in 2 divided doses (maximum daily dose 2 g) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Cefuroxime</td> <td> <ul> <li>30 mg/kg per day orally in 2 doses (maximum daily dose 1 g) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Cephalexin</td> <td> <ul> <li>25 to 100 mg/kg per day orally in 2 to 4 doses (maximum daily dose 4 g) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Clindamycin</td> <td> <ul> <li>30 to 40 mg/kg per day orally in 3 or 4 doses (maximum daily dose 1.8 g) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Cloxacillin (not available in the United States)</td> <td> <ul> <li>25 to 50 mg/kg per day orally in 4 doses (maximum daily dose 2 g) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Doxycycline<sup>&#182;</sup></td> <td> <ul> <li>2 to 4 mg/kg per day orally in 1 or 2 doses (maximum daily dose 200 mg) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Linezolid</td> <td> <ul> <li>&#60;12 years: 30 mg/kg per day orally in 3 doses </li> <li>&#8805;12 years: 600 mg twice per day orally </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Penicillin V</td> <td> <ul> <li>25 to 75 mg/kg per day orally in 3 or 4 doses (maximum daily dose 2 g) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">TMP-SMX</td> <td> <ul> <li>8 to 12 mg/kg per day orally of TMP, 40 to 60 mg/kg per day of SMX (maximum daily dose 320 g of TMP, 1.6 g of SMX) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses above are intended for patients with normal organ function. The dose of daptomycin, vancomycin, and linezolid must be adjusted in the setting of renal insufficiency. Refer to the Lexicomp monographs included with UpToDate for specific recommendations.</div><div class=\"graphic_footnotes\">IV: intravenous; TMP-SMX: trimethoprim-sulfamethoxazole.<br />* Serious illness is defined by toxic appearance, limb-threatening infection, or underlying medical problems that may be associated with poor response or complications (eg, primary immune deficiency, diabetes mellitus).<br />¶ Tetracycline antibiotics, including doxycycline, may cause permanent tooth discoloration for children &lt;8 years if used repeatedly. However, doxycycline binds less readily to calcium than other tetracyclines and, in some studies, was not associated with visible teeth staining in children &lt;8 years.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>American Academy of Pediatrics. Antibacterial drugs for pediatric patients beyond the newborn period. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.881.</LI>&#xD;&#xA;<LI>Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</LI>&#xD;&#xA;<LI>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:147.</LI></OL></div><div id=\"graphicVersion\">Graphic 113299 Version 1.0</div></div></div>"},"113301":{"type":"graphic_table","displayName":"Risk factors for MRSA in children","title":"Risk factors for community-associated and community-onset health care-associated methicillin-resistant <EM>Staphylococcus aureus</EM> infection in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for community-associated and community-onset health care-associated methicillin-resistant <EM>Staphylococcus aureus</EM> infection in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Community-associated MRSA infection</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Skin trauma (eg, \"turf burns,\" lacerations, abrasions, cosmetic body shaving, body piercing, tattoo placement)</li> <li>Crowded living conditions</li> <li>Frequent skin-to-skin contact</li> <li>Sharing potentially contaminated personal items (eg, razors, towels) or sports equipment</li> <li>Challenges in maintaining personal cleanliness or hygiene</li> <li>Limited access to health care</li> <li>Frequent exposure to antimicrobial agents</li> <li>History of boils (furuncles), abscesses, or infection or colonization with MRSA in patient or close contact</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Community-onset health care-associated MRSA infection</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Invasive device</li> <li>History of health care-associated MRSA infection</li> <li>Surgery hospitalization, dialysis, or residence in long-term care facility in previous 12 months</li> <li>Chronic disease (other than asthma or eczema)</li> <li>Antibiotic use in the previous six months</li> <li>Tympanostomy tube for recurrent otitis media</li> <li>Day care attendance</li> <li>Household contact with identified risk factor</li> <li>Age &#60;2 years</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRSA: methicillin-resistant <EM>S. aureus</EM>.</div><div id=\"graphicVersion\">Graphic 113301 Version 1.0</div></div></div>"},"113302":{"type":"graphic_table","displayName":"Empiric antibiotics for S. aureus and streptococcal SSTI","title":"Our approach to empiric antibiotic therapy for suspected <EM>Staphylococcus aureus</EM> or beta-hemolytic <EM>Streptococcus</EM> skin and soft tissue infection in children >28 days<SUP>[1-</SUP><SUP>3]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Our approach to empiric antibiotic therapy for suspected <EM>Staphylococcus aureus</EM> or beta-hemolytic <EM>Streptococcus</EM> skin and soft tissue infection in children &gt;28 days<SUP>[1-</SUP><SUP>3]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"3\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Desired spectrum</td> <td class=\"subtitle1\">First-line therapy</td> <td class=\"subtitle1\">Second-line therapy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">SSTI and hemodynamic instability</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">MRSA<br /> MSSA<br /> Beta-hemolytic <em>Streptococcus</em></td> <td> <p><strong>Parenteral therapy:</strong></p> Vancomycin <strong>plus</strong> either: <ul class=\"decimal_heading\"> <li>Nafcillin, or </li> <li>Oxacillin </li> </ul> </td> <td><strong>One of the following:</strong> <ul class=\"decimal_heading\"> <li>Linezolid IV* </li> <li>Daptomycin IV* </li> <li>Ceftaroline IV* </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Oral therapy:</strong> Hemodynamically unstable children with SSTI should receive parenteral therapy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Purulent/fluctuant SSTI (abscess, furuncle, carbuncle, purulent cellulitis)</td> </tr> <tr> <td class=\"subtitle3_left highlight_gray_text\" colspan=\"3\">High prevalence of MRSA<sup>&#182;</sup> or purulent/fluctuant SSTI of the face, hand, or perineum</td> </tr> <tr> <td class=\"indent2 divider_bottom\" rowspan=\"2\">MRSA</td> <td><strong>Oral therapy with one of the following:</strong> <ul class=\"decimal_heading\"> <li>Clindamycin<sup>&#916;</sup> </li> <li>TMP-SMX </li> <li>Doxycycline<sup>&#9674;</sup> </li> </ul> </td> <td><strong>One of the following:</strong> <ul class=\"decimal_heading\"> <li>Vancomycin IV (if not used for initial therapy) </li> <li>Ceftaroline IV* </li> <li>Linezolid oral or IV* </li> <li>Daptomycin IV* </li> <li>Oral tedizolid<sup>&#167;</sup> (for patients &#8805;18 years) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Parenteral therapy with one of the following:</strong><sup>&#165;</sup> <ul class=\"decimal_heading\"> <li>Clindamycin IV (if the risk of bacteremia is low) </li> <li>Vancomycin IV </li> </ul> </td> <td> <p><strong>One of the following:</strong></p> For patients of all ages: <ul class=\"decimal_heading\"> <li>Vancomycin IV (if not used for initial therapy) </li> <li>Ceftaroline IV* </li> <li>Linezolid IV* </li> <li>Daptomycin IV* </li> </ul> <strong>For patients &#8805;18 years:</strong> <ul class=\"decimal_heading\"> <li>Dalbavancin IV<sup>&#167;</sup> </li> <li>Oritavancin IV<sup>&#167;</sup> </li> <li>Telavancin IV<sup>&#167;</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle3_left highlight_gray_text\" colspan=\"3\">Low prevalence of MRSA<sup>&#182;</sup> and SSTI not on face, hand, or perineum</td> </tr> <tr> <td class=\"indent2 divider_bottom\" rowspan=\"2\">MSSA</td> <td><strong>Oral therapy with one of the following:</strong> <ul class=\"decimal_heading\"> <li>Cephalexin </li> <li>Cefadroxil </li> <li>Cefuroxime </li> <li>Cloxacillin (not available in the United States) </li> </ul> </td> <td><strong>One of the following:</strong> <ul class=\"decimal_heading\"> <li>Oral clindamycin<sup>&#916;</sup> </li> <li>Oral TMP-SMX </li> <li>Oral doxycycline<sup>&#9674;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Parenteral therapy with one of the following:</strong> <ul class=\"decimal_heading\"> <li>Cefazolin </li> <li>Clindamycin </li> <li>Nafcillin IV </li> <li>Oxacillin IV </li> </ul> </td> <td><strong>One of the following<sup>&#165;</sup>:</strong> <ul class=\"decimal_heading\"> <li>Clindamycin IV </li> <li>Vancomycin IV </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cellulitis</td> </tr> <tr> <td class=\"subtitle3_left highlight_gray_text\" colspan=\"3\">Risk factors for MRSA<sup>&#135;</sup></td> </tr> <tr> <td class=\"indent2 divider_bottom\" rowspan=\"2\">Beta-hemolytic <em>Streptococcus</em><br /> MRSA</td> <td><strong>Oral therapy with one of the following:</strong> <ul class=\"decimal_heading\"> <li>Clindamycin<sup>&#916;</sup> (preferred) </li> <li>Amoxicillin plus TMP-SMX </li> <li>Cephalexin plus TMP-SMX </li> <li>Amoxicillin plus doxycycline<sup>&#9674;</sup> </li> <li>Cephalexin plus doxycycline<sup>&#9674;</sup> </li> </ul> </td> <td><strong>One of the following:</strong> <ul class=\"decimal_heading\"> <li>Linezolid (oral or IV)* </li> <li>Vancomycin IV </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Parenteral therapy with one of the following<sup>&#916;</sup>​:</strong> <ul class=\"decimal_heading\"> <li>Clindamycin </li> <li>Vancomycin </li> </ul> </td> <td><strong>One of the following:</strong> <ul class=\"decimal_heading\"> <li>Vancomycin IV (if not used for initial therapy) </li> <li>Ceftaroline IV* </li> <li>Linezolid IV* </li> <li>Daptomycin* </li> </ul> </td> </tr> <tr> <td class=\"subtitle3_left highlight_gray_text\" colspan=\"3\">No risk factors for MRSA<sup>&#135;</sup></td> </tr> <tr> <td class=\"indent2 divider_bottom\" rowspan=\"2\">Beta-hemolytic <em>Streptococcus</em><br /> MSSA</td> <td><strong>Oral therapy with one of the following:</strong> <ul class=\"decimal_heading\"> <li>Cephalexin (preferred) </li> <li>Cefadroxil </li> <li>Cefuroxime </li> <li>Cloxacillin (not available in the United States) </li> </ul> </td> <td><strong>One of the following<sup>&#134;</sup>:</strong> <ul class=\"decimal_heading\"> <li>Oral clindamycin<sup>&#916;</sup> (if not used initially) </li> <li>Oral amoxicillin plus TMP-SMX </li> <li>Oral amoxicillin plus doxycycline<sup>&#9674;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Parenteral therapy with one of the following:</strong> <ul class=\"decimal_heading\"> <li>Cefazolin IV </li> <li>Clindamycin IV </li> <li>Nafcillin IV </li> <li>Oxacillin IV </li> </ul> </td> <td><strong>One of the following<sup>&#165;</sup>:</strong> <ul class=\"decimal_heading\"> <li>Clindamycin IV (if not used initially) </li> <li>Vancomycin IV </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Erysipelas</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Beta-hemolytic <em>Streptococcus</em></td> <td><strong>Oral therapy with one of the following:</strong> <ul class=\"decimal_heading\"> <li>Amoxicillin </li> <li>Penicillin </li> </ul> </td> <td><strong>One of the following:</strong> <ul class=\"decimal_heading\"> <li>Oral cephalexin </li> <li>Oral clindamycin </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Parenteral therapy with one of the following:</strong> <ul class=\"decimal_heading\"> <li>Cefazolin </li> <li>Ceftriaxone </li> </ul> </td> <td><strong>One of the following:</strong> <ul class=\"decimal_heading\"> <li>Clindamycin </li> <li>Vancomycin </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Impetigo or folliculitis at multiple sites</td> </tr> <tr> <td class=\"indent1\">Beta-hemolytic <em>Streptococcus</em><br /> MRSA</td> <td><strong>Oral therapy with one of the following:</strong> <ul class=\"decimal_heading\"> <li>Clindamycin<sup>&#916;</sup> (preferred) </li> <li>Amoxicillin plus TMP-SMX </li> <li>Cephalexin plus TMP-SMX </li> <li>Amoxicillin plus doxycycline<sup>&#9674;</sup> </li> <li>Cephalexin plus doxycycline<sup>&#9674;</sup> </li> </ul> </td> <td>Patients who do not respond to initial therapy for beta-hemolytic <em>Streptococcus</em> and MRSA should be reevaluated for mimics of impetigo and other causes of folliculitis<sup>**</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SSTI: skin and soft tissue infection; MRSA: methicillin-resistant <EM>S. aureus</EM>; MSSA: methicillin-susceptible <EM>S. aureus</EM>; IV: intravenous; TMP-SMX: trimethoprim-sulfamethoxazole.<br />* Consultation with an expert in infectious diseases is suggested to ensure that these are the best options.<br />¶ We consider the prevalence of MRSA to be high when ≥10 to 15% of <EM>S. aureus</EM> isolates are MRSA; other experts may choose to provide coverage for MRSA at different prevalence levels.<br />Δ If the prevalence of clindamycin-resistant <EM>S. aureus</EM> in the community is low (eg, &lt;15%). If <EM>S. aureus</EM> is isolated, D testing is required to evaluate for inducible resistance. Refer to UpToDate content on antibacterial susceptibility testing.<br /><FONT class=lozenge>◊</FONT> Tetracycline antibiotics, including doxycycline, may cause permanent tooth discoloration for children &lt;8 years if used repeatedly. However, doxycycline binds less readily to calcium than other tetracyclines and, in some studies, was not associated with visible teeth staining in children &lt;8 years.<br />§ Refer to UpToDate content on treatment of MRSA skin and soft tissue infections in adults for details.<br />¥ The threshold prevalence of clindamycin-resistant <EM>S. aureus</EM> for choosing vancomycin varies from center to center, usually ranging from 10 to 25%, trying to balance the benefit of definitive therapy for the patient with the risk of increasing vancomycin resistance in the community. Additional considerations in the decision to choose vancomycin include the prevalence of MRSA in the community, the severity of illness, and the turn-around time for susceptibilities.<br />‡ Refer to UpToDate content on epidemiology of MRSA in children.&nbsp;<br />† Dicloxacillin is another option for second-line therapy for beta-hemolytic Streptococcus and MSSA but is infrequently used because many children find it unpalatable.<br />** Refer to UpToDate content on impetigo and folliculitis.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>American Academy of Pediatrics. Antibacterial drugs for pediatric patients beyond the newborn period. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.881.</LI>&#xD;&#xA;<LI>Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</LI>&#xD;&#xA;<LI>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59:147.</LI></OL></div><div id=\"graphicVersion\">Graphic 113302 Version 1.0</div></div></div>"},"113303":{"type":"graphic_algorithm","displayName":"Management cellulitis/erysipelas in children older than 28 days","title":"Suggested approach to initial antimicrobial therapy for cellulitis/erysipelas in children older than 28 days","html":"<div class=\"graphic\"><div style=\"width: 1464px\" class=\"figure\"><div class=\"ttl\">Suggested approach to initial antimicrobial therapy for cellulitis/erysipelas in children older than 28 days</div><div class=\"cntnt\"><img style=\"width:1444px; height:930px;\" src=\"images/PEDS/113303_Celllts_eryspls_chld_gt_28d.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is meant to be used in conjunction with UpToDate content on evaluation and management of suspected <EM>Staphylococcus aureus</EM> and streptococcal skin and soft tissue infections in children.</div><div class=\"graphic_footnotes\">SSTI: skin and soft tissue infection; IV: intravenous; MRSA: methicillin-resistant <EM>S. aureus</EM>; MSSA: methicillin-susceptible <EM>S. aureus</EM>; TMP-SMX: trimethoprim-sulfamethoxazole.<br />* Refer to UpToDate content on treatment of <EM>S. aureus</EM> and streptococcal SSTI in children for doses.<br />¶ The first one or two doses of parenteral therapy may be provided in an emergency department observation or \"short stay\" unit if one is available.<br />Δ Diameter of lesion includes surrounding erythema.<br /><FONT class=lozenge>◊</FONT> Indications for MRSA coverage include previous MRSA infection, known colonization with MRSA, and&nbsp;risk factors for MRSA (eg, penetrating trauma, playing sports that involve close contact or shared equipment, etc). Refer to UpToDate content on MRSA in children.<br />§ Tetracycline antibiotics, including doxycycline, may cause permanent tooth discoloration for children &lt;8 years if used repeatedly. However, doxycycline binds less readily to calcium than other tetracycline antibiotics and, in some studies, was not associated with visible teeth staining in children &lt;8 years.<SUP>[1]</SUP><br />¥ Cloxacillin is not available in the United States.</div><div class=\"graphic_reference\">Prepared with data from:<br /><OL>&#xD;&#xA;<LI>American Academy of Pediatrics Committee on Infectious Diseases. Staphylococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, 2015. p.715.</LI>&#xD;&#xA;<LI>American Academy of Pediatrics Committee on Infectious Diseases. Antimicrobial agents and related therapy. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.881.</LI>&#xD;&#xA;<LI>Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</LI>&#xD;&#xA;<LI>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:147.</LI></OL></div><div id=\"graphicVersion\">Graphic 113303 Version 1.0</div></div></div>"},"113304":{"type":"graphic_algorithm","displayName":"Management purulent/fluctuant SSTI in children older than 28 day","title":"Approach to the initial management of purulent/fluctuant SSTI in children older than 28 days","html":"<div class=\"graphic\"><div style=\"width: 870px\" class=\"figure\"><div class=\"ttl\">Approach to the initial management of purulent/fluctuant SSTI in children older than 28 days</div><div class=\"cntnt\"><img style=\"width:850px; height:754px;\" src=\"images/PEDS/113304_Purlnt_fluctnt_chld_gt_28_d.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is meant to be used in conjunction with UpToDate content on evaluation and management of suspected <EM>Staphylococcus aureus</EM> and SSTIs in children.</div><div class=\"graphic_footnotes\">SSTI: skin and soft tissue infection; I &amp; D: incision and drainage; IV: intravenous; MRSA: methicillin-resistant <EM>S. aureus</EM>; MSSA: methicillin-susceptible <EM>S. aureus</EM>; TMP-SMX: trimethoprim-sulfamethoxazole.<br />* Children with cardiac conditions predisposing to adverse outcomes from infectious endocarditis (eg, unrepaired cyanotic congenital heart disease, repaired congenital heart defects with prosthetic defects, etc) should receive prophylactic antibiotics before I &amp; D. Refer to UpToDate content on antimicrobial prophylaxis for bacterial endocarditis for details.<br />¶ When the etiologic agent and susceptibility are known, antimicrobial therapy can be narrowed as indicated. Refer to UpToDate content on evaluation and management of suspected<EM>&nbsp;S. aureus</EM> and streptococcal&nbsp;SSTI in children for details.<br />Δ The first one or two doses of parenteral therapy may be provided in an emergency department observation or \"short stay\" unit if one is available.<br /><FONT class=lozenge>◊</FONT> Diameter of lesion includes surrounding erythema/cellulitis.<br />§ We consider the local prevalence of MRSA to be high if ≥10 to 15% of <EM>S. aureus</EM> isolates are MRSA. Other experts may use a different threshold.<br />¥ Tetracycline antibiotics, including doxycycline, may cause permanent tooth discoloration for children &lt;8 years if used repeatedly. However, doxycycline binds less readily to calcium than other tetracycline antibiotics and, in some studies, was not associated with visible teeth staining in children &lt;8 years.<SUP>[1]</SUP><br />‡ Cloxacillin is not available in the United States.</div><div class=\"graphic_reference\">Prepared with data from: <br /><OL>&#xD;&#xA;<LI>American Academy of Pediatrics Committee on Infectious Diseases. Staphylococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, 2015. p.715. </LI>&#xD;&#xA;<LI>American Academy of Pediatrics Committee on Infectious Diseases. Antimicrobial agents and related therapy. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.881. </LI>&#xD;&#xA;<LI>Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18. </LI>&#xD;&#xA;<LI>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:147.</LI></OL></div><div id=\"graphicVersion\">Graphic 113304 Version 1.0</div></div></div>"},"113305":{"type":"graphic_figure","displayName":"The Stapfer classification of ERCP-related perforations","title":"The Stapfer classification of ERCP-related perforations","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">The Stapfer classification of ERCP-related perforations</div><div class=\"cntnt\"><img style=\"width:752px; height:640px;\" src=\"images/GAST/113305_Stpfr_clss_ERCP_rel_prfrtin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Stapfer classification divides ERCP-related perforations into four types based on the mechanism, anatomical location, and severity of injury. The four types of perforations are: Type I, lateral or medial wall duodenal perforation; type II, periampullary injuries; type III,&nbsp;bile duct or pancreatic duct injuries; and type IV, retroperitoneal air alone.</div><div class=\"graphic_footnotes\">ERCP: endoscopic retrograde cholangiopancreatography.</div><div id=\"graphicVersion\">Graphic 113305 Version 1.0</div></div></div>"},"113307":{"type":"graphic_diagnosticimage","displayName":"ERCP-related retroduodenal perforation (Type II)","title":"ERCP-related retroduodenal perforation (Type II)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">ERCP-related retroduodenal perforation (Type II)</div><div class=\"cntnt\"><img style=\"width:756px; height:639px;\" src=\"images/GAST/113307_ERCP_retroduodnl_perf_Type2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagnostic image showing ERCP-related retroduodenal perforation (Type II). Retroperitoneal air (arrows) is identified during ERCP and a nasobiliary drain is immediately placed for bile drainage.</div><div class=\"graphic_footnotes\">ERCP: endoscopic retrograde cholangiopancreatography.</div><div id=\"graphicVersion\">Graphic 113307 Version 1.0</div></div></div>"},"113308":{"type":"graphic_algorithm","displayName":"Determining etiology PAI adults","title":"Determining the etiology of primary adrenal insufficiency in adults","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Determining the etiology of primary adrenal insufficiency in adults</div><div class=\"cntnt\"><img style=\"width:578px; height:591px;\" src=\"images/ENDO/113308_Dtrmning_etiology_PAI_adlts.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm reviews the approach to determining the etiology of primary adrenal insufficiency. It is based upon UpToDate content on diagnosis of adrenal insufficiency and causes of primary adrenal insufficiency.</div><div class=\"graphic_footnotes\">PAI: primary adrenal insufficiency; 21-OH-Abs: 21-hydroxylase antibodies; VLCFA: very-long-chain fatty acids; CT: computed tomography.<br />* Congenital adrenal hyperplasia due to 21-hydroxylase deficiency is not included in the algorithm, because it presents in infancy or childhood, not adulthood.<br />¶ The adrenocorticolytic drug mitotane causes PAI. Drugs that inhibit cortisol biosynthesis (ketoconazole and metyrapone) do not usually cause clinically important PAI unless the patient has limited pituitary or adrenal reserve.<br />Δ In adults with autoimmune primary adrenal insufficiency, thyroid disease and type 1 diabetes are the most likely endocrine disorders to also be present (as part of polyglandular autoimmune syndrome type II).<br /><FONT class=lozenge>◊</FONT> To review the characteristic adrenal CT findings of these disorders, refer to UpToDate topic on causes of primary adrenal insufficiency.</div><div class=\"graphic_reference\">Adapted from: Bornstein SR, Allolio B, Arlt W, Barthel A, et al. Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016; 101:364</div><div id=\"graphicVersion\">Graphic 113308 Version 1.0</div></div></div>"},"113311":{"type":"graphic_table","displayName":"Aplasia cutis proposed etiology","title":"Etiologic factors and clinical associations for aplasia cutis congenita","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologic factors and clinical associations for aplasia cutis congenita</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">ACC clinical phenotype</td> <td class=\"subtitle1\">Proposed etiology</td> <td class=\"subtitle1\">Other associations</td> </tr> <tr> <td>Cranial and facial membranous aplasia cutis</td> <td>Developmental: Incomplete closure of embryonic fusion lines</td> <td>Organoid nevi</td> </tr> <tr> <td>Cranial, large, midline, irregular-shaped defects</td> <td>Developmental: Incomplete closure of neural tube and genetic</td> <td>Bone defects, hydrocephalus, arteriovenous fistula, sinus thrombosis</td> </tr> <tr> <td>Reticulated facial lesions</td> <td>Genetic: Chromosomal abnormality</td> <td>X-p22 deletion syndrome</td> </tr> <tr> <td>Truncal or extremity, stellate aplasia cutis</td> <td>Vascular disruption</td> <td>Fetus papyraceus, placental insufficiency, gastrointestinal atresia, abdominal malformations (gastroschisis, omphalocele)</td> </tr> <tr> <td>Extremity, angulated defects</td> <td>Increased skin fragility</td> <td>Epidermolysis bullosa</td> </tr> <tr> <td>Small, scar-like defects</td> <td>Maternal infection</td> <td>Varicella, herpes simplex virus infections</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACC: aplasia cutis congenita.</div><div class=\"graphic_reference\">Original table modified for this publication. From: Drolet BA. Developmental abnormalities. In: Neonatal and Infant Dermatology, 3rd ed, Eichenfield LF, Frieden IJ (Eds), Elsevier Saunders 2015. p. 105. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113311 Version 1.0</div></div></div>"},"113312":{"type":"graphic_table","displayName":"Aplasia cutis congenita in genetic syndromes","title":"Genetic syndromes associated with aplasia cutis congenita","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic syndromes associated with aplasia cutis congenita</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">ACC clinical phenotype</td> <td class=\"subtitle1\">Associated features</td> <td class=\"subtitle1\">Mode of inheritance</td> </tr> <tr> <td>Adams-Oliver syndrome</td> <td>Large, stellate, irregular-shaped, ill-defined scalp defect</td> <td>Terminal transverse limb defects</td> <td>Autosomal dominant, autosomal recessive, sporadic</td> </tr> <tr> <td>Chromosome 16 to 18 defect</td> <td>Large scalp defects</td> <td>Arteriovenous malformation of the scalp with underlying bony defect</td> <td>&nbsp;</td> </tr> <tr> <td>Johanson-Blizzard syndrome</td> <td>Membranous aplasia cutis and small stellate defects of the frontal scalp</td> <td>Dwarfism, mental retardation, deafness, hypothyroidism, pancreatic insufficiency</td> <td>Autosomal recessive</td> </tr> <tr> <td>Opitz syndrome</td> <td>Membranous aplasia cutis</td> <td>Hypertelorism, cleft lip/palate, hypospadias, cryptorchidism</td> <td>&nbsp;</td> </tr> <tr> <td>Oculocerebrocutaneous syndrome (Delleman syndrome)</td> <td>Membranous aplasia cutis</td> <td>Orbital cysts, cerebral malformations, facial skin tags, seizures, developmental delay</td> <td>&nbsp;</td> </tr> <tr> <td>Setleis syndrome (focal facial dermal dysplasia)</td> <td>Temporal aplasia cutis</td> <td>Imperforate anus, upward slanting eyebrows, leonine facies</td> <td>Autosomal recessive</td> </tr> <tr> <td>Trisomy D (13 to 15)</td> <td>Membranous aplasia cutis</td> <td>Holoprosencephaly, seizures, ocular abnormalities, deafness, neural tube defects, congenital heart defects, cleft lip and palate</td> <td>&nbsp;</td> </tr> <tr> <td>X-p22 microdeletion syndrome</td> <td>Bilateral, linear, reticulated defects of the malar cheeks</td> <td>Microphthalmia, sclerocornea</td> <td>&nbsp;</td> </tr> <tr> <td>4p&nbsp;deletion syndrome</td> <td>Not specified</td> <td>Mental retardation, deafness, seizures, ocular abnormalities</td> <td>&nbsp;</td> </tr> <tr> <td>Marfan syndrome</td> <td>Erosions on the vertex and occipital scalp</td> <td>Arachnodactyly, dolichonychia</td> <td>Autosomal dominant [FBN‐1 sequencing, c.6391T&#62;C (p.Cys2131Arg)]</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACC: aplasia cutis congenita.</div><div class=\"graphic_reference\">Original table modified for this publication. From: Drolet BA. Developmental abnormalities. In: Neonatal and Infant Dermatology, 3rd ed, Eichenfield LF, Frieden IJ (Eds), Elsevier Saunders 2015. p. 105. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113312 Version 1.0</div></div></div>"},"113318":{"type":"graphic_table","displayName":"Features suggesting specific etiologies of balanitis","title":"Features suggesting specific etiologies of balanitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features suggesting specific etiologies of balanitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">History or physical exam findings</td> <td class=\"subtitle1\">Etiology suggested</td> </tr> <tr> <td> <ul> <li>History of diabetes mellitus or HIV infection </li> <li>White, curd-like exudate </li> </ul> </td> <td>Candidal infection</td> </tr> <tr> <td> <ul> <li>Purulent or foul-smelling exudate </li> </ul> </td> <td>Bacterial infection</td> </tr> <tr> <td> <ul> <li>Behavioral risk(s) for sexually transmitted infections </li> </ul> </td> <td>Trichomonas, HSV, human papillomavirus, scabies, <em>Mycoplasma genitalium</em></td> </tr> <tr> <td> <ul> <li>Vesicular or ulcerative lesions </li> </ul> </td> <td>HSV, syphilis</td> </tr> <tr> <td> <ul> <li>History of generalized dermatitis </li> </ul> </td> <td>Psoriasis, eczema, lichen planus</td> </tr> <tr> <td> <ul> <li>Erythematous scaly plaques </li> </ul> </td> <td>Psoriasis</td> </tr> <tr> <td> <ul> <li>Pruritic purplish plaques </li> </ul> </td> <td>Lichen planus</td> </tr> <tr> <td> <ul> <li>Constitutional symptoms; polyarthritis </li> <li>Small, painless, ulcerative lesions with a serpiginous border </li> </ul> </td> <td>Circinate balanitis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; HSV: herpes simplex virus.</div><div id=\"graphicVersion\">Graphic 113318 Version 1.0</div></div></div>"},"113319":{"type":"graphic_table","displayName":"Etiologies of balanitis","title":"Etiologies of balanitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies of balanitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infectious</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li><em>Candida albicans</em> </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Anaerobic bacteria </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Streptococcus (group A) </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li><em>Staphylococcus aureus</em> </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li><em>Trichomonas vaginalis</em> </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Herpes simplex virus </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Human papillomavirus </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Syphilis </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Scabies </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\"> <ul class=\"decimal_heading\"> <li><em>Mycoplasma genitalium</em> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Dermatologic</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Psoriasis </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Eczema </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Lichen planus </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\"> <ul class=\"decimal_heading\"> <li>Allergic reactions </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Premalignant</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Lichen sclerosis </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Zoon's balanitis </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Carcinoma in situ (erythroplasia of Queyrat) </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Bowenoid papulosis </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\"> <ul class=\"decimal_heading\"> <li>Bowen's disease </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Reactive arthritis </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Fixed drug eruption </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Balanitis has a wide range of causes, but most cases are related to inadequate hygiene in uncircumcised men. When the foreskin is not routinely retracted and the glans is not cleansed in an appropriate fashion, buildup of sweat, debris, exfoliated skin, and bacteria or fungi can occur, resulting in inflammation. Contributing factors include diabetes mellitus, trauma (eg, zipper injury), obesity, and edematous conditions (eg, congestive heart failure, cirrhosis, nephrotic syndrome). Of cases with identifiable causes, candidal infection is the most common.</div><div class=\"graphic_reference\">Adapted from: Edwards SK, Bunker CB, Ziller F, van der Meijden WI. 2013 European guideline for the management of balanoposthitis. Int J STD AIDS 2014; 25:615.</div><div id=\"graphicVersion\">Graphic 113319 Version 2.0</div></div></div>"},"113321":{"type":"graphic_algorithm","displayName":"Cervical nodal metastasis in differentiated thyroid cancer","title":"Cervical nodal metastasis in differentiated thyroid cancer","html":"<div class=\"graphic\"><div style=\"width: 852px\" class=\"figure\"><div class=\"ttl\">Cervical nodal metastasis in differentiated thyroid cancer</div><div class=\"cntnt\"><img style=\"width:832px; height:814px;\" src=\"images/SURG/113321_Crvcl_mtstss_diffd_thyrd_ca.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Sonographic features suggestive of a metastatic lymph node include enlargement, loss of the fatty hilum, a rounded rather than oval shape, hyperechogenicity, cystic change, calcifications, and peripheral vascularity.<SUP>[1]</SUP><br />¶ Controversial; not all surgeons would perform a prophylactic central compartment neck dissection even in patients with large tumors or high-risk features.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>​Leenhardt L, Erdogan MF, Hegedus L, et al. 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J 2013; 2:147.</LI></OL></div><div id=\"graphicVersion\">Graphic 113321 Version 1.0</div></div></div>"},"113322":{"type":"graphic_picture","displayName":"Chronic plaque psoriasis resolving with hypopigmentation","title":"Chronic plaque psoriasis","html":"<div class=\"graphic\"><div style=\"width: 771px\" class=\"figure\"><div class=\"ttl\">Chronic plaque psoriasis</div><div class=\"cntnt\"><img style=\"width:751px; height:550px;\" src=\"images/DERM/113322_Chrnc_plq_psoriass_hypgmntn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Resolving psoriasis plaque with associated postinflammatory hypopigmentation.</div><div id=\"graphicVersion\">Graphic 113322 Version 1.0</div></div></div>"},"113323":{"type":"graphic_picture","displayName":"Inverse psoriasis in a child","title":"Inverse psoriasis","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Inverse psoriasis</div><div class=\"cntnt\"><img style=\"width:752px; height:265px;\" src=\"images/DERM/113323_Inverse_psoriasis_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inverse psoriasis involving the axillae in a child.</div><div id=\"graphicVersion\">Graphic 113323 Version 1.0</div></div></div>"},"113328":{"type":"graphic_table","displayName":"Gyn care communication","title":"Mindful communication in gynecologic care and abortion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mindful communication in gynecologic care and abortion</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Approach to communication</td> <td class=\"subtitle1\">Instead of</td> </tr> <tr> <td>Introduction sitting at patient's level.</td> <td>Introduction looking down at patient.</td> </tr> <tr> <td>\"Your pregnancy is eight weeks along.\"</td> <td>\"Your baby is eight weeks old.\"</td> </tr> <tr> <td>\"Place your feet in the foot holders.\"</td> <td>\"Place your feet in the stirrups.\"</td> </tr> <tr> <td>\"There is room for you to move down further on the exam table.\"</td> <td>\"Move your bottom down the bed until you feel like you're going to fall off.\"</td> </tr> <tr> <td>\"Allow your knees to fall to the sides.\"</td> <td>\"Open or spread your legs.\"</td> </tr> <tr> <td>\"Your cervix looks healthy and normal.\"</td> <td>\"Your cervix/uterus looks/feels good.\"</td> </tr> <tr> <td>\"You may feel some cool wet cotton to swab away your natural cervical mucous.\"</td> <td>\"I am cleaning your cervix\" (implying the cervix is dirty).</td> </tr> <tr> <td>\"If...then\" statements such as \"If you want the procedure to go as quickly as possible, then hold as still as you can.\"</td> <td>\"You have to hold still.\"</td> </tr> <tr> <td>\"This is the numbing medicine. You may feel a cramp or spreading numbness.\"</td> <td>\"You are going to feel a poke/prick/stick with the injection.\"</td> </tr> <tr> <td>\"We're over halfway through; you're doing great.\"</td> <td>\"It will be a few more minutes.\"</td> </tr> <tr> <td>\"I will place/introduce the IUD or implant.\"</td> <td>\"I will insert the IUD or implant.\"</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IUD: intrauterine device.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodman S, Flaxman G, TEACH Trainers Collaborative Working Group. TEACH Early Abortion Training Workbook, Fifth Edition. UCSF Bixby Center for Global Reproductive Health 2016. Available at: <A href=\"http://teachtraining.org/trainingworkbook/Early-Abortion-Training-Workbook-2016-2.pdf\" target=_blank>http://teachtraining.org/trainingworkbook/Early-Abortion-Training-Workbook-2016-2.pdf</A> (Accessed on May 31, 2017).</div><div id=\"graphicVersion\">Graphic 113328 Version 1.0</div></div></div>"},"113329":{"type":"graphic_picture","displayName":"First-trimester aspiration instruments","title":"Instrument tray for manual uterine aspiration in the first trimester","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Instrument tray for manual uterine aspiration in the first trimester</div><div class=\"cntnt\"><img style=\"width:756px; height:468px;\" src=\"images/OBGYN/113329_Frsttrmstrasprtninstrmts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">From left to right: (top of tray) cervical swab kit (optional), sterile gauze, vaginal speculum; (lower tray) Pratt dilators, flexible uterine cannula, single-toothed tenaculum, ring forceps, control syringe and needle, manual uterine aspirator (MUA); (not pictured) povidone-iodine solution.</div><div class=\"graphic_reference\">Reproduced with permission from: Managing Early Pregnancy Loss. Bixby Center for Global Reproductive Health, UCSF. Copyright © 2017. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113329 Version 1.0</div></div></div>"},"113330":{"type":"graphic_table","displayName":"Indications for sleep evaluation in commercial drivers","title":"Indications for commercial drivers to be evaluated by a sleep medicine physician","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for commercial drivers to be evaluated by a sleep medicine physician</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Primary criteria</td> <td class=\"subtitle1\">Secondary criteria</td> </tr> <tr> <td> <ol class=\"numbers_to_nine\"> <li>BMI &#8805;40 kg/m<sup>2</sup> or </li> <li>BMI &#8805;33 kg/m<sup>2</sup> and either <ol> <li style=\"list-style-type: lower-alpha;\">Hypertension requiring &#8805;2 medications for control or </li> <li style=\"list-style-type: lower-alpha;\">Type 2 diabetes </li> </ol> </li> <li>Sleepiness-related crash or accident, off-road deviation, or rear-ending another vehicle by report or observation </li> <li>Fatigue or sleepiness during the duty period</li> </ol> </td> <td> <ol class=\"numbers_to_nine\"> <li>Symptoms of OSA, which include but are not limited to: <ul class=\"decimal_heading\"> <li>Loud, habitual snoring </li> <li>Witnessed apneas </li> <li>Sleepiness during the major wake period* </li> </ul> </li> <li>BMI 28 to 33 kg/m<sup>2</sup> with any of the following risk factors of OSA<sup>&#182;</sup> <ul class=\"decimal_heading\"> <li>Small or recessed jaw </li> <li>Small airway (modified Mallampati classification of 3 or 4) </li> <li>Neck size &#8805;17 inches (men), &#8805;15.5 inches (women) </li> <li>Hypertension (especially if resistant) </li> <li>Type 2 diabetes, particularly if accompanied by obesity </li> <li>Cardiovascular disease </li> <li>Hypothyroidism (untreated) </li> <li>Age 42 years or older </li> <li>Family history of OSA </li> <li>Male, or postmenopausal female </li> </ul> </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMI: body mass index; OSA: obstructive sleep apnea.<br />* Absence of reported symptoms is less useful than the presence of symptoms.<br />&para; Combination of factors has greater risk than a single risk factor.</div><div class=\"graphic_reference\">Republished with permission of the American Academy of Sleep Medicine, from: Gurubhagavatula I, Sullivan S, Meoli A, et al. Management of obstructive sleep apnea in commercial motor vehicle operators: Recommendations of the AASM Sleep and Transportation Safety Awareness Task Force. J Clin Sleep Med 2017; 13:745; permission conveyed through Copyright Clearance Center, Inc. Copyright &copy; 2017.</div><div id=\"graphicVersion\">Graphic 113330 Version 1.0</div></div></div>"},"113331":{"type":"graphic_figure","displayName":"Gestational sac size by age","title":"Expected gestational sac size by gestational age","html":"<div class=\"graphic\"><div style=\"width: 788px\" class=\"figure\"><div class=\"ttl\">Expected gestational sac size by gestational age</div><div class=\"cntnt\"><img style=\"width:768px; height:390px;\" src=\"images/OBGYN/113331_Gestationalsacsizeage.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Goodman S, Flaxman G, TEACH Trainers Collaborative Working Group. TEACH Early Abortion Training Workbook, Fifth Edition. UCSF Bixby Center for Global Reproductive Health 2016. Available at: <A href=\"http://teachtraining.org/trainingworkbook/Early-Abortion-Training-Workbook-2016-2.pdf\" target=_blank>http://teachtraining.org/trainingworkbook/Early-Abortion-Training-Workbook-2016-2.pdf</A> (Accessed on May 31, 2017).</div><div id=\"graphicVersion\">Graphic 113331 Version 1.0</div></div></div>"},"113334":{"type":"graphic_picture","displayName":"Infant with NL rash","title":"Infant with neonatal lupus rash","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Infant with neonatal lupus rash</div><div class=\"cntnt\"><img style=\"width:763px; height:601px;\" src=\"images/ALLRG/113334_Neonatal_lupus_rash_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Jill P Buyon, MD.</div><div id=\"graphicVersion\">Graphic 113334 Version 2.0</div></div></div>"},"113336":{"type":"graphic_picture","displayName":"HCL involving BM","title":"Hairy cell leukemia involving the bone marrow","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Hairy cell leukemia involving the bone marrow</div><div class=\"cntnt\"><img style=\"width:756px; height:593px;\" src=\"images/HEME/113336_HCL_involving_BM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hairy cell leukemia&nbsp;involving bone marrow (H&amp;E stain) in a typical interstitial pattern. Note the oval to irregular nuclear contours, abundant pale cytoplasm, and distinct cell borders.</div><div class=\"graphic_reference\">Courtesy of Elizabeth A Morgan, MD, Brigham and Women's Hospital.</div><div id=\"graphicVersion\">Graphic 113336 Version 1.0</div></div></div>"},"113340":{"type":"graphic_table","displayName":"CFTR residual function mutations","title":"CFTR residual function mutations approved by the FDA for ivacaftor and tezacaftor-ivacaftor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CFTR residual function mutations approved by the FDA for ivacaftor and tezacaftor-ivacaftor</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"centered\"><em>A1067T</em></td> <td class=\"centered\"><em>E193K</em></td> <td class=\"centered\"><em>L206W</em></td> <td class=\"centered\"><em>R74W</em></td> </tr> <tr> <td class=\"centered\"><em>A455E</em></td> <td class=\"centered\"><em>E56K</em></td> <td class=\"centered\"><em>P67L</em></td> <td class=\"centered\"><em>S945L</em></td> </tr> <tr> <td class=\"centered\"><em>D110E</em></td> <td class=\"centered\"><em>E831X</em></td> <td class=\"centered\"><em>R1070Q</em>*</td> <td class=\"centered\"><em>S977F</em></td> </tr> <tr> <td class=\"centered\"><em>D110H</em></td> <td class=\"centered\"><em>F1052V</em></td> <td class=\"centered\"><em>R1070W</em></td> <td class=\"centered\"><em>2789+5G</em> <span style=\"font-size: 1.6em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace;\">&#8594;</span> <em>A</em></td> </tr> <tr> <td class=\"centered\"><em>D1152H</em></td> <td class=\"centered\"><em>F1074L</em></td> <td class=\"centered\"><em>R117C</em></td> <td class=\"centered\"><em>3272-26A</em> <span style=\"font-size: 1.6em; font-family: consolas, 'andale mono', 'lucida console sans typewriter', monaco, 'courier new', monospace;\">&#8594;</span> <em>G</em></td> </tr> <tr> <td class=\"centered\"><em>D1270N</em></td> <td class=\"centered\"><em>G1069R</em>*</td> <td class=\"centered\"><em>R347H</em></td> <td class=\"centered\"><em>3849+10kbC</em> <span style=\"font-size: 1.6em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace;\">&#8594;</span> <em>T</em></td> </tr> <tr> <td class=\"centered\"><em>D579G</em></td> <td class=\"centered\"><em>K1060T</em></td> <td class=\"centered\"><em>R352Q</em></td> <td class=\"centered\"><em>711+3A</em> <span style=\"font-size: 1.6em; font-family: consolas, 'andale mono', 'lucida console sans typewriter', monaco, 'courier new', monospace;\">&#8594;</span> <em>G</em></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>To&nbsp;meet indications for tezacaftor-ivacaftor, a patient must have cystic fibrosis with&nbsp;at least one copy of&nbsp;one of the above CFTR mutations (except<EM> G1069R</EM> or <EM>R1070Q</EM>), or two copies of the<EM>&nbsp;F508del</EM> mutation.&nbsp;</LI>&#xD;&#xA;<LI>To meet indications for ivacaftor, a patient must have cystic fibrosis with at least one of the above mutations, or a CFTR gating mutation (refer to UpToDate table for CFTR gating mutations). </LI></UL></div><div class=\"graphic_footnotes\">CFTR: cystic fibrosis transmembrane regulator; FDA: US Food and Drug Administration. <br />* <EM>G1069R</EM> and<EM>&nbsp;R1070Q</EM> mutations are approved for ivacaftor but not tezacaftor-ivacaftor.</div><div class=\"graphic_reference\">Adapted from: SYMDECO. Manufacturer's package insert. Available at: <a href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf</a> (Accessed on February 27, 2018).</div><div id=\"graphicVersion\">Graphic 113340 Version 3.0</div></div></div>"},"113341":{"type":"graphic_figure","displayName":"Pelvic autonomic nerves","title":"Pelvic autonomic nerves","html":"<div class=\"graphic\"><div style=\"width: 820px\" class=\"figure\"><div class=\"ttl\">Pelvic autonomic nerves</div><div class=\"cntnt\"><img style=\"width:800px; height:700px;\" src=\"images/OBGYN/113341_Pelvicautonomicnerves.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pelvic autonomic nerves. Superior and inferior hypogastric plexuses.</div><div class=\"graphic_footnotes\">S1 through S4: first through fourth sacral nerves.</div><div class=\"graphic_reference\">Reproduced with permission from: Hoffman B, Schorge J, Bradshaw K, et al. Williams Gynecology, 3rd ed, McGraw-Hill, 2016. p.806. Copyright © 2016 McGraw-Hill Education. McGraw-Hill Education makes no representations or warranties as to the accuracy of any information contained in the McGraw-Hill Education Material, including any warranties of merchantability or fitness for a particular purpose. In no event shall McGraw-Hill Education have any liability to any party for special, incidental, tort, or consequential damages arising out of or in connection with the McGraw-Hill Education Material, even if McGraw-Hill Education has been advised of the possibility of such damages.</div><div id=\"graphicVersion\">Graphic 113341 Version 3.0</div></div></div>"},"113349":{"type":"graphic_algorithm","displayName":"Approach to the diagnosis of chromhidrosis","title":"Approach to the diagnosis of chromhidrosis (colored sweat)","html":"<div class=\"graphic\"><div style=\"width: 716px\" class=\"figure\"><div class=\"ttl\">Approach to the diagnosis of chromhidrosis (colored sweat)</div><div class=\"cntnt\"><img style=\"width:696px; height:621px;\" src=\"images/DERM/113349_Apprch_diagnss_chromhidross.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Refer to UpToDate graphic on common causes of pseudochromhidrosis.<br />&para; Apocrine distribution consists of involvement of the axilla, areola, anogenital skin, and/or malar cheeks.<br />&Delta; In patients with apocrine chromhidrosis, Wood's lamp illumination of blue, green, or yellow sweat will demonstrate yellow fluorescence and confirms the diagnosis of apocrine chromhidrosis. Wood's lamp illumination is not reliable for apocrine chromhidrosis that manifests as darker sweat (black or brown).<br /><span class=\"lozenge\">&loz;</span> Refer to UpToDate graphic on common causes of chromhidrosis.</div><div id=\"graphicVersion\">Graphic 113349 Version 1.0</div></div></div>"},"113371":{"type":"graphic_table","displayName":"Factors for and against an aggressive approach for rabies","title":"Factors for and against an aggressive approach for the treatment of rabies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors&nbsp;for and&nbsp;against an aggressive approach for the treatment of rabies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Factors favoring initiation of an aggressive approach</td> <td class=\"subtitle1\">Factors against initiation of an aggressive approach</td> </tr> <tr> <td>Young age</td> <td>Older age</td> </tr> <tr> <td>Previously healthy</td> <td>Medical comorbidities/immune compromise</td> </tr> <tr> <td>One or more doses of rabies vaccine administered prior to the onset of clinical symptoms</td> <td>No previous history of administration of rabies vaccine</td> </tr> <tr> <td>Early clinical rabies (eg, local sensory symptoms)</td> <td>Late clinical rabies (eg, quadriparesis or coma)</td> </tr> <tr> <td>Infection caused by bat rabies virus</td> <td>Infection caused by dog rabies virus</td> </tr> <tr> <td>Presence of neutralizing anti-rabies virus antibodies in serum and/or cerebrospinal fluid</td> <td>Absence of neutralizing anti-rabies virus antibodies in serum and/or cerebrospinal fluid</td> </tr> <tr> <td>Diagnostic tests negative for rabies virus antigen and rabies virus RNA</td> <td>Diagnostic tests positive for rabies virus antigen and rabies virus RNA</td> </tr> <tr> <td>Access to critical care facilities</td> <td>Lack of access to critical care facilities</td> </tr> <tr> <td>Acceptance that the outcome could result in severe neurological deficits</td> <td>Lack of acceptance that the outcome could result in severe neurological deficits</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 113371 Version 1.0</div></div></div>"},"113372":{"type":"graphic_table","displayName":"Cases of human rabies with recovery","title":"Cases of human rabies with recovery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cases of human rabies with recovery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Location</td> <td class=\"subtitle1\">Year</td> <td class=\"subtitle1\">Age of patient/sex</td> <td class=\"subtitle1\">Transmission</td> <td class=\"subtitle1\">Immunization prior to onset</td> <td class=\"subtitle1\">Outcome*</td> </tr> <tr> <td>United States</td> <td>1970</td> <td>6/M<sup>[1]</sup></td> <td>Bat bite</td> <td>Duck embryo vaccine</td> <td>Complete recovery</td> </tr> <tr> <td>Argentina</td> <td>1972</td> <td>45/F<sup>[2]</sup></td> <td>Dog bite</td> <td>Suckling mouse brain vaccine</td> <td>Moderate sequelae</td> </tr> <tr> <td>United States</td> <td>1977</td> <td>32/M<sup>[3,4]</sup></td> <td>Laboratory (vaccine strain)</td> <td>Pre-exposure vaccination</td> <td>Severe sequelae</td> </tr> <tr> <td>Mexico</td> <td>1992</td> <td>9/M<sup>[5]</sup></td> <td>Dog bite</td> <td>Postexposure vaccination (combination of vaccines)</td> <td>Severe sequelae<sup>&#182;</sup></td> </tr> <tr> <td>India</td> <td>2000</td> <td>6/F<sup>[6]</sup></td> <td>Dog bite</td> <td>Postexposure vaccination (combination of vaccines)</td> <td>Severe sequelae<sup>&#916;</sup></td> </tr> <tr> <td>United States</td> <td>2004</td> <td>15/F<sup>[7,8]</sup></td> <td>Bat bite</td> <td>No postexposure therapy</td> <td>Mild sequelae</td> </tr> <tr> <td>Brazil</td> <td>2008</td> <td>15/M<sup>[9]</sup></td> <td>Bat bite</td> <td>Postexposure vaccination</td> <td>Severe sequelae</td> </tr> <tr> <td>Turkey</td> <td>2008</td> <td>17/M[<sup>10]</sup></td> <td>Dog bite</td> <td>Postexposure vaccination (one dose)</td> <td>Complete recovery</td> </tr> <tr> <td>India</td> <td>2010</td> <td>8/M<sup>[11]</sup></td> <td>Dog bite</td> <td>Postexposure vaccination and rabies immunoglobulin</td> <td>Severe sequelae (remained alive 5 years after acute illness)</td> </tr> <tr> <td>India</td> <td>2011</td> <td>17/M<sup>[12]</sup></td> <td>Dog bite</td> <td>Postexposure vaccination</td> <td>Severe sequelae</td> </tr> <tr> <td>South Africa</td> <td>2012</td> <td>4/M<sup>[13]</sup></td> <td>Dog bite</td> <td>Postexposure vaccination</td> <td>Severe sequelae</td> </tr> <tr> <td>Chile</td> <td>2013</td> <td>25/M<sup>[14]</sup></td> <td>Dog bite</td> <td>Postexposure vaccination (one dose)</td> <td>Moderate sequelae</td> </tr> <tr> <td>India</td> <td>2014</td> <td>16/M<sup>[15,16]</sup></td> <td>Dog bite</td> <td>Postexposure vaccination</td> <td>Severe sequelae</td> </tr> <tr> <td>India</td> <td>2014</td> <td>6/M<sup>[17]</sup></td> <td>Dog bite</td> <td>Postexposure vaccination and equine rabies immune globulin</td> <td>Severe sequelae</td> </tr> <tr> <td>India</td> <td>2014</td> <td>13/M<sup>[18]</sup></td> <td>Dog bite</td> <td>Postexposure vaccination</td> <td>Severe sequelae</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Outcomes include complete recovery, mild sequelae (eg, mild dysarthria, ataxia, and focal dystonia), moderate sequelae (eg, distal paraparesis), and severe sequelae (eg, mute and flaccid quadriplegia).<br />¶ Patient died less than four years after developing rabies with marked neurological sequelae (personal communication).<SUP>[5]</SUP><br />Δ Patient died approximately two years after developing rabies with marked neurological sequelae (personal communication).<SUP>[6]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hattwick MA, Weis TT, Stechschulte CJ, et al. Recovery from rabies. A case report. Ann Intern Med 1972; 76:931.</LI>&#xD;&#xA;<LI>Porras C, Barboza JJ, Fuenzalida E, et al. Recovery from rabies in man. Ann Intern Med 1976; 85:44.</LI>&#xD;&#xA;<LI>CDC. Rabies in a laboratory worker--New York. MMWR 1977; 26:183.</LI>&#xD;&#xA;<LI>Tillotson JR, Axelrod D, Lyman DO. Follow-up on rabies - New York. MMWR 1977; 26:249.</LI>&#xD;&#xA;<LI>Alvarez L, Fajardo R, Lopez E, et al. Partial recovery from rabies in a nine-year-old boy. Pediatr Infect Dis J 1994; 13:1154.</LI>&#xD;&#xA;<LI>Madhusudana SN, Nagaraj D, Uday M, et al. Partial recovery from rabies in a six-year-old girl. Int J Infect Dis 2002; 6:85.</LI>&#xD;&#xA;<LI>Hu WT, Willoughby RE Jr, Dhonau H, Mack KJ. Long-term follow-up after treatment of rabies by induction of coma. N Engl J Med 2007; 357:945.</LI>&#xD;&#xA;<LI>Willoughby RE, Jr., Tieves KS, Hoffman GM, et al. Survival after treatment of rabies with induction of coma. N Engl J Med 2005; 352:2508.</LI>&#xD;&#xA;<LI>Ministerio da Saude in Brazil. Rabies, human survival, bat - Brazil: (Pernambuco). ProMED-mail 2008; 20081114.3599.</LI>&#xD;&#xA;<LI>Karahocagil MK, Akdeniz H, Aylan O, et al. Complete recovery from clinical rabies: case report. Turkiye Klinikleri J Med Sci 2013; 33:547.</LI>&#xD;&#xA;<LI>Netravathi M, Udani V, Mani RS, et al, et al. Unique clinical and imaging findings in a first ever documented PCR positive rabies survival patient: A case report. J Clin Virol 2015; 70:83.</LI>&#xD;&#xA;<LI>de Souza A, Madhusudana SN. Survival from rabies encephalitis. J Neurol Sci 2014; 339:8.</LI>&#xD;&#xA;<LI>Weyer J, Msimang-Dermaux V, Paweska JT, et al. A case of human survival of rabies, South Africa. South African Journal of Infectious Diseases 2016; 31:66.</LI>&#xD;&#xA;<LI>Galvez S, Basque M, Contreras L, et al. Survivor of rabies encephalitis in Chile. Platform presentation at the XXIVth International Meeting on Research Advances and Rabies Control in the Americas in Toronto, Ontario, Canada on October 27, 2013.</LI>&#xD;&#xA;<LI>Thakur BS. 2nd rabies survivor in country at P'kula hospital. Hindustan Times 2014.</LI>&#xD;&#xA;<LI>Kumar KV, Ahmad FM, Dutta V. Pituitary cachexia after rabies encephalitis (Letter). Neurol India 2015; 63:255.</LI>&#xD;&#xA;<LI>Karande S, Muranjan M, Mani RS, et al. Atypical rabies encephalitis in a six-year-old boy: clinical, radiological, and laboratory findings. Int J Infect Dis 2015; 36:1.</LI>&#xD;&#xA;<LI>Manoj S, Mukherjee A, Johri S, Kumar KV. Recovery from rabies, a universally fatal disease. Mil Med Res 2016; 3:21.</LI></OL>Adapted from: Jackson AC. Therapy of human rabies. In Rabies: Scientific basis of the disease and its management, 3rd Edition, Jackson AC (Ed), Elsevier Academic Press, Oxford 2013. p.575.</div><div id=\"graphicVersion\">Graphic 113372 Version 1.0</div></div></div>"},"113379":{"type":"graphic_table","displayName":"Evaluation of the incidental solid pulmonary nodule in adults","title":"Evaluation of the incidental solid pulmonary nodule in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of the incidental solid pulmonary nodule in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nodule size (mm)</td> <td class=\"subtitle1\">Low (&#60;5%)<br /> cancer risk</td> <td class=\"subtitle1\">High (&#62;65%) or<br /> moderate (5 to 65%)<br /> cancer risk</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Solitary</td> </tr> <tr> <td class=\"indent1\">&#60;6</td> <td>No routine follow-up</td> <td>Optional CT at 12 months</td> </tr> <tr> <td class=\"indent1\">6 to 8</td> <td>CT at 6 to 12 months, then consider CT at 18 to 24 months</td> <td>CT at 6 to 12 months, then CT at 18 to 24 months</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#62;8</td> <td>CT at 3 months, then at 9 and 24 months</td> <td>FDG PET/CT, biopsy or resection</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Multiple (evaluation based on largest nodule)</td> </tr> <tr> <td class=\"indent1\">&#60;6</td> <td>No routine follow-up</td> <td>Optional CT at 12 months</td> </tr> <tr> <td class=\"indent1\">&#8805;6</td> <td>CT at 3 to 6 months, then consider CT at 18 to 24 months</td> <td>CT at 3 to 6 months, then CT at 18 to 24 months</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ol class=\"numbers_to_nine\">&#xD;&#xA;    <li>Not applicable to patients age &lt;35 years, in lung cancer screening, with immunosuppression, known pulmonary disease or symptoms or active primary cancer.</li>&#xD;&#xA;    <li>Chest CT performed without contrast as contiguous 1 mm sections using low dose technique.</li>&#xD;&#xA;    <li>Growing or FDG-avid nodules should undergo biopsy or resection. Growth is defined as &gt;1.5 mm increase.</li>&#xD;&#xA;    <li>Nodules unchanged for &gt;2 years are benign.</li>&#xD;&#xA;</ol></div><div class=\"graphic_footnotes\">CT: computed tomography; FDG: 18-fluorodeoxyglucose; PET: positron emission tomography.</div><div class=\"graphic_reference\">Adapted with permission from: MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT Images: From the Fleischner Society. Radiology 2017; 284:228. Copyright &copy; 2017 Radiological Society of North America.</div><div id=\"graphicVersion\">Graphic 113379 Version 1.0</div></div></div>"},"113380":{"type":"graphic_table","displayName":"Evaluation of the incidental subsolid pulmonary nodule in adults","title":"Evaluation of the incidental subsolid pulmonary nodule in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of the incidental subsolid pulmonary nodule in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nodule type<br /> and size (mm)</td> <td class=\"subtitle1\">Recommendation</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Solitary pure ground-glass</td> </tr> <tr> <td class=\"indent1\">&#60;6</td> <td>No routine follow-up.</td> <td>Consider CT at two and four years if patient is considered high risk for cancer.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;6</td> <td>CT at 6 to 12 months to confirm persistence. If unchanged, then CT every two years until five years. Growing nodules should undergo histologic sampling.*</td> <td>Histologic sampling requires resection as ground glass nodules are not amenable to needle biopsy.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Solitary part-solid</td> </tr> <tr> <td class=\"indent1\">&#60;6</td> <td>No routine follow-up.</td> <td><span style=\"font-size: 10px; font-family: HelveticaNeue-Condensed;\"></span> <p style=\"text-align: left;\">In practice, part-solid nodules &#60;6 mm cannot be defined as such until &#8805;6 mm.&nbsp; Consequently, these should be managed as a pure ground-glass nodule.</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;6</td> <td>CT at three to six months to confirm persistence. If unchanged and solid component remains &#60;6 mm, annual CT should be performed for five years. Nodules with solid component &#62;8 mm or growing nodules should undergo histologic sampling.*</td> <td>For nodules with solid component &#8804;8 mm, histologic sampling requires resection as they are not amenable to needle biopsy.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Multiple</td> </tr> <tr> <td class=\"indent1\">&#60;6</td> <td>CT at three to six months. If stable, no routine follow-up.</td> <td>Consider CT at two and four years if patient is considered high risk for cancer.</td> </tr> <tr> <td class=\"indent1\">&#8805;6</td> <td>CT at three to six months. If stable, subsequent evaluation is based on the most suspicious nodule (largest nodule for pure ground-glass and largest solid component for part-solid).</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ol class=\"numbers_to_nine\">&#xD;&#xA;    <li>Not applicable to patients age &lt;35 years, in lung cancer screening, with immunosuppression, known pulmonary disease or symptoms or active primary cancer.</li>&#xD;&#xA;    <li>Chest CT performed without contrast as contiguous 1 mm sections using low dose technique.</li>&#xD;&#xA;    <li>Nodules unchanged for &gt;5 years are benign.</li>&#xD;&#xA;</ol></div><div class=\"graphic_footnotes\">CT: computed tomography.<br />* Growth is defined as &gt;2 mm increase in overall size, increase in attenuation or appearance or enlargement of a solid component.<br /></div><div class=\"graphic_reference\">Adapted with permission from: MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT Images: From the Fleischner Society. Radiology 2017; 284:228. Copyright &copy; 2017 Radiological Society of North America.</div><div id=\"graphicVersion\">Graphic 113380 Version 2.0</div></div></div>"},"113381":{"type":"graphic_picture","displayName":"Proximal subungual onychomycosis 2","title":"Proximal subungual onychomycosis","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Proximal subungual onychomycosis</div><div class=\"cntnt\"><img style=\"width:752px; height:741px;\" src=\"images/DERM/113381_Prxml_sbngl_onychomycosis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and swelling of the proximal nail fold in a patient with mold proximal subungual onychomycosis.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 113381 Version 1.0</div></div></div>"},"113382":{"type":"graphic_figure","displayName":"Vitamin B12 absorption and cellular uptake","title":"Vitamin B12 absorption and cellular uptake","html":"<div class=\"graphic\"><div style=\"width: 796px\" class=\"figure\"><div class=\"ttl\">Vitamin B12 absorption and cellular uptake</div><div class=\"cntnt\"><img style=\"width:776px; height:778px;\" src=\"images/HEME/113382_Nrm_pth_B12_abspt_cell_uptk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vitamin B12 from food is released in the stomach and binds to salivary haptocorrin. Vitamin B12 is released from haptocorrin in the small intestine by pancreatic proteases and is then able to bind intrinsic factor (IF). The IF-vitamin B12 complex binds to the cubam receptor (Cubilin [Cub]&ndash;amnionless [Amn]) in the terminal ileum, followed by internalization and release into the circulation where it is bound by transcobalamins (TC). TC delivers vitamin B12 to the cellular TC receptor (also called CD320). Intracellularly, vitamin B12 is reduced and converted to adenosylcobalamin (in mitochondria) and methylcobalamin (in the cytosol). Refer to UpToDate for additional information about causes of vitamin B12 deficiency and the aspects of absorption with which they interfere.</div><div class=\"graphic_footnotes\">HC: haptocorrin; IF: intrinsic factor; CoA: coenzyme A; THF: tetrahydrofolate; Cub: cubilin; Amn: amnionless; MRP1: multidrug resistance protein 1; TC: transcobalamin.</div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from: Green R. Vitamin B12 deficiency from the perspective of a practicing hematologist. Blood 2017; 129(19):2603; permission conveyed through Copyright Clearance Center, Inc. Copyright &copy; 2017.</div><div id=\"graphicVersion\">Graphic 113382 Version 1.0</div></div></div>"},"113384":{"type":"graphic_diagnosticimage","displayName":"CT of a solid pulmonary nodule","title":"CT of a solid pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">CT of a solid pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:756px; height:704px;\" src=\"images/RADIOL/113384_CTsolidpulmnodule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Solid pulmonary nodule. Chest CT shows a nodule (arrow) of homogeneously solid density in the right middle lobe measuring &lt;30 mm. Pathology showed adenocarcinoma.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Shaunagh McDermott, MD.</div><div id=\"graphicVersion\">Graphic 113384 Version 1.0</div></div></div>"},"113385":{"type":"graphic_diagnosticimage","displayName":"CT and FDG PET of a pure ground-glass pulmonary nodule","title":"CT and FDG PET of a pure ground-glass pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 690px\" class=\"figure\"><div class=\"ttl\">CT and FDG PET of a pure ground-glass pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:670px; height:775px;\" src=\"images/RADIOL/113385_CTFDGPETgrdglspulmndl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pure ground-glass subsolid pulmonary nodule. Chest CT (A) shows a nodule (arrow) of ground-glass density measuring &lt;30 mm in the left upper lobe that on FDG PET (B) demonstrates no tracer avidity (arrow). Pathology showed adenocarcinoma.</div><div class=\"graphic_footnotes\">CT: computed tomography; FDG: fluorodeoxyglucose; PET: positron emission tomography.</div><div class=\"graphic_reference\">Courtesy of Shaunagh McDermott, MD.</div><div id=\"graphicVersion\">Graphic 113385 Version 1.0</div></div></div>"},"113386":{"type":"graphic_diagnosticimage","displayName":"CT of a part-solid pulmonary nodule","title":"CT of a part-solid pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 680px\" class=\"figure\"><div class=\"ttl\">CT of a part-solid pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:660px; height:441px;\" src=\"images/RADIOL/113386_CTpartsolidpulmnodule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Part-solid subsolid pulmonary nodule. Chest CT shows a nodule (arrow) of both ground-glass and solid density measuring &lt;30 mm in the right-upper lobe. Pathology showed adenocarcinoma.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Shaunagh McDermott, MD.</div><div id=\"graphicVersion\">Graphic 113386 Version 1.0</div></div></div>"},"113387":{"type":"graphic_diagnosticimage","displayName":"CT of a pulmonary hamartoma with fat","title":"CT of a pulmonary hamartoma with fat","html":"<div class=\"graphic\"><div style=\"width: 680px\" class=\"figure\"><div class=\"ttl\">CT of a pulmonary hamartoma with fat</div><div class=\"cntnt\"><img style=\"width:660px; height:530px;\" src=\"images/RADIOL/113387_CTpulmhamartomafat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary hamartoma. Chest CT shows a left lung nodule (arrow) containing fat density diagnostic of a hamartoma.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Shaunagh McDermott, MD.</div><div id=\"graphicVersion\">Graphic 113387 Version 1.0</div></div></div>"},"113389":{"type":"graphic_figure","displayName":"Vitamin B12 and folate metabolic roles","title":"Roles of vitamin B12 and folate in the methionine cycle, folate cycle, and DNA synthesis showing the methyl folate \"trap\"","html":"<div class=\"graphic\"><div style=\"width: 796px\" class=\"figure\"><div class=\"ttl\">Roles of vitamin B12 and folate in the methionine cycle, folate cycle, and DNA synthesis showing the methyl folate \"trap\"</div><div class=\"cntnt\"><img style=\"width:776px; height:403px;\" src=\"images/HEME/113389_Intrsctns_methyl_folate_trp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The roles of vitamin B12 and folate in the methionine cycle, folate cycle, and DNA synthesis are shown. The key intersection of vitamin B12 and folate occurs at the methionine synthase (MS) reaction (shown at the left edge&nbsp;between the yellow and blue panels) in which the one-carbon methyl group of methyl-tetrahydrofolate (methylTHF) is transferred to&nbsp;homocysteine to form methionine.&nbsp;Vitamin B12 (as methylcobalamin) acts as a cofactor for this reaction. Tetrahydrofolate regains a one-carbon methylene group through the serine-hydroxymethyltransferase (SHMT) reaction, and the resulting methylenetetrahydrofolate (methyleneTHF)&nbsp;is essential for conversion of deoxyuridine to thymidine in the thymidylate synthase (TS) reaction, which is rate-limiting for DNA synthesis. In vitamin&nbsp;B12 deficiency, folate becomes trapped as methylTHF (the methyl folate \"trap\"). Administration of folic acid can temporarily overcome this block through formation of tetrahydrofolate (THF). The other product of the MS reaction is the essential amino acid methionine, which becomes adenosylated and serves as a universal methyl donor in numerous methyltransferase reactions. The product&nbsp;S-adenosyl-homocysteine&nbsp;(SAH) undergoes reversible hydrolysis, completing the methionine (or remethylation) cycle. The alternative pathway for Hcy disposal, which involves transsulfuration and requires vitamin B6, is not shown.</div><div class=\"graphic_footnotes\">SAM: S-adenosyl-methionine; ATP: adenosine triphosphate; SAH: S-adenosyl-homocysteine; NADP<SUP>+</SUP>: NAD phosphate; NADPH<SUP>+</SUP>: reduced NAD phosphate; H<SUP>+</SUP>: proton; DHFR: dihydrofolate reductase; AHCY hydrolase: adenosyl-homocysteine hydrolase; MS: methionine synthase; B12: Vitamin B12; THF: tetrahydrofolate; SHMT: serine hydroxymethyltransferase; TS: thymidylate synthase; MethylTHF: methylene THF; MTHFR: methylene tetrahydrofolate reductase.</div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from: Green R. Vitamin B12 deficiency from the perspective of a practicing hematologist. Blood 2017; 129(19):2603; permission conveyed through Copyright Clearance Center, Inc. Copyright &copy; 2017.</div><div id=\"graphicVersion\">Graphic 113389 Version 1.0</div></div></div>"},"113390":{"type":"graphic_picture","displayName":"Bone marrow in PA","title":"Bone marrow aspirate in a patient with vitamin B12 deficiency due to pernicious anemia","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Bone marrow aspirate in a patient with vitamin B12 deficiency due to&nbsp;pernicious anemia</div><div class=\"cntnt\"><img style=\"width:547px; height:384px;\" src=\"images/HEME/113390_Bne_marrow_w_pernics_anemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical megaloblastic changes consistent with nuclear-cytoplasmic dyssynchrony&nbsp;are shown. These&nbsp;include abnormal nuclear maturation in erythroid precursors, with variegated, finely granular chromatin (salt and pepper appearance, rather than the normal ground glass appearance) in a proerythroblast in&nbsp;(A) and a giant granulocyte precursor&nbsp;in (B).&nbsp;Original magnification ×100; Wright-Giemsa stain.</div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from: Green R. Vitamin B12 deficiency from the perspective of a practicing hematologist. Blood 2017; 129(19):2603; permission conveyed through Copyright Clearance Center, Inc. Copyright © 2017.</div><div id=\"graphicVersion\">Graphic 113390 Version 1.0</div></div></div>"},"113391":{"type":"graphic_table","displayName":"Definitions for preterm birth","title":"Definitions for preterm birth","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions for preterm birth</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Gestational age criteria</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">World Health Organization</td> </tr> <tr> <td class=\"indent1\">Moderate to late preterm</td> <td>32 to &#60;37 weeks</td> </tr> <tr> <td class=\"indent1\">Very preterm</td> <td>28 to &#60;32 weeks</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Extremely preterm</td> <td>&#60;28 weeks</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Centers for Disease Control and Prevention</td> </tr> <tr> <td class=\"indent1\">Preterm</td> <td>&#60;37 weeks</td> </tr> <tr> <td class=\"indent1\">Late preterm</td> <td>34 to 36 weeks</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Early preterm</td> <td>&#60;34 weeks</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Birth weight criteria</td> </tr> <tr> <td class=\"indent1\">Low birth weight (LBW)</td> <td>&#60;2500 grams</td> </tr> <tr> <td class=\"indent1\">Very low birth weight (VLBW)</td> <td>&#60;1500 grams</td> </tr> <tr> <td class=\"indent1\">Extremely low birth weight (ELBW)</td> <td>&#60;1000 grams</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The lower gestational age limit of preterm birth is 20+0 weeks of gestation. A birth &lt;20 weeks of gestation is called a pregnancy loss, miscarriage, or spontaneous abortion in the United States. Preterm births are described by gestational age, birth weight, and initiating factor (eg, spontaneous preterm birth versus medically indicated preterm birth).</div><div id=\"graphicVersion\">Graphic 113391 Version 1.0</div></div></div>"},"113392":{"type":"graphic_table","displayName":"Adv/disadv of laparoscopic transabdominal and posterior RPA","title":"Advantages and disadvantages of laparoscopic transabdominal and posterior retroperitoneoscopic adrenalectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of laparoscopic transabdominal and posterior retroperitoneoscopic adrenalectomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages/contraindications</td> </tr> <tr> <td><strong>Laparoscopic transabdominal</strong></td> <td> <ul> <li>Can be combined with other transabdominal procedure </li> <li>Easier access for conversion to open procedure </li> <li>More suitable in obese patients </li> </ul> </td> <td> <ul> <li>Need to change position for bilateral adrenalectomy </li> <li>Need to mobilize abdominal structures </li> <li>Not suitable for known or highly suspected malignant tumor (ACC or pheochromocytoma); evidence of invasion into adjacent structures* </li> </ul> </td> </tr> <tr> <td>&nbsp;<strong>Retroperitoneoscopic <li></li> </strong></td> <td> <ul> <li>Do not have to mobilize other organs </li> <li>Not affected by prior abdominal surgery </li> <li>No intraperitoneal insufflation (for patients with potential cardiovascular or respiratory compromise) </li> <li>Same position for bilateral adrenalectomy </li> </ul> </td> <td> <ul> <li>Not suitable for obese patients </li> <li>Short distance between 12<sup>th</sup> rib and iliac crest (&#60;4 cm) </li> <li>Not suitable for known or highly suspected malignant tumor (ACC or pheochromocytoma); evidence of invasion into adjacent structures* </li> </ul> &nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACC: adrenal cortical carcinoma. <br />* Open adrenalectomy is recommended for any known or highly suspected malignant tumor (ACC or pheochromocytoma), or evidence of invasion into adjacent structures. </div><div class=\"graphic_reference\">Reproduced from: Carr AA, Wang TS. Minimally invasive adrenalectomy. Surg Oncol Clin N Am 2016; 25:139. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113392 Version 1.0</div></div></div>"},"113393":{"type":"graphic_movie","displayName":"Ultrasound right internal jugular vein and common carotid artery","title":"Transverse ultrasound image of the right internal jugular vein (lateral) and common carotid artery (medial)","html":"<div class=\"graphic normal\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Transverse ultrasound image of the right internal jugular vein (lateral) and common carotid artery (medial)</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/113393_USrghtIJveincmmnCAvid.mp4\" style=\"width:720px;height:528px\"></div><img style=\"width:730px; height:521px;\" src=\"images/ANEST/113393_USrghtIJveincmmnCAimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that the vein is easily compressible by the ultrasound probe.</div><div class=\"graphic_footnotes\">IJ: internal jugular vein; CA: carotid artery.</div><div class=\"graphic_reference\">Courtesy of Jonathan B Mark, MD.</div><div id=\"graphicVersion\">Graphic 113393 Version 1.0</div></div></div>"},"113394":{"type":"graphic_movie","displayName":"Ultrasound image of occluded right internal jugular vein","title":"Transverse ultrasound image of an occluded right internal jugular vein (lateral) and common carotid artery (medial)","html":"<div class=\"graphic normal\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Transverse ultrasound image of an occluded right internal jugular vein (lateral) and common carotid artery (medial)</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/113394_USoccluddrghtIJveinvid.mp4\" style=\"width:752px;height:512px\"></div><img style=\"width:646px; height:485px;\" src=\"images/ANEST/113394_USoccluddrghtIJveinimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this transverse ultrasound image of the right internal jugular vein (lateral) and common carotid artery (medial), note that the IJ vein is occluded with an organized thrombus and would not be suitable for vascular cannulation.</div><div class=\"graphic_footnotes\">IJ: internal jugular vein; CA: carotid artery.</div><div class=\"graphic_reference\">Courtesy of Jonathan B Mark, MD.</div><div id=\"graphicVersion\">Graphic 113394 Version 1.0</div></div></div>"},"113396":{"type":"graphic_diagnosticimage","displayName":"Midesophageal 2-chamber TEE image of left ventricular thrombus","title":"Midesophageal 2-chamber TEE image of left ventricular thrombus","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Midesophageal 2-chamber TEE image of left ventricular&nbsp;thrombus</div><div class=\"cntnt\"><img style=\"width:756px; height:530px;\" src=\"images/ANEST/113396_LV_thrombus_TEE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This midesophageal 2-chamber TEE image demonstrates a large (18 mm x 53 mm) anterior-apical left ventricular thrombus.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography.</div><div id=\"graphicVersion\">Graphic 113396 Version 1.0</div></div></div>"},"113397":{"type":"graphic_movie","displayName":"Midesophageal 4-chamber TEE video showing LV thrombus","title":"Midesophageal 4-chamber TEE view showing LV thrombus","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Midesophageal 4-chamber TEE view showing LV thrombus</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/113397_4chmbrTEELVthrombusvid.mp4\" style=\"width:704px;height:544px\"></div><img style=\"width:756px; height:530px;\" src=\"images/ANEST/113397_4chmbrTEELVthrombusimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A midesophageal 4-chamber view shows a non-contractile mass in the apex of the left ventricle likely representing thrombus. The severely reduced ejection fraction, akinesis of the apical segments, and presence of spontaneous echo contrast all support the diagnosis of LV thrombus.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; LV: left ventricular.</div><div id=\"graphicVersion\">Graphic 113397 Version 1.0</div></div></div>"},"113398":{"type":"graphic_movie","displayName":"Midesophageal 2-chamber TEE video showing LV thrombus","title":"Midesophageal 2-chamber TEE video showing LV thrombus","html":"<div class=\"graphic normal\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Midesophageal 2-chamber TEE video showing LV thrombus</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/113398_LVthrombusTEEvid.mp4\" style=\"width:752px;height:544px\"></div><img style=\"width:756px; height:530px;\" src=\"images/ANEST/113398_LVthrombusTEEimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A midesophageal 2-chamber TEE view shows a non-contractile mass in the apex of the left ventricle, likely representing thrombus. The underlying ventricular wall is virtually always akinetic or dyskinetic when a left ventricular thrombus is present. In this patient, akinesis of the apical segments, the severely reduced ejection fraction, and presence of spontaneous echo contrast all support the diagnosis of left ventricular thrombus.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; LV: left ventricular.</div><div id=\"graphicVersion\">Graphic 113398 Version 2.0</div></div></div>"},"113408":{"type":"graphic_algorithm","displayName":"Subsequent treatment for advanced NSCLC","title":"Subsequent treatment for advanced NSCLC that progressed on front-line chemotherapy","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Subsequent treatment for advanced NSCLC that progressed on front-line chemotherapy</div><div class=\"cntnt\"><img style=\"width:490px; height:468px;\" src=\"images/ONC/113408_Subsqnt_trtmnt_advncd_NSCLC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NSCLC: non-small cell lung cancer; <EM>ALK</EM>: anaplastic lymphoma kinase; <EM>EGFR</EM>: epidermal growth factor receptor; HER2: human epidermal growth factor receptor 2; PD-L1: programmed death receptor ligand 1; PD-1: anti-programmed death receptor 1.<br />* Appropriate targeted agents are discussed separately. Refer to UpToDate topics on personalized, genotype-directed therapy for advanced non-small cell lung cancer.<br />¶ Patients treated with the carboplatin/pemetrexed/pembrolizumab regimen followed by pembrolizumab maintenance who fit the preceding criteria may be offered retreatment with carboplatin/pemetrexed, with continuation of pembrolizumab. However, studies evaluating this approach are not available.<br />Δ Use of targeted therapies off-label is discussed separately. Refer to UpToDate topics on personalized, genotype-directed therapy for advanced non-small cell lung cancer.<br /><FONT class=lozenge>◊</FONT> For those in whom PD-L1 is absent or has not been assessed, the anti-PD-L1 antibody nivolumab or the anti-PD-1 antibody atezolizumab is appropriate. If PD-L1 is present on at least 1% of tumor cells, either of these agents or pembrolizumab is appropriate therapy. As these agents have not been directly compared, a choice between them should be based on provider preference and insurance coverage.<br />§ Options for single-agent chemotherapy include docetaxel (with or without ramucirumab) regardless of histology; or pemetrexed, for those with nonsquamous histology who have not been exposed to it before. Agents that are used off-label by some experts include gemcitabine, vinorelbine, paclitaxel, and nab-paclitaxel. Refer to UpToDate topics on advanced non-small cell lung cancer: subsequent therapies for previously treated patients.</div><div id=\"graphicVersion\">Graphic 113408 Version 1.0</div></div></div>"},"113418":{"type":"graphic_table","displayName":"Diagnostic findings thunderclap headache","title":"Diagnostic findings for the more common causes of thunderclap headache","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic findings for the more common causes of thunderclap headache</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16.6%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Brain CT</td> <td class=\"subtitle1\">Lumbar puncture</td> <td class=\"subtitle1\">Angiography</td> <td class=\"subtitle1\">Brain MRI</td> </tr> <tr class=\"divider_bottom\"> <td>Aneurysmal subarachnoid hemorrhage</td> <td>Altered consciousness, seizures, meningismus</td> <td>Subarachnoid blood in basilar cisterns and sylvian fissures</td> <td>Elevated red blood cells, xanthochromia</td> <td>Ruptured aneurysm, vasospasm</td> <td>Subarachnoid blood in basilar cisterns and sylvian fissures</td> </tr> <tr class=\"divider_bottom\"> <td>Reversible cerebral vasoconstriction syndrome</td> <td>Recurrent thunderclap headaches</td> <td>Normal, or subarachnoid blood along cortical surface/sulci</td> <td>Normal, mild white blood cell elevation, mild protein elevation</td> <td>Multifocal multivessel vasoconstriction</td> <td>Normal, or subarachnoid blood along cortical surface/sulci, ischemic stroke, cerebral edema, intracerebral hemorrhage</td> </tr> <tr class=\"divider_bottom\"> <td>Carotid and vertebral artery dissection</td> <td>Neck pain, symptoms related to cerebral ischemia, Horner syndrome (carotid dissection)</td> <td>Normal, or ischemic stroke</td> <td>Normal</td> <td>Dissected artery, multifocal, segmental vasoconstriction if associated with reversible cerebral vasoconstriction syndrome</td> <td>Normal, or ischemic stroke</td> </tr> <tr class=\"divider_bottom\"> <td>Cerebral venous sinus thrombosis</td> <td>Focal neurologic deficits, altered mental status, visual changes</td> <td>Dense triangle sign (clot inside the sinus), cord sign (thrombosed cortical or deep vein), venous hemorrhages</td> <td>Elevated opening pressure, high protein</td> <td>Venous sinus thrombosis</td> <td>Normal, or venous infarctions with hemorrhage; MRI evidence of intraluminal thrombus on T1, T2, and susceptibility-weighted imaging sequences</td> </tr> <tr> <td>Spontaneous intracranial hypotension</td> <td>Orthostatic headache, auditory muffling</td> <td>Normal, or subdural collections</td> <td>Low opening pressure</td> <td>Normal</td> <td>Pachymeningeal enhancement, sagging brain, subdural collections</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">From: Schwedt TJ. Thunderclap Headache. Continuum (Minneap Minn) 2015; 21:1058. DOI: <a href=\"http://journals.lww.com/continuum/Abstract/2015/08000/Thunderclap_Headache.13.aspx\" target=\"_blank\">10.1212/CON.0000000000000201</a>. Copyright &copy; 2015 American Academy of Neurology. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113418 Version 1.0</div></div></div>"},"113419":{"type":"graphic_algorithm","displayName":"Initial systemic therapy for NSCLC","title":"Initial systemic therapy for non-small cell lung cancer","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Initial systemic therapy for non-small cell lung cancer</div><div class=\"cntnt\"><img style=\"width:616px; height:560px;\" src=\"images/ONC/113419_Init_systemic_therapy_NSCLC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For patients who progress at any point during initial therapy, refer to UpToDate topics on advanced non-small cell lung cancer: subsequent systemic therapy for previously treated patients.</div><div class=\"graphic_footnotes\">NSCLC: non-small cell lung cancer; PD-L1: programmed death receptor ligand 1; <EM>EGFR</EM>: epidermal growth factor receptor; <EM>ALK</EM>: anaplastic lymphoma kinase.<br />* Examples of actionable driver mutations (and appropriate targeted agents) include the following: &#xD;&#xA;<UL>&#xD;&#xA;<LI><EM>EGFR</EM> (erlotinib, gefitinib, or afatinib)</LI>&#xD;&#xA;<LI><EM>ALK</EM> (crizotinib, ceritinib, or alectinib)</LI>&#xD;&#xA;<LI><EM>ROS1</EM> (crizotinib)</LI></UL>These and others are discussed in more detail separately. Refer to UpToDate topics on personalized, genotype-directed therapy for advanced non-small cell lung cancer.<br />¶ Docetaxel or gemcitabine are appropriate options.<br />Δ Close observation with initiation of second-line therapy at the earliest sign of progression may be an alternative for some patients. Refer to UpToDate topics on systemic therapy for the initial management of advanced non-small cell lung cancer without a driver mutation.<br /><FONT class=lozenge>◊</FONT> Pemetrexed is an acceptable alternative in this setting. Additionally, Some UpToDate experts prefer the combination of bevacizumab and pemetrexed for maintenance, although others prefer single-agent therapy.</div><div id=\"graphicVersion\">Graphic 113419 Version 1.0</div></div></div>"},"113420":{"type":"graphic_algorithm","displayName":"Diagnostic evaluation and management of balanitis","title":"Diagnostic evaluation and management of balanitis","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Diagnostic evaluation and management of balanitis</div><div class=\"cntnt\"><img style=\"width:517px; height:755px;\" src=\"images/PC/113420_Diag_eval_mgnt_balanitis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Hygiene measures include retraction of the foreskin and twice-daily bathing of the affected areas with saline solution.<br />&para; Nystatin cream 100,000 units/g can be used in patients allergic to imidazoles. For patients with severe symptoms, options include a single dose of oral fluconazole 150 mg or the combination a topical imidazole and hydrocortisone 1% cream.</div><div id=\"graphicVersion\">Graphic 113420 Version 1.0</div></div></div>"},"113422":{"type":"graphic_table","displayName":"Causes bowel obstruction CA patients","title":"Causes of bowel obstruction in cancer patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of bowel obstruction in cancer patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Etiology</td> <td class=\"subtitle1\">Pathophysiology</td> </tr> <tr class=\"divider_bottom\"> <td>Constipation</td> <td>Impacted feces, obstipation</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Adhesions</td> <td>Malignant</td> </tr> <tr> <td>Postoperative</td> </tr> <tr> <td class=\"divider_bottom\">Postradiation</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Tumor mass</td> <td>Single or multiple</td> </tr> <tr> <td>Invasion and blockage of bowel (apple core)</td> </tr> <tr> <td class=\"divider_bottom\">Extrinsic compression</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Strangulation</td> <td>Around tumor</td> </tr> <tr> <td class=\"divider_bottom\">Around adhesions</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Ileus</td> <td>Drugs</td> </tr> <tr> <td class=\"divider_bottom\">Peritonitis, hemoperitoneum</td> </tr> <tr class=\"divider_bottom\"> <td>Ascites</td> <td>Large amount of abdominal fluid</td> </tr> <tr> <td>Nonmalignant mass</td> <td>Abscess, phlegmon</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 113422 Version 1.0</div></div></div>"},"113423":{"type":"graphic_table","displayName":"Location of bowel obstruction according to history and symptoms","title":"Differentiating the location of bowel obstruction based upon history and symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differentiating the location of bowel obstruction based upon history and symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptoms</td> <td class=\"subtitle1\">Gastric-proximal small bowel</td> <td class=\"subtitle1\">Distal small bowel or large bowel</td> </tr> <tr> <td>Vomiting</td> <td>Bilious, watery, large volume, no or little odor</td> <td>Particulate, small volume, foul smelling; may be absent</td> </tr> <tr> <td>Pain</td> <td>Early symptom; peri-umbilical, short, intermittent pain</td> <td>Deep visceral; crampy; long intervals between cramps</td> </tr> <tr> <td>Abdominal distension</td> <td>Not necessarily present</td> <td>Present</td> </tr> <tr> <td>Anorexia</td> <td>Always</td> <td>Not necessarily present</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 113423 Version 1.0</div></div></div>"},"113425":{"type":"graphic_table","displayName":"Contraindications to surgery in malignant bowel obstruction","title":"Absolute and relative contraindications to surgery in patients with malignant bowel obstruction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Absolute and relative contraindications to surgery in patients with malignant bowel obstruction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Absolute</td> <td class=\"subtitle1\">Relative</td> </tr> <tr> <td>Recurrent ascites after paracentesis</td> <td>Multiple sites of intraabdominal tumor</td> </tr> <tr> <td>Diffuse palpable abdominal masses</td> <td>Low serum albumin</td> </tr> <tr> <td>Multiple levels of bowel obstruction</td> <td>Previous radiation therapy</td> </tr> <tr> <td>Recent abdominal surgery demonstrating that corrective surgery is technically impossible</td> <td>Poor nutritional status</td> </tr> <tr> <td>Previous surgery showing diffuse metastatic cancer</td> <td>Liver or extraabdominal metastases, including pleural or pulmonary metastases producing dyspnea</td> </tr> <tr> <td>Involvement of proximal stomach</td> <td>Major renal or hepatic dysfunction</td> </tr> <tr> <td>&nbsp;</td> <td>ECOG PS &#8805;2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECOG PS: Eastern Cooperative Oncology Group performance status.</div><div id=\"graphicVersion\">Graphic 113425 Version 1.0</div></div></div>"},"113429":{"type":"graphic_algorithm","displayName":"Algorithm for PPROM presenting at 34 to 36 wks gestation","title":"Algorithm for managing pregnancies first presenting with PPROM at 34+0 to 36+6 weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Algorithm for managing pregnancies first presenting with PPROM at 34+0 to 36+6 weeks of gestation</div><div class=\"cntnt\"><img style=\"width:584px; height:456px;\" src=\"images/OBGYN/113429_Algo_PPROM_34-36_wks.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* The American College of Obstetricians and Gynecologists considers pregnancies \"suboptimally dated\" in the absence of an ultrasound examination before 22+0 weeks of gestation confirming or revising the estimated date of delivery.<br />¶ Refer to UpToDate topic on preterm premature rupture of membranes for a discussion of the components of expectant management. Women are hospitalized during expectant management. Terminate expectant management and deliver if any standard indications for delivery develop (eg, chorioamnionitis, nonreassuring fetal tracing, abruption, etc).<br />Δ Labor is induced if there are no contraindications to vaginal delivery; cesarean delivery is performed for standard indications. Misoprostol or another prostaglandin can be used for cervical ripening if the cervix is unfavorable and there are no contraindications to its use.<br /><FONT class=lozenge>◊</FONT> Refer to UpToDate topic on preterm premature rupture of membranes for a discussion of the advantages and disadvantages of expectant management versus delivery.</div><div id=\"graphicVersion\">Graphic 113429 Version 1.0</div></div></div>"},"113430":{"type":"graphic_algorithm","displayName":"Selecting a bowel prep for colonoscopy","title":"Algorithm for selecting a bowel preparation before colonoscopy in adults","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm&nbsp;for selecting a bowel preparation&nbsp;before colonoscopy in adults</div><div class=\"cntnt\"><img style=\"width:296px; height:447px;\" src=\"images/GAST/113430_Prcs_slct_bowel_prp_clnscpy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm does not substitute for the clinical judgment. Refer to UpToDate topic on bowel preparation before colonoscopy in adults.</div><div class=\"graphic_footnotes\">PEG-ELS: polyethylene glycol-electrolyte solution.<br />*&nbsp;Patients who are at risk of electrolyte abnormalities include patients with a history of congestive heart failure, renal insufficiency, end stage liver disease, and those on diuretic therapy.<br />¶&nbsp;Risk factors for inadequate bowel preparation include the following: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Prior inadequate preparation</LI>&#xD;&#xA;<LI>History of constipation</LI>&#xD;&#xA;<LI>Use of medications associated with constipation (ie, tricyclic antidepressants and opioids)</LI>&#xD;&#xA;<LI>Obesity</LI>&#xD;&#xA;<LI>Diabetes mellitus</LI>&#xD;&#xA;<LI>Dementia or Parkinson disease</LI>&#xD;&#xA;<LI>Cirrhosis</LI>&#xD;&#xA;<LI>Low health literacy</LI>&#xD;&#xA;<LI>Low patient engagement</LI></UL>Δ&nbsp;For patients with&nbsp;history of&nbsp;inadequate preparation, additional measures may include: two days of clear liquids, scheduling a morning procedure, adding a second agent such as magnesium citrate if there are no contraindications.<br /><FONT class=lozenge>◊</FONT> Low volume preparation options include: low volume PEG-ELS or PEG 3350 solutions or magnesium citrate. <br />§ Dosing regimens:&nbsp;Split-dosing: Half of the bowel preparation is given the evening before the colonoscopy and the second half is given on the day of the colonoscopy. The last dose is consumed at least two hours prior to the appointment time. Single dose, same-day: For appointments after 12 noon, a single dose preparation is an alternative. The preparation is started at least six hours prior to colonoscopy and last dose is consumed at least two hours prior to the appointment time.</div><div id=\"graphicVersion\">Graphic 113430 Version 1.0</div></div></div>"},"113434":{"type":"graphic_algorithm","displayName":"HSAT versus PSG","title":"HSAT versus PSG","html":"<div class=\"graphic\"><div style=\"width: 797px\" class=\"figure\"><div class=\"ttl\">HSAT versus PSG</div><div class=\"cntnt\"><img style=\"width:777px; height:715px;\" src=\"images/PULM/113434_HSAT_versus_PSG_Edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HSAT: home sleep apnea testing; PSG: polysomnography; GOLD: global initiative for obstructive lung disease; NYHA: New York Heart Association; COPD: chronic obstructive pulmonary disease; PAT: peripheral arterial tonometry; CPAP: continuous positive airway pressure; AASM: American Academy of Sleep Medicine; OSA: obstructive sleep apnea; CMS: Centers for Medicare and Medicaid Services; AHI: apnea hypopnea index; RDI: respiratory disturbance index.<br />* We agree with the AASM that a split-night rather than full-night in-laboratory PSG may be appropriate in most patients in whom moderate to severe OSA is observed during a minimum of two hours during PSG testing AND in whom at least three hours are available for CPAP titration. However, the CMS will accept an AHI or RDI that is calculated based upon less than two hours of recorded sleep, if the total number of recorded events to calculate the AHI or RDI during sleep testing is at least the number of events that would have been required in a two hour period.<br />&para; In-laboratory PSG remains the gold standard for diagnostic testing for OSA; HSAT is an alternative in a select group of patients. For most patients with suspected mild OSA, in-laboratory PSG is preferred since HSAT may lead to the underdetection of sleep-related events in this population. In patients with suspected moderate to severe OSA, HSAT is adequate only in a select group of patients.<br />&Delta; We favor the AASM definition when clinically assessing patient risk for OSA. The AASM states that patients at high risk of OSA include those with daytime hypersomnolence and at least two of the following three criteria: habitual loud snoring, witnessed apnea or gasping/choking, or diagnosed hypertension. However, for those in whom reliable assessment for the risk of OSA cannot be made, such as those who do not have hypersomnolence, in-laboratory polysomnography is preferred. Refer to UpToDate text on clinical presentation and diagnosis of obstructive sleep apnea in adults; section on screening questionnaires.<br /><span class=\"lozenge\">&loz;</span> Patients may have reasons that prohibit home or laboratory sleep testing such as inability to get to a laboratory, cost, homelessness, space constraints.<br />&sect; In the rare circumstance that a patient has reasons that prohibit both HSAT and in-laboratory PSG, additional testing (eg, overnight oximetry, clinical tools, questionnaires, predictive algorithms) is insensitive. Recurrent attempts should be taken to resolve the issues and get some form of sleep testing or to empirically treat those who are assessed as having OSA.<br />&yen; HSAT should be performed with a technically adequate device that incorporates a minimum of nasal pressure, chest and abdominal inductance plethysmography, and oximetry, OR PAT with oximetry and actigraphy. In addition, it should only be administered by an accredited sleep center under the supervision of a board-certified sleep physician. If one HSAT is negative, inconclusive, or technically inadequate AND the suspicion for OSA remains, in-laboratory PSG should be performed, if feasible. In patients with conditions that increase the risk of non-obstructive breathing, HSAT is considered less accurate and may underdiagnose OSA and/or not detect other sleep-related events.</div><div id=\"graphicVersion\">Graphic 113434 Version 2.0</div></div></div>"},"113438":{"type":"graphic_table","displayName":"Chemo plus trastuzumab vs trastuzumab followed by chemo trials","title":"Findings from three trials evaluating chemo plus trastuzumab versus trastuzumab followed by chemo in HER2-positive metastatic breast cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Findings from three trials evaluating chemo plus trastuzumab versus trastuzumab followed by chemo in HER2-positive metastatic breast cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">HERTAX (n = 101)<sup>[1]</sup></td> <td class=\"subtitle1\">JO17360 (n = 112)<sup>[2]</sup></td> <td class=\"subtitle1\">SAKK 22/99 (n = 175)<sup>[3]</sup></td> </tr> <tr> <td><strong>Treatment schema</strong></td> <td>Tr + Doc (comb)<br /> versus<br /> Tr &#8594; Doc (seq)</td> <td>Tr + Doc (comb)<br /> versus<br /> Tr &#8594; Tr + Doc (seq)</td> <td>Tr + chemo (comb)<br /> versus<br /> Tr &#8594; Tr + chemo (seq)</td> </tr> <tr> <td><strong>Line of treatment</strong></td> <td>First line</td> <td>First line</td> <td>First, second, or third line</td> </tr> <tr> <td><strong>Median first PFS during Tr monotherapy</strong></td> <td>3.9 mo</td> <td>3.7 mo</td> <td>3.7 mo</td> </tr> <tr> <td><strong>Median PFS or TTP following both Tr and chemo</strong></td> <td>PFS 9.4 mo (comb)<br /> versus<br /> PFS 9.9 mo (seq)</td> <td>PFS 14.6 mo (comb)<br /> versus<br /> PFS 12.4 mo (seq)</td> <td>TTP 10.3 mo (comb)<br /> versus<br /> TTP 12.2 mo (seq)</td> </tr> <tr> <td><strong>RECIST RR following both Tr and chemo</strong></td> <td>58 (comb)<br /> versus<br /> 38% (seq)</td> <td>67.9 (comb)<br /> versus<br /> 47.2% (seq)</td> <td>Not reported</td> </tr> <tr> <td><strong>Median OS</strong></td> <td>30.5 mo (comb)<br /> versus<br /> 19.7 mo (seq)</td> <td>Not reached, but HR 2.72 with p = 0.04 in favor of comb</td> <td>36.3 mo (comb)<br /> versus<br /> 35.6 mo (seq)</td> </tr> <tr> <td><strong>Trial caveats</strong></td> <td>Tr was not continued along with docetaxel in the sequential arm</td> <td>Study closed early due to presumption of inferiority of sequential arm at interim analysis</td> <td>Accrual over 13 years; many censored patients due to off protocol endocrine therapy added; study design changed during conduct; chemo regimens not reported</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Tr: trastuzumab; Doc: docetaxel; comb: combination; seq: sequential; PFS: progression-free survival; mo: month;&nbsp;TTP: time to tumor progression; RECIST: Response Evaluation Criteria in Solid Tumors; RR: response rate; OS: overall survival; HR: hazard ratio.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hamberg P, Bos MM, Braun HJ, et al. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. Clin Breast Cancer 2011; 11:103.</LI>&#xD;&#xA;<LI>Inoue K, Nakagami K, Mizutani M, et al. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Res Treat 2010; 119:127.</LI>&#xD;&#xA;<LI>Pagani O, Klingbiel D, Ruhstaller T, et al. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Ann Oncol 2017; 28:305.</LI></OL></div><div id=\"graphicVersion\">Graphic 113438 Version 1.0</div></div></div>"},"113459":{"type":"graphic_table","displayName":"Tool to estimate patient adherance","title":"Tool to estimate patient adherance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tool to estimate patient adherance</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"51%\"></colgroup><colgroup span=\"7\" width=\"7%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td class=\"subtitle1\"><strong>&nbsp;</strong></td> <td class=\"subtitle1\"><strong>Agree<br /> completely</strong></td> <td class=\"subtitle1\"><strong>Agree<br /> mostly</strong></td> <td class=\"subtitle1\"><strong>Agree<br /> somewhat</strong></td> <td class=\"subtitle1\"><strong>Disagree<br /> somewhat</strong></td> <td class=\"subtitle1\"><strong>Disagree<br /> mostly</strong></td> <td class=\"subtitle1\"><strong>Disagree<br /> completely</strong></td> <td class=\"subtitle1\"><strong>Score</strong></td> </tr> <tr> <td>I am convinced of the importance of my prescription medication</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">7</td> <td class=\"centered\">7</td> <td class=\"centered\">20</td> <td class=\"centered\">20</td> <td>&nbsp;</td> </tr> <tr> <td>I worry that my prescription medication will do more harm than good to me</td> <td class=\"centered\">14</td> <td class=\"centered\">14</td> <td class=\"centered\">4</td> <td class=\"centered\">4</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>I feel financially burdened by my out-of-pocket expenses for my prescription medication</td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"7\"><strong>Total:</strong></td> <td><strong>&nbsp;</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Score and interpretation:&#xD;&#xA;<ul>&#xD;&#xA;    <li>​0: Low risk for adherence problems (&gt;75% probability of adherence)</li>&#xD;&#xA;    <li>2 to 7: Medium risk for adherence problems (32 to 75% probability of adherence)</li>&#xD;&#xA;    <li>8 or higher: High risk for adherence problems (&lt;32% probability of adherence)</li>&#xD;&#xA;</ul></div><div class=\"graphic_reference\">Adherence Table image reproduced with permission of Merck Sharp &amp; Co., Inc., Kenilworth, New Jersey, U.S.A. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113459 Version 1.0</div></div></div>"},"113461":{"type":"graphic_figure","displayName":"Candy cane syndrome","title":"Candy cane syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Candy cane syndrome</div><div class=\"cntnt\"><img style=\"width:375px; height:591px;\" src=\"images/SURG/113461_Candy_cane_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Candy cane Roux syndrome in patients who have undergone&nbsp;Roux-en-Y gastric bypass&nbsp;refers to an excessively long blind afferent Roux limb at the gastrojejunostomy causing postprandial pain often relieved by vomiting. It is believed that the blind afferent limb (\"candy cane\") acts as an obstructed loop when filled with food (often preferentially), and the distention of the loop causes pain until the food either spills into the Roux limb or is vomited back out. </div><div class=\"graphic_reference\">Modified from: Aryaie AH, Fayezizadeh M, Wen Y, et al. \"Candy cane syndrome:\" an underappreciated cause of abdominal pain and nausea after Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis 2017.</div><div id=\"graphicVersion\">Graphic 113461 Version 1.0</div></div></div>"},"113466":{"type":"graphic_diagnosticimage","displayName":"OTC normal retina versus MEK inhibitor-associated retinopathy","title":"Optical coherence tomography (OCT) of a normal retina versus one with MEK inhibitor-associated retinopathy","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Optical coherence tomography (OCT) of a normal retina versus one with MEK inhibitor-associated retinopathy</div><div class=\"cntnt\"><img style=\"width:561px; height:243px;\" src=\"images/ONC/113466_OTC_n_rtn_MEK_nhbtr_rtnpthy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) OCT of a normal macula showing the multiple layers of the normal retina.<br />(B) OCT of both eyes in a patient being treated with a MEK inhibitor, demonstrating bilateral, multiple, subretinal serous fluid foci.</div><div id=\"graphicVersion\">Graphic 113466 Version 1.0</div></div></div>"},"113492":{"type":"graphic_figure","displayName":"US map: Distribution of babesiosis","title":"Geographic distribution of babesiosis in the United States (2014)","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Geographic distribution of babesiosis in the United States (2014)</div><div class=\"cntnt\"><img style=\"width:584px; height:413px;\" src=\"images/ID/113492_US_mp_Distr_humn_babesiosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surveillance for babesiosis was conducted by 31 states in 2014. The total number of cases shown is 1731. The cases are mapped to the patients' county of residence, which is not necessarily where they became infected.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Babesiosis maps. Available at: <a href=\"https://www.cdc.gov/parasites/babesiosis/data-statistics/maps/maps.html\" target=\"_blank\">https://www.cdc.gov/parasites/babesiosis/data-statistics/maps/maps.html</a> (Accessed on June 8, 2017).</div><div id=\"graphicVersion\">Graphic 113492 Version 1.0</div></div></div>"},"113527":{"type":"graphic_figure","displayName":"Classification scheme for pelvic fragility fractures","title":"Classification scheme for pelvic fragility fractures<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Classification scheme for pelvic fragility&nbsp;fractures<SUP>[1]</SUP></div><div class=\"cntnt\"><img style=\"width:526px; height:453px;\" src=\"images/EM/113527_Classification_scheme_for_minor_pelvic_fractures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pictures above depict the four basic categories of fragility pelvis fractures. Fracture displacement is the key feature that distinguish between Types I and II&nbsp;from Types III and IV. The wide red lines separated by white indicate displaced fractures. The basic categories are defined as follows:<br /><br />Type I: Anterior ring disruption, either unilateral or bilateral <br /><br />Type II: Non-displaced posterior injuries <br /><br />Type III: Displaced unilateral posterior injury with an anterior pelvic ring injury <br /><br />Type IV: Displaced bilateral posterior injuries. <br /></div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Rommens PM, Ossendorf C, Pairon P, et al. Clinical pathways for fragility fractures of the pelvic ring: personal experience and review of the literature. J Orthop Sci 2015; 20:1.</LI></OL></div><div id=\"graphicVersion\">Graphic 113527 Version 1.0</div></div></div>"},"113534":{"type":"graphic_table","displayName":"Lifestyle modification for diabetes prevention","title":"Lifestyle modification for diabetes prevention","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lifestyle modification for diabetes prevention</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Trial</td> <td class=\"subtitle1\" rowspan=\"2\">n</td> <td class=\"subtitle1\" rowspan=\"2\">Age<br /> (years)</td> <td class=\"subtitle1\" rowspan=\"2\">BMI<br /> (kg/m<sup>2</sup>)</td> <td class=\"subtitle1\" rowspan=\"2\">Intervention</td> <td class=\"subtitle1\" rowspan=\"2\">Study duration<br /> (years)</td> <td class=\"subtitle1\">Weight loss<br /> (mean reduction, kg)</td> <td class=\"subtitle1\">Cumulative incidence diabetes*</td> </tr> <tr> <td class=\"subtitle2\">Lifestyle modification versus control</td> <td class=\"subtitle2\">Lifestyle modification versus control</td> </tr> <tr class=\"divider_bottom\"> <td>Finnish Diabetes Prevention <span style=\"white-space: nowrap;\">Study<sup>[1]</sup></span></td> <td class=\"centered\">522</td> <td class=\"centered\">55</td> <td class=\"centered\">31</td> <td>Lifestyle modification, control</td> <td class=\"centered\">3.2</td> <td>3.5 versus 0.8</td> <td>11 versus 23%</td> </tr> <tr class=\"divider_bottom\"> <td>Diabetes Prevention <span style=\"white-space: nowrap;\">Program<sup>[2]</sup></span></td> <td class=\"centered\">3234</td> <td class=\"centered\">51</td> <td class=\"centered\">34</td> <td>Lifestyle modification, metformin, placebo</td> <td class=\"centered\">3</td> <td>5.6 versus 0.1</td> <td>14 versus 29%<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>China Da Qing Diabetes Prevention <span style=\"white-space: nowrap;\">Study<sup>[3]</sup></span></td> <td class=\"centered\">577</td> <td class=\"centered\">45</td> <td class=\"centered\">25.8</td> <td>Diet, exercise, diet + exercise, control</td> <td class=\"centered\">6</td> <td>2.6 (diet + exercise) versus 0.6</td> <td>46 (diet + exercise) versus 67.7%</td> </tr> <tr> <td>Zensharen Study for Prevention of Lifestyle <span style=\"white-space: nowrap;\">Diseases<sup>[4]</sup></span></td> <td class=\"centered\">641</td> <td class=\"centered\">49</td> <td class=\"centered\">27</td> <td>Lifestyle modification (frequent intervention), control</td> <td class=\"centered\">3</td> <td>2.5 versus 1.1</td> <td>12.2 versus 16.6%</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Trials comparing lifestyle modification with usual care in patients with impaired glucose tolerance or impaired fasting glucose. Lifestyle modifications are typically composed of exercise, diet, and behavioral modification. Age, BMI, and study duration presented as mean (except Zensharen; age reported as median).</div><div class=\"graphic_footnotes\">BMI: body mass index.<br />* Diabetes diagnosed by fasting hyperglycemia or 2-hour plasma glucose tolerance test.<br />&para; Metformin arm, incidence of diabetes 22%.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Tuomilehto J, Lindstr&ouml;m J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343.</li>&#xD;&#xA;    <li>Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.</li>&#xD;&#xA;    <li>Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20:537.</li>&#xD;&#xA;    <li>Saito T, Watanabe M, Nishida J, et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: A randomized controlled trial. Arch Intern Med 2011; 171:1352.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 113534 Version 1.0</div></div></div>"},"113536":{"type":"graphic_figure","displayName":"Predicted overall survival pancreatic CA 8th Ed AJCC stage group","title":"Predicted overall survival for patients with resected pancreatic cancer according to the eighth edition (2017) American Joint Committee on Cancer (AJCC) prognostic stage groups","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Predicted overall survival for patients with resected pancreatic cancer according to the eighth edition (2017) American Joint Committee on Cancer (AJCC) prognostic stage groups</div><div class=\"cntnt\"><img style=\"width:556px; height:660px;\" src=\"images/ONC/113536_Prdctd_ovrl_surv_pancrtc_CA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The eighth edition AJCC Staging System predicts overall survival for patients with resected pancreas cancer and indicates the corresponding number of patients at risk.</div><div class=\"graphic_reference\">Annals of Surgical Oncology, Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis, vol. 24, 2017, p. 2023, Kamarajah SK, Burns WR, Frankel TL, et al, &copy; Society of Surgical Oncology 2017. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 113536 Version 1.0</div></div></div>"},"113538":{"type":"graphic_algorithm","displayName":"Management upper airway obstruction children no foreign body","title":"Management of severe upper airway obstruction not due to a foreign body in children*","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Management of severe upper airway obstruction not due to a foreign body in children*</div><div class=\"cntnt\"><img style=\"width:473px; height:911px;\" src=\"images/EM/113538_Mgmt_up_arwy_obs_chld_no_FB.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RSI: rapid sequence intubation; ICU: intensive care unit; LMA: laryngeal mask airway; OR: operating room.<br />* The following findings suggest upper airway obstruction: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Inspiratory stridor, wheezing, or stertor</LI>&#xD;&#xA;<LI>Suprasternal or supraclavicular retractions</LI>&#xD;&#xA;<LI>Prolonged inspiratory phase</LI>&#xD;&#xA;<LI>Drooling</LI>&#xD;&#xA;<LI>Dysphagia</LI></UL>&nbsp;&nbsp;Positions of comfort to help maintain airway patency in patients with severe obstruction:<br /><UL>&#xD;&#xA;<LI>\"Sniffing\" position (neck is mildly flexed and head is mildly extended)</LI>&#xD;&#xA;<LI>Tripod position (leaning forward while bracing on the arms with neck hyperextended and chin thrust forward)</LI></UL>¶ Refer to UpToDate topics on evaluation of upper airway obstruction in children.<br />Δ For description of the technique and performance of cricothyrotomy and transtracheal ventilation, refer to UpToDate topics on needle and surgical cricothyrotomy.</div><div id=\"graphicVersion\">Graphic 113538 Version 1.0</div></div></div>"},"113540":{"type":"graphic_algorithm","displayName":"Neoadjuvant therapy for locally advanced, hormone-positive BC","title":"Approach for patients with locally advanced, hormone-positive breast cancer receiving neoadjuvant therapy*","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Approach for patients with locally advanced, hormone-positive breast cancer receiving neoadjuvant therapy*</div><div class=\"cntnt\"><img style=\"width:459px; height:837px;\" src=\"images/ONC/113540_Neadj_lcl_adv_hrmn_ps_BC_E1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HER2: human epidermal growth factor receptor 2; NACT: neoadjuvant chemotherapy; BCT: breast-conserving therapy.<br />* Not all patients with locally advanced, hormone-positive breast cancer will need or benefit from neoadjuvant therapy. This algorithm describes the approach for those who warrant neoadjuvant treatment.<br />&para; Chemotherapy and HER2-directed therapy are discussed separately. Refer to UpToDate topics on neoadjuvant therapy for patients with HER2-positive breast cancer.<br />&Delta; An alternative strategy for medically frail patients who cannot tolerate chemotherapy is HER2-directed therapy plus endocrine therapy. However, responses may be less frequent and less durable than when chemotherapy is incorporated. Refer to UpToDate topics on neoadjuvant therapy for HER2-positive breast cancer, section on HER2-targeted therapy without chemotherapy.<br /><span class=\"lozenge\">&loz;</span> Assessment of medically fit versus frail for the purposes of decisions regarding systemic therapy is discussed separately. Refer to UpToDate topics on general principles on the treatment of early-stage and locally advanced breast cancer in older women.<br />&sect; For medically fit patients who warrant neoadjuvant treatment, chemotherapy is the standard approach, provided there are no contraindications. However, we offer endocrine therapy as an acceptable alternative for those who would prefer to avoid chemotherapy, particularly for those with multiple features that would predict a good response to endocrine therapy including low/intermediate grade, estrogen receptor (ER) richness (eg, 50% staining for ER or an Allred score of 7 or 8), and Ki67&lt;15%). Further data are needed to establish the optimal biomarkers for response to neoadjuvant treatment. Refer to UpToDate topics on neoadjuvant therapy for newly-diagnosed hormone receptor positive breast cancer.<br />&yen; Tumors should be reassessed by physical exam routinely during treatment. If there is evidence of progression, patients should proceed directly to surgery.<br />&Dagger; Aromatase inhibitors are preferred over tamoxifen in neoadjuvant endocrine therapy. For patients who decline or are not tolerant of aromatase inhibitors, tamoxifen is an appropriate alternative.<br />&dagger; While assessment after neoadjuvant treatment is typically via physical exam, imaging may be appropriate in certain instances and is discussed elsewhere. Refer to UpToDate topic on general principles of neoadjuvant therapy for breast cancer, section on clinical assessment and indications for imaging.<br />** Contraindications for BCT: Multicentric disease, large tumor relative to breast, diffuse malignant-appearing calcifications, prior chest radiation, or pregnancy.<br />&para;&para; Many patients treated with neoadjuvant endocrine therapy are not appropriate candidates for chemotherapy. However, for those who are candidates for chemotherapy, it may be considered as another alternative in the context of poor response to neoadjuvant endocrine therapy.</div><div id=\"graphicVersion\">Graphic 113540 Version 2.0</div></div></div>"},"113542":{"type":"graphic_table","displayName":"Cervix uteri TNM 2017","title":"Cervix uteri TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cervix uteri TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">The definitions of the T categories correspond to the stages accepted by the F&#233;d&#233;ration Internationale de Gyn&#233;cologie et d'Obst&#233;trique (FIGO). Both systems are included for comparison.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td>&nbsp;</td> <td colspan=\"2\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td>&nbsp;</td> <td colspan=\"2\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>I</td> <td colspan=\"2\">Cervical carcinoma confined to the uterus (extension to corpus should be disregarded)</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td>IA</td> <td colspan=\"2\">Invasive carcinoma diagnosed only by microscopy. Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or less. Vascular space involvement, venous or lymphatic, does not affect classification.</td> </tr> <tr> <td class=\"indent3\">T1a1</td> <td>IA1</td> <td colspan=\"2\">Measured stromal invasion of 3.0 mm or less in depth and 7.0 mm or less in horizontal spread</td> </tr> <tr> <td class=\"indent3\">T1a2</td> <td>IA2</td> <td colspan=\"2\">Measured stromal invasion of more than 3.0 mm and not more than 5.0 mm, with a horizontal spread of 7.0 mm or less</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td>IB</td> <td colspan=\"2\">Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a/IA2. Includes all macroscopically visible lesions, even those with superficial invasion.</td> </tr> <tr> <td class=\"indent3\">T1b1</td> <td>IB1</td> <td colspan=\"2\">Clinically visible lesion 4.0 cm or less in greatest dimension</td> </tr> <tr> <td class=\"indent3\">T1b2</td> <td>IB2</td> <td colspan=\"2\">Clinically visible lesion more than 4.0 cm in greatest dimension</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>II</td> <td colspan=\"2\">Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of the vagina</td> </tr> <tr> <td class=\"indent2\">T2a</td> <td>IIA</td> <td colspan=\"2\">Tumor without parametrial invasion</td> </tr> <tr> <td class=\"indent3\">T2a1</td> <td>IIA1</td> <td colspan=\"2\">Clinically visible lesion 4.0 cm or less in greatest dimension</td> </tr> <tr> <td class=\"indent3\">T2a2</td> <td>IIA2</td> <td colspan=\"2\">Clinically visible lesion more than 4.0 cm in greatest dimension</td> </tr> <tr> <td class=\"indent2\">T2b</td> <td>IIB</td> <td colspan=\"2\">Tumor with parametrial invasion</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>III</td> <td colspan=\"2\">Tumor extending to the pelvic sidewall* and/or involving the lower third of the vagina and/or causing hydronephrosis or nonfunctioning kidney</td> </tr> <tr> <td class=\"indent2\">T3a</td> <td>IIIA</td> <td colspan=\"2\">Tumor involving the lower third of the vagina but not extending to the pelvic wall</td> </tr> <tr> <td class=\"indent2\">T3b</td> <td>IIIB</td> <td colspan=\"2\">Tumor extending to the pelvic wall and/or causing hydronephrosis or nonfunctioning kidney</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>IVA</td> <td colspan=\"2\">Tumor invading the mucosa of the bladder or rectum and/or extending beyond the true pelvis (bullous edema is not sufficient to classify a tumor as T4)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">* The pelvic sidewall is defined as the muscle, fascia, neurovascular structures, and skeletal portions of the bony pelvis. On rectal examination, there is no cancer-free space between the tumor and pelvic sidewall.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td>&nbsp;</td> <td colspan=\"2\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td>&nbsp;</td> <td colspan=\"2\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N0(i+)</td> <td>&nbsp;</td> <td colspan=\"2\">Isolated tumor cells in regional lymph node(s) no greater than 0.2 mm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td>&nbsp;</td> <td colspan=\"2\">Regional lymph node metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td>&nbsp;</td> <td colspan=\"2\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td>IVB</td> <td colspan=\"2\">Distant metastasis (including peritoneal spread or involvement of the supraclavicular, mediastinal, or distant lymph nodes; lung; liver; or bone)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1</td> <td>Any N</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T1a</td> <td>Any N</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class=\"indent1\">T1a1</td> <td>Any N</td> <td>M0</td> <td>IA1</td> </tr> <tr> <td class=\"indent1\">T1a2</td> <td>Any N</td> <td>M0</td> <td>IA2</td> </tr> <tr> <td class=\"indent1\">T1b</td> <td>Any N</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent1\">T1b1</td> <td>Any N</td> <td>M0</td> <td>IB1</td> </tr> <tr> <td class=\"indent1\">T1b2</td> <td>Any N</td> <td>M0</td> <td>IB2</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>Any N</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T2a</td> <td>Any N</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T2a1</td> <td>Any N</td> <td>M0</td> <td>IIA1</td> </tr> <tr> <td class=\"indent1\">T2a2</td> <td>Any N</td> <td>M0</td> <td>IIA2</td> </tr> <tr> <td class=\"indent1\">T2b</td> <td>Any N</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>Any N</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T3a</td> <td>Any N</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T3b</td> <td>Any N</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>Any N</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVB</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 113542 Version 2.0</div></div></div>"},"113543":{"type":"graphic_table","displayName":"Corpus uteri: Carcinoma and carcinosarcoma TNM 2017","title":"Corpus uteri: Carcinoma and carcinosarcoma TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Corpus uteri: Carcinoma and carcinosarcoma TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">The definitions of the T categories correspond to the stages accepted by the F&#233;d&#233;ration Internationale de Gyn&#233;cologie et d'Obst&#233;trique (FIGO). Both systems are included for comparison.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td>&nbsp;</td> <td colspan=\"2\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td>&nbsp;</td> <td colspan=\"2\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>I</td> <td colspan=\"2\">Tumor confined to the corpus uteri, including endocervical glandular involvement*</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td>IA</td> <td colspan=\"2\">Tumor limited to the endometrium or invading less than half the myometrium</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td>IB</td> <td colspan=\"2\">Tumor invading one half or more of the myometrium</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>II</td> <td colspan=\"2\">Tumor invading the stromal connective tissue of the cervix but not extending beyond the uterus. Does NOT include endocervical glandular involvement.</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>III</td> <td colspan=\"2\">Tumor involving serosa, adnexa, vagina, or parametrium</td> </tr> <tr> <td class=\"indent2\">T3a</td> <td>IIIA</td> <td colspan=\"2\">Tumor involving the serosa and/or adnexa (direct extension or metastasis)</td> </tr> <tr> <td class=\"indent2\">T3b</td> <td>IIIB</td> <td colspan=\"2\">Vaginal involvement (direct extension or metastasis) or parametrial involvement</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td>IVA</td> <td colspan=\"2\">Tumor invading the bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td>&nbsp;</td> <td colspan=\"2\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td>&nbsp;</td> <td colspan=\"2\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N0(i+)</td> <td>&nbsp;</td> <td colspan=\"2\">Isolated tumor cells in regional lymph node(s) no greater than 0.2 mm</td> </tr> <tr> <td class=\"indent1\">N1</td> <td>IIIC1</td> <td colspan=\"2\">Regional lymph node metastasis to pelvic lymph nodes</td> </tr> <tr> <td class=\"indent2\">N1mi</td> <td>IIIC1</td> <td colspan=\"2\">Regional lymph node metastasis (greater than 0.2 mm but not greater than 2.0 mm in diameter) to pelvic lymph nodes</td> </tr> <tr> <td class=\"indent2\">N1a</td> <td>IIIC1</td> <td colspan=\"2\">Regional lymph node metastasis (greater than 2.0 mm in diameter) to pelvic lymph nodes</td> </tr> <tr> <td class=\"indent1\">N2</td> <td>IIIC2</td> <td colspan=\"2\">Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes</td> </tr> <tr> <td class=\"indent2\">N2mi</td> <td>IIIC2</td> <td colspan=\"2\">Regional lymph node metastasis (greater than 0.2 mm but not greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes</td> </tr> <tr> <td class=\"indent2\">N2a</td> <td>IIIC2</td> <td colspan=\"2\">Regional lymph node metastasis (greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">Suffix (sn) is added to the N category when metastasis is identified only by sentinel lymph node biopsy.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td>&nbsp;</td> <td colspan=\"2\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td>IVB</td> <td colspan=\"2\">Distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, lung, liver, or bone).<br /> (It excludes metastasis to pelvic or para-aortic lymph nodes, vagina, uterine serosa, or adnexa).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T1a</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class=\"indent1\">T1b</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T3a</td> <td>N0</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T3b</td> <td>N0</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T1-T3</td> <td>N1/N1mi/N1a</td> <td>M0</td> <td>IIIC1</td> </tr> <tr> <td class=\"indent1\">T1-T3</td> <td>N2/N2mi/N2a</td> <td>M0</td> <td>IIIC2</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>Any N</td> <td>M0</td> <td>IVA</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVB</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Histologic grade (G)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>G</strong></td> <td colspan=\"3\"><strong>G definition</strong></td> </tr> <tr> <td class=\"indent1\">GX</td> <td colspan=\"3\">Grade cannot be assessed</td> </tr> <tr> <td class=\"indent1\">G1</td> <td colspan=\"3\">Well differentiated</td> </tr> <tr> <td class=\"indent1\">G2</td> <td colspan=\"3\">Moderately differentiated</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">G3</td> <td colspan=\"3\">Poorly differentiated or undifferentiated</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Histopathology: Degree of differentiation</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cases of carcinoma of the corpus uteri should be grouped according to the degree of differentiation of the endometrioid adenocarcinoma:</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td><strong>G</strong></td> <td colspan=\"3\"><strong>G definition</strong></td> </tr> <tr> <td class=\"indent1\">G1</td> <td colspan=\"3\">5% or less of a nonsquamous or nonmorular solid growth pattern</td> </tr> <tr> <td class=\"indent1\">G2</td> <td colspan=\"3\">6-50% of a nonsquamous or nonmorular solid growth pattern</td> </tr> <tr> <td class=\"indent1\">G3</td> <td colspan=\"3\">More than 50% of a nonsquamous or nonmorular solid growth pattern. Papillary serous, clear cell, and carcinosarcoma are considered high grade.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><em>NOTES on pathologic grading:</em> <ol> <li>Notable nuclear atypia exceeding that which is routinely expected for the architectural grade increases the tumor grade by 1 (ie, 1 to 2 and 2 to 3). </li> <li>Serous, clear cell, and mixed mesodermal tumors are <em>high risk</em> and considered grade 3. </li> <li>Adenocarcinomas with benign squamous elements (squamous metaplasia) are graded according to the nuclear grade of the glandular component. </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Endometrial intraepithelial carcinoma (EIC) should be considered a T1 cancer.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 113543 Version 3.0</div></div></div>"},"113544":{"type":"graphic_table","displayName":"Corpus uteri: Sarcoma TNM 2017","title":"Corpus uteri: Sarcoma TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Corpus uteri: Sarcoma TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Leiomyosarcoma and endometrial stromal sarcoma</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>T category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent2\">TX</td> <td>&nbsp;</td> <td colspan=\"2\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">T0</td> <td>&nbsp;</td> <td colspan=\"2\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>I</td> <td colspan=\"2\">Tumor limited to the uterus</td> </tr> <tr> <td class=\"indent3\">T1a</td> <td>IA</td> <td colspan=\"2\">Tumor 5 cm or less in greatest dimension</td> </tr> <tr> <td class=\"indent3\">T1b</td> <td>IB</td> <td colspan=\"2\">Tumor more than 5 cm</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>II</td> <td colspan=\"2\">Tumor extends beyond the uterus, within the pelvis</td> </tr> <tr> <td class=\"indent3\">T2a</td> <td>IIA</td> <td colspan=\"2\">Tumor involves adnexa</td> </tr> <tr> <td class=\"indent3\">T2b</td> <td>IIB</td> <td colspan=\"2\">Tumor involves other pelvic tissues</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>III</td> <td colspan=\"2\">Tumor infiltrates abdominal tissues</td> </tr> <tr> <td class=\"indent3\">T3a</td> <td>IIIA</td> <td colspan=\"2\">One site</td> </tr> <tr> <td class=\"indent3\">T3b</td> <td>IIIB</td> <td colspan=\"2\">More than one site</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4</td> <td>IVA</td> <td colspan=\"2\">Tumor invades bladder or rectum</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Adenosarcoma</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>T category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent2\">TX</td> <td>&nbsp;</td> <td colspan=\"2\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">T0</td> <td>&nbsp;</td> <td colspan=\"2\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>I</td> <td colspan=\"2\">Tumor limited to the uterus</td> </tr> <tr> <td class=\"indent3\">T1a</td> <td>IA</td> <td colspan=\"2\">Tumor limited to the endometrium/endocervix</td> </tr> <tr> <td class=\"indent3\">T1b</td> <td>IB</td> <td colspan=\"2\">Tumor invades to less than half of the myometrium</td> </tr> <tr> <td class=\"indent3\">T1c</td> <td>IC</td> <td colspan=\"2\">Tumor invades more than half of the myometrium</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>II</td> <td colspan=\"2\">Tumor extends beyond the uterus, within the pelvis</td> </tr> <tr> <td class=\"indent3\">T2a</td> <td>IIA</td> <td colspan=\"2\">Tumor involves adnexa</td> </tr> <tr> <td class=\"indent3\">T2b</td> <td>IIB</td> <td colspan=\"2\">Tumor involves other pelvic tissues</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>III</td> <td colspan=\"2\">Tumor infiltrates abdominal tissues</td> </tr> <tr> <td class=\"indent3\">T3a</td> <td>IIIA</td> <td colspan=\"2\">One site</td> </tr> <tr> <td class=\"indent3\">T3b</td> <td>IIIB</td> <td colspan=\"2\">More than one site</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4</td> <td>IVA</td> <td colspan=\"2\">Tumor invades bladder or rectum</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">All uterine sarcomas</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>N category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td>&nbsp;</td> <td colspan=\"2\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">N0</td> <td>&nbsp;</td> <td colspan=\"2\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N0(i+)</td> <td>&nbsp;</td> <td colspan=\"2\">Isolated tumor cells in regional lymph node(s) no greater than 0.2 mm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">N1</td> <td>IIIC</td> <td colspan=\"2\">Regional lymph node metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">All uterine sarcomas</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>M category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent2\">M0</td> <td>&nbsp;</td> <td colspan=\"2\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1</td> <td>IVB</td> <td colspan=\"2\">Distant metastasis (excluding adnexa, pelvic, and abdominal tissues)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Leiomyosarcoma and endometrial stromal sarcoma</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\"><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent2\">T3a</td> <td>N0</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent2\">T3b</td> <td>N0</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent2\">T1-3</td> <td>N1</td> <td>M0</td> <td>IIIC</td> </tr> <tr> <td class=\"indent2\">T4</td> <td>Any N</td> <td>M0</td> <td>IVA</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVB</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Adenosarcoma</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\"><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent2\">T3a</td> <td>N0</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent2\">T3b</td> <td>N0</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent2\">T1-3</td> <td>N1</td> <td>M0</td> <td>IIIC</td> </tr> <tr> <td class=\"indent2\">T4</td> <td>Any N</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVB</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Grade is not a collected element in leiomyosarcoma, as all are high-grade tumors.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 113544 Version 2.0</div></div></div>"},"113545":{"type":"graphic_table","displayName":"Ovary, fallopian tube, and primary peritoneal carcinoma TNM 2017","title":"Ovary, fallopian tube, and primary peritoneal carcinoma TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ovary, fallopian tube, and primary peritoneal carcinoma TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td>&nbsp;</td> <td colspan=\"2\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td>&nbsp;</td> <td colspan=\"2\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>I</td> <td colspan=\"2\">Tumor limited to ovaries (one or both) or fallopian tube(s)</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td>IA</td> <td colspan=\"2\">Tumor limited to one ovary (capsule intact) or fallopian tube surface; no malignant cells in ascites or peritoneal washings</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td>IB</td> <td colspan=\"2\">Tumor limited to one or both ovaries (capsules intact) or fallopian tubes; no tumor on ovarian or fallopian tube surface; no malignant cells in ascites or peritoneal washings</td> </tr> <tr> <td class=\"indent2\">T1c</td> <td>IC</td> <td colspan=\"2\">Tumor limited to one or both ovaries or fallopian tubes, with any of the following:</td> </tr> <tr> <td class=\"indent3\">T1c1</td> <td>IC1</td> <td colspan=\"2\"> <ul class=\"decimal_heading\"> <li>Surgical spill </li> </ul> </td> </tr> <tr> <td class=\"indent3\">T1c2</td> <td>IC2</td> <td colspan=\"2\"> <ul class=\"decimal_heading\"> <li>Capsule ruptured before surgery or tumor on ovarian or fallopian tube surface </li> </ul> </td> </tr> <tr> <td class=\"indent3\">T1c3</td> <td>IC3</td> <td colspan=\"2\"> <ul class=\"decimal_heading\"> <li>Malignant cells in ascites or peritoneal washings </li> </ul> </td> </tr> <tr> <td class=\"indent1\">T2</td> <td>II</td> <td colspan=\"2\">Tumor involves one or both ovaries or fallopian tubes with pelvic extension below pelvic brim or primary peritoneal cancer</td> </tr> <tr> <td class=\"indent2\">T2a</td> <td>IIA</td> <td colspan=\"2\">Extension and/or implants on the uterus and/or fallopian tube(s) and/or ovaries</td> </tr> <tr> <td class=\"indent2\">T2b</td> <td>IIB</td> <td colspan=\"2\">Extension to and/or implants on other pelvic tissues</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>III</td> <td colspan=\"2\">Tumor involves one or both ovaries or fallopian tubes, or primary peritoneal cancer, with microscopically confirmed peritoneal metastasis outside the pelvis and/or metastasis to the retroperitoneal (pelvic and/or para-aortic) lymph nodes</td> </tr> <tr> <td class=\"indent2\">T3a</td> <td>IIIA2</td> <td colspan=\"2\">Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes</td> </tr> <tr> <td class=\"indent2\">T3b</td> <td>IIIB</td> <td colspan=\"2\">Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T3c</td> <td>IIIC</td> <td colspan=\"2\">Macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td>&nbsp;</td> <td colspan=\"2\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td>&nbsp;</td> <td colspan=\"2\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N0(i+)</td> <td>&nbsp;</td> <td colspan=\"2\">Isolated tumor cells in regional lymph node(s) no greater than 0.2 mm</td> </tr> <tr> <td class=\"indent1\">N1</td> <td>IIIA1</td> <td colspan=\"2\">Positive retroperitoneal lymph nodes only (histologically confirmed)</td> </tr> <tr> <td class=\"indent2\">N1a</td> <td>IIIA1i</td> <td colspan=\"2\">Metastasis up to 10 mm in greatest dimension</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">N1b</td> <td>IIIB1ii</td> <td colspan=\"2\">Metastasis more than 10 mm in greatest dimension</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td>&nbsp;</td> <td colspan=\"2\">No distant metastasis</td> </tr> <tr> <td class=\"indent1\">M1</td> <td>IV</td> <td colspan=\"2\">Distant metastasis, including pleural effusion with positive cytology; liver or splenic parenchymal metastasis; metastasis to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); and transmural involvement of intestine</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td>IVA</td> <td colspan=\"2\">Pleural effusion with positive cytology</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1b</td> <td>IVB</td> <td colspan=\"2\">Liver or splenic parenchymal metastases; metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); transmural involvement of intestine</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T1a</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class=\"indent1\">T1b</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent1\">T1c</td> <td>N0</td> <td>M0</td> <td>IC</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T2a</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T2b</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T1/T2</td> <td>N1</td> <td>M0</td> <td>IIIA1</td> </tr> <tr> <td class=\"indent1\">T3a</td> <td>N0, N1</td> <td>M0</td> <td>IIIA2</td> </tr> <tr> <td class=\"indent1\">T3b</td> <td>N0, N1</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T3c</td> <td>N0, N1</td> <td>M0</td> <td>IIIC</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1a</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1b</td> <td>IVB</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 113545 Version 2.0</div></div></div>"},"113546":{"type":"graphic_table","displayName":"Adjustments to initial ventilator settings in children","title":"Typical adjustments to initial ventilator settings in children by underlying condition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical adjustments to initial ventilator settings in children by underlying condition</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Lung protection strategy for patients with inadequate oxygenation (eg, PARDS)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>PIP: Adjust for target tidal volume 4 to 6 mL/kg (maximum 10 mL/kg); higher PIP (up to 30 to 40 cm H<sub>2</sub>O) required for poor lung compliance </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>PEEP: Increase for hypoxemia, atelectasis, may be &#62;10 cm H<sub>2</sub>O </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>SpO<sub>2</sub>: Target 88 to 92%/55 to 88 mmHg </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>PaO<sub>2</sub>: Target 88 to 92%/55 to 88 mmHg </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Obstructive airway disease causing inadequate ventilation (eg, status asthmaticus or bronchiolitis)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>RR: Near or below physiologic to prevent breath-stacking and dynamic hyperinflation </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>I<sub>T</sub>: Low/normal, goal I:E of 1:3 to 1:5 or greater </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>PIP: &#62;Plateau pressure and &#60;40 cm H<sub>2</sub>O </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>PaCO<sub>2</sub>: Permissive hypercapnia, goal pH &#62;7.20 </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Airway protection</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Minimize settings to maintain adequate oxygenation and ventilation and avoid ventilator-associated lung injury </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PARDS: pediatric acute respiratory distress syndrome; PIP: peak inspiratory pressure; PEEP: positive end-expiratory pressure; SpO<SUB innerHtml>2: </SUB>oxygen saturation; PaO<SUB>2</SUB>: arterial oxygen tension;&nbsp;RR: respiratory rate; I<SUB>T</SUB>: inspiratory time.<br />* Consultation with an expert in the mechanical ventilation of children (eg, pediatric intensivist or pediatric anesthesiologist) is strongly encouraged. Regardless of ventilator settings employed, the physician must assess ventilator settings shortly after initiation and frequently thereafter and adjust them as needed to meet oxygenation and ventilation goals as the natural course of the underlying pathophysiology evolves.</div><div id=\"graphicVersion\">Graphic 113546 Version 2.0</div></div></div>"},"113548":{"type":"graphic_table","displayName":"Volume-controlled initial ventilator settings in children","title":"Initial settings for volume-controlled mechanical ventilation in children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial settings for volume-controlled mechanical ventilation in children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Infant<br /> (&#60;1 year of age)</td> <td class=\"subtitle1\">Toddler/child<br /> (1 to 12 years)</td> <td class=\"subtitle1\">Adolescent<br /> (&#62;12 years)</td> </tr> <tr> <td rowspan=\"2\"><strong>Tidal volume (mL)</strong></td> <td>5 to 8 mL/kg (healthy lungs)</td> <td>5 to 8 mL/kg (healthy lungs)</td> <td>5 to 8 mL/kg (healthy lungs)</td> </tr> <tr> <td>3 to 6 mL/kg (lung protective strategy)</td> <td>3 to 6 mL/kg (lung protective strategy)</td> <td>3 to 6 mL/kg (lung protective strategy)</td> </tr> <tr> <td><strong>Rate (breaths/minute)</strong></td> <td>20 to 30</td> <td>15 to 25</td> <td>12 to 20</td> </tr> <tr> <td><strong>PEEP (cm H<sub>2</sub>O)</strong></td> <td>3 to 8</td> <td>3 to 8</td> <td>3 to 8</td> </tr> <tr> <td><strong>Pressure support (cm H<sub>2</sub>O)</strong><sup>&#182;</sup></td> <td>Minimum 6 to 10</td> <td>Minimum 6 to 10</td> <td>Minimum 6 to 10</td> </tr> <tr> <td><strong>Peak inspiratory flow (L/minute)</strong></td> <td>Adjusted to fit desired inspiratory time</td> <td>Adjusted to fit desired inspiratory time</td> <td>Adjusted to fit desired inspiratory time</td> </tr> <tr> <td><strong>Inspiratory time (seconds)</strong> Targeted, based upon changes to inspiratory flow</td> <td>0.4 to 0.6</td> <td>0.7 to 0.9</td> <td>0.9 to 1.2</td> </tr> <tr> <td><strong>FiO<sub>2</sub> (%)</strong><sup>&#916;</sup></td> <td>Start with 1.0, rapidly wean to &#8804;0.6</td> <td>Start with 1.0, rapidly wean to &#8804;0.6</td> <td>Start with 1.0, rapidly wean to &#8804;0.6</td> </tr> <tr> <td><strong>Flow trigger (L/minute)</strong></td> <td>0.25 to 0.5</td> <td>0.8 to 2</td> <td>0.8 to 2</td> </tr> <tr> <td><strong>Pressure support cycle</strong></td> <td>10 to 25% of peak flow rate</td> <td>10 to 25% of peak flow rate</td> <td>10 to 25% of peak flow rate</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PEEP: positive end-expiratory pressure; FiO<sub>2</sub>: fraction of inspired oxygen.<br />* Consultation with an expert in the mechanical ventilation of children (eg, pediatric intensivist or pediatric anesthesiologist) is strongly encouraged. Regardless of ventilator settings employed, the physician must assess ventilator settings shortly after initiation and frequently thereafter and adjust them as needed to meet oxygenation and ventilation goals as the natural course of the underlying pathophysiology evolves.<br />&para; Adjust according to endotracheal tube size: 3 to 3.5 mm: 10 cm H<sub>2</sub>O; 4 to 4.5 mm: 8 cm H<sub>2</sub>O; &ge;5 mm: 6 cm H<sub>2</sub>O.<br />&Delta; Wean to 0.60 or below to maintain arterial oxygen tension (PaO<sub>2</sub>) 60 to 80, oxygen saturation (SpO<sub>2</sub>) 92 to 97% when required PEEP is &lt;10 cm H<sub>2</sub>O; if required PEEP is &ge;10 cm H<sub>2</sub>O then targeted oxygen saturation may be reduced to 88 to 92% for those patients with pediatric adult respiratory distress syndrome (PARDS).</div><div id=\"graphicVersion\">Graphic 113548 Version 2.0</div></div></div>"},"113549":{"type":"graphic_table","displayName":"Initial pressure-controlled ventilator settings in children","title":"Initial settings for pressure-controlled mechanical ventilation in children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial settings for pressure-controlled mechanical ventilation in children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Infant<br /> (&#60;1 year of age)</td> <td class=\"subtitle1\">Toddler/child<br /> (1 to 12 years)</td> <td class=\"subtitle1\">Adolescent<br /> (&#62;12 years)</td> </tr> <tr> <td><strong>PIP (cm H<sub>2</sub>O)</strong><sup>&#182;</sup></td> <td>16 to 25</td> <td>16 to 25</td> <td>16 to 25</td> </tr> <tr> <td><strong>PEEP (cm H<sub>2</sub>O)</strong><sup>&#182;</sup></td> <td>3 to 7</td> <td>3 to 7</td> <td>3 to 7</td> </tr> <tr> <td><strong>Rate (breaths/minute)</strong></td> <td>20 to 30</td> <td>15 to 25</td> <td>12 to 20</td> </tr> <tr> <td><strong>Inspiratory time (seconds)</strong></td> <td>0.4 to 0.6</td> <td>0.7 to 0.9</td> <td>0.9 to 1.2</td> </tr> <tr> <td><strong>Pressure support (cm H<sub>2</sub>O)</strong><sup>&#916;</sup></td> <td>Minimum 6 to 10</td> <td>Minimum 6 to 10</td> <td>Minimum 6 to 10</td> </tr> <tr> <td><strong>FiO<sub>2</sub> (%)</strong><sup>&#9674;</sup></td> <td>Start with 1.0, rapidly wean to &#8804;0.6</td> <td>Start with 1.0, rapidly wean to &#8804;0.6</td> <td>Start with 1.0, rapidly wean to &#8804;0.6</td> </tr> <tr> <td><strong>Flow trigger (L/minute)</strong></td> <td>0.25 to 0.5</td> <td>0.8 to 2</td> <td>0.8 to 2</td> </tr> <tr> <td><strong>Pressure support cycle</strong></td> <td>10 to 25% of peak flow rate</td> <td>10 to 25% of peak flow rate</td> <td>10 to 25% of peak flow rate</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PIP: peak inspiratory pressure; PEEP: positive end-expiratory pressure; FiO<SUB>2</SUB>: fraction of inspired oxygen.<br />* Consultation with an expert in the mechanical ventilation of children (eg, pediatric intensivist or pediatric anesthesiologist) is strongly encouraged. Regardless of ventilator settings employed, the physician must assess ventilator settings shortly after initiation and frequently thereafter and adjust them as needed to meet oxygenation and ventilation goals as the natural course of the underlying pathophysiology evolves.<br />¶ Initial pressure settings can be established based upon pressures identified during manual ventilation with a bag and a manometer/standalone respiratory mechanics monitor prior to switching to the ventilator.<br />Δ Adjust according to endotracheal tube size: 3 to 3.5 mm: 10 cm H<SUB>2</SUB>O; 4 to 4.5 mm: 8 cm H<SUB>2</SUB>O; ≥5 mm: 6 cm H<SUB>2</SUB>O.<br /><FONT class=lozenge>◊</FONT> Wean to 0.60 or below to maintain arterial oxygen tension (PaO<SUB>2</SUB>) 60 to 80, oxygen saturation (SpO<SUB>2</SUB>) 92 to 97% when required PEEP is &lt;10 cm H<SUB>2</SUB>O; if required PEEP is ≥10 cm H<SUB>2</SUB>O then targeted oxygen saturation may be reduced to 88 to 92% for those patients with pediatric acute respiratory distress syndrome (PARDS).</div><div id=\"graphicVersion\">Graphic 113549 Version 2.0</div></div></div>"},"113555":{"type":"graphic_table","displayName":"Standard range of motion lower extremity joints","title":"Standard range of motion for lower extremity joints","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Standard range of motion for lower extremity joints</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Hip</td> </tr> <tr> <td class=\"indent1\">Flexion</td> <td>120 degrees</td> </tr> <tr> <td class=\"indent1\">Extension (hyper)</td> <td>30 degrees</td> </tr> <tr> <td class=\"indent1\">Abduction</td> <td>45 degrees</td> </tr> <tr> <td class=\"indent1\">Adduction</td> <td>30 degrees</td> </tr> <tr> <td class=\"indent1\">External (lateral) rotation</td> <td>45 degrees</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Internal (medial) rotation</td> <td>40 degrees</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Knee</td> </tr> <tr> <td class=\"indent1\">Flexion</td> <td>135 degrees</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Extension</td> <td>0 degrees (straight leg)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Ankle</td> </tr> <tr> <td class=\"indent1\">Dorsiflexion</td> <td>20 degrees</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Plantarflexion</td> <td>50 degrees</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Ankle/foot</td> </tr> <tr> <td class=\"indent1\">Inversion</td> <td>35 degrees</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Eversion</td> <td>15 degrees</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">First MTP</td> </tr> <tr> <td class=\"indent1\">Dorsiflexion</td> <td>70 degrees</td> </tr> <tr> <td class=\"indent1\">Plantarflexion</td> <td>30 degrees</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The measurements above are generally accepted normal ranges of motion for the lower extremity joints listed. Individual patient measurements will vary. Gross asymmetries between limbs and substantially limited motion at a particular joint suggests pathology or increased risk for injury.</div><div class=\"graphic_footnotes\">MTP: metatarsophalangeal.</div><div id=\"graphicVersion\">Graphic 113555 Version 1.0</div></div></div>"},"113558":{"type":"graphic_figure","displayName":"Pressure-control ventilator settings","title":"Pressure-control ventilator settings","html":"<div class=\"graphic\"><div style=\"width: 770px\" class=\"figure\"><div class=\"ttl\">Pressure-control ventilator settings</div><div class=\"cntnt\"><img style=\"width:750px; height:662px;\" src=\"images/EM/113558_Pressure_cntrl_vntltr_sttng.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: OpenPediatrics, Boston Children's Hospital (accessed on June 13, 2017).</div><div id=\"graphicVersion\">Graphic 113558 Version 1.0</div></div></div>"},"113559":{"type":"graphic_figure","displayName":"Volume-controlled ventilator settings","title":"Volume-controlled ventilator settings","html":"<div class=\"graphic\"><div style=\"width: 771px\" class=\"figure\"><div class=\"ttl\">Volume-controlled ventilator settings</div><div class=\"cntnt\"><img style=\"width:751px; height:660px;\" src=\"images/EM/113559_Volume_cntrl_vntltr_setting.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ventilator appearance during volume-controlled ventilation: The clinician sets the tidal volume, peak inspiratory flow rate, ventilation rate (mandatory breath rate), PEEP, and oxygen concentration. These settings determine the PIP, which will vary according to the patient's lung compliance and airway resistance.</div><div class=\"graphic_footnotes\">SIMV: synchronous intermittent mandatory ventilation; PS: pressure support; PEEP: positive end-expiratory pressure; PIP: peak inspiratory pressure; FiO<SUB>2</SUB>: fraction of inspired oxygen.</div><div class=\"graphic_reference\">Reproduced with permission from: OpenPediatrics, Boston Children's Hospital (accessed on June 13, 2017).</div><div id=\"graphicVersion\">Graphic 113559 Version 2.0</div></div></div>"},"113564":{"type":"graphic_picture","displayName":"Darier nail white lines","title":"Nail longitudinal white lines in Darier disease","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Nail longitudinal white lines in Darier disease</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/113564_Darier_nail_white_lines.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 113564 Version 1.0</div></div></div>"},"113565":{"type":"graphic_picture","displayName":"Darier nail red lines","title":"Nail changes in Darier disease","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Nail changes in Darier disease</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/113565_Darier_nail_red_lines.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both longitudinal white and red lines and longitudinal ridging are visible on the nails of this patient with Darier disease.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 113565 Version 1.0</div></div></div>"},"113566":{"type":"graphic_picture","displayName":"Darier nail notch","title":"Notching of the free nail border in Darier disease","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Notching of the free nail border in Darier disease</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/113566_Darier_nail_notch.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 113566 Version 1.0</div></div></div>"},"113569":{"type":"graphic_algorithm","displayName":"Types of adverse reactions to food","title":"Types of adverse reactions to food","html":"<div class=\"graphic\"><div style=\"width: 821px\" class=\"figure\"><div class=\"ttl\">Types of adverse reactions to food</div><div class=\"cntnt\"><img style=\"width:801px; height:203px;\" src=\"images/ALLRG/113569_Type_adverse_reaction_food.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div class=\"graphic_reference\">Reproduced from: Boyce JA, Assa'ad A, Burks AW, et al. Guidelines for the diagnosis and management of food allergy in the United States: Report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010; 126:S1. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113569 Version 1.0</div></div></div>"},"113571":{"type":"graphic_picture","displayName":"Leg length discrepancy anatomic landmarks","title":"Leg length discrepancy anatomic landmarks","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leg length discrepancy anatomic landmarks</div><div class=\"cntnt\"><img style=\"width:284px; height:768px;\" src=\"images/SM/113571_Lglngthdscrpantmclndmrk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above indicates several anatomic landmarks that are used during a preliminary assessment of potential leg length discrepancy. Each of these three landmarks should be at approximately equal height when observing a standing patient from the rear.</div><div class=\"graphic_footnotes\">PSIS: posterior superior iliac spine.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 113571 Version 1.0</div></div></div>"},"113572":{"type":"graphic_picture","displayName":"Darier ocular","title":"Ocular manifestations of Darier disease","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Ocular manifestations of Darier disease</div><div class=\"cntnt\"><img style=\"width:570px; height:750px;\" src=\"images/DERM/113572_Darier_ocular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Left lower eyelid. Loss of lashes, conjunctival injection, and meibomian capping can be seen. The disruption of the mucocutaneous junction is seen across the eyelid margin. Middle lamellar shortening secondary to tarsal \"melt\" can be slightly appreciated from the figure.<br />(B) Periodic acid-Schiff, magnification x100. Shows cells in the epidermis with dark cytoplasm that may represent \"corps ronds\" cells seen in Darier disease (arrow).</div><div class=\"graphic_reference\">From: Czyz C, Sharma P, Grossniklaus HE, et al. Clinical and pathologic eyelid alterations in a patient with Darier disease. Ophthal Plast Reconstr Surg 2011; 27:e170. DOI: <a href=\"http://journals.lww.com/op-rs/Abstract/2011/11000/Clinical_and_Pathologic_Eyelid_Alterations_in_a.46.aspx\" target=\"_blank\">10.1097/IOP.0b013e31820cd645</a>. Copyright &copy; 2011 American Society of Ophthalmic Plastic and Reconstructive Surgery. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113572 Version 1.0</div></div></div>"},"113574":{"type":"graphic_picture","displayName":"Tinea nigra on the palm","title":"Tinea nigra","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Tinea nigra</div><div class=\"cntnt\"><img style=\"width:756px; height:557px;\" src=\"images/DERM/113574_Tinea_nigra_palm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented patch on the palm.</div><div class=\"graphic_reference\">Courtesy of F Gómez-Daza, MD.</div><div id=\"graphicVersion\">Graphic 113574 Version 1.0</div></div></div>"},"113575":{"type":"graphic_picture","displayName":"Tinea nigra on the palm 2","title":"Tinea nigra","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Tinea nigra</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/113575_Tinea_nigra_palm_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented patch on the palm.</div><div class=\"graphic_reference\">Courtesy of F Gómez-Daza, MD.</div><div id=\"graphicVersion\">Graphic 113575 Version 1.0</div></div></div>"},"113576":{"type":"graphic_picture","displayName":"Tinea nigra macule on the palm","title":"Tinea nigra","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Tinea nigra</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/113576_Tinea_nigra_macule_palm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Irregular, hyperpigmented macule on the palm.</div><div id=\"graphicVersion\">Graphic 113576 Version 1.0</div></div></div>"},"113577":{"type":"graphic_picture","displayName":"Tinea nigra on the finger","title":"Tinea nigra","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Tinea nigra</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/113577_Tinea_nigra_finger.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented patch on the finger.</div><div id=\"graphicVersion\">Graphic 113577 Version 1.0</div></div></div>"},"113578":{"type":"graphic_picture","displayName":"Plantar tinea nigra","title":"Tinea nigra","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Tinea nigra</div><div class=\"cntnt\"><img style=\"width:640px; height:444px;\" src=\"images/DERM/113578_Plantar_tinea_nigra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented patch on the sole of the foot.</div><div id=\"graphicVersion\">Graphic 113578 Version 1.0</div></div></div>"},"113580":{"type":"graphic_picture","displayName":"Plantar tinea nigra close view","title":"Tinea nigra","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Tinea nigra</div><div class=\"cntnt\"><img style=\"width:640px; height:480px;\" src=\"images/DERM/113580_Plantar_tinea_nigra_close.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented patch on the sole of the foot.</div><div id=\"graphicVersion\">Graphic 113580 Version 1.0</div></div></div>"},"113582":{"type":"graphic_picture","displayName":"Dermoscopy of tinea nigra","title":"Tinea nigra","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Tinea nigra</div><div class=\"cntnt\"><img style=\"width:756px; height:578px;\" src=\"images/DERM/113582_Dermoscopy_tinea_nigra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dermoscopic image showing pigment in a spicular pattern that does not follow the pattern of the dermatoglyphics (skin lines).</div><div id=\"graphicVersion\">Graphic 113582 Version 1.0</div></div></div>"},"113583":{"type":"graphic_picture","displayName":"Tinea nigra potassium hydroxide (KOH) preparation","title":"Tinea nigra","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Tinea nigra</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/113583_Tinea_nigra_KOH_prep.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Potassium hydroxide preparation showing pigmented, ochre-colored, thick, irregular hyphae.</div><div class=\"graphic_reference\">Courtesy of F Gómez-Daza, MD.</div><div id=\"graphicVersion\">Graphic 113583 Version 1.0</div></div></div>"},"113586":{"type":"graphic_picture","displayName":"Culture of Hortaea werneckii","title":"<EM>Hortaea werneckii</EM>","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\"><EM>Hortaea werneckii</EM></div><div class=\"cntnt\"><img style=\"width:756px; height:517px;\" src=\"images/DERM/113586_Culture_Hortaea_werneckii.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Culture of <EM>Hortaea werneckii</EM> demonstrating both yeast and filamentous growth phases.</div><div id=\"graphicVersion\">Graphic 113586 Version 1.0</div></div></div>"},"113587":{"type":"graphic_picture","displayName":"Microscopy of Hortaea werneckii culture","title":"<EM>Hortaea werneckii</EM>","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\"><EM>Hortaea werneckii</EM></div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/113587_Micrscpy_Hortaea_werneckii.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microscopy of <EM>Hortaea werneckii</EM> culture showing yeasts with septae as well as the filamentous phase.</div><div id=\"graphicVersion\">Graphic 113587 Version 1.0</div></div></div>"},"113588":{"type":"graphic_picture","displayName":"Tinea nigra pathology","title":"Tinea nigra","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Tinea nigra</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/113588_Tinea_nigra_pathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pigmented spores and hyphae in the stratum corneum.</div><div id=\"graphicVersion\">Graphic 113588 Version 1.0</div></div></div>"},"113590":{"type":"graphic_picture","displayName":"Phytophotodermatitis on hand","title":"Phytophotodermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Phytophotodermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/113590_Phytophotodermatitis_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented patch on the hand.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 113590 Version 1.0</div></div></div>"},"113592":{"type":"graphic_picture","displayName":"Fixed drug eruption on hand","title":"Fixed drug eruption","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Fixed drug eruption</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/113592_Fixed_drug_eruption_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented patch on the hand.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 113592 Version 1.0</div></div></div>"},"113598":{"type":"graphic_figure","displayName":"Babesiosis life cycle","title":"Life cycle of babesiosis","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Life cycle of babesiosis</div><div class=\"cntnt\"><img style=\"width:586px; height:478px;\" src=\"images/ID/113598_Babesiosis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The <EM>Babesia microti</EM> life cycle involves two hosts, which include a rodent, primarily the white-footed mouse, <EM>Peromyscus leucopus</EM>, and a tick in the genus <EM>Ixodes</EM>. Human infection is accidental; humans are not definitive reservoir hosts. The dashed blue arrows convey the parts of the life cycle that occur in humans; the solid red arrows convey the parts of the life cycle that occur outside of humans. During a blood meal, a <EM>Babesia</EM>-infected tick introduces sporozoites into the mouse host <STRONG>(1)</STRONG>. Sporozoites enter erythrocytes and undergo asexual reproduction (budding) <STRONG>(2)</STRONG>. In the blood, some parasites differentiate into male and female gametes, although these cannot be distinguished by light microscopy <STRONG>(3)</STRONG>. The definitive host is the tick. Once ingested by an appropriate tick <STRONG>(4)</STRONG>, gametes unite and undergo a sporogonic cycle resulting in sporozoites <STRONG>(5)</STRONG>. Transovarial transmission (also known as vertical, or hereditary, transmission) has been documented for \"large\" <EM>Babesia</EM> species but not for the \"small\" <EM>Babesia</EM>, such as <EM>B. microti</EM> <STRONG>(A)</STRONG>.<br />Humans enter the cycle when bitten by infected ticks. During a blood meal, a <EM>Babesia</EM>-infected tick introduces sporozoites into the human host <STRONG>(6)</STRONG>. Sporozoites enter erythrocytes <STRONG>(B)</STRONG> and undergo asexual replication (budding) <STRONG>(7)</STRONG>. Multiplication of the blood-stage parasites is responsible for the clinical manifestations of the disease. Humans usually are dead-end hosts. However, human-to-human transmission is well recognized to occur via contaminated blood transfusions <STRONG>(8)</STRONG>.</div><div class=\"graphic_reference\">From: Centers for Disease Control and Prevention. Parasites - Babesiosis. Available at: <A href=\"https://www.cdc.gov/parasites/babesiosis/biology.html\" target=_blank>https://www.cdc.gov/parasites/babesiosis/biology.html</A> (Accessed on June 14, 2017).</div><div id=\"graphicVersion\">Graphic 113598 Version 2.0</div></div></div>"},"113599":{"type":"graphic_diagnosticimage","displayName":"MRI appearance of low-grade oligodendroglioma","title":"MRI appearance of low-grade oligodendroglioma","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">MRI appearance of low-grade oligodendroglioma</div><div class=\"cntnt\"><img style=\"width:525px; height:266px;\" src=\"images/NEURO/113599_MRI_apprnc_lw_grd_glioma_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain MRI in a 40-year-old male presenting with first-time generalized tonic-clonic seizure. Pathology confirmed a WHO grade II oligodendroglioma, IDH1 mutant, 1p19q-codeleted.<br />(Panel A) Axial FLAIR image showing a T2-hyperintense, expansile mass in the right frontal lobe.<br />(Panel B) Post-contrast axial T1-weighted image showing no appreciable contrast enhancement. </div><div class=\"graphic_footnotes\">IDH1: isocitrate dehydrogenase type 1; FLAIR: fluid-attenuated inversion recovery; MRI: magnetic resonance imaging; WHO: World Health Organization.</div><div id=\"graphicVersion\">Graphic 113599 Version 1.0</div></div></div>"},"113600":{"type":"graphic_figure","displayName":"Manometry in rumination syndrome","title":"Esophageal, gastric, and, abdominal pressure in rumination syndrome","html":"<div class=\"graphic\"><div style=\"width: 1222px\" class=\"figure\"><div class=\"ttl\">Esophageal, gastric, and, abdominal pressure&nbsp;in rumination syndrome</div><div class=\"cntnt\"><img style=\"width:1202px; height:520px;\" src=\"images/GAST/113600_Gastricprssrruminatnsyn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Antroduodenal manometric tracing showing \"R\" waves with simultaneous pressurization associated with pH events in the esophagus.<br />(B) High resolution esophageal manometry showing two gastric pressure events associated with return of gastric content into the proximal esophagus as shown in the impedance tracing.<br />(C) Diaphragmatic EMG recording associated with a rumination episode. There is an increase in EMG activity of intercostals, anterior abdominal muscles but reduction in diaphragmatic tracing.<br />The asterisks in panels A and B represent the R-wave, whereas the arrow denotes this in panel C.</div><div class=\"graphic_footnotes\">UES: upper esophageal sphincter; LES: lower esophageal sphincter; PIP: pressure inversion point; EMG: electromyography.</div><div class=\"graphic_reference\">From: Absah I, Rishi A, Talley NJ, et al. Rumination syndrome: pathophysiology, diagnosis, and treatment. Neurogastroenterol Motil 2017; 29:e12954. <A href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/nmo.12954/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1111/nmo.12954/abstract</A>. Copyright © 2017. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 113600 Version 2.0</div></div></div>"},"113602":{"type":"graphic_table","displayName":"Criteria for rumination syndrome in adults","title":"Rome IV criteria for rumination syndrome in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rome IV criteria for rumination syndrome in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Diagnostic criteria*</td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_to_nine\"> <li>Persistent or recurrent regurgitation of recently ingested food into the mouth with subsequent spitting or remastication and swallowing </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol class=\"numbers_to_nine\" start=\"2\"> <li>Regurgitation is not preceded by retching </li> </ol> </td> </tr> <tr> <td class=\"subtitle2_left\">Supportive remarks</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Effortless regurgitation events are usually not preceded by nausea </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Regurgitant contains recognizable food that might have a pleasant taste </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>The process tends to cease when the regurgitated material becomes acidic </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Criteria fulfilled for the last three months with symptom onset at least six months before diagnosis</div><div class=\"graphic_reference\">Reproduced from: Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology 2016; 150:1380. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113602 Version 1.0</div></div></div>"},"113604":{"type":"graphic_table","displayName":"Criteria for pediatric rumination syndrome","title":"Rome IV pediatric diagnostic criteria for rumination syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rome IV pediatric&nbsp;diagnostic criteria for rumination syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diagnostic criteria* for rumination syndrome</td> </tr> <tr> <td class=\"subtitle2_left\">Must include all of the following:</td> </tr> <tr> <td> <ol> <li>Repeated regurgitation and rechewing or expulsion of food that: </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ol style=\"list-style-type: lower-alpha;\"> <li>Begins soon after ingestion of a meal </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ol style=\"list-style-type: lower-alpha;\" start=\"2\"> <li>Does not occur during sleep </li> </ol> </td> </tr> <tr> <td> <ol start=\"2\"> <li>Not preceded by retching </li> </ol> </td> </tr> <tr> <td> <ol start=\"3\"> <li>After appropriate evaluation, the symptoms cannot be fully explained by another medical condition. An eating disorder must be ruled out. </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Criteria fulfilled for at least 2 months before diagnosis.</div><div class=\"graphic_reference\">Reproduced from: Hyams JS, Di Lorenzo C, Saps M, et al. Functional Disorders: Children and Adolescents. Gastroenterology 2016. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113604 Version 1.0</div></div></div>"},"113606":{"type":"graphic_picture","displayName":"Palmar lichen planus","title":"Lichen planus","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Lichen planus</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/113606_Palmar_lichen_planus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented papules and plaques on the wrists and palms.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 113606 Version 1.0</div></div></div>"},"113607":{"type":"graphic_figure","displayName":"Representation of a typical anesthesia workstation","title":"Representation of a typical anesthesia workstation","html":"<div class=\"graphic\"><div style=\"width: 656px\" class=\"figure\"><div class=\"ttl\">Representation of a typical anesthesia workstation</div><div class=\"cntnt\"><img style=\"width:636px; height:857px;\" src=\"images/ANEST/113607_Reptypclanesthswrksttn.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Butterworth JF, Mackey DC, Wasnick JD. The anesthesia machine. In: Morgan &amp; Mikhail's Clinical Anesthesiology, 5th ed, McGraw-Hill 2013. Copyright © 2013 McGraw-Hill Education. McGraw-Hill Education makes no representations or warranties as to the accuracy of any information contained in the McGraw-Hill Education Material, including any warranties of merchantability or fitness for a particular purpose. In no event shall McGraw-Hill Education have any liability to any party for special, incidental, tort, or consequential damages arising out of or in connection with the McGraw-Hill Education Material, even if McGraw-Hill Education has been advised of the possibility of such damages.</div><div id=\"graphicVersion\">Graphic 113607 Version 1.0</div></div></div>"},"113608":{"type":"graphic_figure","displayName":"Components of a standard circle breathing system","title":"Components of the circle breathing system","html":"<div class=\"graphic\"><div style=\"width: 836px\" class=\"figure\"><div class=\"ttl\">Components of the circle breathing system</div><div class=\"cntnt\"><img style=\"width:816px; height:614px;\" src=\"images/ANEST/113608_Standardcirclebrthngsys.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">APL valve: adjustable pressure-limiting (\"pop-off\") valve.</div><div class=\"graphic_reference\">From: Loeb RG, Feldman J. Anesthesia Machines. In: Encyclopedia of Medical Devices and Instrumentation, 2nd ed, Webster JG (Ed), Wiley, Hoboken, NJ 2006. <A href=\"http://onlinelibrary.wiley.com/book/10.1002/0471732877\" target=_blank>http://onlinelibrary.wiley.com/book/10.1002/0471732877</A>. Copyright © 2006. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 113608 Version 1.0</div></div></div>"},"113614":{"type":"graphic_picture","displayName":"Iliotibial band syndrome point of maximal tenderness","title":"Iliotibial band syndrome point of maximal tenderness","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Iliotibial band syndrome point of maximal tenderness</div><div class=\"cntnt\"><img style=\"width:756px; height:366px;\" src=\"images/SM/113614_Iltibial_bnd_synd_pt_mx_tds.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The point where the iliotibial band (ITB) courses over the lateral femoral epicondyle is typically the site of maximal tenderness in patients with ITB syndrome. In the photographs above, this site is marked by the examiner's thumb.</div><div class=\"graphic_reference\">Courtesy of Jonathan Jackson, MD.</div><div id=\"graphicVersion\">Graphic 113614 Version 1.0</div></div></div>"},"113615":{"type":"graphic_movie","displayName":"Noble Test for iliotibial band syndrome","title":"Noble Test for iliotibial band syndrome","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Noble Test for iliotibial band syndrome</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/113615_Nbltstiliotblbndsynvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:756px; height:425px;\" src=\"images/SM/113615_Nbltstiliotblbndsynimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Noble Compression Test shown in this video clip is used to confirm the diagnosis of iliotibial band syndrome.</div><div class=\"graphic_reference\">Courtesy of Jonathan Jackson, MD.</div><div id=\"graphicVersion\">Graphic 113615 Version 1.0</div></div></div>"},"113616":{"type":"graphic_picture","displayName":"Ankle dorsiflexion examination with knee extended","title":"Ankle dorsiflexion examination with knee extended","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Ankle dorsiflexion examination with knee extended</div><div class=\"cntnt\"><img style=\"width:754px; height:459px;\" src=\"images/SM/113616_Ankle_drsflxn_exam_knee_ext.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ankle dorsiflexion can be examined while the patient is seated with their knee extended. If the ankle cannot be passively dorsiflexed to a neutral position, restricted motion of the posterior calf muscle complex is the usual cause.</div><div class=\"graphic_reference\">Courtesy of Jonathan Jackson, MD.</div><div id=\"graphicVersion\">Graphic 113616 Version 1.0</div></div></div>"},"113617":{"type":"graphic_picture","displayName":"Single leg shallow knee bend","title":"Single leg shallow knee bend","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Single leg shallow knee bend</div><div class=\"cntnt\"><img style=\"width:756px; height:455px;\" src=\"images/SM/113617_Single_leg_shallow_kne_bend.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The single leg shallow knee bend can be used as a screening examination&nbsp;for hip abductor weakness. When a person with normal strength performs the movement, the pelvis remains level and the hip and knee maintain their alignment, as seen in photographs A and B above. In a person with hip abductor weakness, the movement causes the pelvis to tilt towards the standing leg, while the knee of standing leg caves in (ie, moves medial to the ipsilateral hip). This is demonstrated in photograph C above. </div><div class=\"graphic_reference\">Courtesy of Jonathan Jackson, MD.</div><div id=\"graphicVersion\">Graphic 113617 Version 1.0</div></div></div>"},"113619":{"type":"graphic_figure","displayName":"Epidural catheter tips","title":"Epidural catheter tips","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epidural catheter tips</div><div class=\"cntnt\"><img style=\"width:409px; height:416px;\" src=\"images/ANEST/113619_Epidural_catheter_tips.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A variety of epidural catheters are available, including those with multiple holes and a closed end (A) and those with a single end hole (B). Wire reinforced catheters are available with a single end hole (C), and with multiple holes and a closed end. For further information, refer to UpToDate content on epidural anesthesia technique.</div><div id=\"graphicVersion\">Graphic 113619 Version 1.0</div></div></div>"},"113633":{"type":"graphic_table","displayName":"Six RCTs of 3 vs 6 months of oxaliplatin-based adjuv Rx colon CA","title":"Characteristics of six separate randomized trials of three versus six months of adjuvant chemotherapy for resected colon cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of six separate randomized trials of three versus six months of adjuvant chemotherapy for resected colon cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Trial, reference</td> <td class=\"subtitle1\">Number</td> <td class=\"subtitle1\">Chemotherapy regimens</td> <td class=\"subtitle1\">CAPOX (%)</td> <td class=\"subtitle1\">Disease stage</td> <td class=\"subtitle1\">Tumor location</td> <td class=\"subtitle1\">Enrolling country</td> <td class=\"subtitle1\">Clinical trial info</td> </tr> <tr class=\"divider_bottom\"> <td>TOSCA<sup>[1]</sup></td> <td class=\"centered\">3759</td> <td>CAPOX or FOLFOX4</td> <td class=\"centered\">35</td> <td>III, high-risk II</td> <td>Colon</td> <td>Italy</td> <td>NCT00646607</td> </tr> <tr class=\"divider_bottom\"> <td>SCOT<sup>[2]</sup></td> <td class=\"centered\">6088</td> <td>CAPOX or mFOLFOX6</td> <td class=\"centered\">67</td> <td>III, high-risk II</td> <td>Colon</td> <td>United Kingdom, Denmark, Spain, Astral, Sweden, New Zealand</td> <td>NCT00749450</td> </tr> <tr class=\"divider_bottom\"> <td>IDEA<sup>[3]</sup></td> <td class=\"centered\">2022</td> <td>CAPOX or mFOLFOX6</td> <td class=\"centered\">10</td> <td>III</td> <td>Colon or rectum</td> <td>France</td> <td>NCT00958737</td> </tr> <tr class=\"divider_bottom\"> <td>C80702</td> <td class=\"centered\">2500</td> <td>mFOLFOX6</td> <td class=\"centered\">0</td> <td>III, high-risk II</td> <td>Colon</td> <td>United States, Canada</td> <td>NCT01150045</td> </tr> <tr class=\"divider_bottom\"> <td>HORG</td> <td class=\"centered\">2000</td> <td>CAPOX or FOLFOX4</td> <td class=\"centered\">58</td> <td>III, high-risk II</td> <td>Colon</td> <td>Greece</td> <td>NCT01308086</td> </tr> <tr> <td>ACHIEVE<sup>[4]</sup></td> <td class=\"centered\">1313</td> <td>CAPOX or mFOLFOX6</td> <td class=\"centered\">75</td> <td>III</td> <td>Colon</td> <td>Japan</td> <td>UMIN 000008543</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CAPOX: capecitabine plus oxaliplatin; FOLFOX: oxaliplatin plus leucovorin and short-term infusional fluorouracil; mFOLFOX: modified FOLFOX; C80702: Cancer and Leukemia Group B/Southwest Oncology Group trial C80702; HORG: Hellenic Oncology Research Group.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Sobrero AF, Lonardi S, Rosati G, et al. FOLFOX4/XELOX in stage II–III colon cancer: Efficacy results of the Italian three or six colon adjuvant (TOSCA) trial. J Clin Oncol 2017; 35:3501 (suppl; abstr 3501).</LI>&#xD;&#xA;<LI>Iveson TJ, Kerr RS, Saunders MP, et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomized, phase 3, non-inferiority trial. Lancet Oncol 2018; 19:562.&nbsp;</LI>&#xD;&#xA;<LI>Andre T, Bonnetain F, Mineur L, et al. Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. J Clin Oncol 2017; 35:3500 (suppl; abstr 3500).</LI>&#xD;&#xA;<LI>Eto T, Kotaka M, Manaka D, et al. An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: Compliance and safety of the phase III Japanese ACHIEVE trial. J Clin Oncol; 34:3550. (suppl; abstr 3550).</LI></OL></div><div id=\"graphicVersion\">Graphic 113633 Version 2.0</div></div></div>"},"113634":{"type":"graphic_figure","displayName":"Building a conventional regimen for MDR-TB","title":"Building a conventional regimen for treatment of adults with multidrug-resistant tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 693px\" class=\"figure\"><div class=\"ttl\">Building a conventional regimen for treatment of adults with multidrug-resistant tuberculosis</div><div class=\"cntnt\"><img style=\"width:673px; height:669px;\" src=\"images/ID/113634_Bldg_convntnal_rgmn_MDR_TB.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Not available in the United States.<br />&para; Streptomycin: Use only if not previously used and if documented susceptibility.<br />&Delta; Awaiting approval by the US Food and Drug Administration.</div><div class=\"graphic_reference\">Modified with permission from: Curry International Tuberculosis Center and California Department of Public Health, 2016: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition, p. 72. Copyright © 2016 Curry International Tuberculosis Center.</div><div id=\"graphicVersion\">Graphic 113634 Version 1.0</div></div></div>"},"113635":{"type":"graphic_table","displayName":"Conventional regimens for MDR/XDR-TB","title":"Conventional regimens for treatment of adults with drug-resistant tuberculosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conventional regimens for treatment of adults with drug-resistant tuberculosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"35%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pattern of drug resistance</td> <td class=\"subtitle1\">Suggested regimen</td> <td class=\"subtitle1\">Minimum duration of treatment</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>INH and RIF (&#177; SM)</td> <td>PZA, EMB, newer-generation fluoroquinolone (MFX or high-dose LFX), and injectable agent during the intensive phase (for at least 6 months beyond culture conversion), and 1 additional oral agent (LZD, ETA, CS or PAS).</td> <td>18 months beyond culture conversion</td> <td>In patients with extensive or cavitary disease, a longer duration for the injectable agent may be considered, as well as an additional oral drug. Consider using more than 1 additional oral drug if there has been prior use of PZA or EMB.</td> </tr> <tr class=\"divider_bottom\"> <td>INH, RIF (&#177; SM), and EMB or PZA</td> <td>EMB or PZA (if available), a newer-generation fluoroquinolone (MFX or high-dose LFX), injectable agent during the intensive phase (for at least 6 months beyond culture conversion), and 2 additional oral agents (LZD, ETA, CS, or PAS).</td> <td>18 months beyond culture conversion</td> <td>In patients with extensive or cavitary disease, a longer duration for the injectable agent may be considered, as well as an additional oral drug.</td> </tr> <tr class=\"divider_bottom\"> <td>INH, RIF, EMB, PZA (&#177; SM)</td> <td>Injectable agent during the intensive phase (for at least 6 months beyond culture conversion), and a newer-generation fluoroquinolone (MFX or high-dose LFX), and 3 to 4 oral agents (LZD, ETA, CS, PAS or additional second- or third-line agents if needed).</td> <td>18 months beyond culture conversion</td> <td>In patients with extensive or cavitary disease, a longer duration for the injectable agent may be considered.</td> </tr> <tr class=\"divider_bottom\"> <td>INH, RIF, EMB, PZA, fluoroquinolone</td> <td>4 to 5 second- or third-line drugs (include LZD, BDQ, or DLM) and an injectable agent.</td> <td>24 months beyond culture conversion</td> <td>Duration of injectables should be at least 12 months if tolerated. Consider high-dose MFX. Consider surgery. TDM may be useful.</td> </tr> <tr class=\"divider_bottom\"> <td>INH, RIF, EMB, PZA, injectables</td> <td>MFX (or high-dose LFX) plus at least 4 to 5 second- or third-line oral drugs. Include LZD, BDQ, or DLM, if available. Include an injectable drug if there is 1 available to which the isolate is susceptible.</td> <td>24 months beyond culture conversion</td> <td>Consider surgery. TDM may be useful.</td> </tr> <tr> <td>INH, RIF, fluoroquinolone, injectable (XDR)</td> <td>5 to 6 second- and third-line agents. LZD, BDQ, or DLM should be used; high-dose MFX can be added (unless documented resistance). Use PZA and/or EMB if remains susceptible. Include an injectable drug if there is 1 available to which the isolate is susceptible.</td> <td>24 months beyond culture conversion</td> <td>Consider high-dose INH treatment if low-level resistance is documented. Consider surgery. TDM may be useful.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MDR: multidrug resistant; XDR: extensively drug resistant; TB: tuberculosis; INH: isoniazid; RIF: rifampin; SM: streptomycin; PZA: pyrazinamide; EMB: ethambutol; MFX: moxifloxacin; LFX: levofloxacin; LZD: linezolid; ETA: ethionamide; CS: cycloserine; PAS: para-aminosalicyclic acid; BDQ: bedaquiline; DLM: delamanid; TDM: therapeutic drug monitoring.</div><div class=\"graphic_reference\">Modified with permission from: Curry International Tuberculosis Center and California Department of Public Health, 2016: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition, p. 260. Copyright &copy; 2016 Curry International Tuberculosis Center.</div><div id=\"graphicVersion\">Graphic 113635 Version 1.0</div></div></div>"},"113639":{"type":"graphic_algorithm","displayName":"Inpatient evaluation of new-onset myoclonus","title":"Evaluation of new-onset myoclonus in the hospitalized patient","html":"<div class=\"graphic\"><div style=\"width: 862px\" class=\"figure\"><div class=\"ttl\">Evaluation of new-onset myoclonus in the hospitalized patient</div><div class=\"cntnt\"><img style=\"width:842px; height:821px;\" src=\"images/NEURO/113639_Eval_new-onset_myoclonus.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm represents an overview of the approach to a hospitalized patient with new-onset of myoclonus. Refer to UpToDate topics on classification and evaluation of myoclonus and symptomatic myoclonus for further details.</div><div class=\"graphic_footnotes\">EEG: electroencephalography; CSF: cerebrospinal fluid; EMG: electromyography; MRI: magnetic resonance imaging; SEPs: somatosensory evoked potentials.<br />* Drugs that may precipitate or exacerbate myoclonus: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Psychiatric medications (eg, tricyclic antidepressants, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, lithium).</LI>&#xD;&#xA;<LI>Antibiotics (eg, penicillins, cephalosporins, quinolones).</LI>&#xD;&#xA;<LI>Narcotics (particularly meperidine and morphine).</LI>&#xD;&#xA;<LI>Anticonvulsants.</LI>&#xD;&#xA;<LI>Anesthetics.</LI>&#xD;&#xA;<LI>Contrast media.</LI>&#xD;&#xA;<LI>Cardiac medications (eg, calcium channel blockers, antiarrhythmic agents).</LI>&#xD;&#xA;<LI>Drug withdrawal from certain agents (eg, sedatives).</LI></UL>¶ Laboratory tests for myoclonus generally include: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Electrolytes (including calcium and magnesium).</LI>&#xD;&#xA;<LI>Bismuth.</LI>&#xD;&#xA;<LI>Glucose.</LI>&#xD;&#xA;<LI>Renal and hepatic function tests.</LI>&#xD;&#xA;<LI>Thyroid antibodies and thyroid function tests.</LI>&#xD;&#xA;<LI>Vitamin E level.</LI>&#xD;&#xA;<LI>Paraneoplastic antibodies.</LI>&#xD;&#xA;<LI>Drug and toxin screen if clinical suspicion of undisclosed substance intake or use of illicit or prescribed psychoactive medications.</LI>&#xD;&#xA;<LI>Infection workup if encephalopathy or localizing signs of infection, fever, or leukocytosis.</LI>&#xD;&#xA;<LI>Lumbar puncture and CSF analysis in cases with encephalopathy, signs of infection, suspicion for immune-mediated disorder, or suspicion for prion disease.</LI></UL>Δ Clinical electrophysiologic testing, used to distinguish involuntary movements and to determine anatomic and physiologic classification of myoclonus, may employ multiple techniques, including: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Surface EMG.</LI>&#xD;&#xA;<LI>Simultaneous electroencephalography-electromyography polygraphy (EEG-EMG polygraphy).</LI>&#xD;&#xA;<LI>SEPs.</LI>&#xD;&#xA;<LI>Jerk-locked back-averaging of EEG transients and/or SEPs to EMG discharges.</LI>&#xD;&#xA;<LI>Long latency EMG responses to peripheral nerve stimulation (eg, C reflex).</LI></UL><FONT class=lozenge>◊</FONT> Refer to UpToDate text for details.</div><div id=\"graphicVersion\">Graphic 113639 Version 1.0</div></div></div>"},"113645":{"type":"graphic_algorithm","displayName":"Example septic shock trigger tool","title":"Septic shock trigger/identification tool","html":"<div class=\"graphic\"><div style=\"width: 1018px\" class=\"figure\"><div class=\"ttl\">Septic shock trigger/identification tool</div><div class=\"cntnt\"><img style=\"width:998px; height:909px;\" src=\"images/EM/113645_Ex_septic_shock_triggr_tool.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">American Academy of Pediatrics trigger tool for early septic shock recognition.</div><div class=\"graphic_footnotes\">ED: emergency department; SCD: sickle cell disease; MR/CP: magnetic resonance cholangiopancreatography; bpm: beats per minute; PALS: Pediatric Advanced Life Support; BP: blood pressure.</div><div class=\"graphic_reference\">Courtesy of the Pediatric Septic Shock Collaborative of the American Academy of Pediatrics. From: Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock. Crit Care Med 2017; 45:1061. DOI: <A href=\"http://journals.lww.com/ccmjournal/fulltext/2017/06000/American_College_of_Critical_Care_Medicine.18.aspx\" target=_blank>10.1097/CCM.0000000000002425</A>. Copyright © 2017. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113645 Version 1.0</div></div></div>"},"113648":{"type":"graphic_figure","displayName":"Spectrum of signs of LAST","title":"Spectrum of presenting signs of LAST","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Spectrum of presenting signs of LAST</div><div class=\"cntnt\"><img style=\"width:505px; height:515px;\" src=\"images/ANEST/113648_Spectrum_signs_LAST.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The frequency of symptoms and signs referable to CV, CNS, or both is given for the 93 cases in this review.</div><div class=\"graphic_footnotes\">LAST: local anesthetic systemic toxicity; CV: cardiovascular; CNS: central nervous system.</div><div class=\"graphic_reference\">From: Di Gregorio G, Neal JM, Rosenquist RW, Weinberg GL. Clinical presentation of local anesthetic systemic toxicity: A review of published cases, 1979 to 2009. Reg Anesth Pain Med 2010; 35:181. DOI: <A href=\"http://journals.lww.com/rapm/fulltext/2010/03000/Clinical_Presentation_of_Local_Anesthetic_Systemic.11.aspx\" target=_blank>10.1097/AAP.0b013e3181d2310b</A>. Copyright © 2010 European Society of Regional Anaesthesia and Pain Therapy (ESRA), the Asian and Oceanic Society of Regional Anesthesia (AOSRA), and the Latin American Society of Regional Anesthesia (LASRA). Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113648 Version 1.0</div></div></div>"},"113649":{"type":"graphic_figure","displayName":"Spectrum of CNS signs of LAST","title":"Spectrum of central nervous system signs of LAST","html":"<div class=\"graphic\"><div style=\"width: 749px\" class=\"figure\"><div class=\"ttl\">Spectrum of central nervous system signs of LAST</div><div class=\"cntnt\"><img style=\"width:729px; height:513px;\" src=\"images/ANEST/113649_Spectrum_CNS_signs_LAST.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The distribution frequencies of all reported signs of CNS toxicity among published cases of LAST.</div><div class=\"graphic_footnotes\">CNS: central nervous system; LAST: local anesthetic systemic toxicity.</div><div class=\"graphic_reference\">From: Di Gregorio G, Neal JM, Rosenquist RW, Weinberg GL. Clinical presentation of local anesthetic systemic toxicity: A review of published cases, 1979 to 2009. Reg Anesth Pain Med 2010; 35:181. DOI: <a href=\"http://journals.lww.com/rapm/fulltext/2010/03000/Clinical_Presentation_of_Local_Anesthetic_Systemic.11.aspx\" target=\"_blank\">10.1097/AAP.0b013e3181d2310b</a>. Copyright &copy; 2010 European Society of Regional Anaesthesia and Pain Therapy (ESRA), the Asian and Oceanic Society of Regional Anesthesia (AOSRA), and the Latin American Society of Regional Anesthesia (LASRA). Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113649 Version 1.0</div></div></div>"},"113650":{"type":"graphic_figure","displayName":"Spectrum of CV signs of LAST","title":"Spectrum of cardiovascular signs of LAST","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Spectrum of cardiovascular signs of LAST</div><div class=\"cntnt\"><img style=\"width:712px; height:514px;\" src=\"images/ANEST/113650_Spectrum_CV_signs_LAST.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The distribution frequencies of all reported signs of CV toxicity during LAST.</div><div class=\"graphic_footnotes\">CV: cardiovascular; LAST: local anesthetic systemic toxicity; VT: ventricular tachycardia; VF: ventricular fibrillation.</div><div class=\"graphic_reference\">From: Di Gregorio G, Neal JM, Rosenquist RW, Weinberg GL. Clinical presentation of local anesthetic systemic toxicity: A review of published cases, 1979 to 2009. Reg Anesth Pain Med 2010; 35:181. DOI: <A href=\"http://journals.lww.com/rapm/fulltext/2010/03000/Clinical_Presentation_of_Local_Anesthetic_Systemic.11.aspx\" target=_blank>10.1097/AAP.0b013e3181d2310b</A>. Copyright © 2010 European Society of Regional Anaesthesia and Pain Therapy (ESRA), the Asian and Oceanic Society of Regional Anesthesia (AOSRA), and the Latin American Society of Regional Anesthesia (LASRA). Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113650 Version 2.0</div></div></div>"},"113651":{"type":"graphic_figure","displayName":"Dengue map – Americas","title":"Dengue risk in the Americas and the Caribbean<sup>[1]</sup>","html":"<div class=\"graphic\"><div style=\"width: 951px\" class=\"figure\"><div class=\"ttl\">Dengue risk in the Americas and the Caribbean<sup>[1]</sup></div><div class=\"cntnt\"><img style=\"width:931px; height:633px;\" src=\"images/ID/113651_Dengue_map_Americas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Risk areas are shown on a national level except for where evidence exists of different risk levels at subnational regions. Areas that are too small to be seen on the regional maps are labeled in dark blue or light blue depending on their risk categorization.</div><div class=\"graphic_footnotes\"><FONT color=#0000ff></FONT></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>​Jentes ES, Lash RR, Johansson MA, et al. Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians. J Travel Med 2016; 23:taw062.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: The Centers for Disease Control and Prevention and Brunette GW (Ed). CDC Health Information for International Travel 2018. Oxford University Press, New York, 2017.</div><div id=\"graphicVersion\">Graphic 113651 Version 1.0</div></div></div>"},"113652":{"type":"graphic_figure","displayName":"Dengue map – Africa and Middle East","title":"Dengue risk in Africa and the Middle East<sup>[1]</sup>","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Dengue risk in Africa and the Middle East<sup>[1]</sup></div><div class=\"cntnt\"><img style=\"width:548px; height:808px;\" src=\"images/ID/113652_Dengue_map_Africa_Mid_East.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Risk areas are shown on a national level except for where evidence exists of different risk levels at subnational regions. Areas that are too small to be seen on the regional maps are labeled in dark blue or light blue depending on their risk categorization.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Jentes ES, Lash RR, Johansson MA, et al. Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians. J Travel Med 2016; 23:taw062.</li>&#xD;&#xA;</ol>&#xD;&#xA;​Reproduced from: The Centers for Disease Control and Prevention and Brunette GW (Ed). CDC Health Information for International Travel 2018. Oxford University Press, New York, 2017.</div><div id=\"graphicVersion\">Graphic 113652 Version 1.0</div></div></div>"},"113653":{"type":"graphic_figure","displayName":"Dengue map – Asia and Oceania","title":"Dengue risk in Asia and Oceania<sup>[1]</sup>","html":"<div class=\"graphic\"><div style=\"width: 953px\" class=\"figure\"><div class=\"ttl\">Dengue risk in Asia and Oceania<sup>[1]</sup></div><div class=\"cntnt\"><img style=\"width:933px; height:635px;\" src=\"images/ID/113653_Dengue_map_Asia_Oceania.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Risk areas are shown on a national level except for where evidence exists of different risk levels at subnational regions. Areas that are too small to be seen on the regional maps are labeled in dark blue or light blue depending on their risk categorization.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Jentes ES, Lash RR, Johansson MA, et al. Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians. J Travel Med 2016; 23:taw062.</li>&#xD;&#xA;</ol>&#xD;&#xA;​Reproduced from: The Centers for Disease Control and Prevention and Brunette GW (Ed). CDC Health Information for International Travel 2018. Oxford University Press, New York, 2017.</div><div id=\"graphicVersion\">Graphic 113653 Version 1.0</div></div></div>"},"113654":{"type":"graphic_table","displayName":"Travel exposure history","title":"Obtaining an exposure history in returned travelers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Obtaining an exposure history in returned travelers</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Exposure history</td> <td class=\"subtitle1\">Examples</td> <td class=\"subtitle1\">Typical infections/pathogens to consider</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">General</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"> <ul> <li>When did you travel? </li> </ul> </td> <td>Rainy season</td> <td>Malaria, dengue, chikungunya, Japanese encephalitis, West Nile virus, and other mosquito-borne infections</td> </tr> <tr> <td>Dry season</td> <td>Meningococcal disease (<em>Neisseria meningitidis</em>)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>How long did you travel? </li> </ul> </td> <td>Long stay</td> <td>Tuberculosis</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>What kind of places did you stay in? </li> </ul> </td> <td>Local house, rudimentary construction</td> <td>Numerous pathogens, especially vector borne and rodent borne</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Where did you visit? </li> </ul> </td> <td>Rural areas</td> <td>Numerous vector-borne diseases and food- and water-borne pathogens</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>What was the main reason for your trip? </li> </ul> </td> <td>Visiting friends and relatives</td> <td>Malaria, enteric fever, tuberculosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Specific exposures</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>What did you do? </li> </ul> </td> <td>Visit relatives, field research, construction, safaris, visit slums, help in clinic, sightsee, attend meetings, teach/attend classes</td> <td>Pathogens vary depending on activities. Travelers active outdoors may have exposure to ticks, mosquitoes, and other vectors and associated infections (eg, malaria, rickettsiosis, leishmaniasis), whereas travelers with close contact with local people may have exposure via blood, secretions, or direct contact (eg, HIV, hepatitis B, meningococcus, tuberculosis).</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>What did you eat or drink? </li> </ul> </td> <td>Tap water, ice in drinks, raw vegetables, undercooked meats, questionable hygiene practices</td> <td><em>Salmonella</em> spp, <em>Shigella</em> spp, <em>Campylobacter</em> spp, hepatitis A, hepatitis E, amebic dysentery or liver abscess, eosinophilic meningitis</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Did you have unpasteurized dairy, for example, home-made cheese? </li> </ul> </td> <td>Unpasteurized dairy</td> <td><em>Brucella</em>, other, <em>Listeria</em></td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\"> <ul> <li>Did you eat raw or undercooked foods? </li> </ul> </td> <td>Undercooked meats</td> <td><em>Campylobacter</em>, <em>Salmonella</em>, <em>Escherichia coli</em> O157, <em>Toxoplasma</em>, <em>Trichinella</em></td> </tr> <tr> <td>Undercooked shellfish</td> <td>Hepatitis A, Vibrios, <em>Clonorchis</em>, <em>Paragonimus</em></td> </tr> <tr> <td>Raw vegetables, watercress</td> <td><em>Fasciola</em></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Did you have any insect bites such as mosquito bites? </li> </ul> </td> <td>Mosquitoes</td> <td>Malaria; many arboviruses, including dengue, Japanese encephalitis, West Nile virus, Rift Valley fever</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Did you have any tick bites or go hiking or walk through tall grasses or woods? </li> </ul> </td> <td>Ticks</td> <td>Rickettsia (in travelers most commonly <em>Rickettsia africae</em>), <em>Babesia</em>, <em>Anaplasma</em>, <em>Ehrlichia</em>, Lyme disease, Crimean-Congo hemorrhagic fever, tick-borne encephalitis</td> </tr> <tr> <td class=\"indent1\" rowspan=\"7\"> <ul> <li>Did you notice any fleas or other vectors, or bugs, or were you around animals that might have had fleas or lice? </li> </ul> </td> <td>Fleas</td> <td><em>Rickettsia typhi</em> (endemic typhus), <em>Yersinia pestis</em></td> </tr> <tr> <td>Lice</td> <td><em>Rickettsia prowazekii</em> (epidemic typhus), <em>Borrelia</em> (relapsing fever)</td> </tr> <tr> <td>Mites</td> <td><em>Orientia tsutsugamushi</em> (scrub typhus)</td> </tr> <tr> <td>Sandflies</td> <td><em>Leishmania</em></td> </tr> <tr> <td>Black flies</td> <td><em>Onchocerca volvulus</em></td> </tr> <tr> <td>Triatomine bugs</td> <td>American trypanosomiasis</td> </tr> <tr> <td>Tsetse flies</td> <td>African trypanosomiasis</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Were you in large gatherings? </li> </ul> </td> <td>Air-borne particles, crowded living conditions</td> <td>Influenza, measles, other respiratory infections</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Did you participate in digging, excavating, or construction? </li> </ul> </td> <td>Soil, excavations</td> <td><em>Coccidioides imitis</em> (coccidioidomycosis), <em>Histoplasma capsulatum</em> (histoplasmosis)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Did you swim, wade, or splash around in fresh water? </li> </ul> </td> <td>Swimming in lakes, ponds, rivers, streams</td> <td><em>Schistosoma</em>, <em>Leptospira</em></td> </tr> <tr> <td class=\"indent1\" rowspan=\"5\"> <ul> <li>Did you have close contact with any animals? Any bites, scratches, or licks? </li> </ul> </td> <td>Bites, spelunking</td> <td>Rabies</td> </tr> <tr> <td>Handling animals</td> <td><em>Brucella</em>, anthrax, <em>Yersinia pestis</em>, <em>Coxiella burnetti</em>, <em>Francisella tularensis</em>, <em>Toxoplasma</em></td> </tr> <tr> <td>Primates</td> <td>Simian B virus</td> </tr> <tr> <td>Rodents</td> <td><em>Yersinia pestis</em>, hantaviruses, Lassa fever and other hemorrhagic fevers, rat-bite fever, <em>Rickettsia typhi</em></td> </tr> <tr> <td>Birds</td> <td><em>Chlamydophila psittaci</em>, avian influenza</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Did you have sexual contact or contact with blood, body fluids, secretions, or procedures that may expose you to these? </li> </ul> </td> <td>Sexual contact; injections, transfusion, medical procedure, tattoos, piercings, dental work, shaving by barber with reused razor</td> <td>Acute HIV; hepatitis A, B, C, D; CMV, EBV; syphilis; viral hemorrhagic fevers</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Immunization history</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\"> <ul> <li>Have you had routine immunizations, and were they updated before travel? </li> </ul> </td> <td>Verify immunity to these routine vaccines</td> <td>MMR, polio, Td/Tdap, hepatitis B, influenza, chickenpox</td> </tr> <tr> <td>Age-specific recommendations</td> <td>HPV, shingles, pneumococcal</td> </tr> <tr> <td>Asplenic host recommendations</td> <td><em>Haemophilus influenzae</em> b, meningococcal, pneumococcal</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Have you had travel immunizations? </li> </ul> </td> <td class=\"centered\">&ndash;</td> <td>Hepatitis A, Japanese encephalitis, meningococcal, polio, rabies, typhoid, yellow fever</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Wilson ME, Chen LH. Fever in returning travelers. Sci Am Med 2015. Copyright &copy; 2017 Decker. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113654 Version 2.0</div></div></div>"},"113655":{"type":"graphic_figure","displayName":"Travel infections and incubation period","title":"Common travel-associated infections and their incubation periods","html":"<div class=\"graphic\"><div style=\"width: 661px\" class=\"figure\"><div class=\"ttl\">Common travel-associated infections and their incubation periods</div><div class=\"cntnt\"><img style=\"width:641px; height:843px;\" src=\"images/ID/113655_Travel_infection_incubtn_pd.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Most common diagnoses and range of incubation periods (in days; 0 = day of exposure).<sup>[1]</sup></div><div class=\"graphic_footnotes\">SFG: spotted fever group.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Ryan ET, Wilson ME, Kain KC. Illness after international travel. N Engl J Med 2002; 347:505.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Wilson ME, Chen LH. Fever in returning travelers. Sci Am Med 2015. Copyright &copy; 2017 Decker. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113655 Version 1.0</div></div></div>"},"113656":{"type":"graphic_table","displayName":"Key diagnoses for fever and travel","title":"Key \"cannot-miss\" diagnoses associated with fever and travel","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key \"cannot-miss\" diagnoses associated with fever and travel</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnosis*</td> <td class=\"subtitle1\">Distribution</td> </tr> <tr> <td>Amebic liver abscess</td> <td>Worldwide</td> </tr> <tr> <td>Bartonellosis</td> <td>Worldwide</td> </tr> <tr> <td>Enteric fever</td> <td>South Asia, Southeast Asia, Africa, Central America, South America</td> </tr> <tr> <td>Legionnaires disease</td> <td>Worldwide</td> </tr> <tr> <td>Leptospirosis</td> <td>Worldwide, with higher prevalence in warm climate</td> </tr> <tr> <td>Malaria</td> <td>Africa, Oceania, South Asia, Southeast Asia, Central America, South America</td> </tr> <tr> <td>Melioidosis</td> <td>Southeast Asia, Oceania, Africa; sporadic infections in Western Hemisphere</td> </tr> <tr> <td>Meningococcal meningitis or sepsis</td> <td>Worldwide</td> </tr> <tr> <td>Plague</td> <td>Foci worldwide</td> </tr> <tr> <td>Relapsing fever, louse borne</td> <td>Sub-Saharan Africa</td> </tr> <tr> <td>Relapsing fever, tick borne</td> <td>Worldwide, in discrete areas</td> </tr> <tr> <td>Rickettsial infections, including spotted fever group rickettsioses and typhus fevers</td> <td>Worldwide, involving different species</td> </tr> <tr> <td>Staphylococcal and streptococcal sepsis</td> <td>Worldwide</td> </tr> <tr> <td>Trypanosomiasis, East African</td> <td>East Africa</td> </tr> <tr> <td>Tuberculosis (miliary; meningitis)</td> <td>Worldwide</td> </tr> <tr> <td>Tularemia</td> <td>Worldwide</td> </tr> <tr> <td>Viral hemorrhagic fevers</td> <td>Multiple etiologies with specific distribution</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Diseases listed in alphabetical order. Can be fatal and treatable with a specific intervention and/or diagnosis is critical because of public health and infection control implications.</div><div class=\"graphic_footnotes\">* Specific therapy available for all diagnoses except for some viral hemorrhagic fevers.</div><div class=\"graphic_reference\">Reproduced with permission from: Wilson ME, Chen LH. Fever in returning travelers. Sci Am Med 2015. Copyright &copy; 2017 Decker. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113656 Version 1.0</div></div></div>"},"113657":{"type":"graphic_table","displayName":"Causes of fever by geographic area","title":"Common causes of fever, by geographic area","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of fever, by geographic area</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Geographic area</td> <td class=\"subtitle1\">Common tropical diseases causing fever</td> <td class=\"subtitle1\">Other infections causing outbreaks or clusters in travelers</td> </tr> <tr> <td>Caribbean</td> <td>Chikungunya, dengue, malaria (Haiti), Zika</td> <td>Acute histoplasmosis, leptospirosis</td> </tr> <tr> <td>Central America</td> <td>Chikungunya, dengue, malaria (primarily <em>Plasmodium vivax</em>), Zika</td> <td>Leptospirosis, histoplasmosis, coccidioidomycosis</td> </tr> <tr> <td>South America</td> <td>Chikungunya, dengue, malaria (primarily <em>P. vivax</em>), Zika</td> <td>Bartonellosis, leptospirosis, enteric fever, histoplasmosis</td> </tr> <tr> <td>South-central Asia</td> <td>Chikungunya, dengue, malaria (primarily non-falciparum)</td> <td>Chikungunya</td> </tr> <tr> <td>Southeast Asia</td> <td>Dengue, malaria (primarily non-falciparum)</td> <td>Chikungunya, leptospirosis</td> </tr> <tr> <td>Sub-Saharan Africa</td> <td>Malaria (primarily <em>P. falciparum</em>), tickborne rickettsiae (main cause of fever in southern Africa), acute schistosomiasis, dengue</td> <td>African trypanosomiasis, chikungunya, enteric fever, filariasis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: The Centers for Disease Control and Prevention and Brunette GW (Ed). CDC Health Information for International Travel 2018. Oxford University Press, New York, 2017.</div><div id=\"graphicVersion\">Graphic 113657 Version 1.0</div></div></div>"},"113660":{"type":"graphic_figure","displayName":"Sequence of perilunate ligament injury","title":"Sequence of perilunate ligament injury","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Sequence of perilunate ligament injury</div><div class=\"cntnt\"><img style=\"width:494px; height:583px;\" src=\"images/SM/113660_Sequence_of_perilunate_ligament_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perilunate ligament injuries generally progress in four sequential stages (represented by the numbers in the image above), depending upon the force involved. In stage 1, the scapholunate ligament ruptures. While this causes instability between the scaphoid and lunate, dislocation rarely occurs. In stage 2, the capitolunate ligament ruptures and the capitate sometimes dislocates. In stage 3, the lunotriquetral ligament ruptures and the lunate dislocates dorsally, but the lunate remains aligned with the radius when seen on an anteroposterior radiograph. Stage 4 injury involves volar dislocation of the lunate into the carpal tunnel. </div><div id=\"graphicVersion\">Graphic 113660 Version 1.0</div></div></div>"},"113666":{"type":"graphic_figure","displayName":"eGFR over time during follow-up in SPRINT participants with CKD","title":"Estimated glomerular filtration rate (eGFR) over time during follow-up in SPRINT participants with chronic kidney disease (CKD)","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Estimated glomerular filtration rate (eGFR) over time during follow-up in SPRINT participants with chronic kidney disease (CKD)</div><div class=\"cntnt\"><img style=\"width:764px; height:546px;\" src=\"images/NEPH/113666_eGFRovrtmSPRINTprtctCKD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two phases of eGFR changes during follow-up in the SPRINT participants with CKD. The rate of change in eGFR using the values at&nbsp;six months after randomization as the baseline was -0.47 mL/minute/1.73 m<SUP>2</SUP> per year in the intensive group (dashed line and triangles) and -0.32 mL/minute/1.73 m<SUP>2</SUP> per year in the standard group (solid line and circles). Open symbols denote fasting visits; closed symbols denote nonfasting visits.</div><div class=\"graphic_footnotes\">SPRINT: Systolic Blood Pressure Intervention&nbsp;Trial.</div><div class=\"graphic_reference\">Republished with permission of the American Society of Nephrology, from: Cheung AK, Rahman M, Reboussin DM, et al. Effects of Intensive BP Control in CKD. J Am Soc Nephrol 2017. Copyright &copy; 2017; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 113666 Version 2.0</div></div></div>"},"113667":{"type":"graphic_table","displayName":"Electrical power loss alarm","title":"Electrical power loss alarm","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Electrical power loss alarm</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Manifestations</td> <td> <ul> <li>Alarm message that system is running on battery. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Loss of room lighting. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Power loss in other devices. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Blank display(s). </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\"> <ul> <li>Ventilator stops cycling if no battery backup. </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"9\">Potential causes</td> <td> <ul> <li>Patient factors (none). </li> </ul> </td> </tr> <tr> <td> <ul> <li>Equipment factors. </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Mains failure </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Facility-wide </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>At circuit breaker </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>At ground fault circuit interrupt (GFCI) outlet </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Blown fuse (potentially in extension outlet) </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Anesthesia workstation unplugged </li> </ul> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <ul> <li>Battery exhausted </li> </ul> </ul> </td> </tr> <tr> <td rowspan=\"8\">Suggested responses</td> <td> <ul> <li>Check patient &ndash; may need to manually ventilate, may need to manually monitor if power loss to electronic monitors. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Anesthesia workstation pneumatic oxygen delivery preserved. Electronic displays and ventilator work until battery is exhausted. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Obtain other light sources if lighting power is lost (emergency flashlight, cell phone). </li> </ul> </td> </tr> <tr> <td> <ul> <li>Try another electrical outlet (most ORs supplied by more than one circuit breaker), ideally an outlet connected to the emergency power grid. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Unplug last device plugged in or activated, then reset circuit breaker or replace blown fuse. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Conserve battery supply. </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Convert to spontaneous/manual ventilation mode (if electrically powered ventilator) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Notify facility. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OR: operating room.</div><div id=\"graphicVersion\">Graphic 113667 Version 1.0</div></div></div>"},"113668":{"type":"graphic_table","displayName":"Oxygen supply pressure alarm","title":"O<SUB>2</SUB> supply pressure alarm","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">O<SUB>2</SUB>&nbsp;supply pressure alarm</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Manifestations</td> <td> <ul> <li>Alarm message for&nbsp;O<sub>2</sub> supply pressure low </li> </ul> </td> </tr> <tr> <td> <ul> <li>Loss of&nbsp;O<sub>2</sub> and nitrous oxide flow </li> </ul> </td> </tr> <tr> <td> <ul> <li>Loss of air flow on some anesthesia workstations (with failsafe valve on the air piping) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Loss of auxiliary&nbsp;O<sub>2</sub> flow </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\"> <ul> <li>Loss of ventilator cycling (with pneumatically powered ventilator) </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">Potential causes</td> <td> <ul> <li>Patient factors (none) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Equipment factors </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Loss of pipeline O<sub>2 </sub>supply </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Facility-wide </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>At zone valve </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>O<sub>2 </sub>pipeline hose disconnected </li> </ul> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <ul> <li>Empty backup O<sub>2 </sub>cylinder </li> </ul> </ul> </td> </tr> <tr> <td rowspan=\"8\">Suggested responses</td> <td> <ul> <li>Open backup O<sub>2 </sub>cylinder </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>If this does not restore O<sub>2</sub> flow, then the backup cylinder is empty or not properly mounted </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Conserve&nbsp;O<sub>2</sub> </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Terminate mechanical ventilation (if pneumatically powered ventilator) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Decrease&nbsp;O<sub>2</sub> flows (main and auxiliary flowmeters) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>May still be able to administer air with inhalational anesthetics even with loss of&nbsp;O<sub>2</sub> pressure </li> </ul> </td> </tr> <tr> <td> <ul> <li>Obtain additional backup&nbsp;O<sub>2</sub> cylinder that fits the anesthesia workstation yoke </li> </ul> </td> </tr> <tr> <td> <ul> <li>Ventilate with manual resuscitation bag connected to separate&nbsp;O<sub>2</sub> cylinder if no&nbsp;O<sub>2</sub> or air flow from anesthesia workstation </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">O<sub>2</sub>: oxygen.</div><div id=\"graphicVersion\">Graphic 113668 Version 1.0</div></div></div>"},"113669":{"type":"graphic_table","displayName":"Apnea alarm overview","title":"Apnea alarm overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Apnea alarm overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"19\">Mechanical ventilation</td> <td> <ul> <li>Apnea - pressure only </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>False alarm &ndash; threshold set too high </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Breathing system leak </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Pressure sensor tube disconnect or obstruction </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Apnea - flow only </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>False alarm &ndash; high threshold (eg, neonate) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Malfunctioning flow sensor (eg, due to moisture or broken filament) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Apnea-CO<sub>2</sub> only </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Capnometer sample line crack or disconnect </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Esophageal intubation </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Cardiac arrest </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Apnea-flow and apnea-CO<sub>2</sub> </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Breathing system obstruction </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Large cuff leak (no exhaled gas into breathing system) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Esophageal intubation </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Apnea-pressure and apnea-flow and apnea-CO<sub>2</sub> </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Breathing system disconnect </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Ventilator turned off or cycling failure malfunction </li> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <ul> <li>Lower airway suction (gastric tube in trachea, tracheal/bronchial suction) </li> </ul> </ul> </td> </tr> <tr> <td rowspan=\"17\">Spontaneous or manual ventilation</td> <td> <ul> <li>Apnea-pressure only </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>False alarm &ndash; When switching from mechanical to spontaneous ventilation (apnea-pressure not applicable in spontaneous mode) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Apnea-flow only </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>False alarm &ndash; high threshold (neonate) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Incomplete endotracheal tube kink or obstruction </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Breathing system disconnect with patient still connected to CO<sub>2</sub> sampling site </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Malfunctioning flow sensor (eg, due to moisture or broken filament) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Apnea-CO<sub>2</sub> only </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Capnometer sample line crack or disconnect </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Apnea-flow and apnea-CO<sub>2</sub> </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Patient apnea </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Breathing system obstruction </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Airway (ETT or LMA) obstruction </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Breathing system disconnect </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Lower airway suction (gastric tube in trachea, tracheal/bronchial suction) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Esophageal intubation </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Cardiac arrest </li> </ul> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Differential diagnosis based on mode of ventilation and combination of alarms.</div><div class=\"graphic_footnotes\">CO<sub>2</sub>: carbon dioxide; ETT: endotracheal tube; LMA: laryngeal mask airway.</div><div id=\"graphicVersion\">Graphic 113669 Version 1.0</div></div></div>"},"113670":{"type":"graphic_table","displayName":"Apnea-pressure alarm","title":"Apnea-pressure alarm","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Apnea-pressure alarm</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Manifestations</td> <td> <ul> <li>Empty bellows </li> </ul> </td> </tr> <tr> <td> <ul> <li>Empty reservoir bag (in fresh-gas-decoupled circle breathing system) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Non-moving ventilator bellows or piston </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"24\">Potential causes</td> <td> <ul> <li>Patient factors (none) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Equipment factors </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>False alarm </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>When switching from mechanical to spontaneous ventilation </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Threshold pressure alarm setting too high </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Pressure sensor line disconnect or obstruction </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Reduction or loss of gas flow into breathing system </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Leak within anesthesia machine downstream of flowmeters </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Leak within vaporizer (only happens when vaporizer is dialed on; often filler cap left open) </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Detached or obstructed fresh gas hose </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Fresh gas misdirected to auxiliary common gas outlet </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Breathing system leak or disconnection </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>At airway (cuff or mask leak) </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Within breathing system </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <ul> <li>Tubing connections loose or disconnected </li> </ul> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <ul> <li>CO<sub>2</sub> absorbent canister cracked or not sealed properly </li> </ul> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <ul> <li>Gas analyzer sample line loose or disconnected </li> </ul> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <ul> <li>Leaking ventilator relief valve </li> </ul> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>In ventilator </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Negative pressure applied to breathing system (also refer to table on negative airway pressure alarm) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Gastric tube in trachea </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Intentional tracheal/bronchial suctioning (eg, fiberoptic) </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Malfunctioning scavenger system via ventilator relief valve </li> </ul> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <ul> <li>Ventilator turned off or cycling failure malfunction </li> </ul> </ul> </td> </tr> <tr> <td rowspan=\"7\">Suggested responses</td> <td> <ul> <li>Determine whether patient ventilation is occurring (examine chest, auscultate lungs, check CO<sub>2</sub> waveform and respiratory monitors, check SpO<sub>2</sub>) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Look for breathing circuit disconnection </li> </ul> </td> </tr> <tr> <td> <ul> <li>Fill breathing circuit with high fresh gas flows </li> </ul> </td> </tr> <tr> <td> <ul> <li>Disconnect patient and quickly pressure test breathing system to determine if leak is in the workstation or at the airway </li> </ul> </td> </tr> <tr> <td> <ul> <li>Verify that ventilator is operating </li> </ul> </td> </tr> <tr> <td> <ul> <li>Switch to manual ventilation </li> </ul> </td> </tr> <tr> <td> <ul> <li>If necessary, ventilate with manual resuscitation device connected to&nbsp;O<sub>2</sub> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Only pertinent during mechanical positive pressure ventilation - refer to other apnea alarms for spontaneous or manual ventilation.</div><div class=\"graphic_footnotes\">CO<SUB>2</SUB>: carbon dioxide; SpO<SUB>2</SUB>: pulse oximetry; O<SUB>2</SUB>: oxygen.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Raphael DT, Weller RS, Doran DJ. A response algorithm for the low-pressure alarm condition.&nbsp;Anesth Analg&nbsp;1988; 67:876.</LI></OL></div><div id=\"graphicVersion\">Graphic 113670 Version 1.0</div></div></div>"},"113671":{"type":"graphic_table","displayName":"Apnea-flow alarm","title":"Apnea-flow alarm","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Apnea-flow alarm</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Manifestations</td> <td> <ul> <li>Non-moving ventilator bellows or piston </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>No patient respiratory motion </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"13\">Potential causes</td> <td> <ul> <li>Patient factors </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Patient apnea (no respiratory effort) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Equipment factors </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>False alarm </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>High threshold (neonate) </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Malfunctioning flow sensor (moisture, burnt out filament) </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Exhaled gas exiting breathing system before flowmeter </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Large cuff leak (no exhaled gas into breathing system) </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Lower airway suction (gastric tube in trachea, tracheal/bronchial suction) </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Breathing system leak or disconnection </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Breathing system obstruction </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Airway (ETT or LMA) obstruction </li> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <ul> <li>Ventilator turned off or cycling failure malfunction </li> </ul> </ul> </td> </tr> <tr> <td rowspan=\"5\">Suggested responses</td> <td> <ul> <li>Determine whether patient ventilation is occurring (examine chest, auscultate lungs, check CO<sub>2</sub> waveform and respiratory monitors, check SpO<sub>2</sub>) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Look for breathing circuit disconnection or obstruction </li> </ul> </td> </tr> <tr> <td> <ul> <li>Verify that ventilator is operating </li> </ul> </td> </tr> <tr> <td> <ul> <li>Switch to manual ventilation </li> </ul> </td> </tr> <tr> <td> <ul> <li>If necessary, ventilate with manual resuscitation device connected to oxygen </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ETT: endotracheal tube; LMA: laryngeal mask airway; CO<SUB>2</SUB>: carbon dioxide; SpO<SUB>2</SUB>: pulse oximetry.</div><div id=\"graphicVersion\">Graphic 113671 Version 1.0</div></div></div>"},"113672":{"type":"graphic_table","displayName":"Apnea-carbon dioxide alarm","title":"Apnea-CO<SUB>2</SUB> alarm","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Apnea-CO<SUB>2</SUB> alarm</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td>Manifestations</td> <td> <ul> <li>Loss of capnogram </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"14\">Potential causes</td> <td> <ul> <li>Patient factors </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Patient apnea (no respiratory effort) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Esophageal intubation </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Cardiac arrest </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Equipment factors </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>False alarm </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Capnometer sample line crack or disconnect </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Exhaled gas exiting breathing system before sampling site </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Large cuff leak (no exhaled gas into breathing system) </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Lower airway suction (gastric tube in trachea, tracheal/bronchial suction) </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Breathing system disconnect </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Breathing system obstruction </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Airway (ETT or LMA) obstruction </li> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <ul> <li>Ventilator turned off or cycling failure malfunction </li> </ul> </ul> </td> </tr> <tr> <td rowspan=\"7\">Suggested responses</td> <td> <ul> <li>Check circulation (electrocardiogram and plethysmogram) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Determine whether patient ventilation is occurring (examine chest, auscultate lungs, check respiratory monitors, check SpO<sub>2</sub>) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Rule out esophageal intubation if recently intubated </li> </ul> </td> </tr> <tr> <td> <ul> <li>Look for breathing circuit disconnection or obstruction </li> </ul> </td> </tr> <tr> <td> <ul> <li>Verify that ventilator is operating </li> </ul> </td> </tr> <tr> <td> <ul> <li>Switch to manual ventilation </li> </ul> </td> </tr> <tr> <td> <ul> <li>If necessary, ventilate with manual resuscitation device connected to&nbsp;O<sub>2 </sub></li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CO<SUB>2</SUB>: carbon dioxide; ETT: endotracheal tube; LMA: laryngeal mask airway; SpO<SUB>2</SUB>: pulse oximetry; O<SUB>2</SUB>: oxygen.</div><div id=\"graphicVersion\">Graphic 113672 Version 1.0</div></div></div>"},"113673":{"type":"graphic_table","displayName":"High airway pressure alarm","title":"High airway pressure alarm","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">High airway pressure alarm</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Manifestations</td> <td> <ul> <li>Elevated airway pressure on gauge </li> </ul> </td> </tr> <tr> <td> <ul> <li>Increased slope of pressure-volume loop </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>\"Tidal volume not delivered, pressure limit\" alarm message </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"20\">Potential causes</td> <td> <ul> <li>Patient factors </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Low compliance </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Coughing or bucking </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Surgical peritoneal insufflation </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Intentional single lung ventilation </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Mainstem intubation </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Pulmonary edema </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Pneumothorax, especially tension pneumothorax </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>High resistance </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Bronchospasm </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Laryngospasm </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Airway obstruction by mucous, blood, foreign body </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Equipment factors </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Kinked or obstructed endotracheal tube </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Increased delivered tidal volume </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>High fresh gas flow rate with uncompensated ventilator </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Oxygen flush during inspiration </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Breath-stacking due to inadequate expiratory time </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Obstructed breathing system at inspiratory hose </li> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <ul> <ul> <li>Improperly placed equipment such as PEEP valve or humidifier </li> </ul> </ul> </ul> </td> </tr> <tr> <td rowspan=\"4\">Suggested responses</td> <td> <ul> <li>Check patient (look for movement and signs of coughing, observe patient chest movement, auscultate lungs) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Look at shape of airway pressure curve and expiratory portion of flow-volume loop (to differentiate high resistance from low compliance) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Look at shape of capnogram (to diagnose small airway resistance) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Pass suction catheter down endotracheal tube (to detect kink, mucous plug, or other obstruction) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PEEP: positive end-expiratory pressure.</div><div id=\"graphicVersion\">Graphic 113673 Version 1.0</div></div></div>"},"113674":{"type":"graphic_table","displayName":"Continuous airway pressure alarm","title":"Continuous airway pressure alarm","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Continuous airway pressure alarm</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Manifestations</td> <td> <ul> <li>Continuous elevated airway pressure on gauge </li> </ul> </td> </tr> <tr> <td> <ul> <li>Recent increase in PEEP setting </li> </ul> </td> </tr> <tr> <td> <ul> <li>Hyperinflated reservoir bag </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Recent conversion from facemask to ETT or LMA </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"11\">Potential causes</td> <td> <ul> <li>Patient factors (none) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Equipment factors </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Obstruction of expiratory limb of breathing system </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>PEEP valve </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Expiratory one-way valve </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Obstructed breathing system exhaust </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>APL valve closed or obstructed </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Ventilator relief valve closed or obstructed </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Tubing obstruction between relief valve(s) and scavenger </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Scavenger system outflow obstruction </li> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <ul> <ul> <li>Low scavenger outflow with blocked safety valve </li> </ul> </ul> </ul> </td> </tr> <tr> <td rowspan=\"4\">Suggested responses</td> <td> <ul> <li>Disconnect patient from breathing system </li> </ul> </td> </tr> <tr> <td> <ul> <li>Open APL valve </li> </ul> </td> </tr> <tr> <td> <ul> <li>Turn down fresh gas flow rate </li> </ul> </td> </tr> <tr> <td> <ul> <li>Verify scavenger system operational </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PEEP: positive end-expiratory pressure; ETT: endotracheal tube; LMA: laryngeal mask airway; APL: adjustable pressure limiting.</div><div id=\"graphicVersion\">Graphic 113674 Version 1.0</div></div></div>"},"113675":{"type":"graphic_table","displayName":"Negative airway pressure alarm","title":"Negative airway pressure alarm","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Negative airway pressure alarm</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Manifestations</td> <td> <ul> <li>Airway pressure less than zero </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Collapsed reservoir bag or bellows </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\">Potential causes</td> <td> <ul> <li>Patient factors </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Patient generated inspiratory pressure with empty reservoir bag or ventilator bellows </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Equipment factors </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Suction applied below airway </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Gastric tube in trachea </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Tracheal/bronchial suction (eg, fiberoptic) </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Suction applied above airway </li> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <ul> <ul> <li>Malfunctioning scavenger system </li> </ul> </ul> </ul> </td> </tr> <tr> <td rowspan=\"2\">Suggested responses</td> <td> <ul> <li>Immediately disconnect airway from breathing system </li> </ul> </td> </tr> <tr> <td> <ul> <li>Fill breathing system with oxygen flush or high fresh gas flows </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 113675 Version 1.0</div></div></div>"},"113676":{"type":"graphic_table","displayName":"Low inspired oxygen alarm","title":"Low inspired O<sub>2</sub> alarm","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Low inspired O<sub>2</sub> alarm</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Manifestations</strong></td> <td> <ul> <li>Lower than expected FiO<sub>2</sub> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Low SpO<sub>2</sub> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Low anesthetic agent concentration (if air entrainment into breathing system) </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"13\"><strong>Potential causes</strong></td> <td> <ul> <li>Patient factors </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Patient O<sub>2</sub> consumption and gas sampling exceeds O<sub>2</sub> flow rate </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Equipment factors </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Gas piping system crossover </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Mis-filled O<sub>2</sub> source </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>O<sub>2</sub> pipeline hose misconnection </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Gas blender between O<sub>2</sub> pipeline and anesthesia machine </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Gas piping crossover within anesthesia machine </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Cracked O<sub>2</sub> flowmeter </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Air entrainment into the breathing system </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Circuit disconnection with spontaneous breathing </li> </ul> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <ul> <li>Circuit disconnection with hanging-bellows ventilator </li> </ul> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <ul> <ul> <li>Circuit disconnection with piston ventilator </li> </ul> </ul> </ul> </td> </tr> <tr> <td rowspan=\"5\"><strong>Suggested responses</strong></td> <td> <ul> <li>Increase O<sub>2</sub> flow rate and decrease flow rate of other gases </li> </ul> </td> </tr> <tr> <td> <ul> <li>Consider wrong gas malfunction if inspired O<sub>2</sub> concentration does not increase </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Open backup O<sub>2</sub> cylinder <strong>AND</strong> disconnect O<sub>2</sub> pipeline hose if pipeline crossover suspected </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Do not use auxiliary O<sub>2</sub> flowmeter on the anesthesia workstation - it has the same O<sub>2</sub> source as main O<sub>2</sub> flowmeter </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Ventilate with manual resuscitation bag connected to a different O<sub>2</sub> cylinder </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FiO<sub>2</sub>: fraction of inspired oxygen; SpO<sub>2</sub>: pulse oximetry; O<sub>2</sub>: oxygen.</div><div id=\"graphicVersion\">Graphic 113676 Version 1.0</div></div></div>"},"113677":{"type":"graphic_table","displayName":"High inspired carbon dioxide alarm","title":"High inspired CO<SUB>2</SUB> alarm","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">High inspired CO<SUB>2</SUB> alarm</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Manifestations</td> <td> <ul> <li>Abnormal capnogram shape with elevated baseline </li> </ul> </td> </tr> <tr> <td> <ul> <li>Discolored CO<sub>2</sub> absorbent </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Abnormal motion of one-way valves </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"12\">Potential causes</td> <td> <ul> <li>Patient factors </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>High respiratory rate, small tidal volume in pediatrics </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Malignant hyperthermia </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Equipment factors </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Exhausted CO<sub>2</sub> absorbent </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Open self-sealing CO<sub>2</sub> canister connection (ie, quick-connect) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Intentional CO<sub>2</sub> administration (eg, single ventricle neonates) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Excessive apparatus deadspace relative to tidal volume (eg, neonate) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Incompetent (stuck open) inspiratory valve </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Incompetent (stuck open) expiratory valve </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Low levels of inspired CO<sub>2</sub> occur with rebreathing circuits such as Mapleson D or Bain circuits </li> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <ul> <li>Breathing system disconnect (during spontaneous breathing) </li> </ul> </ul> </td> </tr> <tr> <td rowspan=\"5\">Suggested responses</td> <td> <ul> <li>Increase fresh gas flow rate to above minute ventilation (inspired CO<sub>2</sub> will disappear if absorbent is exhausted or decrease with Mapleson breathing system) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Replace CO<sub>2</sub> absorbent and check that canister is properly connected </li> </ul> </td> </tr> <tr> <td> <ul> <li>Increase minute ventilation (to compensate for rebreathing) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Inspect, vibrate, dry, and/or repair one-way valves </li> </ul> </td> </tr> <tr> <td> <ul> <li>Switch ventilator mode (spontaneous-manual versus mechanical) if incompetent one-way valve on fresh gas decoupled breathing system </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CO<sub>2</sub>: carbon dioxide.</div><div id=\"graphicVersion\">Graphic 113677 Version 1.0</div></div></div>"},"113678":{"type":"graphic_table","displayName":"Low inspired anesthetic agent","title":"Low inspired anesthetic agent","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Low inspired anesthetic agent</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Manifestations</td> <td> <ul> <li>Signs of \"light\" anesthesia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Lower than intended measured anesthetic concentration (typically no alarm set for this) </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\">Potential causes</td> <td> <ul> <li>Patient factors (none) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Equipment factors </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Empty vaporizer </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Loose vaporizer cap </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Improperly seated vaporizer </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Air entrainment into breathing system </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Wrong agent in vaporizer </li> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <ul> <li>Anesthetic degradation by soda lime or baralyme </li> </ul> </ul> </td> </tr> <tr> <td rowspan=\"6\">Suggested responses</td> <td> <ul> <li>Fill vaporizer </li> </ul> </td> </tr> <tr> <td> <ul> <li>Check vaporizer cap and connection to manifold </li> </ul> </td> </tr> <tr> <td> <ul> <li>Switch vaporizers </li> </ul> </td> </tr> <tr> <td> <ul> <li>Check CO<sub>2</sub> absorbent for heat or discoloration, especially at top of canister </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Replace CO<sub>2</sub> absorbent </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Convert to intravenous anesthetic </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CO<sub>2</sub>: carbon dioxide.</div><div id=\"graphicVersion\">Graphic 113678 Version 1.0</div></div></div>"},"113681":{"type":"graphic_figure","displayName":"LNg52/5 (Mirena) IUD and inserter","title":"LNg52/5 (Mirena) IUD and inserter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">LNg52/5 (Mirena) IUD and inserter</div><div class=\"cntnt\"><img style=\"width:369px; height:954px;\" src=\"images/OBGYN/113681_LNg525MirenaIUDinserter.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Image copyright © 2017 Bayer. Used with permission.</div><div id=\"graphicVersion\">Graphic 113681 Version 1.0</div></div></div>"},"113683":{"type":"graphic_figure","displayName":"LNg52/5 (Mirena) IUD loaded into insertion device","title":"LNg52/5 (Mirena) IUD loaded into insertion device","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">LNg52/5 (Mirena) IUD loaded into insertion device</div><div class=\"cntnt\"><img style=\"width:592px; height:902px;\" src=\"images/OBGYN/113683_MirenaIUDloadinsrtndevc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Move slider all the way to the forward position to load the IUD into the inserter.</div><div class=\"graphic_reference\">Image copyright © 2017 Bayer. Used with permission.</div><div id=\"graphicVersion\">Graphic 113683 Version 1.0</div></div></div>"},"113684":{"type":"graphic_figure","displayName":"LNg52/5 (Mirena) IUD insertion into uterus","title":"LNg52/5 (Mirena) IUD insertion into uterus and deployment of device","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">LNg52/5 (Mirena) IUD insertion into uterus and deployment of device</div><div class=\"cntnt\"><img style=\"width:578px; height:896px;\" src=\"images/OBGYN/113684_MirenaIUDinsertionuterus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Move the slider back to the mark to release and open the arms.</div><div class=\"graphic_reference\">Image copyright © 2017 Bayer. Used with permission.</div><div id=\"graphicVersion\">Graphic 113684 Version 1.0</div></div></div>"},"113685":{"type":"graphic_figure","displayName":"Copper IUD (ParaGard) positioning of device arms","title":"Copper IUD (ParaGard) positioning of device arms into the inserter","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Copper IUD (ParaGard) positioning of device arms into the inserter</div><div class=\"cntnt\"><img style=\"width:610px; height:310px;\" src=\"images/OBGYN/113685_CopperIUDpostnngdvcarms.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arms of the device are bent toward the opening of the inserter while the insertion tube is pushed toward and rotated onto the device ends.</div><div class=\"graphic_reference\">© 2017 Teva Women's Health, Inc. All rights reserved. Used with permission. PARAGARD® is a registered trademark of Teva Women's Health, Inc.</div><div id=\"graphicVersion\">Graphic 113685 Version 1.0</div></div></div>"},"113689":{"type":"graphic_figure","displayName":"LNg19.5/5 (Kyleena) IUD insertion system","title":"LNg19.5/5 (Kyleena) IUD insertion system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">LNg19.5/5 (Kyleena) IUD insertion system</div><div class=\"cntnt\"><img style=\"width:378px; height:954px;\" src=\"images/OBGYN/113689_LNg205KyleenaIUDinsrtn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">LNg19.5/5 (Kyleena) IUD is pre-loaded into the insertion device.</div><div class=\"graphic_reference\">Image copyright © 2017 Bayer. Used with permission.</div><div id=\"graphicVersion\">Graphic 113689 Version 2.0</div></div></div>"},"113691":{"type":"graphic_algorithm","displayName":"Algorithm for evaluation of chronic cough in children","title":"Algorithm for the evaluation of chronic cough in children","html":"<div class=\"graphic\"><div style=\"width: 1071px\" class=\"figure\"><div class=\"ttl\">Algorithm for the evaluation of chronic cough in children</div><div class=\"cntnt\"><img style=\"width:1051px; height:1223px;\" src=\"images/PEDS/113691_Eval_chron_cough_child_ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PBB: protracted bacterial bronchitis.<br />* Refer to UpToDate content on specific cough pointers in children.<br />¶ Refer to UpToDate content on causes of chronic cough in children.<br />Δ A child with a dry cough and no specific cough pointers can be safely watched without treatment (the watch and wait approach). The child should be followed and reevaluated in two to four weeks if the chronic cough does not resolve or if new symptoms emerge. Alternatively, a time-limited trial of asthma medications or acid suppressing medications may be done; refer to UpToDate content for patient selection and precautions.</div><div id=\"graphicVersion\">Graphic 113691 Version 1.0</div></div></div>"},"113693":{"type":"graphic_picture","displayName":"Cutaneomucosal venous malformation","title":"Cutaneomucosal venous malformation","html":"<div class=\"graphic\"><div style=\"width: 775px\" class=\"figure\"><div class=\"ttl\">Cutaneomucosal venous malformation</div><div class=\"cntnt\"><img style=\"width:755px; height:485px;\" src=\"images/DERM/113693_Cutaneomucsl_venous_mlfrmtn.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Laurence M Boon, MD, PhD.</div><div id=\"graphicVersion\">Graphic 113693 Version 1.0</div></div></div>"},"113694":{"type":"graphic_picture","displayName":"Glomuvenous malformation","title":"Glomuvenous malformation","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Glomuvenous malformation</div><div class=\"cntnt\"><img style=\"width:517px; height:753px;\" src=\"images/DERM/113694_Glomuvenous_malformation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Glomuvenous malformation in a plaque-like configuration on the thigh of a 52-year-old male patient.</div><div class=\"graphic_reference\">Courtesy of Laurence M Boon, MD, PhD.</div><div id=\"graphicVersion\">Graphic 113694 Version 1.0</div></div></div>"},"113695":{"type":"graphic_picture","displayName":"Blue rubber bleb nevus syndrome GI","title":"Blue rubber bleb nevus syndrome","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Blue rubber bleb nevus syndrome</div><div class=\"cntnt\"><img style=\"width:541px; height:496px;\" src=\"images/DERM/113695_Blue_rbbr_blb_nvs_syndrm_GI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Venous malformations involving the small bowel in a six-year-old child with blue rubber bleb nevus syndrome.&nbsp;</div><div class=\"graphic_reference\">Courtesy of Laurence M Boon, MD, PhD.</div><div id=\"graphicVersion\">Graphic 113695 Version 1.0</div></div></div>"},"113696":{"type":"graphic_picture","displayName":"Maffucci syndrome hand","title":"Maffucci syndrome","html":"<div class=\"graphic\"><div style=\"width: 675px\" class=\"figure\"><div class=\"ttl\">Maffucci syndrome</div><div class=\"cntnt\"><img style=\"width:655px; height:750px;\" src=\"images/DERM/113696_Maffucci_syndrome_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large venous malformations and severe deformity of the hand in a patient with Maffucci syndrome.</div><div class=\"graphic_reference\">Courtesy of Laurence M Boon, MD, PhD.</div><div id=\"graphicVersion\">Graphic 113696 Version 1.0</div></div></div>"},"113697":{"type":"graphic_diagnosticimage","displayName":"Venous malformation magnetic resonance imaging","title":"Magnetic resonance imaging of a large venous malformation","html":"<div class=\"graphic\"><div style=\"width: 729px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of a large venous malformation</div><div class=\"cntnt\"><img style=\"width:709px; height:732px;\" src=\"images/DERM/113697_Venous_malformation_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal T2-weighted MRI of the shoulder showing an extensive venous malformation involving subcutaneous fat and muscles of the shoulder and thoracic wall. </div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Laurence M Boon, MD, PhD.</div><div id=\"graphicVersion\">Graphic 113697 Version 1.0</div></div></div>"},"113698":{"type":"graphic_picture","displayName":"Venous malformation shoulder","title":"Venous malformation","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Venous malformation</div><div class=\"cntnt\"><img style=\"width:571px; height:446px;\" src=\"images/DERM/113698_Venous_malformation_shouldr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large venous malformation of the shoulder and thoracic wall.</div><div class=\"graphic_reference\">Courtesy of Laurence M Boon, MD, PhD.</div><div id=\"graphicVersion\">Graphic 113698 Version 1.0</div></div></div>"},"113699":{"type":"graphic_figure","displayName":"Needle placement for leg compartment pressure measurement","title":"Needle placement for leg compartment pressure measurement","html":"<div class=\"graphic\"><div style=\"width: 780px\" class=\"figure\"><div class=\"ttl\">Needle placement for leg compartment pressure measurement</div><div class=\"cntnt\"><img style=\"width:760px; height:708px;\" src=\"images/SM/113699_Demoneedleplacement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photographs above&nbsp;demonstrate&nbsp;needle placement when measuring pressures for each of the four leg compartments: anterior (A); lateral (B); deep posterior (C);&nbsp;superficial posterior (D).&nbsp;To access the deep posterior compartment, the clinician may need to angle&nbsp;the needle horizontally to&nbsp;pass behind the tibia.</div><div class=\"graphic_reference\">From: Flick D, Flick R. Chronic exertional compartment syndrome testing. Curr Sports Med Rep 2015; 14:380. DOI: <A href=\"http://journals.lww.com/acsm-csmr/fulltext/2015/09000/Chronic_Exertional_Compartment_Syndrome_Testing.14.aspx\" target=_blank>10.1249/JSR.0000000000000187</A>. Copyright © 2015 American College of Sports Medicine. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113699 Version 1.0</div></div></div>"},"113703":{"type":"graphic_picture","displayName":"Actinic purpura 2","title":"Actinic purpura","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Actinic purpura</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/113703_Actinic_purpura_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Actinic purpura, also called Bateman purpura or senile purpura, presenting with ecchymotic macules on the forearm skin with signs of severe sun damage.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 113703 Version 1.0</div></div></div>"},"113704":{"type":"graphic_figure","displayName":"Physiologic effects of ghrelin","title":"Physiologic effects of ghrelin","html":"<div class=\"graphic\"><div style=\"width: 643px\" class=\"figure\"><div class=\"ttl\">Physiologic effects of ghrelin</div><div class=\"cntnt\"><img style=\"width:623px; height:656px;\" src=\"images/ENDO/113704_Physiologic_effects_ghrelin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Circulating ghrelin concentrations are highest during periods of fasting.&nbsp;Ghrelin's physiologic effects have been determined by intravenous administration of the hormone to achieve normal systemic serum concentrations or by blocking ghrelin's effects in vivo.&nbsp;Tissue-specific effects have also been confirmed by application of ghrelin in vitro.</div><div class=\"graphic_footnotes\">ACTH: corticotropin; SNS: sympathetic nervous system; BAT: brown adipose tissue; IGF-1: insulin-like growth factor-1.</div><div class=\"graphic_reference\">From: Müller TD, Nogueiras R, Andermann ML, et al. Ghrelin. Mol Metab 2015; 4:437. Copyright © 2015 Elsevier Inc. Available at: <A href=\"http://www.sciencedirect.com/science/article/pii/S2212877815000605?showall%3Dtrue%26via%3Dihub\" target=_blank>http://www.sciencedirect.com/science/article/pii/S2212877815000605?showall%3Dtrue%26via%3Dihub</A> (Accessed June 21, 2017). Reproduced under the terms of the <A href=\"https://creativecommons.org/licenses/by/4.0/\" target=_blank>Creative Commons Attribution License</A>.</div><div id=\"graphicVersion\">Graphic 113704 Version 1.0</div></div></div>"},"113705":{"type":"graphic_figure","displayName":"Diaphragmatic breathing","title":"Diaphragmatic breathing","html":"<div class=\"graphic\"><div style=\"width: 743px\" class=\"figure\"><div class=\"ttl\">Diaphragmatic breathing</div><div class=\"cntnt\"><img style=\"width:723px; height:535px;\" src=\"images/GAST/113705_Diaphragmaticbreathing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients are instructed to place one hand on the abdomen and one on the chest.&nbsp;They are&nbsp;instructed to slowly inhale through the nose, and during inhalation, only the hand on the abdomen should rise, and the hand on the chest should move minimally. Patients then slowly exhale via the mouth.</div><div class=\"graphic_reference\">Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113705 Version 1.0</div></div></div>"},"113706":{"type":"graphic_table","displayName":"Colonoscopic surveillance of patients with IBD","title":"Terminology for reporting findings on colonoscopic surveillance of patients with inflammatory bowel disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Terminology for reporting findings on colonoscopic surveillance of patients with inflammatory bowel disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Term</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td><strong>Visible dysplasia</strong></td> <td>Dysplasia identified on targeted biopsies from a lesion visualized at colonoscopy</td> </tr> <tr> <td class=\"indent1\">Polypoid</td> <td>Lesion protruding from the mucosa into the lumen &#8805;2.5 mm</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Pedunculated </li> </ul> </td> <td>Lesion attached to the mucosa by a stalk</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Sessile </li> </ul> </td> <td>Lesion not attached to the mucosa by a stalk (entire base is contiguous with the mucosa)</td> </tr> <tr> <td class=\"indent1\">Nonpolypoid</td> <td>Lesion with little (&#60;2.5 mm) or no protrusion above the mucosa</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Superficial elevated </li> </ul> </td> <td>Lesion with protrusion but &#60;2.5 mm above the lumen (less than the height of the closed cup of a biopsy forceps)</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Flat </li> </ul> </td> <td>Lesion without protrusion above the mucosa</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Depressed </li> </ul> </td> <td>Lesion with at least a portion depressed below the level of the mucosa</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">General descriptors</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Ulcerated </li> </ul> </td> <td>Ulceration (fibrinous-appearing base with depth) within the lesion</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul class=\"decimal_heading\"> <li>Border </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <ul> <li>Distinct border </li> </ul> </ul> </td> <td>Lesion's border is discrete and can be distinguished from surrounding mucosa</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <ul> <li>Indistinct border </li> </ul> </ul> </td> <td>Lesion's border is not discrete and cannot be distinguished from surrounding mucosa</td> </tr> <tr> <td><strong>Invisible dysplasia</strong></td> <td>Dysplasia identified on random (non-targeted) biopsies of colon mucosa without a visible lesion</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Laine L, Kaltenbach T, Barkun A, et al. SCENIC International Consensus Statement on Surveillance and Management of Dysplasia in Inflammatory Bowel Disease. Gastroenterology 2015; 148:639. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113706 Version 1.0</div></div></div>"},"113707":{"type":"graphic_algorithm","displayName":"CD patients in clinical remission after surgery","title":"Algorithm for management of Crohn disease patients in clinical remission after surgery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of Crohn disease&nbsp;patients in clinical remission after surgery</div><div class=\"cntnt\"><img style=\"width:447px; height:391px;\" src=\"images/GAST/113707_CD_ptnts_cln_rem_aftr_srgry.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm does not substitute for the clinical judgement of the treating specialist. Refer to UpToDate topics for additional details on the medical management of Crohn disease.<br /></div><div class=\"graphic_footnotes\">CD: Crohn disease; AZA: azathioprine; 6MP: 6-mercaptopurine.<br />* Lower risk patients: Nonsmokers, no prior surgery, long-standing CD, history of focal, short stricture. Higher risk patients: Smokers, history of greater than one prior CD surgery, penetrating/fistulizing disease, patients under age 30 years.<br />¶ If symptoms of active Crohn disease develop, refer to the UpToDate content regarding evaluation and management of Crohn disease.<br />Δ For patients naïve to treatment, begin postoperative therapy with AZA/6-MP and 3 months of metronidazole if no history of intolerance to metronidazole. For patients previously treated with AZA/6-MP or anti-TNF, begin anti-TNF agent.<br /><FONT class=lozenge>◊</FONT> Rutgeerts ≥i2.<br />§ Check fecal calprotectin and C-reactive protein every 6 months for 2 years after surgery.<br />¥ For patients on anti-TNF: Options include increasing anti-TNF dose, changing to another biologic, or adding AZA/6-MP. <br />For patients on AZA/6-MP: Start anti-TNF agent with or without continuation of AZA/6-MP.<br />​</div><div id=\"graphicVersion\">Graphic 113707 Version 1.0</div></div></div>"},"113717":{"type":"graphic_picture","displayName":"Multifocal venous malformation","title":"Multifocal venous malformation​","html":"<div class=\"graphic\"><div style=\"width: 760px\" class=\"figure\"><div class=\"ttl\">Multifocal venous malformation​</div><div class=\"cntnt\"><img style=\"width:740px; height:753px;\" src=\"images/DERM/113717_Multifocal_venous_malformtn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Venous malformation located in the subcutaneous tissue in a patient with sporadic multifocal venous malformations.</div><div class=\"graphic_reference\">Courtesy of Laurence M Boon, MD, PhD.</div><div id=\"graphicVersion\">Graphic 113717 Version 1.0</div></div></div>"},"113719":{"type":"graphic_figure","displayName":"Web space infection of the hand","title":"Web space infection of the hand","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Web space infection of the hand</div><div class=\"cntnt\"><img style=\"width:540px; height:280px;\" src=\"images/SURG/113719_Web_space_infection_of_the_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This type of hand infection/abscess begins at the palmar aspect of the web space. Pus then passes over the distal edge of the deep transverse metacarpal ligament to enter the dorsal aspect of the web space. The abscess is now dumbbell shaped and resembles dress shirt buttons from the 19<SUP>th </SUP>century, hence the name \"collar button/shirt stud (en bouton de chemise) abscess.\" Although most of the pus is palmar, the abscess usually points dorsal.</div><div class=\"graphic_reference\">Modified from:<br /><OL>&#xD;&#xA;<LI>Kanavel AB. Infections of the Hand: A Guide to the Surgical Treatment of Acute and Chronic Suppurative Processes in the Fingers, Hand, and Forearm, 4th ed, Lea &amp; Febiger, New York 1921.</LI>&#xD;&#xA;<LI>Bunnell S. Surgery of the Hand, 3rd ed, JB Lippincott Co, Philadelphia 1956.</LI>&#xD;&#xA;<LI>Kalbfell E, Adams NS, Cullen WT. Collar button abscess. Eplasty 2016; 16:ic6.</LI></OL></div><div id=\"graphicVersion\">Graphic 113719 Version 1.0</div></div></div>"},"113720":{"type":"graphic_table","displayName":"Daily actigraphy log example","title":"Daily actigraphy log","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Daily actigraphy log</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup span=\"5\" width=\"6%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"5\">Response</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Morning questions</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>What time did you go to bed (use 24-hour clock or AM/PM)?</li> </ol> </td> <td colspan=\"5\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ol start=\"2\"> <li>How long did it take you to fall asleep (hours/minutes)?</li> </ol> </td> <td colspan=\"5\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ol start=\"3\"> <li>Did you wake up during the night last night (yes/no)?</li> </ol> </td> <td colspan=\"5\">&nbsp;</td> </tr> <tr> <td class=\"indent2\"> <ol style=\"list-style-type: lower-alpha;\"> <li>How many times did you wake up?</li> </ol> </td> <td colspan=\"5\">&nbsp;</td> </tr> <tr> <td class=\"indent2\"> <ol style=\"list-style-type: lower-alpha;\" start=\"2\"> <li>How long were you awake, in total, after you initially fell asleep (hours/minutes)?</li> </ol> </td> <td colspan=\"5\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ol start=\"4\"> <li>How long did you sleep last night (hours/minutes)?</li> </ol> </td> <td colspan=\"5\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ol start=\"5\"> <li>Rate the quality of your sleep (1 = excellent; 5 = poor)</li> </ol> </td> <td class=\"centered\">1</td> <td class=\"centered\" style=\"border-left: #ffffff 1px solid;\">2</td> <td class=\"centered\" style=\"border-left: #ffffff 1px solid;\">3</td> <td class=\"centered\" style=\"border-left: #ffffff 1px solid;\">4</td> <td class=\"centered\" style=\"border-left: #ffffff 1px solid;\">5</td> </tr> <tr> <td class=\"indent1\"> <ol start=\"6\"> <li>What time did you wake up this morning (use 24-hour clock or AM/PM)?</li> </ol> </td> <td colspan=\"5\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ol start=\"7\"> <li>What time did you get out of bed (use 24-hour clock or AM/PM)?</li> </ol> </td> <td colspan=\"5\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ol start=\"8\"> <li>How difficult was it to wake up? (1 = very easy; 5 = very hard)</li> </ol> </td> <td class=\"centered\">1</td> <td class=\"centered\" style=\"border-left: #ffffff 1px solid;\">2</td> <td class=\"centered\" style=\"border-left: #ffffff 1px solid;\">3</td> <td class=\"centered\" style=\"border-left: #ffffff 1px solid;\">4</td> <td class=\"centered\" style=\"border-left: #ffffff 1px solid;\">5</td> </tr> <tr> <td class=\"indent1\"> <ol start=\"9\"> <li>How alert do you feel now? (1 = wide awake; 5 = very sleepy)</li> </ol> </td> <td class=\"centered\">1</td> <td class=\"centered\" style=\"border-left: #ffffff 1px solid;\">2</td> <td class=\"centered\" style=\"border-left: #ffffff 1px solid;\">3</td> <td class=\"centered\" style=\"border-left: #ffffff 1px solid;\">4</td> <td class=\"centered\" style=\"border-left: #ffffff 1px solid;\">5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol start=\"10\"> <li>How refreshed do you feel? (1 = very rested; 5 = not at all)</li> </ol> </td> <td class=\"centered\">1</td> <td class=\"centered\" style=\"border-left: #ffffff 1px solid;\">2</td> <td class=\"centered\" style=\"border-left: #ffffff 1px solid;\">3</td> <td class=\"centered\" style=\"border-left: #ffffff 1px solid;\">4</td> <td class=\"centered\" style=\"border-left: #ffffff 1px solid;\">5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"6\"><strong>Comments:</strong><br /> &nbsp;<br /> &nbsp;<br /> &nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Evening questions</td> </tr> <tr> <td class=\"indent1\"> <ol start=\"11\"> <li>Did you nap today (yes/no)?</li> </ol> </td> <td colspan=\"5\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ol start=\"12\"> <li>How long was your longest nap (hours/minutes)?</li> </ol> </td> <td colspan=\"5\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ol start=\"13\"> <li>What time did your nap start (use 24-hour clock or AM/PM)?</li> </ol> </td> <td colspan=\"5\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ol start=\"14\"> <li>How much time did you nap, planned plus unplanned (hours/minutes)?</li> </ol> </td> <td colspan=\"5\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ol start=\"15\"> <li>What activities consumed the majority of your time?</li> </ol> </td> <td colspan=\"5\"> <ol class=\"numbers_to_nine\" style=\"list-style-type: lower-alpha;\"> <li>Computer</li> <li>Television</li> <li>Reading/paperwork</li> <li>Housework</li> <li>Other, specify:<br /> &nbsp;<hr style=\"background-color: #000000;\" /> </li> </ol> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 113720 Version 1.0</div></div></div>"},"113721":{"type":"graphic_table","displayName":"Common causes of acute cough","title":"Common causes of acute cough","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of acute cough</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Associated clinical features</td> </tr> <tr> <td>Upper respiratory tract infection (URI), or common cold</td> <td>Rhinorrhea, nasal obstruction, sneezing, scratchy or sore throat, malaise, headache</td> </tr> <tr> <td>Acute bronchitis</td> <td>Antecedent&nbsp;(URI), absence of high fever or other systemic signs or symptoms, absence of signs of consolidation on chest exam</td> </tr> <tr> <td>Pneumonia</td> <td>Fever, tachycardia, tachypnea, signs of consolidation on chest exam, mental status change in those &#62;75 years old</td> </tr> <tr> <td>Post-nasal drip</td> <td>Post-nasal drainage, need to clear throat, rhinorrhea</td> </tr> <tr> <td>Gastroesophageal reflux disorder</td> <td>Heartburn, regurgitation, dysphagia</td> </tr> <tr> <td>Asthma</td> <td>History of episodic wheezing, shortness of breath, allergen exposure&nbsp;or exercise</td> </tr> <tr> <td>ACE inhibitor use</td> <td>Nonproductive cough, tickling or scratchy sensation in the throat</td> </tr> <tr> <td>Heart failure</td> <td>Shortness of breath, orthopnea, gallop rhythm, elevated jugular venous pulse, peripheral edema</td> </tr> <tr> <td>Pulmonary embolism</td> <td>Tachycardia, shortness of breath, pleuric chest pain, hemoptysis</td> </tr> <tr> <td>Lung cancer</td> <td>Past or present smoking history, change in a chronic \"smoker's cough,\" hemoptysis, signs of focal airway obstruction on chest exam</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 113721 Version 3.0</div></div></div>"},"113725":{"type":"graphic_table","displayName":"Differential diagnosis of chromoblastomycosis","title":"Differential diagnosis of chromoblastomycosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of chromoblastomycosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infectious diseases</td> </tr> <tr> <td class=\"indent1\"><strong>Fungi</strong></td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Systemic mycoses </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <ul> <li>Coccidioidomycosis, blastomycosis, paracoccidioidomycosis </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Implantation mycoses </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <ul> <li>Fixed sporotrichosis, eumycetoma, phaeohyphomycosis, lobomycosis </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Cutaneous mycoses </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <ul> <li>Granulomatous dermatophytosis, Majocchi granuloma, granulomatous candidiasis </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Bacteria</strong></td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Ecthyma, cutaneous tuberculosis, leprosy, actinomycetoma, nocardiosis, botryomycosis, tertiary syphilis, yaws, mycobacteriosis (eg, <em>Mycobacterium marinum</em>, <em>Mycobacterium fortuitum)</em> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Protozoa</strong></td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Cutaneous leishmaniasis, rhinosporidiosis </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Virus</strong></td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Verrucae, papilloma </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Helminths</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Filariasis </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Noninfectious diseases</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Squamous cell carcinoma, mycosis fungoides, psoriasis, sarcoidosis, systemic lupus erythematosus, mossy foot </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Queiroz-Telles F, de Hoog S, Santos DW, et al. Chromoblastomycosis. Clin Microbiol Rev 2017; 30:233. Copyright &copy; 2017 American Society for Microbiology.</div><div id=\"graphicVersion\">Graphic 113725 Version 1.0</div></div></div>"},"113726":{"type":"graphic_algorithm","displayName":"Algorithm for treatment of patients with sick sinus syndrome","title":"Algorithm for treatment of patients with sick sinus syndrome","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Algorithm for treatment of patients with sick sinus syndrome</div><div class=\"cntnt\"><img style=\"width:451px; height:749px;\" src=\"images/CARD/113726_Alg_trmt_pat_sck_sns_syndrm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; BP: blood pressure; IV: intravenous; PPM: permanent pacemaker; SSS: sick sinus syndrome.<br />* The initial dose of atropine is 0.5 mg IV push. This dose may be repeated every three to five minutes to a total dose of 3 mg.<br />¶ While transcutaneous pacing may be initially successful in stabilizing the patient, it may not be consistently reliable and is frequently uncomfortable for the patient. Prepare for urgent transvenous pacing (if required) and obtain central venous access (preferably right internal jugular vein access).<br />Δ Dopamine IV infusion typically begins at a dose of 2 mcg/kg/minute and can be titrated up to 20 mcg/kg/minute if needed for heart rate and blood pressure augmentation.<br /><FONT class=lozenge>◊</FONT> Epinephrine IV infusion typically begins at a dose of 2 mcg/minute and can be titrated up to 20 mcg/minute if needed for heart rate and blood pressure augmentation.<br />§ Isoproterenol IV infusion typically begins at a dose of 2 mcg/minute and can be titrated up to 10 mcg/minute if needed for heart rate and blood pressure augmentation.<br />¥ Reversible causes of SSS may include drugs (eg, beta blockers, calcium channel blockers, digoxin), ischemia, and autonomic imbalance.</div><div id=\"graphicVersion\">Graphic 113726 Version 1.0</div></div></div>"},"113728":{"type":"graphic_figure","displayName":"Ocular manifestations of Alport syndrome","title":"Ocular manifestations of Alport syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ocular manifestations of Alport syndrome</div><div class=\"cntnt\"><img style=\"width:424px; height:682px;\" src=\"images/PEDS/113728_Ocular manifestations of Alport syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A&nbsp;is a picture of a patient with Alport's syndrome and anterior lenticonus. Panel C demonstrates the regular conical protrusion on the anterior aspect of the lens due to thinning of the lens capsule compared with the normal lens as shown in panel B. </div><div class=\"graphic_reference\">(A) Reproduced with permission from: Al-Mahmood AM, Al-Swailem SA, Al-Khalaf A, Al-Binali GY. Progressive lenticonus in a patient with alport syndrome. Middle East Afr J Ophthalmol 2010; 17(4):379-81. Copyright © 2010&nbsp;Wolters Kluwer Medknow, all rights reserved.</div><div id=\"graphicVersion\">Graphic 113728 Version 1.0</div></div></div>"},"113730":{"type":"graphic_diagnosticimage","displayName":"MRI appearance of low-grade astrocytoma","title":"MRI appearance of low-grade astrocytoma","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">MRI appearance of low-grade astrocytoma</div><div class=\"cntnt\"><img style=\"width:764px; height:406px;\" src=\"images/NEURO/113730_MRI_low-grade_glioma_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain MRI in a 34-year-old male presenting with&nbsp;left leg focal motor seizure. Axial (A) and coronal (B) FLAIR images show a T2-hyperintense, expansile mass in the right posterior frontal lobe, centered in the precentral gyrus, with no surrounding edema. Contrast imaging showed no enhancement. Pathology confirmed a WHO grade II astroctyoma, IDH1 mutant.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery; WHO: World Health Organization; IDH: isocitrate dehydrogenase.</div><div id=\"graphicVersion\">Graphic 113730 Version 1.0</div></div></div>"},"113732":{"type":"graphic_algorithm","displayName":"Management of muscle invasive bladder cancer","title":"Management of muscle invasive bladder cancer","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Management of muscle invasive bladder cancer</div><div class=\"cntnt\"><img style=\"width:484px; height:248px;\" src=\"images/ONC/113732_Mgmt_mscl-invsv_bladder_CA.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TURBT: transurethral resection of bladder tumor; CT: computed tomography; MRI: magnetic resonance imaging.<br />​* CT/MRI of abdomen and pelvis, chest imaging, other testing as clinically indicated.<br />¶ Refer to the UpToDate topic on treatment of metastatic urothelial carcinoma of the bladder.<br />Δ For patients who undergo radical cystectomy without prior chemotherapy, adjuvant chemotherapy can be considered. Refer to the UpToDate topic on adjuvant chemotherapy for muscle invasive urothelial carcinoma bladder.<br /><FONT class=lozenge>◊</FONT> Refer to discussion in the UpToDate topic on bladder preservation treatment options for muscle invasive urothelial bladder cancer.</div><div id=\"graphicVersion\">Graphic 113732 Version 1.0</div></div></div>"},"113733":{"type":"graphic_diagnosticimage","displayName":"Left temporal glioblastoma","title":"Left temporal glioblastoma","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">Left temporal glioblastoma</div><div class=\"cntnt\"><img style=\"width:765px; height:409px;\" src=\"images/NEURO/113733_MRIhighgradeglioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain MRI in a 53-year-old male presenting with several weeks of headaches and word-finding difficulties. FLAIR (A) and postcontrast T1-weighted images (B) show a large, T2-hyperintense mass in the left temporal lobe with heterogeneous enhancement and central necrosis. Pathology confirmed a WHO grade IV glioblastoma.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery; WHO: World Health Organization.</div><div id=\"graphicVersion\">Graphic 113733 Version 2.0</div></div></div>"},"113736":{"type":"graphic_table","displayName":"Causes of cystic lung disease in adults","title":"Causes of cystic lung disease in adults*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of cystic lung disease in adults*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td>Amyloidosis<sup>&#182;</sup></td> </tr> <tr> <td>Bronchopulmonary dysplasia (lung cysts likely a consequence of infection)</td> </tr> <tr> <td>Congenital/genetic (eg, <strong>Birt-Hogg-Dub&#233; syndrome</strong>, Down syndrome, neurofibromatosis, Proteus syndrome)</td> </tr> <tr> <td>Erdheim Chester disease</td> </tr> <tr> <td>Fire-eater's lung</td> </tr> <tr> <td>Fungi (eg, coccidioidomycosis, <em>Pneumocystic jirovecii</em>)</td> </tr> <tr> <td>Hypersensitivity pneumonitis</td> </tr> <tr> <td>Hyper immunoglobulin-E syndrome (due to recurrent staphylococcal pneumonia)</td> </tr> <tr> <td>Light chain deposition disease<sup>&#916;</sup></td> </tr> <tr> <td><strong>Lymphangioleiomyomatosis</strong> (sporadic or related to tuberous sclerosis complex)</td> </tr> <tr> <td><strong>Lymphoid interstitial pneumonia</strong><sup>&#9674;</sup> (eg, associated with Sj&#246;gren syndrome, immunodeficiency)</td> </tr> <tr> <td>Paragonimiasis</td> </tr> <tr> <td>Primary and metastatic tumors (eg, lung adenocarcinoma, metastatic gastrointestinal and genitourinary adenocarcinoma, lymphoma, mesenchymal cystic hamartoma, metastatic sarcomas, pleuropulmonary blastoma)</td> </tr> <tr> <td>Recurrent respiratory papillomatosis (involving lung parenchyma in adult)</td> </tr> <tr> <td>Smoking-related interstitial lung disease (desquamative interstitial pneumonia, <strong>pulmonary Langerhans cell histiocytosis</strong>, respiratory bronchiolitis interstitial lung disease)</td> </tr> <tr> <td>Staphylococcal pneumonia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The four most common causes are identified in bold.<br />¶ Typically, cystic lung disease caused by amyloid is immunoglobulin light chain (AL) amyloid and may be seen in combination with Sjögren syndrome. Amyloid fibrils are positive on Congo red stain and have green birefringence under polarized light.<br />Δ Light chain deposition disease (LCDD) does not have beta-pleated sheet configuration so it is negative on Congo red staining and does not have green birefringence under polarized light.<br /><FONT class=lozenge>◊</FONT> May be associated with follicular bronchiolitis.</div><div id=\"graphicVersion\">Graphic 113736 Version 1.0</div></div></div>"},"113737":{"type":"graphic_table","displayName":"Cysts, blebs, bullae, cavities, honeycombing, pneumatoceles","title":"Cysts, blebs, bullae, cavities, honeycombing, pneumatoceles: Definitions and features<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cysts, blebs, bullae, cavities, honeycombing, pneumatoceles: Definitions and features<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Features</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td><strong>Bleb</strong></td> <td>Previously, \"bleb\" referred to a rounded, subpleural lucency, &#60;1 cm diameter. Now considered to be a type of bulla, and use of the term is discouraged.</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Bulla</strong></td> <td>Rounded, focal, thin-walled (&#60;1 mm); usually several centimeters in diameter, can fill hemithorax, can be seen in association with emphysema.</td> <td>Emphysema.</td> </tr> <tr> <td><strong>Bronchiectasis</strong></td> <td>Dilated, thick-walled bronchi can look cystic, but are in communication with airway; may be clustered.</td> <td>Cystic fibrosis, primary ciliary dysfunction, common variable immunodeficiency, postinfectious.</td> </tr> <tr> <td><strong>Cavity</strong></td> <td>Thick walled (&#62;4 mm) may be partially filled with fluid, debris, mycetoma. Can be within a mass, nodule, or area of consolidation.</td> <td>Necrotizing bacterial pneumonia, mycobacterial or fungal infection, neoplasm (eg, bronchogenic carcinoma if single; metastatic cancer if multiple), granulomatosis with polyangiitis (GPA) and other vasculitides.</td> </tr> <tr> <td><strong>Cyst</strong></td> <td>Round or irregular, variable size, thin-walled (&#60;2 mm thick), may be associated with nodules.</td> <td>Birt-Hogg-Dub&#233; syndrome, lymphangioleiomyomatosis, lymphocytic interstitial pneumonia, pulmonary Langerhans cell histiocytosis.</td> </tr> <tr> <td><strong>Emphysema</strong></td> <td>Rounded or polygonal lucencies without walls; variable size. Paraseptal emphysema is bounded by pleura and interlobular septa; centrilobular emphysema has an upper lobe predilection.</td> <td>Alpha-1 antitrypsin deficiency, lung injury due to cigarette smoking or indoor cooking fires.</td> </tr> <tr> <td><strong>Honeycombing</strong></td> <td>Clusters of round, 3 to 10 mm diameter lucencies, wall-thickness 1 to 3 mm; may be multitiered, typically in a subpleural location, associated with traction bronchiectasis and septal thickening.</td> <td>Asbestosis, idiopathic pulmonary fibrosis (IPF), usual interstitial pneumonia in systemic rheumatic disease, chronic hypersensitivity pneumonitis.</td> </tr> <tr> <td><strong>Pneumatocele</strong></td> <td>Often postinfectious, may be solitary or multiple, typically transient.</td> <td>Postinfectious (eg, <em>Staphylococcus aureus&nbsp;pneumonia, Pneumocystis jirovecii </em>pneumonia, coccidioidomycosis), post-traumatic, hydrocarbon inhalation.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008; 246:697.</LI></OL></div><div id=\"graphicVersion\">Graphic 113737 Version 1.0</div></div></div>"},"113738":{"type":"graphic_table","displayName":"Cystic lung disease features","title":"Cystic lung disease: Clinical, laboratory, and radiographic features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cystic lung disease: Clinical, laboratory, and radiographic features</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cystic lung disease</td> <td class=\"subtitle1\">Distinctive clinical features</td> <td class=\"subtitle1\">Typical CT features*</td> <td class=\"subtitle1\">Confirmation of diagnosis (in association with compatible chest CT)</td> </tr> <tr class=\"divider_bottom\"> <td>LAM</td> <td> <ul> <li>Occurs almost exclusively in females (occasionally in males with TSC) </li> <li>Renal angiomyolipomas in up to 50% of cases </li> <li>Retroperitoneal or pelvic lymphangioleiomyomas </li> <li>Chylous effusion, chylous ascites </li> <li>May be accompanied by clinical features of TSC </li> </ul> </td> <td> <ul> <li>Small, thin-walled, round cysts varying little in size or shape, uniformly distributed throughout the lungs </li> </ul> </td> <td>One of the following: <ul> <li>Noncontrast abdomen/pelvis CT or MRI demonstrating renal angiomyolipoma or cystic lymphangioleiomyoma </li> <li>Presence of chylous pleural effusion or ascites<sup>&#182;</sup> </li> <li>Serum VEGF-D &#62;800 pg/mL </li> <li>Presence of TSC </li> <li>Transbronchial or surgical lung biopsy demonstrating diagnostic histological features<sup>&#916;</sup> (if all of the above are absent) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>PLCH</td> <td> <ul> <li>Nearly all affected individuals are current or former cigarette smokers<sup>&#9674;</sup> </li> <li>Diabetes insipidus </li> <li>Bone lesions </li> </ul> </td> <td> <ul> <li>Mix of nodules and thick-walled cysts (early stages) or bizarrely shaped cysts varying in size and shape (advanced stages) </li> <li>Upper and mid-lung zone distribution with sparing of costophrenic angles </li> </ul> </td> <td>One of the following: <ul> <li>BAL with &#8805;5% CD1a-positive cells </li> <li>Transbronchial or surgical lung biopsy demonstrating diagnostic histological features </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>BHD</td> <td> <ul> <li>Fibrofolliculomas </li> <li>Renal neoplasms, typically multifocal hybrid oncocytic tumors or chromophobe renal cell carcinomas </li> <li>Family history of pneumothorax or renal neoplasms </li> </ul> </td> <td> <ul> <li>Bilateral thin-walled round or lentiform cysts of variable sizes, often subpleural and/or abutting the mediastinum, with a lower lung zone predominance </li> </ul> </td> <td>One of the following: <ul> <li>Biopsy-proven skin fibrofolliculoma </li> <li>Bilateral, multifocal hybrid oncocytic renal tumors or chromophobe renal cell carcinomas </li> <li>Genetic testing positive for <em>FLCN</em> mutation </li> </ul> <strong>NOTE:</strong> Lung biopsy NOT helpful </td> </tr> <tr> <td>LIP</td> <td> <ul> <li>Underlying autoimmune or immunodeficiency state in 80% of cases </li> <li>Sj&#246;gren syndrome is most common underlying disorder </li> </ul> </td> <td> <ul> <li>Thin-walled cysts, typically few in number, associated with ground glass opacities and centrilobular nodules </li> </ul> </td> <td> <ul> <li>Serologic testing for HIV and systemic rheumatic disease (eg, antinuclear antibody, anti-Ro/SSA, anti-La/SSB, rheumatoid factor) adds support to clinical diagnosis </li> <li>Lacrimal gland or lip biopsy </li> <li>Surgical lung biopsy, when a definitive diagnosis is needed to guide therapy </li> </ul> <strong>NOTE:</strong> Transbronchial biopsy size too small to be definitive for LIP, so TBLB only helpful if an alternate diagnosis suspected (eg, LAM) </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; LAM: lymphangioleiomyomatosis; TSC: tuberous sclerosis complex; MRI: magnetic resonance imaging; VEGF-D: vascular endothelial growth factor-D; PLCH: pulmonary Langerhans cell histiocytosis; BAL: bronchoalveolar lavage; CD1-a: CD1 antigen; BHD: Birt-Hogg-Dubé syndrome; FLCN: folliculin; LIP: lymphoid interstitial pneumonia; TBLB: transbronchial lung biopsy; HRCT: high resolution computed tomography.<br />* While these features are characteristic, they are not pathognomonic.<br />¶ Pleural fluid should be assessed for chyle and LAM cells (atypical smooth muscle-like cells that display positive immunohistochemical staining for melanocytic markers, such as human melanoma black [HMB]-45). If no evidence of chylous pleural fluid and abdominal-pelvic HRCT shows ascites, perform paracentesis with assessment for chyle and LAM cells.<br />Δ The two hallmark histopathologic features of pulmonary LAM are lung cysts and smooth muscle-like LAM cells.<br /><FONT class=lozenge>◊</FONT> Other cystic lung diseases can occur in smokers, but PLCH is almost unheard of in those without cigarette smoke exposure.</div><div id=\"graphicVersion\">Graphic 113738 Version 1.0</div></div></div>"},"113740":{"type":"graphic_diagnosticimage","displayName":"Pneumatoceles","title":"Pneumatoceles in right upper lobe following treatment for pneumonia","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Pneumatoceles in right upper lobe following treatment for pneumonia</div><div class=\"cntnt\"><img style=\"width:604px; height:679px;\" src=\"images/PULM/113740_Pneumatoceles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial high resolution computed tomography image showing numerous pneumatoceles, focal lucencies without visible walls, in a patient recovering from pneumonia. The lucencies are in areas of normal lung and associated with focal ground-glass opacity.</div><div class=\"graphic_reference\">Courtesy of W. Richard Webb, MD.</div><div id=\"graphicVersion\">Graphic 113740 Version 1.0</div></div></div>"},"113742":{"type":"graphic_diagnosticimage","displayName":"LIP with cystic lung disease","title":"Lymphocytic interstitial pneumonia with cystic lung disease in Sjögren syndrome","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Lymphocytic interstitial pneumonia with cystic lung disease in Sjögren syndrome</div><div class=\"cntnt\"><img style=\"width:600px; height:452px;\" src=\"images/PULM/113742_LIP_cystic_lung_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial high resolution computed tomography image from a patient with Sjögren syndrome and lymphocytic interstitial pneumonia.&nbsp;Scattered lung cysts of variable size are present.</div><div class=\"graphic_reference\">Courtesy of Jorge Alberto Carrillo Bayona, MD.</div><div id=\"graphicVersion\">Graphic 113742 Version 1.0</div></div></div>"},"113743":{"type":"graphic_diagnosticimage","displayName":"LIP with lung cysts in HIV/AIDS","title":"Lymphocytic interstitial pneumonia with lung cysts in HIV/AIDS","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Lymphocytic interstitial pneumonia with lung cysts in HIV/AIDS</div><div class=\"cntnt\"><img style=\"width:756px; height:561px;\" src=\"images/PULM/113743_LIP_lung_cysts_HIV_AIDS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial high resolution computed tomography image from a patient with lymphocytic interstitial pneumonia due to HIV/AIDS showing small lung nodules in a perilymphatic pattern. Also, subpleural nodules are visible in relation to the major fissure (upper left).</div><div class=\"graphic_reference\">Courtesy of W. Richard Webb, MD.</div><div id=\"graphicVersion\">Graphic 113743 Version 1.0</div></div></div>"},"113744":{"type":"graphic_picture","displayName":"Pancreas divisum, minor papilla sphincterotomy","title":"Pancreas divisum, minor papilla sphincterotomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreas divisum, minor papilla sphincterotomy</div><div class=\"cntnt\"><img style=\"width:444px; height:469px;\" src=\"images/PEDS/113744_Pncrs_dvsm_min_sphnctrtmy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) A cannula is introduced into the minor papilla (arrow), which is located above the major papilla (dashed arrow).<br />(Panel B) A wire (arrow) is introduced into the dorsal pancreatic duct.<br />(Panel C) After sphincterotomy of the minor pancreatic papilla, a pancreatic stent (arrow) is placed into the dorsal pancreatic duct to prevent pancreatitis.</div><div class=\"graphic_reference\">Courtesy of Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 113744 Version 1.0</div></div></div>"},"113745":{"type":"graphic_diagnosticimage","displayName":"Chronic calcific pancreatitis with PRSS1 mutation","title":"Chronic calcific pancreatitis in a patient with a mutation in the <EM>PRSS1</EM> gene","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Chronic calcific pancreatitis in a patient with a mutation in the <EM>PRSS1</EM> gene</div><div class=\"cntnt\"><img style=\"width:766px; height:682px;\" src=\"images/PEDS/113745_Chro_calc_pancreatits_PRSS1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">12-year-old boy with documented recurrent acute pancreatitis for five years, now with chronic calcific pancreatitis. The evaluation revealed a mutation in the <EM>PRSS1</EM> gene (at p.R122H). The patient presented with worsening constant pain.<br />(Panel A) CT of the abdomen revealed a ductal stone, with proximal pancreatic duct dilation.<br />(Panel B) ERCP was performed, revealing a dilated main pancreatic duct, with a filling defect (arrow) representing a stone.<br />(Panel C) The stone was successfully extracted using a basket.</div><div class=\"graphic_footnotes\">CT: computed tomography; ERCP: endoscopic retrograde cholangiopancreatography.</div><div class=\"graphic_reference\">Courtesy of Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 113745 Version 1.0</div></div></div>"},"113748":{"type":"graphic_table","displayName":"Twin pregnancy nutritional recommendations","title":"Twin pregnancy nutritional recommendations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Twin pregnancy nutritional recommendations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">First trimester</td> <td class=\"subtitle1\">Second trimester</td> <td class=\"subtitle1\">Third trimester</td> </tr> <tr class=\"divider_bottom\"> <td>Maternal weight/weight gain</td> <td>Assess maternal pregravid BMI, determine BMI-specific weight gain goals</td> <td>Assess/counsel regarding maternal BMI-specific weight gain (each prenatal care visit)</td> <td>Assess/counsel regarding maternal BMI-specific weight gain (each prenatal care visit)</td> </tr> <tr> <td colspan=\"4\">Caloric requirements (kcal &times; kg<sup>&ndash;1</sup> &times; d<sup>&ndash;1</sup>)</td> </tr> <tr> <td class=\"indent1\">Normal BMI</td> <td class=\"centered\">40 to 45</td> <td class=\"divider_bottom\" rowspan=\"3\">Alter as necessary for weight gain goal</td> <td class=\"divider_bottom\" rowspan=\"3\">Alter as necessary for weight gain goal</td> </tr> <tr> <td class=\"indent1\">Underweight</td> <td class=\"centered\">42 to 50</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Overweight</td> <td class=\"centered\">30 to 35</td> </tr> <tr> <td colspan=\"4\">Micronutrient supplement (daily total intake)</td> </tr> <tr> <td class=\"indent1\">MVI with iron (30 mg elemental tablets)</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Calcium (mg)</td> <td class=\"centered\">1500</td> <td class=\"centered\">2500</td> <td class=\"centered\">2500</td> </tr> <tr> <td class=\"indent1\">Vitamin D (international units)</td> <td class=\"centered\">1000</td> <td class=\"centered\">1000</td> <td class=\"centered\">1000</td> </tr> <tr> <td class=\"indent1\">Magnesium (mg)</td> <td class=\"centered\">400</td> <td class=\"centered\">800</td> <td class=\"centered\">800</td> </tr> <tr> <td class=\"indent1\">Zinc (mg)</td> <td class=\"centered\">15</td> <td class=\"centered\">30</td> <td class=\"centered\">30</td> </tr> <tr> <td class=\"indent1\">DHA/EPA (mg)</td> <td class=\"centered\">300 to 500</td> <td class=\"centered\">300 to 500</td> <td class=\"centered\">300 to 500</td> </tr> <tr> <td class=\"indent1\">Folic acid (mg)</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vitamin C/E (mg/international units)</td> <td class=\"centered\">500 to 1000/400</td> <td class=\"centered\">500 to 1000/400</td> <td class=\"centered\">500 to 1000/400</td> </tr> <tr class=\"divider_bottom\"> <td>Nutritional consultation</td> <td>Yes</td> <td>Repeat if not at weight gain goal, anemia, GDM</td> <td>Repeat if not at weight gain goal, anemia, GDM</td> </tr> <tr class=\"divider_bottom\"> <td>Laboratory nutritional assessment</td> <td>Hemoglobin ferritin folate/B12 early screen for GDM (risk factors) vitamin D</td> <td>Follow up abnormalities from first trimester</td> <td>Hemoglobin ferritin GDM screen with or without vitamin D</td> </tr> <tr> <td>Risk factor-appropriate exercise or reduction in activity</td> <td>Screen</td> <td>Screen</td> <td>Screen</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Daily energy intake is divided over three meals and three snacks, with 20% of calories from protein, 40% of calories from low-glycemic index carbohydrates, and 40% of calories from fat.</div><div class=\"graphic_footnotes\">BMI: body mass index; MVI: multivitamin; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; GDM: gestational diabetes mellitus.</div><div class=\"graphic_reference\">From: Goodnight W, Newman R. Optimal nutrition for improved twin pregnancy outcome. Obstet Gynecol 2009; 114:1121. DOI: <a href=\"http://journals.lww.com/greenjournal/Abstract/2009/11000/Optimal_Nutrition_for_Improved_Twin_Pregnancy.24.aspx\" target=\"_blank\">10.1097/AOG.0b013e3181bb14c8</a>. Copyright &copy; 2009 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113748 Version 1.0</div></div></div>"},"113752":{"type":"graphic_figure","displayName":"Thalassemia survival rates after HCT","title":"Survival rates for 1493 individuals with thalassemia who underwent hematopoietic cell transplantation between the years 2000 to 2010","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Survival rates for 1493 individuals with thalassemia who underwent hematopoietic cell transplantation&nbsp;between the years&nbsp;2000 to 2010</div><div class=\"cntnt\"><img style=\"width:532px; height:648px;\" src=\"images/HEME/113752_Surv_trans_recs_2000_2010.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows outcomes for the entire population (all ages [mostly children], all donors, all sources of hematopoietic stem cells). Overall survival is shown in&nbsp;(A) and thalassemia-free survival is shown in&nbsp;(B). The probabilities in the table are for overall survival and thalassemia-free survival at two years. Refer to UpToDate for additional discussion of the factors that affect outcomes and our approach to thalassemia&nbsp;management.</div><div class=\"graphic_reference\">Reprinted by permission of Macmillan Publishers Ltd: Bone Marrow Transplantation. Baronciani D, Angelucci E, Potschger U, et al. Hematopoietic stem cell transplantation in thalassemia: A report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010. Bone Marrow Transplant 2016; 51:536. Copyright &copy; 2016. <a href=\"http://www.nature.com/bmt\" target=\"_blank\">www.nature.com/bmt</a>.</div><div id=\"graphicVersion\">Graphic 113752 Version 1.0</div></div></div>"},"113753":{"type":"graphic_table","displayName":"Airway management closed head injury","title":"Airway management for patients with closed head injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Airway management for patients with closed head injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Key points:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>In a patient with a DA, perform awake intubation if the patient is awake (GCS &#8805;9), cooperative, hemodynamically stable, and able to maintain adequate O<sub>2</sub> saturation.* </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Keep cerebral perfusion pressure at 60 to 70 mmHg.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Avoid hypoxia and hypercarbia. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DA: difficult airway; GCS: Glasgow coma scale; O<SUB>2</SUB>: oxygen.<br />*Patients with a brain injury may NOT be cooperative and this will make awake intubation challenging.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Carney N, Totten AM, O'Reilly C, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery 2017; 80:6.</LI></OL>Based on Hagberg CA, Kaslow O. Difficult airway management algorithm in trauma: Updated by COTEP. ASA Monitor 2014; 78:56. Copyright © 2014 American Society of Anesthesiologists. A copy of the full text can be obtained from ASA, 1061 American Lane, Schaumburg, IL, 60173-4973 or online at <A href=\"http://www.asahq.org/\" target=_blank>www.asahq.org</A>.</div><div id=\"graphicVersion\">Graphic 113753 Version 2.0</div></div></div>"},"113755":{"type":"graphic_table","displayName":"Photodynamic therapy patient handout","title":"Sample handout for patients undergoing photodynamic therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample handout for patients undergoing photodynamic therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">What is photodynamic therapy (PDT)?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">PDT is a procedure for treating actinic keratoses, which are precancerous lesions that occur mostly in sun-exposed areas of the skin. A medicated solution or gel that makes you more sensitive to light will be applied to the affected area. Your dermatologist will inform you how long the medication needs to stay on your skin prior to light exposure.</td> </tr> <tr> <td class=\"subtitle2_left\">What to expect during the treatment?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">There may be a painful or stinging sensation during the treatment. The degree of discomfort can vary&nbsp;among individuals. You will wear protective goggles during the treatment to protect your eyes from the bright light.</td> </tr> <tr> <td class=\"subtitle2_left\">What to expect after the treatment?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">On the day of treatment, there may be mild to moderate redness on the treated area. One day later, you may develop more intense redness. This will remain for three to four days, along with a \"stretchy\" feeling and some mild peeling, similar to a healing sunburn reaction. Very rarely, one might get some tiny blisters on the treated area. You may be prescribed a soothing ointment that can be helpful during those first few days. All of these changes are expected to settle down in a week to ten days.</td> </tr> <tr> <td class=\"subtitle2_left\">Can I shave before the treatment?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Facial hair can interfere with PDT, but please do not shave on the morning of your treatment. We do not recommend shaving the treated areas for several days afterwards.</td> </tr> <tr> <td class=\"subtitle2_left\">Should I stop any medications prior to the treatment?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Retinoid-containing creams or gels and tetracycline antibiotics (such as doxycycline or minocycline) should be stopped one to two weeks before the treatment because they can make your skin more sensitive to the light. Your dermatologist will review your medication list and determine whether you are on any other phototoxic medications that should be held temporarily.</td> </tr> <tr> <td class=\"subtitle2_left\">Can PDT cause a flare of cold sores?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Occasionally, there might be a flare up of herpes simplex infection after PDT. If you have a history of herpes simplex \"cold sores,\" let us know, and we can prescribe an oral antiviral medication for you to prevent this.</td> </tr> <tr> <td class=\"subtitle2_left\">What precautions do I have to take after the treatment?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">The most important precaution is that you <strong>must</strong> stay out of direct sunlight and strong commercial lighting for 48 hours after the treatment. You will be given an informational flyer once you finish the treatment, which contains detailed aftercare instructions.</td> </tr> <tr> <td class=\"subtitle2_left\">When to follow-up with dermatology?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">We recommend scheduling a clinic appointment with us at approximately three months after the treatment to assess how well your actinic keratoses have responded.</td> </tr> <tr> <td class=\"subtitle2_left\">Is PDT safe?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">PDT is generally very safe. It is one of the most popular noninvasive treatments for precancerous lesions.</td> </tr> <tr> <td class=\"subtitle2_left\">Should I bring anything to my visit?</td> </tr> <tr> <td class=\"indent1\">You should bring a broad-brim hat to protect your face and scalp from the sun or sun-protective clothing if we are treating other parts of your body.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 113755 Version 1.0</div></div></div>"},"113758":{"type":"graphic_table","displayName":"Photodynamic therapy off-label indications","title":"Off-label indications of photodynamic therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Off-label indications of photodynamic therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Cutaneous T cell lymphoma, localized patch-plaque<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Disseminated superficial actinic porokeratosis (DSAP)<sup>[2]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Extramammary Paget's disease<sup>[3]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Granuloma annulare<sup>[4]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Hidradenitis suppurativa<sup>[5]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Hypertrophic/keloid scars<sup>[6]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Leishmaniasis, cutaneous<sup>[7]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Lichen sclerosus<sup>[8,9]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Linear porokeratosis<sup>[10]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Molluscum contagiosum in human immunodeficiency virus<sup>[11]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Nonmelanoma skin cancer prevention in solid organ transplant recipients<sup>[12]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Nonmelanoma skin cancer treatment in solid organ transplant recipients<sup>[13]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Necrobiosis lipoidica<sup>[14]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Psoriasis<sup>[15]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Rosacea<sup>[16]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Sebaceous hyperplasia<sup>[17]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Verrucae (hand/foot and genital)<sup>[18,19]</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Quereux G, Brocard A, Saint-Jean M, et al. Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: a prospective open study and review of the literature. J Am Acad Dermatol 2013; 69:890.</LI>&#xD;&#xA;<LI>Fernandez-Guarino M, Harto A, Perez-Garcia B, et al. Photodynamic therapy in disseminated superficial actinic porokeratosis. J Eur Acad Dermatol Venereol 2009; 23:176.</LI>&#xD;&#xA;<LI>Fontanelli R, Papadia A, Martinell F, et al. Photodynamic therapy with M-ALA as non surgical treatment option in patients with primary extramammary Paget's disease. Gynecol Oncol 2013; 130:90.</LI>&#xD;&#xA;<LI>Weisenseel P, Kuznetsov AV, Molin S, et al. Photodynamic therapy for granuloma annulare: more than a shot in the dark. Dermatology 2008; 217:329.</LI>&#xD;&#xA;<LI>Valladares-Narganes LM, Rodriguez-Prieto MA, Blanco-Suarez MD, et al. Treatment of hidradenitis suppurativa with intralesional photodynamic therapy using a laser diode attached to an optical cable: a promising new approach. Br J Dermatol 2015; 172:1136.</LI>&#xD;&#xA;<LI>Ud-Din S, Thomas G, Morris J, Bayat A. Photodynamic therapy: an innovative approach to the treatment of keloid disease evaluated using subjective and objective non-invasive tools. Arch Dermatol Res 2013; 305:205.</LI>&#xD;&#xA;<LI>van der Snoek EM, Robinson DJ, van Hellemond JJ, Nuemann HA. A review of photodynamic therapy in cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2008; 22:918.</LI>&#xD;&#xA;<LI>Mazdziarz A, Osuch B, Kowalska M, et al. Photodynamic Therapy in the Treatment of Vulvar Lichen Sclerosus. Photodiagnosis Photodyn Ther 2017.</LI>&#xD;&#xA;<LI>Shi L, Miao F, Zhang LL, et al. Comparison of 5-Aminolevulinic Acid Photodynamic Therapy and Clobetasol Propionate in Treatment of Vulvar Lichen Sclerosus. Acta Derm Venereol 2016; 96:684.</LI>&#xD;&#xA;<LI>Aird GA, Sitenga JL, Nguyen AH, et al. Light and laser treatment modalities for disseminated superficial actinic porokeratosis: a systematic review. Lasers Med Sci 2017; 32:945.</LI>&#xD;&#xA;<LI>Moiin A. Photodynamic therapy for molluscum contagiosum infection in HIV-coinfected patients: review of 6 patients. J Drugs Dermatol 2003; 2:637.</LI>&#xD;&#xA;<LI>de Graaf YG, Kennedy C, Wolterbeek R, et al. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J Invest Dermatol 2006; 126:569.</LI>&#xD;&#xA;<LI>Guleng GE, Helsing P. Photodynamic therapy for basal cell carcinomas in organ-transplant recipients. Clin Exp Dermatol 2012; 37:367.</LI>&#xD;&#xA;<LI>Berking C, Hegyi J, Arenberg P, et al. Photodynamic therapy of necrobiosis lipoidica--a multicenter study of 18 patients. Dermatology 2009; 218:136.</LI>&#xD;&#xA;<LI>Almutawa F, Thalib L, Hekman D, et al. Efficacy of localized phototherapy and photodynamic therapy for psoriasis: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed 2015; 31:5.</LI>&#xD;&#xA;<LI>Bryld LE, Jemec GB. Photodynamic therapy in a series of rosacea patients. J Eur Acad Dermatol Venereol 2007; 21:1199.</LI>&#xD;&#xA;<LI>Alster TS, Tanzi EL. Photodynamic therapy with topical aminolevulinic acid and pulsed dye laser irradiation for sebaceous hyperplasia. J Drugs Dermatol 2003; 2:501.</LI>&#xD;&#xA;<LI>Nucci V, Torchia D, Cappugi P. Treatment of anogenital condylomata acuminata with topical photodynamic therapy: report of 14 cases and review. Int J Infect Dis 2010; 14:e280.</LI>&#xD;&#xA;<LI>Stender IM, Na R, Fogh H, et al. Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial. Lancet 2000; 355:963.</LI></OL></div><div id=\"graphicVersion\">Graphic 113758 Version 1.0</div></div></div>"},"113765":{"type":"graphic_figure","displayName":"Aminolevulinic acid-mediated photodynamic therapy","title":"Basic principle of aminolevulinic acid-mediated photodynamic therapy","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Basic principle of aminolevulinic acid-mediated photodynamic therapy</div><div class=\"cntnt\"><img style=\"width:764px; height:448px;\" src=\"images/DERM/113765_Amlvlnc_cd_md_phtdymc_thrpy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The addition of exogenous aminolevulinic acid bypasses the first regulatory step (ie, feedback inhibition by heme [dashed arrow]) in the heme synthesis pathway, thereby allowing PPIX to build up to high levels. Activation of PPIX by light causes free radical-based photochemistry that ultimately kills the cancer cell.</div><div class=\"graphic_footnotes\">PBG-D: porphobilinogen oxidase; CPO: coproporphyrinogen oxidase; PPIX: protoporphyrin IX; FC: ferrochelatase.</div><div id=\"graphicVersion\">Graphic 113765 Version 1.0</div></div></div>"},"113767":{"type":"graphic_figure","displayName":"Absorption spectrum of protoporphyrin IX","title":"Absorption spectrum of protoporphyrin IX","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Absorption spectrum of protoporphyrin IX</div><div class=\"cntnt\"><img style=\"width:724px; height:508px;\" src=\"images/DERM/113767_Absptn_spctrm_prtprphyrn_IX.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The major peak at approximately 400 nm is targeted during blue light photodynamic therapy. Amongst the other smaller peaks in the spectrum, the 635 nm peak (targeted by red light) is advantageous because this peak is unique to PPIX (not shared by heme in blood).</div><div class=\"graphic_footnotes\">PPIX: protoporphyrin IX.</div><div id=\"graphicVersion\">Graphic 113767 Version 1.0</div></div></div>"},"113768":{"type":"graphic_table","displayName":"ERAS Society recommendations for gynecologic surgery","title":"ERAS Society recommendations for gynecologic surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ERAS Society recommendations for gynecologic surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Preoperative</td> <td class=\"subtitle1\">Intraoperative</td> <td class=\"subtitle1\">Postoperative</td> </tr> <tr> <td> <ul> <li>Patient education </li> </ul> </td> <td> <ul> <li>Short-acting anesthetic </li> </ul> </td> <td> <ul> <li>Thromboembolism prophylaxis </li> </ul> </td> </tr> <tr> <td> <ul> <li>Smoking cessation four weeks preoperatively </li> </ul> </td> <td> <ul> <li>Standardized ventilation strategy </li> </ul> </td> <td> <ul> <li>Extended chemoprophylaxis for patients with laparotomy for abdominal or pelvic malignancy </li> </ul> </td> </tr> <tr> <td> <ul> <li>Alcohol cessation four weeks preoperatively as indicated </li> </ul> </td> <td> <ul> <li>Postoperative nausea and vomiting prophylaxis </li> </ul> </td> <td> <ul> <li>Maintenance of normovolemia: Discontinue IV fluids within 24 hours postoperatively </li> </ul> </td> </tr> <tr> <td> <ul> <li>Avoidance of mechanical bowel preparation preoperatively </li> </ul> </td> <td> <ul> <li>Minimally invasive surgery when appropriate and available </li> </ul> </td> <td> <ul> <li>Initiation of a regular diet within the first 24 hours postoperatively </li> </ul> </td> </tr> <tr> <td> <ul> <li>Ingestion of clear fluids up to two hours prior to anesthetic induction </li> </ul> </td> <td> <ul> <li>Avoid routine nasogastric intubation; remove at end of procedure if used </li> </ul> </td> <td> <ul> <li>Consider use of postoperative laxatives and chewing gum </li> </ul> </td> </tr> <tr> <td> <ul> <li>Ingestion of solids up to six hours prior to anesthetic induction </li> </ul> </td> <td> <ul> <li>Maintain normothermia with warming device </li> </ul> </td> <td> <ul> <li>Maintain normal blood glucose levels, treat hyperglycemia, avoid hypoglycemia </li> </ul> </td> </tr> <tr> <td> <ul> <li>Carbohydrate loading preoperatively </li> </ul> </td> <td> <ul> <li>Maintain euvolemia: Avoid very restrictive or liberal fluid regimens </li> </ul> </td> <td> <ul> <li>Multimodal postoperative analgesia, including NSAIDs, acetaminophen, gabapentin, and dexamethasone, unless contraindicated </li> </ul> </td> </tr> <tr> <td> <ul> <li>Avoidance of routine preoperative sedative use </li> </ul> </td> <td><strong><em></em></strong></td> <td> <ul> <li>For open general gynecologic surgery, consider a transversus abdominis plane block (TAP block) or surgical site infiltration, in combination with non-opioid analgesic agents</li> </ul> </td> </tr> <tr> <td> <ul> <li>Cessation of oral contraception prior to surgery </li> </ul> </td> <td>&nbsp;</td> <td> <ul> <li>For laparoscopic general gynecologic or gynecologic oncologic surgery, a multimodal approach should be employed </li> </ul> </td> </tr> <tr> <td> <ul> <li>Antibiotic prophylaxis </li> </ul> </td> <td>&nbsp;</td> <td> <ul> <li>Avoid routine intraperitoneal drain placement </li> </ul> </td> </tr> <tr> <td> <ul> <li>Hair clipping </li> </ul> </td> <td>&nbsp;</td> <td> <ul> <li>Discontinue urinary catheters for postoperative bladder drainage by 24 hours postoperatively </li> </ul> </td> </tr> <tr> <td> <ul> <li>Chlorhexidine-alcohol for skin preparation </li> </ul> </td> <td>&nbsp;</td> <td> <ul> <li>Mobilize early, within 24 hours of surgery </li> </ul> </td> </tr> <tr> <td> <ul> <li>For gynecologic oncology, consider placement of TEA, but additional IV opioids may be required </li> </ul> </td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ERAS: Enhanced Recovery After Surgery; VTE: venous thromboembolism; IV: intravenous; NSAIDs: nonsteroidal anti-inflammatory drugs; TAP: transverse abdominis plane; TEA: thoracic epidural anesthesia.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Nelson G, Altman AD, Nick A, et al. Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations &mdash; Part I. Gynecol Oncol 2016; 140:313.</li>&#xD;&#xA;    <li>Nelson G, Altman AD, Nick A, et al. Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations &mdash; Part II. Gynecol Oncol 2016; 140:323.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 113768 Version 3.0</div></div></div>"},"113769":{"type":"graphic_table","displayName":"Example of ERAS pathway for gynecologic surgery","title":"Example of ERAS patient instructions and order set for gynecologic surgery<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of ERAS patient instructions and order set for gynecologic surgery<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Preoperative outpatient (prior to surgery)</td> </tr> <tr> <td class=\"indent1\">Eat a regular diet until midnight the night before surgery.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Drink clear fluids until two hours prior to surgery.</td> </tr> <tr> <td class=\"subtitle1_single\">Preoperative inpatient (one hour before surgery), unless contraindicated</td> </tr> <tr> <td class=\"indent1\">Administer acetaminophen 1000 mg orally once. </td> </tr> <tr> <td class=\"indent1\">Administer celecoxib 400 mg orally once.</td> </tr> <tr> <td class=\"indent1\">Administer gabapentin 600 mg orally once.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Apply a warming blanket 30 minutes prior to operation.</td> </tr> <tr> <td class=\"subtitle1_single\">Intraoperative inpatient (during surgery)</td> </tr> <tr> <td class=\"indent1\">Anesthesiology team:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Continue warming blanket intraoperatively. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Use short-acting anesthetic agents when able. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Administer prophylaxis for postoperative nausea and vomiting. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Maintain euvolemia. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Minimize long-acting opioids. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Administer IV ketorolac 15 to 30 mg at end of operation if patient is appropriate candidate. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Surgical team:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Inject skin, subcutaneous tissue, and fascia with local bupivacaine or liposomal bupivacaine, as appropriate. Consider TAP block, if appropriate. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Discontinue transurethral Foley catheter if appropriate at end of case (eg, no bladder injury, nonurogynecologic surgery). </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Postoperative inpatient</td> </tr> <tr> <td class=\"indent1\">Wean oxygen early.</td> </tr> <tr> <td class=\"indent1\">VTE risk assessment and thromboembolism prophylaxis:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>First ambulation within&nbsp;3 hours postoperative. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Ambulate in hallway at least three times per day. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Up in chair for all meals. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Out of bed (walks and chair) for a total of&nbsp;6 hours per day. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Follow standard VTE prophylaxis regimens. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Diet and fluids:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>General diet beginning day of surgery. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Maintenance intravenous fluids 1 mL/kg/hour; discontinue once patient has ingested 600 mL of oral intake or at 8 AM the day after surgery, whichever comes first. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Analgesia:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Acetaminophen 500 to 1000 mg orally every&nbsp;6 hours for 48 hours. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>If NSAIDs are appropriate: Ketorolac 15 to 30 mg&nbsp;IV every&nbsp;6 hours for 24 hours postoperatively, followed by ibuprofen 600 mg orally every 6 hours for 24 hours. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>If NSAIDs are not appropriate: Tramadol 50 to 100 mg orally every&nbsp;6 hours as needed for pain. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Oxycodone 5 mg orally every&nbsp;4 hours as needed for pain score of 4 to 6 or 10 mg orally every&nbsp;4 hours as needed for pain score of 7 to 10 (begin 24 hours after last intrathecal morphine dose, if applicable*). </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Breakthrough pain not relieved by oral oxycodone: Hydromorphone 0.2 to 0.5 mg IV; repeat once after&nbsp;5 minutes if needed. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Postoperative nausea and vomiting:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Ondansetron, prochlorperazine if needed. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Bowel regimen to prevent constipation:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Senna 8.6 mg 1 to 2 tablets orally nightly. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Docusate 100 mg orally twice a day. </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Other laxative (eg, magnesium hydroxide, bisacodyl, or PEG 3350 [17 g]), if needed. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Bladder catheter:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>If transurethral Foley catheter in place, perform void trial if feasible on morning of postoperative day 1. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Analgesic doses shown are for patients with normal organ function. Dose reduction or avoidance of certain agents is necessary for older or debilitated adults, patients with low cardiac output, pulmonary disease, or renal impairment.</div><div class=\"graphic_footnotes\">IV: intravenous; TAP: transverse abdominis plane; VTE: venous thromboembolism; NSAIDs: nonsteroidal anti-inflammatory drugs; PEG 3350: polyethylene glycol 3350.<br />* If additional opioids are required, obtain pain service clinician approval because of risk of delayed respiratory depression with use of intrathecal morphine.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Kalogera E, Bakkum-Gamez JN, Jankowski CJ, et al. Enhanced recovery in gynecologic surgery. Obstet Gynecol 2013; 122:319.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 113769 Version 1.0</div></div></div>"},"113770":{"type":"graphic_algorithm","displayName":"Evaluation of possible or probable brain tumor in adults","title":"Evaluation of possible or probable brain tumor in adults","html":"<div class=\"graphic\"><div style=\"width: 793px\" class=\"figure\"><div class=\"ttl\">Evaluation of possible or probable brain tumor in adults</div><div class=\"cntnt\"><img style=\"width:773px; height:909px;\" src=\"images/NEURO/113770_Evaluationbraintumoradlt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CT: computed tomography; abd: abdomen; CNS: central nervous system; LP: lumbar puncture; IgH: immunoglobulin heavy chain; MR: magnetic resonance.<br />* MRI with contrast is the optimal study for resolution of brain tumors. CT with contrast should be obtained in patients with a contraindication to MRI (eg, pacemaker). Refer to related UpToDate content for the evaluation of brain masses in patients with human immunodeficiency virus (HIV).<br />&para; Lumbar puncture is not advised for large lesions associated with midline shift, obstructive hydrocephalus, or mass effect on the fourth ventricle.<br />&Delta; Urgency of neurosurgical evaluation for newly discovered brain tumor depends on the clinical stability of the patient, symptom severity, tumor size and location, and suspicion for malignancy. Patients should be referred to a high-volume center with subspecialty neurosurgical expertise in brain tumors, when possible.<br /><span class=\"lozenge\">&loz;</span> Differential diagnosis of brain tumors on neuroimaging varies based on location and whether the lesion is enhancing or nonenhancing. Refer to related UpToDate content on the evaluation and diagnosis of brain tumors in adults for additional details.</div><div id=\"graphicVersion\">Graphic 113770 Version 2.0</div></div></div>"},"113777":{"type":"graphic_algorithm","displayName":"Incidental solitary solid pulmonary nodule evaluation","title":"Incidental solitary solid pulmonary nodule evaluation","html":"<div class=\"graphic\"><div style=\"width: 1037px\" class=\"figure\"><div class=\"ttl\">Incidental solitary solid pulmonary nodule evaluation</div><div class=\"cntnt\"><img style=\"width:1017px; height:1079px;\" src=\"images/PULM/113777_Inctlsltysdplmryndlevl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm applies to asymptomatic, immunocompetent adults, age &gt;35 years without malignancy that is actively under treatment or follow-up. It is not designed for use in other populations or in those undergoing lung cancer screening. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances and patient preferences to make adjustments, as necessary. Chest CT should be performed without contrast as contiguous thin (ie, 1 mm) images on a helical scanner using low radiation dose techniques.</div><div class=\"graphic_footnotes\">CT: computed tomography; FDG: fluorodeoxyglucose; PET: positron emission tomography.<br />* Nodule is a well-defined opacity completely surrounded by lung parenchyma measuring &lt;30 mm in longest dimension.<br />¶ Growth is defined as &gt;2 mm increase in overall size.<br />Δ If the chest CT reveals findings relevant to nodule diagnosis (eg, other nodules or masses, mediastinal lymphadenopathy, or findings of pulmonary inflammation or infection), subsequent workup should be based on these findings.<br /><FONT class=lozenge>◊</FONT> Nodule size is defined as the average of long and short axes in axial cross-section.<br />§ Likelihood of malignancy assessed either clinically or by quantitative predictive models.<br />¥ Timing of chest CT is relative to the date of the initial nodule detection.<br />‡ Another chest CT at 18 to 24 months is an option if stability of nodules is equivocal.<br />† FDG PET/CT is an option in patients at intermediate cancer risk or those considered high medical risk for biopsy. FDG-avid nodules proceed to tissue sampling. FDG-nonavid nodules are triaged to annual CT surveillance.<br />** Followup interval should be the same or longer than the preceding one that showed no nodule growth. In addition, longer interval is needed to&nbsp;demonstrate unequivocal&nbsp;growth for smaller nodules.</div><div id=\"graphicVersion\">Graphic 113777 Version 3.0</div></div></div>"},"113778":{"type":"graphic_algorithm","displayName":"Incidental solitary subsolid pulmonary nodule evaluation","title":"Incidental solitary subsolid pulmonary nodule evaluation","html":"<div class=\"graphic\"><div style=\"width: 659px\" class=\"figure\"><div class=\"ttl\">Incidental solitary subsolid pulmonary nodule evaluation</div><div class=\"cntnt\"><img style=\"width:639px; height:797px;\" src=\"images/PULM/113778_Incsltyssdplmnryndlevl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm applies to asymptomatic, immunocompetent adults, age &gt;35 years without malignancy that is actively under treatment or follow-up. It is not designed for use in other populations or in those undergoing lung cancer screening. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances and patient preferences to make adjustments, as necessary. Chest CT should be performed without contrast as contiguous thin (ie, 1 mm) images on a helical scanner using low radiation dose techniques.</div><div class=\"graphic_footnotes\">CT: computed tomography.<br />* Nodule is a well-defined opacity completely surrounded by lung parenchyma measuring &lt;30 mm in longest dimension.<br />¶ Growth is defined as &gt;2 mm increase in overall size, increase in attenuation or appearance or enlargement of a solid component.<br />Δ If the chest CT reveals findings relevant to nodule diagnosis (eg, other nodules or masses, mediastinal lymphadenopathy, or findings of pulmonary inflammation or infection), subsequent workup should be based on these findings.<br /><FONT class=lozenge>◊</FONT> Nodule size is defined as the average of long and short axes in axial cross-section.<br />§ Ground glass nodules &gt;20 mm are managed with resection in some cases.<br />¥ Timing of chest CT is relative to the date of the initial nodule detection.<br />‡ If solid portion of nodule is &gt;8 mm and if clinical suspicion for malignancy is high, this CT can be deferred and the clinician may proceed to the next step with the assumption of a persistent non-enlarging, part-solid nodule.<br />† If nodule is persistent but not growing and the solid portion is &gt;8 mm, FDG PET/CT is an option. FDG-avid nodules proceed to tissue sampling. FDG non-avid nodules are triaged to annual CT surveillance.</div><div id=\"graphicVersion\">Graphic 113778 Version 2.0</div></div></div>"},"113779":{"type":"graphic_algorithm","displayName":"Incidental multiple pulmonary nodules evaluation","title":"Incidental multiple pulmonary nodules evaluation","html":"<div class=\"graphic\"><div style=\"width: 1080px\" class=\"figure\"><div class=\"ttl\">Incidental multiple pulmonary nodules evaluation</div><div class=\"cntnt\"><img style=\"width:1060px; height:1249px;\" src=\"images/PULM/113779_Incdtlmltplplmnryndlevl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm applies to asymptomatic, immunocompetent adults, age &gt;35 years without malignancy that is actively under treatment or follow-up. It is not designed for use in other populations or in those undergoing lung cancer screening. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances and patient preferences to make adjustments, as necessary. Chest CT should be performed without contrast as contiguous thin (ie, 1 mm) images on a helical scanner using low radiation dose techniques.</div><div class=\"graphic_footnotes\">CT: computed tomography.<br />* Nodule is a well-defined opacity completely surrounded by lung parenchyma measuring &lt;30 mm in longest dimension.<br />¶ For multiple nodules, choice of solid versus subsolid is based on the largest or the predominant pattern.<br />Δ Chest CT should be performed without contrast as contiguous thin (ie, 1 mm) images on a helical scanner using low radiation dose techniques.<br /><FONT class=lozenge>◊</FONT> Growth is defined as &gt;2 mm increase in overall size. For subsolid nodules, growth can also be an increase in attenuation or appearance or enlargement of a solid component.<br />§ If the chest CT reveals findings relevant to nodule diagnosis (eg, other nodules or masses, mediastinal lymphadenopathy, or findings of pulmonary inflammation or infection), subsequent workup should be based on these findings.<br />¥ Suspicious nodule is the one with the largest or, for part solid nodules, the one with the most solid component.<br />‡ Nodule size is defined as the average of long and short axes in axial cross-section.<br />† Likelihood of malignancy assessed either clinically or by quantitative predictive models.<br />** Chest CT follow-up at 12 months is optional in patients who are high or intermediate risk for malignancy.<br />¶¶ Timing of chest CT is relative to the date of the initial nodule detection.<br />ΔΔ Optional chest CT at 18 to 24 months if stability of nodules is equivocal.<br /><FONT class=double_lozenge>◊◊</FONT> If solid portion of nodule is &gt;8 mm and if clinical suspicion for malignancy is high, this CT can be deferred and the clinician may proceed to the next step with the assumption of a persistent non-enlarging, part-solid nodule.<br />§§ If nodule is persistent but not growing and the solid portion is &gt;8 mm, FDG PET/CT is an option. FDG-avid nodules proceed to tissue sampling. FDG non-avid nodules are triaged to annual CT surveillance.</div><div id=\"graphicVersion\">Graphic 113779 Version 3.0</div></div></div>"},"113780":{"type":"graphic_figure","displayName":"Multiple-hit hypothesis for cancer deconditioning","title":"Multiple-hit hypothesis for cancer deconditioning","html":"<div class=\"graphic\"><div style=\"width: 763px\" class=\"figure\"><div class=\"ttl\">Multiple-hit hypothesis for cancer deconditioning</div><div class=\"cntnt\"><img style=\"width:743px; height:454px;\" src=\"images/ONC/113780_Mlt_ht_hythss_cncr_dcndtnng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple-hit hypothesis for cancer deconditioning.</div><div class=\"graphic_reference\">Current Anesthesiology Reports, Perioperative implications of neoadjuvant therapies and optimization strategies for cancer surgery, vol. 4, 2015, p. 305, Sahai SK, Ismail H, &copy; Springer Science + Business Media New York 2015. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 113780 Version 1.0</div></div></div>"},"113782":{"type":"graphic_diagnosticimage","displayName":"Endoscopic view of biliary sphincterotomy","title":"Endoscopic view of biliary sphincterotomy","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Endoscopic view of biliary sphincterotomy</div><div class=\"cntnt\"><img style=\"width:488px; height:481px;\" src=\"images/GAST/113782_Endscpc_vw_bilry_sphnctrtmy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This endoscopic image shows a biliary sphincterotomy (arrowhead) and the pancreatic duct orifice (arrow). The pancreatic duct orifice should be avoided when using endoscopic therapy to control bleeding.</div><div class=\"graphic_reference\">Courtesy of the Digestive Endoscopy Unit, Catholic University in Rome, Italy.</div><div id=\"graphicVersion\">Graphic 113782 Version 1.0</div></div></div>"},"113783":{"type":"graphic_table","displayName":"Enhanced recovery after surgery (ERAS) implementation grid","title":"Enhanced recovery after surgery (ERAS) program implementation grid","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Enhanced recovery after surgery (ERAS) program implementation grid</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup span=\"7\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Timeline</td> <td class=\"subtitle1\" rowspan=\"2\">Tasks</td> <td class=\"subtitle1\" colspan=\"7\">Roles</td> </tr> <tr> <td class=\"subtitle2\">Surgeons</td> <td class=\"subtitle2\">Anesthesiologists</td> <td class=\"subtitle2\">Residents and physician assistants</td> <td class=\"subtitle2\">Nursing</td> <td class=\"subtitle2\">Pharmacy</td> <td class=\"subtitle2\">Surgery scheduling</td> <td class=\"subtitle2\">Information technology</td> </tr> <tr class=\"divider_bottom\"> <td><strong>t-16 weeks</strong></td> <td> <p>Establish steering committee representative/liaison</p> Identify literature and ERAS resources for dissemination within department and steering committee</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td><strong>t-15 weeks</strong></td> <td>Read specialty-specific ERAS literature</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>t-14 weeks</strong></td> <td>Establish intradepartment consensus on ERAS target population and ERAS elements for adoption</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>t-13 weeks</strong></td> <td>Meet to obtain interdisciplinary consensus on ERAS elements and executors</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>t-12 weeks</strong></td> <td> <p>Work on order sets with information technology</p> Announce initiative to departments/stakeholders</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td>Work on order sets with other groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>t-10 weeks</strong></td> <td>Plan site(s) of preoperative education, patient education materials, and letter</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td><strong>t-9 weeks</strong></td> <td>Create formal educational materials for surgeons, anesthesiologists, nurses containing rationale and ERAS elements</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>t-8 weeks</strong></td> <td> <p>Begin mailing new preoperative letter</p> Surgeons begin scheduling patients as ERAS</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>t-7 to 5 weeks</strong></td> <td> <p>Send reminders of scheduling&nbsp;ERAS status&nbsp;for surgical patients</p> <p>Preoperative ordering</p> Go-live dates to all stakeholders</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td><strong>t-4 weeks</strong></td> <td> <p>Preoperative patient education begins</p> Obtain preoperative drink </td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>t-2 weeks</strong></td> <td>Order sets sign-off</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td>Order sets sign-off and ready for go-live activation</td> </tr> <tr class=\"divider_bottom\"> <td><strong>t-0 (clinical go-live)</strong></td> <td>Preoperative briefing</td> <td>Preoperative briefing</td> <td>Preoperative briefing</td> <td>Use preoperative, intraoperative, postoperative order sets</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Verify smooth go-live of preoperative, intraoperative, postoperative order sets</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Following go-live</strong></td> <td>Clinical huddles</td> <td>Clinical huddles</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Ongoing</strong></td> <td>Quality improvement data collection</td> <td>Quality improvement data collection</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">ERAS steering committee members (meet every one to four weeks as a full group or subgroup): Hospital-wide steering committee project manager (hospital), project manager (per department), and each specialty listed should have a representative.</div><div class=\"graphic_footnotes\">ERAS: enhanced recovery after surgery.</div><div class=\"graphic_reference\">Courtesy of Mallika Anand, MD, MS.</div><div id=\"graphicVersion\">Graphic 113783 Version 2.0</div></div></div>"},"113791":{"type":"graphic_picture","displayName":"Livedoid vasculopathy stellate ulcers","title":"Livedoid vasculopathy","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Livedoid vasculopathy</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/113791_Livdoid_vsclpthy_stllt_ulcr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"Punched-out,\" stellate ulcers in a patient with livedoid vasculopathy.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 113791 Version 1.0</div></div></div>"},"113792":{"type":"graphic_picture","displayName":"Livedoid vasculopathy with hyperpigmentation and ulceration","title":"Livedoid vasculopathy","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Livedoid vasculopathy</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/113792_Lvdd_vsclpthy_hyppgmtn_ulcr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ivory-white, plaque-like areas, hyperpigmentation, and ulceration.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 113792 Version 1.0</div></div></div>"},"113793":{"type":"graphic_picture","displayName":"Livedoid vasculopathy multiple features","title":"Livedoid vasculopathy","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Livedoid vasculopathy</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/113793_Livdoidvsclpthymultplftr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patchy, incomplete livedo reticularis-like pattern on the feet and atrophie blanche, telangiectasias, and stellate ulcers on the lower leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 113793 Version 1.0</div></div></div>"},"113797":{"type":"graphic_picture","displayName":"Web space infection affecting dorsal and palmar hand","title":"Web space infection affecting dorsal and palmar hand","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Web space infection affecting dorsal and palmar hand</div><div class=\"cntnt\"><img style=\"width:616px; height:756px;\" src=\"images/SURG/113797_Wb_sp_infct_af_drsl_plmr_hd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photos show the dorsal (A) and palmar (B) appearance of an infection emanating from the second web space. </div><div class=\"graphic_reference\">Reproduced with permission from: Kalbfell E, Adams NS, Cullen WT. Collar button abscess. Eplasty 2016; 16:ic6. Copyright &copy; 2017 Elle Kalbfell, BS, Nicholas S. Adams, MD, and William T. Cullen, MD, MA, FACS. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113797 Version 1.0</div></div></div>"},"113799":{"type":"graphic_table","displayName":"Stage-stratified survival intrahep cholangio AJCC 7th vs 8th ed","title":"Stage-stratified comparison in 5-year survival outcomes between the 7th (2010) and 8th (2017) edition of the AJCC staging system, Kaplan-Meier analysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stage-stratified comparison in 5-year survival outcomes between the 7th (2010) and 8th (2017) edition of the AJCC staging system, Kaplan-Meier analysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">N (%)</td> <td class=\"subtitle1\">5-year (%)</td> <td class=\"subtitle1\">95% CI</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">AJCC 7th edition*</td> </tr> <tr> <td class=\"indent1\">I</td> <td>93 (18.1)</td> <td>58.8</td> <td>44.9-70.3</td> </tr> <tr> <td class=\"indent1\">II</td> <td>110 (21.4)</td> <td>38.8</td> <td>26.5-51.0</td> </tr> <tr> <td class=\"indent1\">III</td> <td>70 (13.6)</td> <td>39.7</td> <td>24.1-54.9</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">IVa</td> <td>242 (46.9)</td> <td>18.4</td> <td>11.9-6.1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">AJCC 8th edition<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Ia</td> <td>15 (5.1)</td> <td>90.0</td> <td>47.3-98.5</td> </tr> <tr> <td class=\"indent1\">Ib</td> <td>18 (6.1)</td> <td>50.6</td> <td>19.9-75.0</td> </tr> <tr> <td class=\"indent1\">II</td> <td>37 (12.5)</td> <td>55.1</td> <td>34.5-71.7</td> </tr> <tr> <td class=\"indent1\">IIIa</td> <td>22 (7.4)</td> <td>49.7</td> <td>16.6-76.2</td> </tr> <tr> <td class=\"indent1\">IIIb</td> <td>204 (68.9)</td> <td>16.2</td> <td>9.5-24.5</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AJCC: American Joint Committed on Cancer; N: number of patients.<br />* N = 515.<br />¶ N = 296.</div><div class=\"graphic_reference\">From: Spolverato G, Bagante F, Weiss M, et al. Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. J Surg Oncol 2017; 115:696. <A href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1002/jso.24569/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1002/jso.24569/abstract</A>. Copyright © 2017 Wiley Periodicals, Inc. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 113799 Version 1.0</div></div></div>"},"113806":{"type":"graphic_table","displayName":"Management of spinal cord ischemia: Rapid overview","title":"Monitoring and management of spinal cord ischemia during thoracic aortic repair: Rapid overview*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monitoring and management of spinal cord ischemia during thoracic aortic repair: Rapid overview*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td>Intraoperative continuous neuromonitoring of MEPs and/or SSEPs are used to identify any <strong>evidence of spinal cord ischemia</strong>. The following overview of intraoperative <strong>treatment of spinal cord ischemia</strong> assumes preoperative placement of an intra-arterial catheter for continuous monitoring of MAP and a lumbar intrathecal catheter for continuous monitoring of CSF pressure.</td> </tr> <tr> <td class=\"subtitle1_single\">Assessments and communications</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>If the neuromonitoring technician reports spinal cord ischemia, immediately communicate regarding specific evidence </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Check anesthetic agents and doses to assess possible interference with neuromonitoring* </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Communicate with surgeon to assess potential effects of surgical procedure on spinal cord perfusion </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Assess MAP and prepare to treat if MAP is &#60;80 mmHg </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Assess CSF pressure and prepare to treat if CSF pressure is &#62;10 mmHg </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Calculate SCPP: SCPP = MAP minus CSF pressure </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Initial treatment</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Increase MAP to &#8805;80 mmHg in 5 mmHg increments, up to 100 mmHg: <ul> <li>Administer vasopressor therapy </li> <li>Expand intravascular volume (if appropriate) </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Drain CSF via intrathecal drain to decrease CSF pressure to 8 to 10 mmHg: <ul> <li>Limit CSF drainage to &#60;20 mL during the first hour of surgery </li> <li>Limit CSF drainage to &#60;40 mL during any four-hour period </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Recalculate SCPP; maintain SCPP &#8805;70 mmHg: <ul> <li>Also check CVP; if CVP&#62;CSF pressure, increase MAP further to increase the likelihood that SCPP is maintained &#8805;70 mmHg </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Ensure optimal oxygen delivery to the spinal cord: <ul> <li>Maintain adequate cardiac output </li> <li>Maintain optimal O<sub>2</sub> content in blood perfusing the spinal cord (high arterial PaO<sub>2</sub>, high Hgb saturation, adequate Hgb level &#8805;8 mg/dL) </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Further treatment (if evidence of spinal cord ischemia is still present)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Communicate with neuromonitoring technician regarding any changes in evidence of spinal cord ischemia (improving, worsening, or no change) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Reassess MAP; continue efforts to increase MAP up to 100 mmHg </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Reassess CSF pressure; continue efforts to drain CSF to decrease CSF pressure to 8 to 10 mmHg </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Recalculate SCPP; maintain SCPP &#8805;70 mmHg: <ul> <li>Also check CVP; if CVP&#62;CSF pressure, increase MAP further to increase the likelihood that SCPP will be maintained &#8805;70 mmHg </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Consult surgeon regarding possible additional surgical treatments (eg, reimplantation of intercostal vessels, distal aortic perfusion) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>(In some cases, there are no additional options to eliminate spinal cord ischemia; however, neuromonitoring is continued) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Prepare for postoperative management</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Plan for postoperative monitoring for spinal cord ischemia<sup>&#182;</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MEPs: motor evoked potentials; SSEPs: somatosensory evoked potentials; MAP: mean arterial pressure; CSF: cerebrospinal fluid; SCPP: spinal cord perfusion pressure; CVP: central venous pressure; O<SUB>2</SUB>: oxygen; PaO<SUB>2</SUB>: partial pressure of oxygen; Hgb: hemoglobin.<br />* Refer to UpToDate content discussing neuromonitoring in surgery and anesthesia.<br />¶ Refer to UpToDate content and algorithm for treatment of spinal cord ischemia after thoracic aortic repair.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Sinha AC, Cheung AT: Spinal cord protection and thoracic aortic surgery. Curr Opin Anaesthesiol 2010; 23:95.</li>&#xD;&#xA;    <li>Estrera AL, Sheinbaum R, Miller CC, et al. Cerebrospinal fluid drainage during thoracic aortic repair: safety and current management. Ann Thorac Surg 2009; 88:9.</li>&#xD;&#xA;    <li>Estrera AL, Sheinbaum R, Miller CC 3rd, et al. Neuromonitor-guided repair of thoracoabdominal aortic aneurysms. J Thorac Cardiovasc Surg 2010; 140:S131.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 113806 Version 2.0</div></div></div>"},"113810":{"type":"graphic_algorithm","displayName":"Recommended approach for mgmt disputed treatment requests ICU","title":"Five-society recommended approach for the management of disputed treatment requests in the intensive care unit (ICU)","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Five-society recommended approach for the management of disputed treatment requests in the intensive care unit (ICU)</div><div class=\"cntnt\"><img style=\"width:510px; height:507px;\" src=\"images/ONC/113810_Rc_ap_mg_disp_trmt_rqut_ICU.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Refer to the UpToDate graphic on Steps for resolving conflict regarding potentially inappropriate therapy.</div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright &copy; 2017 American Thoracic Society. Bosslet GT, Pope TM, Rubenfeld GD, et al. An official ATS/AACN/ACCP/ESICM/SCCM policy statement: Responding to requests for potentially inappropriate treatments in intensive care units. Am J Respir Crit Care Med 2015; 191:1318-1380. The <em>American Journal of Respiratory and Critical Care Medicine</em> is an official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 113810 Version 1.0</div></div></div>"},"113816":{"type":"graphic_table","displayName":"Clinical grading of VKC","title":"Clinical grading of vernal keratoconjunctivitis obtained from the classification tree analysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical grading of vernal keratoconjunctivitis obtained from the classification tree analysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Clinical findings</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr> <td>0 quiescent</td> <td>Absence of symptoms</td> <td>No treatment</td> </tr> <tr> <td>1 mild</td> <td>Presence of symptoms,<span style=\"color: black;\">&nbsp;but no corneal involvement</span></td> <td>Antiallergic eye drops occasionally</td> </tr> <tr> <td>2 moderate</td> <td>Presence of <span style=\"color: black;\">symptoms including photophobia,&nbsp;but no corneal involvement</span></td> <td>Antiallergic eye drops daily</td> </tr> <tr> <td>3 severe</td> <td>Presence of <span style=\"color: black;\">symptoms&nbsp;including photophobia, plus mild to moderate SPK</span></td> <td><span style=\"color: black;\">Antiallergic eye drops daily and pulsed low-dose topical corticosteroid</span></td> </tr> <tr> <td>4 very severe</td> <td>Presence of symptoms <span style=\"color: black;\">including </span><span style=\"color: black;\">photophobia, plus&nbsp;diffuse SPK or corneal ulce</span>r</td> <td><span style=\"color: black;\">Pulsed high-dose topical corticosteroid&nbsp;and eventual&nbsp;surgical removal of corneal plaqu</span>e</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SPK: superficial punctuate keratopathy.</div><div class=\"graphic_reference\">Reproduced from: Sacchetti M, Lambiase A, Mantelli F, et al. Tailored approach to the treatment of vernal keratoconjunctivitis. Ophthalmology 2010; 117:1294. Table used with the permission of Elsevier, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113816 Version 1.0</div></div></div>"},"113819":{"type":"graphic_table","displayName":"Steps for resolving conflict regarding pot inapprop therapy","title":"Recommended steps for resolution of conflict regarding potentially inappropriate treatments","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended steps for resolution of conflict regarding potentially inappropriate treatments</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"centered\"><strong>1.</strong></td> <td>Before initiation of and throughout the formal conflict-resolution procedure, clinicians should enlist expert consultation to aid in achieving a negotiated agreement.</td> </tr> <tr> <td class=\"centered\"><strong>2.</strong></td> <td>Surrogate(s) should be given clear notification in writing regarding the initiation of the formal conflict-resolution procedure, and the steps and timeline to be expected in this process.</td> </tr> <tr> <td class=\"centered\"><strong>3.</strong></td> <td>Clinicians should obtain a second medical opinion to verify the prognosis and the judgment that the requested treatment is inappropriate.</td> </tr> <tr> <td class=\"centered\"><strong>4.</strong></td> <td>There should be case review by an interdisciplinary institutional committee.</td> </tr> <tr> <td class=\"centered\"><strong>5.</strong></td> <td>If the committee agrees with the clinicians, then clinicians should offer the option to seek a willing provider at another institution and should facilitate this process.</td> </tr> <tr> <td class=\"centered\"><strong>6.</strong></td> <td>If the committee agrees with the clinicians and no willing provider can be found, surrogate(s) should be informed of their right to seek case review by an independent appeals body.</td> </tr> <tr> <td class=\"centered\"><strong>7a.</strong></td> <td>If the committee or appellate body agrees with the patient or surrogate's request for life-prolonging treatment, clinicians should provide these treatments or transfer the patient to a willing provider.</td> </tr> <tr> <td class=\"centered\"><strong>7b.</strong></td> <td>If the committee agrees with the clinicians' judgment, no willing provider can be found, and the surrogate does not seek independent appeal or the appeal affirms the clinicians' position, clinicians may withhold or withdraw the contested treatments and should provide high-quality palliative care.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright © 2017 American Thoracic Society. From: Bosslet GT, Pope TM, Rubenfeld GD, et al. An Official ATS/AACN/ACCP/ESICM/SCCM Policy Statement: Responding to Requests for Potentially Inappropriate Treatments in Intensive Care Units. Am J Respir Crit Care Med 2015; 191:1318-30. The <EM>American Journal of Respiratory and Critical Care Medicine</EM> is an official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 113819 Version 1.0</div></div></div>"},"113828":{"type":"graphic_table","displayName":"Schwartz score diagnostic criteria for long QT syndrome (LQTS)","title":"Schwartz score diagnostic criteria for long QT syndrome (LQTS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Schwartz score diagnostic criteria for long QT syndrome (LQTS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"90%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Points</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Electrocardiographic findings*</td> </tr> <tr> <td> <ol style=\"list-style-type: upper-alpha;\"> <li>QTc<sup>&#182;</sup> </li> </ol> </td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>&#8805;480 ms </li> </ul> </td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>460 to 479 ms </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>450 to 459 ms (in males) </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td> <ol style=\"list-style-type: upper-alpha;\" start=\"2\"> <li>QTc<sup>&#182;</sup> fourth minute of recovery from exercise stress test &#8805;480 ms </li> </ol> </td> <td class=\"centered\">1</td> </tr> <tr> <td> <ol style=\"list-style-type: upper-alpha;\" start=\"3\"> <li>Torsades de pointes<sup>&#916;</sup> </li> </ol> </td> <td class=\"centered\">2</td> </tr> <tr> <td> <ol style=\"list-style-type: upper-alpha;\" start=\"4\"> <li>T wave alternans </li> </ol> </td> <td class=\"centered\">1</td> </tr> <tr> <td> <ol style=\"list-style-type: upper-alpha;\" start=\"5\"> <li>Notched T wave in 3 leads </li> </ol> </td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td> <ol style=\"list-style-type: upper-alpha;\" start=\"6\"> <li>Low heart rate for age<sup>&#9674;</sup> </li> </ol> </td> <td class=\"centered\">0.5</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Clinical history</td> </tr> <tr> <td> <ol style=\"list-style-type: upper-alpha;\"> <li>Syncope<sup>&#916;</sup> </li> </ol> </td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>With stress </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Without stress </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td> <ol style=\"list-style-type: upper-alpha;\" start=\"2\"> <li>Congenital deafness </li> </ol> </td> <td class=\"centered\">0.5</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Family history</td> </tr> <tr> <td> <ol style=\"list-style-type: upper-alpha;\"> <li>Family members with definite LQTS<sup>&#167;</sup> </li> </ol> </td> <td class=\"centered\">1</td> </tr> <tr> <td> <ol style=\"list-style-type: upper-alpha;\" start=\"2\"> <li>Unexplained sudden cardiac death below age 30 among immediate family members<sup>&#167;</sup> </li> </ol> </td> <td class=\"centered\">0.5</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">SCORE:&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>&le;1 point = low probability of long QT syndrome (LQTS).</li>&#xD;&#xA;    <li>1.5 to 3 points = intermediate probability of LQTS.</li>&#xD;&#xA;    <li>&ge;3.5 points = high probability of LQTS.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">* In the absence of medications or disorders known to affect these electrocardiographic features.<br />¶ QTc calculated by Bazett's formula where QTc = QT/√RR.<br />Δ Mutually exclusive.<br /><FONT class=lozenge>◊</FONT> Resting heart rate below the second percentile for age.<br />§ The same family member cannot be counted in A and B.</div><div class=\"graphic_reference\">From: Schwartz PJ, Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation 2011; 124:2181. DOI: <a href=\"http://circ.ahajournals.org/content/124/20/2181\" target=\"_blank\">10.1161/CIRCULATIONAHA.111.062182</a>. Copyright &copy; 2011 American Heart Association. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113828 Version 2.0</div></div></div>"},"113829":{"type":"graphic_table","displayName":"WHO vulvar tumor classific","title":"WHO Classification of tumors of the vulva*<SUP>¶</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO Classification of tumors of the vulva*<SUP>¶</SUP></div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table style=\"border-bottom: medium none;\" cellspacing=\"0\"> <colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Epithelial tumors</td> </tr> <tr> <td class=\"subtitle2_single\">Squamous cell tumors and precursors</td> <td class=\"centered divider_bottom\">&nbsp;</td> </tr> <tr> <td class=\"indent2\"><strong>Squamous intraepithelial lesions</strong></td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent3\">Low-grade squamous intraepithelial lesion</td> <td class=\"centered\">8077/0</td> </tr> <tr> <td class=\"indent3\">High-grade squamous intraepithelial lesion</td> <td class=\"centered\">8077/2</td> </tr> <tr> <td class=\"indent3\">Differentiated-type vulvar intraepithelial neoplasia</td> <td class=\"centered\">8071/2<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\"><strong>Squamous cell carcinoma</strong></td> <td class=\"centered\">8070/3</td> </tr> <tr> <td class=\"indent3\">Keratinizing</td> <td class=\"centered\">8071/3</td> </tr> <tr> <td class=\"indent3\">Non-keratinizing</td> <td class=\"centered\">8072/3</td> </tr> <tr> <td class=\"indent3\">Basaloid</td> <td class=\"centered\">8083/3</td> </tr> <tr> <td class=\"indent3\">Warty</td> <td class=\"centered\">8051/3</td> </tr> <tr> <td class=\"indent3\">Verrucous</td> <td class=\"centered\">8051/3</td> </tr> <tr> <td class=\"indent2\"><strong>Basal cell carcinoma</strong></td> <td class=\"centered\">8090/3</td> </tr> <tr> <td class=\"indent2\"><strong>Benign squamous lesions</strong></td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent3\">Condyloma acuminatum</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent3\">Vestibular papilloma</td> <td class=\"centered\">8052/0</td> </tr> <tr> <td class=\"indent3\">Seborrheic keratosis</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">Keratoacanthoma</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_single\">Glandular tumors</td> <td class=\"centered divider_bottom\">&nbsp;</td> </tr> <tr> <td class=\"indent2\"><strong>Paget disease</strong></td> <td class=\"centered\">8542/3</td> </tr> <tr> <td class=\"indent2\"><strong>Tumors arising from Bartholin and other specialized anogenital glands</strong></td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent3\">Bartholin gland carcinomas</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent3\"> <ul class=\"decimal_heading\"> <li>Adenocarcinoma </li> </ul> </td> <td class=\"centered\">8140/3</td> </tr> <tr> <td class=\"indent3\"> <ul class=\"decimal_heading\"> <li>Squamous cell carcinoma </li> </ul> </td> <td class=\"centered\">8070/3</td> </tr> <tr> <td class=\"indent3\"> <ul class=\"decimal_heading\"> <li>Adenosquamous carcinoma </li> </ul> </td> <td class=\"centered\">8560/3</td> </tr> <tr> <td class=\"indent3\"> <ul class=\"decimal_heading\"> <li>Adenoid cystic carcinoma </li> </ul> </td> <td class=\"centered\">8200/3</td> </tr> <tr> <td class=\"indent3\"> <ul class=\"decimal_heading\"> <li>Transitional cell carcinoma </li> </ul> </td> <td class=\"centered\">8120/3</td> </tr> <tr> <td class=\"indent3\">Adenocarcinoma of mammary gland type</td> <td class=\"centered\">8500/3</td> </tr> <tr> <td class=\"indent3\">Adenocarcinoma of Skene gland origin</td> <td class=\"centered\">8140/3</td> </tr> <tr> <td class=\"indent3\">Phyllodes tumor, malignant</td> <td class=\"centered\">9020/3</td> </tr> <tr> <td class=\"indent2\"><strong>Adenocarcinomas of other types</strong></td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent3\">Adenocarcinoma of sweat gland type</td> <td class=\"centered\">8140/3</td> </tr> <tr> <td class=\"indent3\">Adenocarcinoma of intestinal type</td> <td class=\"centered\">8140/3</td> </tr> <tr> <td class=\"indent2\"><strong>Benign tumors and cysts</strong></td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent3\">Papillary hidradenoma</td> <td class=\"centered\">8405/0</td> </tr> <tr> <td class=\"indent3\">Mixed tumor</td> <td class=\"centered\">8940/0</td> </tr> <tr> <td class=\"indent3\">Fibroadenoma</td> <td class=\"centered\">9010/0</td> </tr> <tr> <td class=\"indent3\">Adenoma</td> <td class=\"centered\">8140/0</td> </tr> <tr> <td class=\"indent3\">Adenomyoma</td> <td class=\"centered\">8932/0</td> </tr> <tr> <td class=\"indent3\">Bartholin gland cyst</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent3\">Nodular Bartholin gland hyperplasia</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent3\">Other vestibular gland cysts</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">Other cysts</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_single\">Neuroendocrine tumors</td> <td class=\"centered divider_bottom\">&nbsp;</td> </tr> <tr> <td class=\"indent2\"><strong>High-grade neuroendocrine carcinoma</strong></td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent3\">Small cell neuroendocrine carcinoma</td> <td class=\"centered\">8041/3</td> </tr> <tr> <td class=\"indent3\">Large cell neuroendocrine carcinoma</td> <td class=\"centered\">8013/3</td> </tr> <tr> <td class=\"indent2\"><strong>Merkel cell tumor</strong></td> <td class=\"centered\">8247/3</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Neuroectodermal tumors</td> </tr> <tr> <td class=\"subtitle2_single\">Ewing sarcoma</td> <td class=\"centered divider_bottom\">9364/3</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Soft tissue tumors</td> </tr> <tr> <td class=\"subtitle2_single\">Benign tumors</td> <td class=\"centered divider_bottom\">&nbsp;</td> </tr> <tr> <td class=\"indent2\"><strong>Lipoma</strong></td> <td class=\"centered\">8850/0</td> </tr> <tr> <td class=\"indent2\"><strong>Fibroepithelial stromal polyp</strong></td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent2\"><strong>Superficial angiomyxoma</strong></td> <td class=\"centered\">8841/0<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\"><strong>Superficial myofibroblastoma</strong></td> <td class=\"centered\">8825/0</td> </tr> <tr> <td class=\"indent2\"><strong>Cellular angiofibroma</strong></td> <td class=\"centered\">9160/0</td> </tr> <tr> <td class=\"indent2\"><strong>Angiomyofibroblastoma</strong></td> <td class=\"centered\">8826/0</td> </tr> <tr> <td class=\"indent2\"><strong>Aggressive angiomyxoma</strong></td> <td class=\"centered\">8841/0<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\"><strong>Leiomyoma</strong></td> <td class=\"centered\">8890/0</td> </tr> <tr> <td class=\"indent2\"><strong>Granular cell tumor</strong></td> <td class=\"centered\">9580/0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><strong>Other benign tumors</strong></td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_single\">Malignant tumors</td> <td class=\"centered divider_bottom\">&nbsp;</td> </tr> <tr> <td class=\"indent2\"><strong>Rhabdomyosarcoma</strong></td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent3\">Embryonal</td> <td class=\"centered\">8910/3</td> </tr> <tr> <td class=\"indent3\">Alveolar</td> <td class=\"centered\">8920/3</td> </tr> <tr> <td class=\"indent2\"><strong>Leiomyosarcoma</strong></td> <td class=\"centered\">8890/3</td> </tr> <tr> <td class=\"indent2\"><strong>Epithelioid sarcoma</strong></td> <td class=\"centered\">8804/3</td> </tr> <tr> <td class=\"indent2\"><strong>Alveolar soft part sarcoma</strong></td> <td class=\"centered\">9581/3</td> </tr> <tr> <td class=\"indent2\"><strong>Other sarcomas</strong></td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent3\">Liposarcoma</td> <td class=\"centered\">8850/3</td> </tr> <tr> <td class=\"indent3\">Malignant peripheral nerve shealth tumor</td> <td class=\"centered\">9540/3</td> </tr> <tr> <td class=\"indent3\">Kaposi sarcoma</td> <td class=\"centered\">9140/3</td> </tr> <tr> <td class=\"indent3\">Fibrosarcoma</td> <td class=\"centered\">8810/3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">Dermatofibrosarcoma protuberans</td> <td class=\"centered\">8832/1<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Melanocytic tumors</td> </tr> <tr> <td class=\"subtitle2_single\">Melanocytic naevi</td> <td class=\"centered divider_bottom\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">Congenital melanocytic naevus</td> <td class=\"centered\">8761/0</td> </tr> <tr> <td class=\"indent2\">Acquired melanocytic naevus</td> <td class=\"centered\">8720/0</td> </tr> <tr> <td class=\"indent2\">Blue naevus</td> <td class=\"centered\">8780/0</td> </tr> <tr> <td class=\"indent2\">Atypical melanocytic naevus of genital type</td> <td class=\"centered\">8720/0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Dysplastic melanocytic naevus</td> <td class=\"centered\">8727/0</td> </tr> <tr> <td class=\"subtitle2_single\">Malignant melanoma</td> <td class=\"centered divider_bottom\">8720/3</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Germ cell tumors</td> </tr> <tr> <td class=\"subtitle2_single\">Yolk sac tumor</td> <td class=\"centered divider_bottom\">9071/3</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Lymphoid and myeloid tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Lymphomas</strong></td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_single\">Myeloid neoplasms</td> <td class=\"centered divider_bottom\">&nbsp;</td> </tr> <tr> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"2\"><strong>Secondary tumors</strong></td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WHO: World Health Organization; IARC: International Agency for Research on Cancer.<br />* The morphology codes are from the International Classification of Diseases for Oncology (ICD-O).<SUP>[1]</SUP> Behavior is coded /0 for benign tumors; /1 for unspecified, borderline, or uncertain behavior; /2 for carcinoma in situ and grade III intraepithelial neoplasia; and /3 for malignant tumors.<br />¶ The classification is modified from the previous WHO classification of tumors,<SUP>[2]</SUP> taking into account changes in our understanding of these lesions.<br />Δ These new codes were approved by the IARC/WHO Committee for ICD-O in 2013.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology (ICD-O), 3rd ed, World Health Organization, Geneva 2000.</LI>&#xD;&#xA;<LI>Tavassoli FA, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs (IARC WHO Classification of Tumours). International Agency for Research on Cancer, Lyon 2003.</LI></OL>Reprinted from: World Health Organization Classification of Tumours of the Female Reproductive Organs, International Agency for Research on Cancer, Vol. 6, Kurman RJ, Carcangiu ML, Herrington S, Young RH, Tumours of the vulva, p. 230, Copyright © 2014.</div><div id=\"graphicVersion\">Graphic 113829 Version 1.0</div></div></div>"},"113841":{"type":"graphic_algorithm","displayName":"Algorithm for diagnosis and management of undiagnosed MI","title":"Approach to the patient with an incidental finding on electrocardiogram suggestive of previously undiagnosed myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Approach to the patient with an incidental finding on electrocardiogram suggestive of previously undiagnosed myocardial infarction</div><div class=\"cntnt\"><img style=\"width:295px; height:322px;\" src=\"images/CARD/113841_AlgoDXmgmtundgnsdMIed1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; MI: myocardial infarction.<br />* Refer to relevant UpToDate topic for criteria.<br />¶ Two-dimensional echocardiography is preferred, radionuclide ventriculography, myocardial perfusion imaging, cardiac magnetic resonance imaging, or computed tomographic angiography are reasonable other imaging tests.<br />Δ Refer to relevant UpToDate topics for more information.</div><div id=\"graphicVersion\">Graphic 113841 Version 1.0</div></div></div>"},"113843":{"type":"graphic_table","displayName":"Antibiotics for C. pneumoniae pneumonia in adults","title":"Recommended antibiotics for treatment of pneumonia caused by <em>Chlamydia pneumoniae</em> in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended antibiotics for treatment of pneumonia caused by <em>Chlamydia pneumoniae</em> in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Duration*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Preferred</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Azithromycin</td> <td>500 mg orally on day 1 followed by 250 mg once daily on days 2 to 5</td> <td class=\"centered\">5 days</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Alternatives</td> </tr> <tr> <td class=\"indent1\">Clarithromycin</td> <td>500 mg immediate-release orally twice daily or 1000 mg extended-release once daily</td> <td class=\"centered\">10 days</td> </tr> <tr> <td class=\"indent1\">Doxycycline<sup>&#182;</sup></td> <td>100 mg orally or IV twice daily</td> <td class=\"centered\">10 days</td> </tr> <tr> <td class=\"indent1\">Levofloxacin<sup>&#916;</sup></td> <td>500 or 750 mg orally or IV once daily</td> <td class=\"centered\">7 to 10 days</td> </tr> <tr> <td class=\"indent1\">Moxifloxacin</td> <td>400 mg orally or IV once daily</td> <td class=\"centered\">10 days</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenously.<br />* Suggested durations derived from studies demonstrating microbiologic eradication of <em>C. pneumoniae</em> in patient with community-acquired pneumonia (CAP); duration may differ from those recommended for CAP in general.<br />&para; Doxycycline should not be used in pregnant women. The IV preparation of doxycycline is a venous irritant; other IV antimicrobials are generally preferred when parenteral treatment is warranted.<br />&Delta; Dose adjustment is needed in setting of renal impairment.</div><div id=\"graphicVersion\">Graphic 113843 Version 2.0</div></div></div>"},"113849":{"type":"graphic_figure","displayName":"Push method for delivery of impacted fetal head","title":"Push method for delivery of the impacted fetal head at cesarean","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Push method for delivery of the impacted fetal head at cesarean</div><div class=\"cntnt\"><img style=\"width:454px; height:399px;\" src=\"images/OBGYN/113849_Push_method_for_delivery_of_impacted_fetal_head.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abdominovaginal delivery (push method)&nbsp;refers to a procedure in which an assistant places his/her gloved, cupped hand into the vagina to gently disengage and push the impacted fetal head up into the uterus for cesarean delivery&nbsp;. Three or four fingers are separated and spread over a large area of fetal skull to avoid exerting excessive focal pressure, which can be traumatic. The operating obstetrician also assists from above by providing steady upward traction on the fetal shoulders and by attempting to flex the fetal head or at least prevent further deflexion</div><div class=\"graphic_reference\">​Manning JB, Tolcher MC, Chandraharan E, Rose CH. Delivery of an Impacted Fetal Head During Cesarean: A Literature Review and Proposed Management Algorithm. Obstet Gynecol Surv 2015; 70:719.</div><div id=\"graphicVersion\">Graphic 113849 Version 1.0</div></div></div>"},"113850":{"type":"graphic_algorithm","displayName":"Acne fulminans management algorithm","title":"Management of acne fulminans","html":"<div class=\"graphic\"><div style=\"width: 858px\" class=\"figure\"><div class=\"ttl\">Management of acne fulminans</div><div class=\"cntnt\"><img style=\"width:838px; height:778px;\" src=\"images/DERM/113850_Acne_fulminans_mnge_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Other agents such as testosterone and anabolic steroids have been implicated as well.<br />&para; Tapering usually requires four to eight weeks.</div><div class=\"graphic_reference\">Reproduced with permission from: Greywal T, Zaenglein AL, Baldwin HE, et al. Evidence-based recommendations for the management of acne fulminans and its variants. J Am Acad Dermatol 2017; 77:109. Copyright &copy; 2017 American Acne and Rosacea Society. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113850 Version 1.0</div></div></div>"},"113853":{"type":"graphic_table","displayName":"Travel-associated infections, by incubation period - II","title":"Travel-associated infections, by incubation period - II","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Travel-associated infections, by incubation period - II</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Usual incubation period (range)</td> <td class=\"subtitle1\">Distribution</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Incubation &#60;14 days</td> </tr> <tr> <td class=\"indent1\">Chikungunya</td> <td>2 to 4 days (1 to 14 days)</td> <td>Tropics, subtropics</td> </tr> <tr> <td class=\"indent1\">Dengue</td> <td>4 to 8 days (3 to 14 days)</td> <td>Topics, subtropics</td> </tr> <tr> <td class=\"indent1\">Encephalitis, arboviral (Japanese encephalitis, tickborne encephalitis, West Nile virus, other)</td> <td>3 to 14 days (1 to 20 days)</td> <td>Specific agents vary by region</td> </tr> <tr> <td class=\"indent1\">Enteric fever</td> <td>7 to 18 days (3 to 60 days)</td> <td>Especially in Indian subcontinent</td> </tr> <tr> <td class=\"indent1\">Acute HIV</td> <td>10 to 28 days (10 days to 6 weeks)</td> <td>Worldwide</td> </tr> <tr> <td class=\"indent1\">Influenza</td> <td>1 to 3 days</td> <td>Worldwide, can also be acquired while traveling</td> </tr> <tr> <td class=\"indent1\">Legionellosis</td> <td>5 to 6 days (2 to 10 days)</td> <td>Widespread</td> </tr> <tr> <td class=\"indent1\">Leptospirosis</td> <td>7 to 12 days (2 to 26 days)</td> <td>Widespread, most common in tropical areas</td> </tr> <tr> <td class=\"indent1\">Malaria, <em>Plasmodium falciparum</em></td> <td>6 to 30 days (98% onset within 3 months of travel)</td> <td>Tropics, subtropics</td> </tr> <tr> <td class=\"indent1\">Malaria, <em>P. vivax</em></td> <td>8 days to 12 months (almost half have onset &#62;30 days after completion of travel)</td> <td>Widespread in tropics and subtropics</td> </tr> <tr> <td class=\"indent1\">Spotted-fever rickettsiae</td> <td>Few days to 2 to 3 weeks</td> <td>Causative species vary by region</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Zika virus infection</td> <td>3 to 14 days</td> <td>Widespread in Latin America; endemic through much of Africa, Southeast Asia, and Pacific Islands</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Incubation 14 days to 6 weeks</td> </tr> <tr> <td class=\"indent1\">Encephalitis, arboviral; enteric fever; acute HIV; leptospirosis; malaria</td> <td>Refer to above incubation periods for relevant diseases</td> <td>Refer to above distribution for relevant diseases</td> </tr> <tr> <td class=\"indent1\">Amebic liver abscess</td> <td>Weeks to months</td> <td>Most common in resource-poor countries</td> </tr> <tr> <td class=\"indent1\">Hepatitis A</td> <td>28 to 30 days (15 to 50 days)</td> <td>Most common in resource-poor countries</td> </tr> <tr> <td class=\"indent1\">Hepatitis E</td> <td>26 to 42 days (2 to 9 weeks)</td> <td>Widespread</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Acute schistosomiasis (Katayama syndrome)</td> <td>4 to 8 weeks</td> <td>Most common in sub-Saharan Africa</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Incubation &#62;6 weeks</td> </tr> <tr> <td class=\"indent1\">Amebic liver abscess, hepatitis E, malaria, acute schistosomiasis</td> <td>Refer to above incubation periods for relevant diseases</td> <td>Refer to above distribution for relevant diseases</td> </tr> <tr> <td class=\"indent1\">Hepatitis B</td> <td>90 days (60 to 150 days)</td> <td>Widespread</td> </tr> <tr> <td class=\"indent1\">Leishmaniasis, visceral</td> <td>2 to 10 months (10 days to years)</td> <td>Asia, Africa, Latin America, southern Europe, and the Middle East</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> <td>Primary, weeks; reactivation, years</td> <td>Global distribution, rates and levels of resistance vary widely</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Wilson ME. Fever in Returned Travelers. In: CDC Health Information for International Travel 2018. Available at: <A href=\"https://wwwnc.cdc.gov/travel/yellowbook/2018/post-travel-evaluation/fever-in-returned-travelers\" target=_blank>https://wwwnc.cdc.gov/travel/yellowbook/2018/post-travel-evaluation/fever-in-returned-travelers</A> (Accessed July 7, 2017).</div><div id=\"graphicVersion\">Graphic 113853 Version 1.0</div></div></div>"},"113863":{"type":"graphic_picture","displayName":"Phototherapy for neonatal jaundice","title":"Phototherapy for newborn infant with neonatal jaundice","html":"<div class=\"graphic\"><div style=\"width: 658px\" class=\"figure\"><div class=\"ttl\">Phototherapy for newborn infant with neonatal jaundice</div><div class=\"cntnt\"><img style=\"width:638px; height:358px;\" src=\"images/PEDS/113863_Hospital_phototherapy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Copyright &copy; Design that Matters, Inc. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 113863 Version 1.0</div></div></div>"},"113868":{"type":"graphic_table","displayName":"Comparison of intrauterine adhesion classification systems","title":"Comparison of intrauterine adhesion classification systems","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of intrauterine adhesion classification systems</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"35%\"></colgroup><colgroup width=\"65%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Source</td> <td class=\"subtitle1\">Summary of classification</td> </tr> <tr> <td>March et al<sup>[1]</sup></td> <td>Adhesions classified as minimal, moderate, or severe based on hysteroscopic assessment of the degree of uterine cavity involvement.</td> </tr> <tr> <td>Hamou et al<sup>[2]</sup></td> <td>Adhesions classified as isthmic, marginal, central, or severe according to hysteroscopic assessment.</td> </tr> <tr> <td>Valle and Sciarra<sup>[3]</sup></td> <td>Adhesions classified as mild, moderate, or severe according to hysteroscopic assessment and extent of occlusion (partial or total) at HSG.</td> </tr> <tr> <td>Wamsteker; European Society for Hysteroscopy<sup>[4]</sup></td> <td>Complex system classifies IUAs as Grades I through IV with several subtypes and incorporates a combination of hysteroscopic and HSG findings and clinical symptoms.</td> </tr> <tr> <td>American Fertility Society<sup>[5]</sup></td> <td>Complex scored system of mild, moderate, or severe IUAs based on extent of endometrial cavity obliteration, appearance of adhesions, and patient menstrual characteristics based on hysteroscopic or HSG assessment.</td> </tr> <tr> <td>Donnez and Nisolle<sup>[6]</sup></td> <td>Adhesions classified into six grades on the basis of location, with postoperative pregnancy rate the primary driver. Hysteroscopy or HSG are used for assessment.</td> </tr> <tr> <td>Nasr et al<sup>[7]</sup></td> <td>Complex system creates a prognostic score by incorporating menstrual and obstetric history with IUA findings at hysteroscopic assessment.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HSG: hysterosalpingograpy; IUA: intrauterine adhesion.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>March C, Israel R, March A. Hysteroscopic managment of intrauterine adhesions. Am J Obstet Gynecol 1978; 130:653.</li>&#xD;&#xA;    <li>Hamou J, Salat-Baroux J, Siegler A. Diagnosis and treatment of intrauterine adhesions by microhysteroscopy. Fertil Steril 1983; 39:321.</li>&#xD;&#xA;    <li>Valle RF, Sciarra JJ. Intrauterine adhesions: Hysteroscopic diagnosis, classification, treatment, and reproductive outcome. Am J Obstet Gynecol 1988; 158:1459.</li>&#xD;&#xA;    <li>Wamsteker K. European Society for Hysteroscopy (ESH) classification of IUA. 1989.</li>&#xD;&#xA;    <li>American Fertility Society classifications of adnexal adhesions, distal tubal occlusion, tubal occlusion secondary to tubal ligation, tubal pregnancies, M&uuml;llerian anomalies and intrauterine adhesions. Fertil Steril 1988; 49:944.</li>&#xD;&#xA;    <li>Donnez J, Nisolle M. Hysteroscopic adheisolysis of intrauterine adhesions (Asherman syndrome), Donnez J (Ed), Parthenon Publishing Group, London 1994.</li>&#xD;&#xA;    <li>Nasr A, Al-Inany H, Thabet S, Aboulghar M. A clinicohysteroscopic scoring system of intrauterine adhesions. Gynecol Obstet Invest 2000; 50:178.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: AAGL Advancing Minimally Invasive Gynecology Worldwide. AAGL practice report: practice guidelines for management of intrauterine synechiae. J Minim Invasive Gynecol 2010; 17:1. Table used with the permission of Elsevier, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113868 Version 1.0</div></div></div>"},"113882":{"type":"graphic_table","displayName":"Nocardia susceptibilities","title":"General antimicrobial susceptibility patterns for the most common <EM>Nocardia</EM> species","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">General antimicrobial susceptibility patterns for the most common <EM>Nocardia</EM> species</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"6\" width=\"12.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\"><em>N. farcinica</em></td> <td class=\"subtitle1\"><em>N. nova</em></td> <td class=\"subtitle1\"><em>N. brasiliensis</em></td> <td class=\"subtitle1\"><em>N. cyriacigeorgica</em></td> <td class=\"subtitle1\"><em>N. abscessus</em></td> <td class=\"subtitle1\"><em>N. otitidiscaviarum</em></td> </tr> <tr> <td><strong>Trimethoprim-sulfamethoxazole</strong></td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> </tr> <tr> <td><strong>Imipenem</strong></td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> <td class=\"centered\">R</td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> <td class=\"centered\">R</td> </tr> <tr> <td><strong>Amikacin</strong></td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> </tr> <tr> <td><strong>Linezolid</strong></td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> </tr> <tr> <td><strong>Tobramycin</strong></td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> </tr> <tr> <td><strong>Amoxicillin-clavulanate</strong></td> <td class=\"centered\">S</td> <td class=\"centered\">R</td> <td class=\"centered\">S</td> <td class=\"centered\">R</td> <td class=\"centered\">S</td> <td class=\"centered\">R</td> </tr> <tr> <td><strong>Ceftriaxone</strong></td> <td class=\"centered\">R</td> <td class=\"centered\">S</td> <td class=\"centered\">R</td> <td class=\"centered\">S</td> <td class=\"centered\">S</td> <td class=\"centered\">R</td> </tr> <tr> <td><strong>Ciprofloxacin</strong></td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> </tr> <tr> <td><strong>Clarithromycin</strong></td> <td class=\"centered\">R</td> <td class=\"centered\">S</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> </tr> <tr> <td><strong>Doxycycline</strong></td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">S</td> <td class=\"centered\">R</td> </tr> <tr> <td><strong>Minocycline</strong></td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">S</td> <td class=\"centered\">R</td> </tr> <tr> <td><strong>Erythromycin</strong></td> <td class=\"centered\">R</td> <td class=\"centered\">S</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> <td class=\"centered\">R</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Common antimicrobial susceptibility patterns for the most common <EM>Nocardia</EM> species are outlined in the table; species are labeled as susceptible if &gt;80% of isolates tested were susceptible and as resistant if &gt;80% of isolates tested were resistant. Such data may be of use when therapy is commenced before antimicrobial susceptibility results are available. The table summarizes data extracted from four studies.<SUP>[1-4]</SUP> The four studies included are not directly comparable because of differences in the number of isolates and species included, antibiotics tested, and the methods of susceptibility testing used. Moxifloxacin was included in only one study; in this report, 81% of 36 <EM>N. farcinica</EM> isolates were susceptible to moxifloxacin.<SUP>[2]</SUP></div><div class=\"graphic_footnotes\">S: susceptible; R: resistant.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Valdezate S, Garrido N, Carrasco G, et al. Epidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain. J Antimicrob Chemother 2017; 72:754.</LI>&#xD;&#xA;<LI>McTaggart LR, Doucet J, Witkowska M, Richardson SE. Antimicrobial susceptibility among clinical Nocardia species identified by multilocus sequence analysis. Antimicrob Agents Chemother 2015; 59:269.</LI>&#xD;&#xA;<LI>Coussement J, Lebeaux D, van Delden C, et al. Nocardia infection in solid organ transplant recipients: a multicenter European case-control study. Clin Infect Dis 2016; 63:338.</LI>&#xD;&#xA;<LI>Uhde KB, Pathak S, McCullum I Jr, et al. Antimicrobial-resistant nocardia isolates, United States, 1995-2004. Clin Infect Dis 2010; 51:1445.</LI></OL></div><div id=\"graphicVersion\">Graphic 113882 Version 1.0</div></div></div>"},"113889":{"type":"graphic_picture","displayName":"Chromoblastomycosis early lesion","title":"Chromoblastomycosis","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Chromoblastomycosis</div><div class=\"cntnt\"><img style=\"width:612px; height:477px;\" src=\"images/DERM/113889_Chromoblastomycss_erly_lesn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scaly papule on the knee.</div><div class=\"graphic_reference\">Reproduced from: Mycopathologia, Challenges in the therapy of chromoblastomycosis, Vol. 175, 2013, p. 477, Queiroz-Telles F, Santos DW, © Springer Science+Business Media Dordrecht 2013. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 113889 Version 1.0</div></div></div>"},"113890":{"type":"graphic_picture","displayName":"Nodular chromoblastomycosis","title":"Chromoblastomycosis","html":"<div class=\"graphic\"><div style=\"width: 770px\" class=\"figure\"><div class=\"ttl\">Chromoblastomycosis</div><div class=\"cntnt\"><img style=\"width:750px; height:520px;\" src=\"images/DERM/113890_Nodular_chromoblastomycosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodular morphology.</div><div id=\"graphicVersion\">Graphic 113890 Version 1.0</div></div></div>"},"113891":{"type":"graphic_picture","displayName":"Tumorous chromoblastomycosis","title":"Chromoblastomycosis","html":"<div class=\"graphic\"><div style=\"width: 704px\" class=\"figure\"><div class=\"ttl\">Chromoblastomycosis</div><div class=\"cntnt\"><img style=\"width:684px; height:461px;\" src=\"images/DERM/113891_Tumrs_chromoblastomycss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tumorous morphology.</div><div class=\"graphic_reference\">Reproduced from: Mycopathologia, Challenges in the therapy of chromoblastomycosis, Vol. 175, 2013, p. 477, Queiroz-Telles F, Santos DW, © Springer Science+Business Media Dordrecht 2013. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 113891 Version 1.0</div></div></div>"},"113893":{"type":"graphic_table","displayName":"Incidence of intrauterine adhesions by pregnancy and procedure","title":"Prospective incidence of intrauterine adhesions by pregnancy and procedure type","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prospective incidence of intrauterine adhesions by pregnancy and procedure type</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Procedure</td> <td class=\"subtitle1\">Incidence (%)</td> <td class=\"subtitle1\">Reference</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Gravid</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">SAB</td> <td rowspan=\"2\">Suction D&#38;C</td> <td class=\"centered\">15</td> <td>Gilman et al<sup>[1]</sup></td> </tr> <tr> <td class=\"centered\">19</td> <td>Hooker et al<sup>[2]</sup></td> </tr> <tr> <td class=\"indent1\">First trimester TOP</td> <td>Suction D&#38;C</td> <td class=\"centered\">21</td> <td>Hooker et al<sup>[3]</sup></td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\">Retained POC*</td> <td rowspan=\"3\">Hysteroscopic resection</td> <td class=\"centered\">6</td> <td>Smorgick et al<sup>[4]</sup></td> </tr> <tr> <td class=\"centered\">13</td> <td>Hooker et al<sup>[5]</sup></td> </tr> <tr> <td class=\"centered\">19</td> <td>Barel et al<sup>[6]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Suction D&#38;C</td> <td class=\"centered\">30</td> <td>Hooker et al<sup>[5]</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Gynecologic</td> </tr> <tr> <td class=\"indent1\">Septum</td> <td>Hysteroscopic septum resection (bipolar)</td> <td class=\"centered\">24</td> <td>Yu et al<sup>[7]</sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Fibroids</td> <td>Hysteroscopic myomectomy (bipolar)</td> <td class=\"centered\">8</td> <td>Touboul et al<sup>[8]</sup></td> </tr> <tr> <td>Abdominal myomectomy</td> <td class=\"centered\">22</td> <td>Bhandari et al<sup>[9]</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SAB: spontaneous abortion; D&amp;C: dilation and curettage; TOP: termination of pregnancy; POC: products of conception.<br />* Pregnancy types preceding retained POC for each study: Smorgick et al<sup>[5]</sup> includes data from surgical and medical TOP, SAB, and postpartum from vaginal and caesarean deliveries; Hooker et al<sup>[6]</sup> includes data from first- and second-trimester pregnancies, postpartum, and otherwise not reported; Barel et al<sup>[7]</sup> includes data from surgical and medical TOP, SAB, and postpartum from vaginal and caesarean deliveries.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Gilman AR, Dewar KM, Rhone SA, Fluker MR. Intrauterine adhesions following miscarriage: Look and learn. J Obstet Gynaecol Can 2016; 38:453.</li>&#xD;&#xA;    <li>Hooker AB, Lemmers M, Thurkow AL, et al. Systematic review and meta-analysis of intrauterine adhesions after miscarriage: Prevalence, risk factors and long-term reproductive outcome. Hum Reprod Update 2014; 20:262.</li>&#xD;&#xA;    <li>Hooker A, Fraenk D, Br&ouml;lmann H, Huirne J. Prevalence of intrauterine adhesions after termination of pregnancy: A systematic review. Eur J Contracept Reprod Health Care 2016; 21:329.</li>&#xD;&#xA;    <li>Smorgick N, Barel O, Fuchs N, et al. Hysteroscopic management of retained products of conception: Meta-analysis and literature review. Eur J Obstet Gynecol Reprod Biol 2014; 173:19.</li>&#xD;&#xA;    <li>Hooker AB, Aydin H, Br&ouml;lmann HA, Huirne JA. Long-term complications and reproductive outcome after the management of retained products of conception: aA systematic review. Fertil Steril 2016; 105:156.</li>&#xD;&#xA;    <li>Barel O, Krakov A, Pansky M, et al. Intrauterine adhesions after hysteroscopic treatment for retained products of conception: What are the risk factors? Fertil Steril 2015; 103:775.</li>&#xD;&#xA;    <li>Yu X, Yuhan L, Dongmei S, et al. The incidence of postoperative adhesion following transection of uterine septum: A cohort study comparing three different adjuvant therapies. Eur J Obstet Gynecol Reprod Biol 2016; 201:61.</li>&#xD;&#xA;    <li>Touboul C, Fernandez H, Deffieux X, et al. Uterine synechiae after bipolar hysteroscopic resection of submucosal myomas in patients with infertility. Fertil Steril 2009; 92:1690.</li>&#xD;&#xA;    <li>Bhandari S, Ganguly I, Agarwal P, et al. Effect of myomectomy on endometrial cavity: a prospective study of 51 cases. J Hum Reprod Sci 2016; 9:107.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Salazar CA, Isaacson K, Morris S. A comprehensive review of Asherman's syndrome: Causes, symptoms and treatment options. Curr Opin Obstet Gynecol 2017; 29:249. DOI: <a href=\"http://journals.lww.com/co-obgyn/Abstract/2017/08000/A_comprehensive_review_of_Asherman_s_syndrome__.10.aspx\" target=\"_blank\">10.1097/GCO.0000000000000378</a>. Copyright &copy; 2017. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113893 Version 1.0</div></div></div>"},"113894":{"type":"graphic_picture","displayName":"Cicatricial chromoblastomycosis","title":"Chromoblastomycosis","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Chromoblastomycosis</div><div class=\"cntnt\"><img style=\"width:648px; height:455px;\" src=\"images/DERM/113894_Cicatrcl_chromoblastomycss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cicatricial morphology.</div><div class=\"graphic_reference\">Reproduced from: Mycopathologia, Challenges in the therapy of chromoblastomycosis, Vol. 175, 2013, p. 477, Queiroz-Telles F, Santos DW, © Springer Science+Business Media Dordrecht 2013. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 113894 Version 1.0</div></div></div>"},"113895":{"type":"graphic_picture","displayName":"Chromoblastomycosis with black dots","title":"Chromoblastomycosis","html":"<div class=\"graphic\"><div style=\"width: 781px\" class=\"figure\"><div class=\"ttl\">Chromoblastomycosis</div><div class=\"cntnt\"><img style=\"width:761px; height:319px;\" src=\"images/DERM/113895_Chromoblastomycosis_blck_dt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A nodular plaque lesion of chromoblastomycosis with several \"black dots\" (arrows).<br />(B) Pathognomonic muriform cells in a potassium hydroxide (KOH) wet mount.</div><div class=\"graphic_reference\">Reproduced from: Current Fungal Infection Reports, Chromoblastomycosis in the Clinical Practice, Vol. 6, 2012, p. 312, Queiroz-Telles F, Santos DW, &copy; Springer Science+Business Media New York 2012. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 113895 Version 1.0</div></div></div>"},"113896":{"type":"graphic_picture","displayName":"Chromoblastomycosis macromorphology and micromorphology","title":"Chromoblastomycosis","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Chromoblastomycosis</div><div class=\"cntnt\"><img style=\"width:581px; height:760px;\" src=\"images/DERM/113896_Chrmblmycs_macr_micrmrphlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Macromorphology of <EM innerHtml>Fonsecaea pedrosoi</EM>.<br />(B) Micromorphology of <EM>F. pedrosoi</EM>.</div><div class=\"graphic_reference\">Reproduced with permission from: Queiroz-Telles F. Chromoblastomycosis: A neglected tropical disease. Rev Inst Med Trop Sao Paulo 2015; 57:46. Copyright &copy; 2015 Universidade de S&atilde;o Paulo. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113896 Version 1.0</div></div></div>"},"113897":{"type":"graphic_picture","displayName":"Verrucous chromoblastomycosis","title":"Chromoblastomycosis","html":"<div class=\"graphic\"><div style=\"width: 589px\" class=\"figure\"><div class=\"ttl\">Chromoblastomycosis</div><div class=\"cntnt\"><img style=\"width:569px; height:380px;\" src=\"images/DERM/113897_Verrucous_chromoblastomycss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Verrucous morphology.</div><div class=\"graphic_reference\">From: Esterre P, Queiroz-Telles F. Management of chromoblastomycosis: novel perspectives. Curr Opin Infect Dis 2006; 19:148. DOI: <A href=\"http://journals.lww.com/co-infectiousdiseases/Abstract/2006/04000/Management_of_chromoblastomycosis__novel.6.aspx\" target=_blank>10.1097/01.qco.0000216625.28692.67</A>. Copyright © 2006. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113897 Version 1.0</div></div></div>"},"113898":{"type":"graphic_algorithm","displayName":"Management of SMZL","title":"Management of splenic marginal zone lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management of splenic marginal zone lymphoma</div><div class=\"cntnt\"><img style=\"width:338px; height:619px;\" src=\"images/HEME/113898_ManagementSMZL.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CR: complete remission; PR: partial remission.<br />* Splenectomy is an alternative for patients with localized symptoms due to splenomegaly. Splenectomy is not expected to benefit patients with disseminated nodal involvement outside of the splenic hilum or those with cytopenias due to extensive bone marrow involvement. Splenectomy is preferred for patients with suspected large cell transformation within the spleen. Asplenic patients are at risk for a fulminant sepsis syndrome, usually caused by encapsulated organisms. Whenever elective splenectomy is considered, patients should undergo appropriately timed preoperative immunization.<br />&para; The following autoimmune complications occur in approximately 20% of cases and require specific management: Autoimmune hemolytic anemia, immune thrombocytopenia, cold agglutinin disease, antiphospholipid antibodies, acquired von Willebrand disease, and acquired C1-esterase inhibitor deficiency.</div><div id=\"graphicVersion\">Graphic 113898 Version 1.0</div></div></div>"},"113899":{"type":"graphic_picture","displayName":"Plaque chromoblastomycosis","title":"Chromoblastomycosis","html":"<div class=\"graphic\"><div style=\"width: 704px\" class=\"figure\"><div class=\"ttl\">Chromoblastomycosis</div><div class=\"cntnt\"><img style=\"width:684px; height:459px;\" src=\"images/DERM/113899_Plaq_chromoblastomycss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plaque morphology.</div><div class=\"graphic_reference\">Reproduced from: Mycopathologia, Challenges in the therapy of chromoblastomycosis, Vol. 175, 2013, p. 477, Queiroz-Telles F, Santos DW, © Springer Science+Business Media Dordrecht 2013. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 113899 Version 1.0</div></div></div>"},"113900":{"type":"graphic_picture","displayName":"Plaque chromoblastomycosis on buttock","title":"Chromoblastomycosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Chromoblastomycosis</div><div class=\"cntnt\"><img style=\"width:756px; height:542px;\" src=\"images/DERM/113900_Plaq_chromoblastmycss_bttck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plaque morphology.</div><div class=\"graphic_reference\">Courtesy of Dr. Flavio Queiroz-Telles, MD, PhD.</div><div id=\"graphicVersion\">Graphic 113900 Version 1.0</div></div></div>"},"113901":{"type":"graphic_algorithm","displayName":"Approach to selecting treatments for panic disorder","title":"Approach to selecting treatments for panic disorder with or without agoraphobia in adults","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">Approach to selecting treatments for panic disorder with or without agoraphobia in adults</div><div class=\"cntnt\"><img style=\"width:563px; height:1031px;\" src=\"images/PSYCH/113901_Aprch_slct_trtmnt_pnc_dsrdr.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CBT: cognitive-behavioral therapy; SSRI: selective serotonin reuptake inhibitor; SNRI: serotonin-norepinephrine reuptake inhibitor; MAOI: monoamine oxidase inhibitor; SUD: substance use disorder.<br />* In addition to the medication suggestions that follow, CBT is a reasonable treatment alternative at each step where the patient has not sufficiently responded.<br />¶ Patients who have had a \"minimal\" or \"inadequate\" response should be switched to another medication. Patients who have had a partial response should be maintained on the current medication with one of the listed medications added adjunctively.<br />Δ Provided that the patient can adhere to medication and dietary restrictions. MAOI cannot be used concurrently with SSRI/SNRI. Discontinuation of SSRI/SNRI should be followed by a washout period based on the drug's half-life prior to initiating MAOI. (Refer to UpToDate topic for more information.)</div><div id=\"graphicVersion\">Graphic 113901 Version 1.0</div></div></div>"},"113902":{"type":"graphic_picture","displayName":"Chromoblastomycosis on the face","title":"Chromoblastomycosis","html":"<div class=\"graphic\"><div style=\"width: 770px\" class=\"figure\"><div class=\"ttl\">Chromoblastomycosis</div><div class=\"cntnt\"><img style=\"width:750px; height:501px;\" src=\"images/DERM/113902_Chromoblastomycosis_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chromoblastomycosis involving the face.</div><div id=\"graphicVersion\">Graphic 113902 Version 1.0</div></div></div>"},"113903":{"type":"graphic_picture","displayName":"Verrucous chromoblastomycosis 2","title":"Verrucous chromoblastomycosis","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Verrucous chromoblastomycosis</div><div class=\"cntnt\"><img style=\"width:533px; height:751px;\" src=\"images/DERM/113903_Verrucous_chromoblstmycss_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Verrucous morphology.</div><div id=\"graphicVersion\">Graphic 113903 Version 1.0</div></div></div>"},"113904":{"type":"graphic_picture","displayName":"Nodular chromoblastomycosis 2","title":"Chromoblastomycosis","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Chromoblastomycosis</div><div class=\"cntnt\"><img style=\"width:604px; height:752px;\" src=\"images/DERM/113904_Nodlr_chromoblastomycosis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodular morphology.</div><div id=\"graphicVersion\">Graphic 113904 Version 1.0</div></div></div>"},"113905":{"type":"graphic_picture","displayName":"Chromoblastomycosis mixed morphologies","title":"Chromoblastomycosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Chromoblastomycosis</div><div class=\"cntnt\"><img style=\"width:756px; height:425px;\" src=\"images/DERM/113905_Chromoblastomycss_mxd_morph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mixed lesion composed of plaque, nodular, and verrucous features involving the lower limb.</div><div class=\"graphic_reference\">Reproduced from: Mycopathologia, Challenges in the therapy of chromoblastomycosis, Vol. 175, 2013, p. 477, Queiroz-Telles F, Santos DW, © Springer Science+Business Media Dordrecht 2013. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 113905 Version 1.0</div></div></div>"},"113906":{"type":"graphic_picture","displayName":"Chromoblastomycosis with lymphedema","title":"Chromoblastomycosis","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Chromoblastomycosis</div><div class=\"cntnt\"><img style=\"width:752px; height:427px;\" src=\"images/DERM/113906_Chromoblastomycss_lymphdema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic lymphedema and hyperkeratotic lesions in the upper limb.</div><div class=\"graphic_reference\">Reproduced with permission from: Queiroz-Telles F, de Hoog S, Santos DW, et al. Chromoblastomycosis. Clin Microbiol Rev 2017; 30:233. Copyright &copy; 2017 American Society for Microbiology.</div><div id=\"graphicVersion\">Graphic 113906 Version 1.0</div></div></div>"},"113907":{"type":"graphic_figure","displayName":"Chromoblastomycosis world map","title":"Global distribution of chromoblastomycosis based upon published cases","html":"<div class=\"graphic\"><div style=\"width: 828px\" class=\"figure\"><div class=\"ttl\">Global distribution of chromoblastomycosis based upon published cases</div><div class=\"cntnt\"><img style=\"width:808px; height:442px;\" src=\"images/DERM/113907_Chromoblastomycoss_wrld_map.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">F: <EM>Fonsecaea</EM>; C: <EM>Cladophialophora</EM>.</div><div class=\"graphic_reference\">Reproduced with permission from: Queiroz-Telles F, de Hoog S, Santos DW, et al. Chromoblastomycosis. Clin Microbiol Rev 2017; 30:233. Copyright © 2017 American Society for Microbiology.</div><div id=\"graphicVersion\">Graphic 113907 Version 1.0</div></div></div>"},"113910":{"type":"graphic_picture","displayName":"Hypospadias repair: Double diaper and catheter","title":"Hypospadias repair: Double diaper with bladder catheter in male infant","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Hypospadias repair: Double diaper with bladder catheter in male infant</div><div class=\"cntnt\"><img style=\"width:715px; height:498px;\" src=\"images/PEDS/113910_Hypospds_repr_Dbl_dpr_cath.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Picture of an infant requiring a bladder catheter following hypospadias repair and showing the use of double diapers with the catheter pushed through a hole cut into the inner diaper, with urine draining directly into the outer diaper.</div><div id=\"graphicVersion\">Graphic 113910 Version 1.0</div></div></div>"},"113911":{"type":"graphic_picture","displayName":"Hypospadias repair: Dressing","title":"Dressing after hypospadias repair in a male infant","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Dressing after hypospadias repair in a male infant</div><div class=\"cntnt\"><img style=\"width:536px; height:714px;\" src=\"images/PEDS/113911_Hypospadias_repair_Dressing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Picture of an infant following hypospadias repair showing a clear plastic dressing covered by gauze pads taped around the penis and bladder catheter.</div><div id=\"graphicVersion\">Graphic 113911 Version 1.0</div></div></div>"},"113912":{"type":"graphic_table","displayName":"Classification of hypospadias","title":"Classification of hypospadias based on physical findings*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of hypospadias based on physical findings*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"18%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup span=\"4\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Classification</td> <td class=\"subtitle1\">Approximate relative frequency (%)</td> <td class=\"subtitle1\">Ectopic urethral location</td> <td class=\"subtitle1\">Penile curvature<sup>&#182;</sup></td> <td class=\"subtitle1\">Foreskin appearance</td> <td class=\"subtitle1\">Management</td> </tr> <tr class=\"divider_bottom\"> <td>Forme fruste of hypospadias (incomplete or partial presence of hypospadias)</td> <td class=\"centered\">10</td> <td>Normal location with a urethral pit or ectopic urethra on the distal glans</td> <td>Normal</td> <td>Normal to mild asymmetric ventral deficiency (incomplete closure around the glans)</td> <td> <ul> <li>No surgical correction or further evaluation needed </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Standard hypospadias with normal glans width (maximal diameter &#8805;14 mm)</td> <td class=\"centered\">40</td> <td>Distal urethral location on glans or coronal margin</td> <td>Normal to mild</td> <td>Ventral deficiency with a dorsal hooded appearance</td> <td> <ul> <li>Surgical correction in most cases, however, families may choose observation </li> <li>No other evaluation</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">25</td> <td>Proximal urethral location on penile shaft, at the penoscrotal junction, or within the scrotum</td> <td>Moderate</td> <td>Ventral deficiency with a dorsal hooded appearance</td> <td> <ul> <li>Surgical correction required </li> <li>No other evaluation </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Severe with an abnormally small glans (maximal diameter &#60;14 mm)</td> <td class=\"centered\">20</td> <td>Scrotum or perineum with an abnormally small glans (maximal diameter &#60;14 mm)</td> <td>Severe</td> <td>Ventral penile foreskin tethering (referred to as short urethral plate) or fusion of the foreskin to the scrotum</td> <td> <ul> <li>Surgical correction required (usually two-stage procedure)* </li> <li>Endocrine evaluation to detect disorders of sex development* </li> </ul> </td> </tr> <tr> <td>Other variants</td> <td class=\"centered\">5</td> <td colspan=\"4\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Chordee without hypospadias</td> <td class=\"centered\">&nbsp;</td> <td>Normal urethral opening and glans</td> <td>Mild to severe</td> <td>Normal</td> <td> <ul> <li>Surgical correction of chordee </li> <li>No other evaluation </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Megameatus intact prepuce</td> <td class=\"centered\">&nbsp;</td> <td>Large urethral opening at the coronal margin</td> <td>Normal</td> <td>Normal</td> <td> <ul> <li>Correction is usually performed based on family preference </li> <li>No other evaluation </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Refer to topics for further details on diagnosis and management.<br />¶ Penile curvature is assessed when the penis is erect and classified as normal (0 to 15 degrees), mild (15 to 40 degrees), moderate (40 to 80 degrees), and severe (&gt;80 degrees).</div><div id=\"graphicVersion\">Graphic 113912 Version 1.0</div></div></div>"},"113913":{"type":"graphic_picture","displayName":"Severe hypospadias and penoscrotal transposition","title":"Severe hypospadias and penoscrotal transposition","html":"<div class=\"graphic\"><div style=\"width: 692px\" class=\"figure\"><div class=\"ttl\">Severe hypospadias and penoscrotal transposition</div><div class=\"cntnt\"><img style=\"width:672px; height:714px;\" src=\"images/PEDS/113913_Svr_hypospds_pnscrtl_trnptn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with severe hypospadias and penoscrotal transposition (scrotum inserts above the penis and the penis is abnormally located below the scrotum). The urethral meatus (arrow) is located in the perineum/scrotal area.</div><div id=\"graphicVersion\">Graphic 113913 Version 1.0</div></div></div>"},"113914":{"type":"graphic_picture","displayName":"Duplicated urethra: male infant","title":"Duplicated urethra in a male infant","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Duplicated urethra in a male infant</div><div class=\"cntnt\"><img style=\"width:725px; height:438px;\" src=\"images/PEDS/113914_Duplicated_urethra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A demonstrates two urethral openings with the arrow pointing to the ectopic functioning urethra.<br />Panel B demonstrates the placement of two catheters showing that both are open urethras and neither is a blind urethral pit.</div><div id=\"graphicVersion\">Graphic 113914 Version 1.0</div></div></div>"},"113915":{"type":"graphic_picture","displayName":"Chordee with normal urethra ","title":"Chordee with normal urethra in a male infant","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Chordee with normal urethra in a male infant</div><div class=\"cntnt\"><img style=\"width:724px; height:474px;\" src=\"images/PEDS/113915_Chordee_normal_urethra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with chordee (penile curvature) and normal urethral meatus with a thin urethra along the penile shaft (dashed arrows) and a normal meatus and penile glans (arrows).</div><div id=\"graphicVersion\">Graphic 113915 Version 1.0</div></div></div>"},"113916":{"type":"graphic_picture","displayName":"Hypospadias glanular separation","title":"Hypospadias glanular separation in an infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypospadias glanular separation in an infant</div><div class=\"cntnt\"><img style=\"width:336px; height:438px;\" src=\"images/PEDS/113916_Hypospadias_glanular_seprtn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Male infant with hypospadias and glanular separation (dashed arrow) and lack of complete glans closure (arrow).</div><div id=\"graphicVersion\">Graphic 113916 Version 1.0</div></div></div>"},"113917":{"type":"graphic_figure","displayName":"Placement of uterine tourniquet","title":"Placement of uterine tourniquet for managing uterine hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Placement of uterine tourniquet for managing uterine hemorrhage</div><div class=\"cntnt\"><img style=\"width:483px; height:340px;\" src=\"images/OBGYN/113917_Uterine_tourniquet_for_control_of_postpartum_hemorrhage.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 113917 Version 2.0</div></div></div>"},"113918":{"type":"graphic_figure","displayName":"Clamp across the utero-ovarian vessels and ligament","title":"Clamp across the utero-ovarian vessels and ligament to reduce uterine bleeding","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Clamp across the utero-ovarian vessels and ligament to reduce uterine bleeding</div><div class=\"cntnt\"><img style=\"width:477px; height:404px;\" src=\"images/OBGYN/113918_Clamp_across_the_utero-ovarian_ligaments.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 113918 Version 2.0</div></div></div>"},"113919":{"type":"graphic_table","displayName":"Conditions associated with a difficult cholecystectomy","title":"Conditions associated with a difficult cholecystectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with a difficult cholecystectomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Difficulty in operative access and exposure:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Previous upper abdominal surgery </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Obesity </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Inflammatory processes involving the gallbladder:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Severe chronic cholecystitis </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Older age, male sex </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Multiple prior attacks of biliary colic </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Thickened gallbladder wall on ultrasound </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Shrunken, contracted gallbladder on imaging </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Acute cholecystitis </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Gangrenous cholecystitis </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Emphysematous cholecystitis </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <ul> <li>Perforated gallbladder </li> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Mirizzi's syndrome </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Other conditions:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cirrhosis </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A difficult cholecystectomy may be predicted preoperatively based on these patient characteristics, based on which the surgeon should take steps to ensure the safe performance of the procedure. </div><div id=\"graphicVersion\">Graphic 113919 Version 1.0</div></div></div>"},"113920":{"type":"graphic_picture","displayName":"Initial laparoscopic access in a morbidly obese patient","title":"Initial laparoscopic access in a morbidly obese patient","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Initial laparoscopic access in a morbidly obese patient</div><div class=\"cntnt\"><img style=\"width:509px; height:758px;\" src=\"images/SURG/113920_ntl_lprscpc_cs_mrbd_bs_ptnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Initial laparoscopic access in a morbidly obese patient.<br />(A) A closed Veress needle technique is used, inserted approximately 15 cm below the xiphoid for the initial camera port. The port should be 5 mm in size and placed under optical guidance.<br />(B) Position of the camera port and dissecting ports in this patient.</div><div id=\"graphicVersion\">Graphic 113920 Version 1.0</div></div></div>"},"113921":{"type":"graphic_diagnosticimage","displayName":"Critical view of safety in pt with cholecystitis and cirrhosis","title":"Critical view of safety in a patient with cholecystitis and cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 779px\" class=\"figure\"><div class=\"ttl\">Critical view of safety in a patient with cholecystitis and cirrhosis</div><div class=\"cntnt\"><img style=\"width:759px; height:260px;\" src=\"images/SURG/113921_Crt_vw_sfty_chlcystts_crhss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Critical view of safety in a patient with cholecystitis and cirrhosis. Both the anterior (A) and posterior (B) doublet views are shown.</div><div id=\"graphicVersion\">Graphic 113921 Version 1.0</div></div></div>"},"113922":{"type":"graphic_picture","displayName":"Aspiration of distended gallbladder","title":"Aspiration of distended gallbladder","html":"<div class=\"graphic\"><div style=\"width: 769px\" class=\"figure\"><div class=\"ttl\">Aspiration of distended gallbladder</div><div class=\"cntnt\"><img style=\"width:749px; height:524px;\" src=\"images/SURG/113922_Aspiration_distended_glbldr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aspiration of a distended gallbladder with some gangrenous changes and an omental pack due to acute cholecystitis.</div><div id=\"graphicVersion\">Graphic 113922 Version 1.0</div></div></div>"},"113923":{"type":"graphic_picture","displayName":"Subtotal fenestrating cholecystectomy","title":"Subtotal fenestrating cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 665px\" class=\"figure\"><div class=\"ttl\">Subtotal fenestrating cholecystectomy</div><div class=\"cntnt\"><img style=\"width:645px; height:763px;\" src=\"images/SURG/113923_Subttl_fnstrtng_chlcystctmy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subtotal fenestrating cholecystectomy in a patient with severe acute cholecystitis.<br />(A) The neck of the gallbladder is open, showing multiple stones. A gauze sponge is placed below the gallbladder to catch any stones and facilitate their removal.<br />(B) Appearance of the subtotal remnant (arrows). The neck of the gallbladder that remains in situ is outlined (dashed lines).</div><div id=\"graphicVersion\">Graphic 113923 Version 1.0</div></div></div>"},"113924":{"type":"graphic_diagnosticimage","displayName":"Intraoperative cholangiogram","title":"A completed intraoperative cholangiogram","html":"<div class=\"graphic\"><div style=\"width: 771px\" class=\"figure\"><div class=\"ttl\">A completed intraoperative cholangiogram</div><div class=\"cntnt\"><img style=\"width:751px; height:631px;\" src=\"images/SURG/113924_Intraoperative_cholangiogrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Complete intraoperative cholangiogram in a laparoscopic cholecystectomy. The cystic duct, common bile duct, common hepatic duct, and right and left hepatic ducts are seen as well as smooth tapering of the common bile duct into the duodenum. Also note contrast within the duodenum.</div><div class=\"graphic_footnotes\">CD: cystic duct; CBD: common bile duct; CHD: common hepatic duct; RHD: right hepatic duct; LHD: left hepatic duct; Duo: duodenum.</div><div id=\"graphicVersion\">Graphic 113924 Version 1.0</div></div></div>"},"113925":{"type":"graphic_picture","displayName":"ICG fluorescent cholangiography lap chole","title":"ICG fluorescent cholangiography laparoscopic cholecystectomy.","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">ICG fluorescent cholangiography laparoscopic cholecystectomy.</div><div class=\"cntnt\"><img style=\"width:763px; height:432px;\" src=\"images/SURG/113925_ICG_flsct_chlngrpy_df_glbld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Indocyanine green (ICG) fluorescent cholangiography. The cystic duct (CD) and common bile duct (CBD) demonstrate green fluorescent appearance on the ICG mode. Note the background green fluorescence on the liver (L). The white light appearance is seen in the upper left hand panel.</div><div id=\"graphicVersion\">Graphic 113925 Version 1.0</div></div></div>"},"113926":{"type":"graphic_picture","displayName":"Interdigital intertrigo","title":"Interdigital intertrigo caused by <EM>Fusarium</EM> spp","html":"<div class=\"graphic\"><div style=\"width: 691px\" class=\"figure\"><div class=\"ttl\">Interdigital intertrigo caused by <EM>Fusarium</EM> spp</div><div class=\"cntnt\"><img style=\"width:671px; height:495px;\" src=\"images/ID/113926_Interdigital_intertrigo.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Nucci M, Varon AG, Garnica M, et al. Increased incidence of invasive fusariosis with cutaneous portal of entry, Brazil. Emerg Infect Dis 2013; 19:1567. Available at: <A href=\"https://wwwnc.cdc.gov/eid/article/19/10/12-0847_article\" target=_blank>https://wwwnc.cdc.gov/eid/article/19/10/12-0847_article</A> (Accessed July 12, 2017).</div><div id=\"graphicVersion\">Graphic 113926 Version 1.0</div></div></div>"},"113927":{"type":"graphic_picture","displayName":"Interdigital intertrigo with lymphangitic spread","title":"Interdigital intertrigo with lymphangitic spread caused by <EM>Fusarium</EM> spp ","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Interdigital intertrigo with lymphangitic spread caused by <EM>Fusarium</EM> spp </div><div class=\"cntnt\"><img style=\"width:598px; height:442px;\" src=\"images/ID/113927_Intdgtl_intrg_lymphgtc_sprd.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Nucci M, Varon AG, Garnica M, et al. Increased incidence of invasive fusariosis with cutaneous portal of entry, Brazil. Emerg Infect Dis 2013; 19:1567. Available at: <A href=\"https://wwwnc.cdc.gov/eid/article/19/10/12-0847_article\" target=_blank>https://wwwnc.cdc.gov/eid/article/19/10/12-0847_article</A> (Accessed July 12, 2017).</div><div id=\"graphicVersion\">Graphic 113927 Version 1.0</div></div></div>"},"113934":{"type":"graphic_diagnosticimage","displayName":"Normal and abnormal rest perfusion imaging in suspected ACS","title":"Normal and abnormal rest myocardial perfusion imaging in patients with suspected acute coronary syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal and abnormal rest myocardial perfusion imaging in patients with suspected acute coronary syndrome</div><div class=\"cntnt\"><img style=\"width:412px; height:303px;\" src=\"images/CARD/113934_Nm_abnm_rt_prfn_img_spt_ACS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of normal (Panel A) and an abnormal (Panel B) rest myocardial perfusion imaging in patients with suspected acute coronary syndromes. In both panels, two contiguous tomograms are displayed in the short-axis (SA), horizontal long-axis (HLA), and vertical long-axis (VLA) orientations. The study in Panel A shows normal homogeneous uptake of the perfusion tracer in all walls consistent with normal resting myocardial blood flow. The likelihood of an ACS is very low. In Panel B, there is a resting perfusion defect in the distal portion of the anterior wall (arrow) and the apex (arrowhead). These findings are consistent with a resting blood flow abnormality and an ACS, likely due to severe stenosis in the left anterior descending coronary artery.</div><div class=\"graphic_footnotes\">ACS: acute coronary syndrome.</div><div id=\"graphicVersion\">Graphic 113934 Version 1.0</div></div></div>"},"113938":{"type":"graphic_figure","displayName":"Grades of internal hemorrhoids","title":"Grades of internal hemorrhoids<sup>[1,2]</sup>","html":"<div class=\"graphic\"><div style=\"width: 702px\" class=\"figure\"><div class=\"ttl\">Grades of internal hemorrhoids<sup>[1,2]</sup></div><div class=\"cntnt\"><img style=\"width:682px; height:569px;\" src=\"images/SURG/113938_Grades_internal_hemorrhoids.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on details of treatment options for internal hemorrhoids.</div><div class=\"graphic_footnotes\">RBL: rubber band ligation.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Jacobs D. Clinical practice. Hemorrhoids. N Engl J Med 2014; 371:944.</li>&#xD;&#xA;    <li>Hall JF. Modern management of hemorrhoidal disease. Gastroenterol Clin North Am 2013; 42:759.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 113938 Version 1.0</div></div></div>"},"113942":{"type":"graphic_figure","displayName":"Shift work actigram","title":"Shift work actigram","html":"<div class=\"graphic\"><div style=\"width: 1149px\" class=\"figure\"><div class=\"ttl\">Shift work actigram</div><div class=\"cntnt\"><img style=\"width:1129px; height:719px;\" src=\"images/SLEEP/113942_Shift_work_actigram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These actigraphic recordings are from a nurse who works the day shift and a nurse who works the night shift. A 24-hour time interval (ranging from 12:00 PM to 12:00 PM) is depicted on the X-axis; sequential dates are depicted on the Y-axis. Note that typical sleep periods (eg, 10:00 PM to 6:00 AM) are in the center of the actigram. The actigram denotes physical activity in black, which correlates with wakefulness. An absence of physical activity correlates with pronounced inactivity and periods of sleep. Periods of sleep (aqua) are determined by the actigraphy software. This actigram also provides light exposure by wavelength, including white, red, green, and blue. In this figure, the day shift nurse appears to go to bed between 11:00 PM and 12:30 AM each night and gets out of bed between 6:00 AM and 7:00 AM each day with the exception of day 3 (Saturday), when he/she appears to stay in bed until 9:00 AM. In contrast, the night shift nurse has variable sleep-wake periods that correspond to his/her work schedule. For example, he/she appears to go to bed between 11:00 PM and 3:00 AM on days 2 to 4 and between 8:00 AM and 8:30 AM on days 5 to 7.</div><div id=\"graphicVersion\">Graphic 113942 Version 1.0</div></div></div>"},"113950":{"type":"graphic_figure","displayName":"Endouterine square hemostatic sutures","title":"Endouterine square hemostatic sutures","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Endouterine square hemostatic sutures</div><div class=\"cntnt\"><img style=\"width:527px; height:351px;\" src=\"images/OBGYN/113950_Endouterine_square_hemostatic_sutures.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from: Arduini M, Epicoco G, Clerici G, et al. B-Lynch suture, intrauterine balloon, and endouterine hemostatic suture for the management of postpartum hemorrhage due to placenta previa accreta. Int J Obstet Gynecol 2010; 108:191.</div><div id=\"graphicVersion\">Graphic 113950 Version 1.0</div></div></div>"},"113953":{"type":"graphic_figure","displayName":"Range of KIT mutations in GIST","title":"Range of KIT mutations in gastrointestinal stromal tumors (GIST)","html":"<div class=\"graphic\"><div style=\"width: 710px\" class=\"figure\"><div class=\"ttl\">Range of KIT mutations in gastrointestinal stromal tumors (GIST)</div><div class=\"cntnt\"><img style=\"width:690px; height:520px;\" src=\"images/ONC/113953_KITmutationsGIST.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">KIT is a type III receptor tyrosine kinase that is comprised of extracellular ligand-binding and dimerization domains, a transmembrane sequence, as well as an intracellular juxtamembrane domain and kinase domain, which is split by an 80 amino acid insert. Mutations in exon 11 of KIT, which encode the juxtamembrane domain and are seen in approximately 70% of GISTs, relieve its autoinhibitory function and lead to constitutive, ligand-independent activation of the receptor. Mutations in the dimerization domain, encoded by exon 9 (approximately 12% of GISTs), allow receptor dimerization in the absence of ligand and likewise lead to activation of the kinase. Mutations in the kinase domain (exons 13/14, ATP-binding, phosphotransferase region; exons 17/18, activation loop) are rare in primary, imatinib-naïve GISTs. However, because they favor the active conformation of the kinase, leading to impaired binding of imatinib, they comprise the most prominent imatinib resistance mechanism. A comparison of the relative effectiveness of IM, SU, and REGO in GIST with the most frequent KIT secondary mutations is shown on the right.</div><div class=\"graphic_footnotes\">IM: imatinib; SU: sunitinib; REGO: regorafenib; ATP: adenosine 5'-triphosphate.</div><div class=\"graphic_reference\">Adapted with permission from: Clinical Cancer Research, 2009, Vol. 5, Issue 24, pp. 7510-7518, Gramza AW, Corless CL, Heinrich MC, Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors, with permission from AACR.</div><div id=\"graphicVersion\">Graphic 113953 Version 2.0</div></div></div>"},"113954":{"type":"graphic_figure","displayName":"KIT signaling in GIST","title":"KIT signaling in gastrointestinal stromal tumors (GIST)","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">KIT signaling in gastrointestinal stromal tumors (GIST)</div><div class=\"cntnt\"><img style=\"width:598px; height:465px;\" src=\"images/ONC/113954_KITsignalingGIST.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Physiologic KIT activation is triggered by binding of the dimeric KIT ligand (SCF) to the extracellular, ligand-binding domain of the KIT receptor tyrosine kinase. This in turn leads to homodimerization of two KIT molecules, which is accompanied by structural changes in the receptor and activation (autophosphorylation) of the intracellular KIT kinase domain. The phosphorylated tyrosine residues on KIT serve as binding sites for various cell signaling proteins, resulting in the activation of various signaling cascades, such as the PI3-K/AKT/mTOR, RAS/RAF/MAPK, and the JAK/STAT pathways. Ultimately, the activated KIT receptor stimulates intracellular signaling pathways controlling cell proliferation, adhesion, apoptosis, survival, and differentiation.</div><div class=\"graphic_footnotes\">SCF: stem cell factor; PI3K: phosphoinositide 3-kinase; PDK1/2: pyruvate dehydrogenase kinase isoenzymes 1 and 2; GRB2: growth factor receptor-bound protein 2; MEK: mitogen-activated protein kinase kinase; mTOR: mechanistic target of rapamycin; STAT: signal transducer and activator of transcription; MAPK: mitogen-activated protein kinase.</div><div class=\"graphic_reference\">Reproduced with permission from: Mutation Analysis: Kit and PDGFRA. Available at: <A href=\"http://www.gistsupport.org/about-gist/mutation-analysis-kit-and-pdgfra/\" target=_blank>http://www.gistsupport.org/about-gist/mutation-analysis-kit-and-pdgfra/</A> (accessed on July 14, 2017). Copyright © GIST Support International. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113954 Version 2.0</div></div></div>"},"113955":{"type":"graphic_picture","displayName":"Benign cephalic histiocytosis 1","title":"Benign cephalic histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Benign cephalic histiocytosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/113955_Bngn_cephalc_histiocytoss_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow-red papules and small plaques on the face of an infant with benign cephalic histiocytosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 113955 Version 1.0</div></div></div>"},"113956":{"type":"graphic_picture","displayName":"Benign cephalic histiocytosis 2","title":"Benign cephalic histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Benign cephalic histiocytosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/113956_Bngn_cephalc_histiocytoss_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Disseminated, yellowish-brown papules on the face of an infant with benign cephalic histiocytosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 113956 Version 1.0</div></div></div>"},"113958":{"type":"graphic_diagnosticimage","displayName":"CT of GIST","title":"CT of gastrointestinal stromal tumor (GIST)","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">CT of gastrointestinal stromal tumor (GIST)</div><div class=\"cntnt\"><img style=\"width:553px; height:757px;\" src=\"images/ONC/113958_CTGIST.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial image of a contrast-enhanced&nbsp;CT scan of the abdomen, showing a 4 cm hyperenhancing mass arising from the submucosa of the body of the stomach. <br />(B) Axial image of a contrast-enhanced&nbsp;CT scan of the abdomen of a patient who presented with gastrointestinal bleeding. Exophytic GIST arising from the second portion of the duodenum, with area of ulceration along the descending duodenum into the mass.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 113958 Version 1.0</div></div></div>"},"113961":{"type":"graphic_algorithm","displayName":"Adult with high probability of pulmonary embolism","title":"Evaluation of the nonpregnant adult with high probability of pulmonary embolism","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Evaluation of the nonpregnant adult with high probability of pulmonary embolism</div><div class=\"cntnt\"><img style=\"width:456px; height:437px;\" src=\"images/PULM/113961_Adlt_hi_prob_plmnry_emblsm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT pulmonary angiography is also called chest CT angiogram with contrast and is tailored for to evaluate the pulmonary arteries. A conventional chest CT with contrast is not adequate to exclude PE.</div><div class=\"graphic_footnotes\">PE: pulmonary embolism; CT: computed tomography.<br />* We prefer the Wells criteria to determine the pretest probability of PE, although the modified Geneva score or clinical gestalt is also appropriate. Refer to UpToDate text for details.<br />&para; Feasibility requires adequate scanner technology. Also the patient must be able to lie flat, to cooperate with exam breath-holding instructions, have a body habitus that can fit into scanner, and no contraindications for iodinated contrast.<br />&Delta; Repeat CT pulmonary angiography for more definitive results may be worthwhile if the factor causing poor image quality can be mitigated (eg, patient more capable of co-operating with positioning and breath-holding instructions). Repeat imaging is unlikely to prove useful if exam is nondiagnostic from factors such as scanner technology, body habitus, or indwelling metallic foreign bodies.<br /><span class=\"lozenge\">&loz;</span> Feasibility requires a chest radiograph demonstrating clear lungs and a patient able to lie still for &gt;30 minutes.<br />&sect; Further testing first involves revisiting the feasibility of CT pulmonary angiography. If CT pulmonary angiography is still not feasible then lower extremity compression ultrasonography with Doppler is appropriate.</div><div id=\"graphicVersion\">Graphic 113961 Version 1.0</div></div></div>"},"113962":{"type":"graphic_algorithm","displayName":"Adult with intermediate probability of pulmonary embolism","title":"Evaluation of the nonpregnant adult with intermediate probability of pulmonary embolism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Evaluation of the nonpregnant adult with intermediate probability of pulmonary embolism</div><div class=\"cntnt\"><img style=\"width:358px; height:559px;\" src=\"images/PULM/113962_Adlt_int_prob_plmnry_emblsm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT pulmonary angiography is also called chest CT angiogram with contrast and is tailored for to evaluate the pulmonary arteries. A conventional chest CT with contrast is not adequate to exclude PE.</div><div class=\"graphic_footnotes\">PE: pulmonary embolism; CT: computed tomography.<br />* We prefer the Wells criteria to determine the pretest probability of PE, although the modified Geneva score or clinical gestalt is also appropriate. Refer to UpToDate text for details.<br />&para; Some experts proceed directly to CT pulmonary angiography in patients on the higher end of the intermediate risk spectrum (eg, Wells score 4 to 6) or in those with limited cardiopulmonary reserve.<br />&Delta; Feasibility requires adequate scanner technology. Also the patient must be able to lie flat, to cooperate with exam breath-holding instructions, have a body habitus that can fit into scanner, and no contraindications for iodinated contrast.<br /><span class=\"lozenge\">&loz;</span> Repeat CT pulmonary angiography for more definitive results may be worthwhile if the factor causing poor image quality can be mitigated (eg, patient more capable of cooperating with positioning and breath-holding instructions). Repeat imaging is unlikely to prove useful if exam was nondiagnostic due to factors such as scanner technology, body habitus, or indwelling metallic foreign bodies.<br />&sect; Feasibility requires a chest radiograph demonstrating clear lungs and a patient able to lie still for &gt;30 minutes.<br />&yen; Further testing first involves revisiting the feasibility of CT pulmonary angiography. If CT pulmonary angiography is still not feasible then lower extremity compression ultrasonography with Doppler is appropriate.</div><div id=\"graphicVersion\">Graphic 113962 Version 1.0</div></div></div>"},"113963":{"type":"graphic_algorithm","displayName":"Adult with low probability of pulmonary embolism","title":"Evaluation of the nonpregnant adult with low probability of pulmonary embolism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Evaluation of the nonpregnant adult with low probability of pulmonary embolism</div><div class=\"cntnt\"><img style=\"width:430px; height:847px;\" src=\"images/PULM/113963_Adlt_low_prob_plmnry_emblsm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT pulmonary angiography is also called chest CT angiogram with contrast and is tailored for to evaluate the pulmonary arteries. A conventional chest CT with contrast is not adequate to exclude PE.</div><div class=\"graphic_footnotes\">PE: pulmonary embolism; DVT: deep vein thrombosis; CT: computed tomography; PERC: pulmonary embolism rule-out criteria.<br />* We prefer the Wells criteria to determine the pretest probability of PE, although the modified Geneva score or clinical gestalt is also appropriate. Refer to UpToDate text for details.<br />&para; PERC is best used in the emergency department in patients with a low clinical pretest probability of PE and is not suitable for other clinical settings or in those with an intermediate or high pretest probability of PE. Some experts choose not to use PERC and proceed directly to sensitive D-Dimer testing.<br />&Delta; Feasibility requires adequate scanner technology. Also the patient must be able to lie flat, to cooperate with exam breath-holding instructions, have a body habitus that can fit into scanner, and no contraindications for iodinated contrast.<br /><span class=\"lozenge\">&loz;</span> Repeat CT pulmonary angiography for more definitive results may be worthwhile if the factor causing poor image quality can be mitigated (eg, patient more capable of cooperating with positioning and breath-holding instructions). Repeat imaging is unlikely to prove useful if exam was nondiagnostic due to factors such as scanner technology, body habitus, or indwelling metallic foreign bodies.<br />&sect; Feasibility requires a chest radiograph demonstrating clear lungs and a patient able to lie still for &gt;30 minutes.<br />&yen; Further testing first involves revisiting the feasibility of CT pulmonary angiography. If CT pulmonary angiography is still not feasible then lower extremity compression ultrasonography with Doppler is appropriate.</div><div id=\"graphicVersion\">Graphic 113963 Version 1.0</div></div></div>"},"113965":{"type":"graphic_figure","displayName":"Sitting position for posterior craniotomy","title":"Sitting position for posterior craniotomy","html":"<div class=\"graphic\"><div style=\"width: 829px\" class=\"figure\"><div class=\"ttl\">Sitting position for posterior craniotomy</div><div class=\"cntnt\"><img style=\"width:809px; height:527px;\" src=\"images/ANEST/113965_Sit_pos_postrr_craniotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sitting position may be used for posterior fossa craniotomy or cervical spine surgery. Venous pooling can cause decreased cardiac output, hypotension, and decreased cerebral perfusion. The sitting position for craniotomy is associated with a higher risk of venous air embolism and pneumocephalus than other surgical positions. For further information, refer to UpToDate content on patient positioning for surgery and anesthesia, section on the sitting position.</div><div class=\"graphic_reference\">Illustration by Kiran Guthikonda, MD, PhD, Dartmouth-Hitchcock Medical Center.</div><div id=\"graphicVersion\">Graphic 113965 Version 1.0</div></div></div>"},"113969":{"type":"graphic_figure","displayName":"Shoulder positioning with face support","title":"Shoulder positioning with face support","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">Shoulder positioning with face support</div><div class=\"cntnt\"><img style=\"width:792px; height:545px;\" src=\"images/ANEST/113969_Shoulder_pos_face_support.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The beach chair position is often used for shoulder surgery. This position can cause venous pooling, reduced cardiac output, hypotension, and reduced cerebral perfusion. For further information, refer to UpToDate content on patient positioning for surgery and anesthesia, section on the sitting position.</div><div class=\"graphic_reference\">Illustration by Kiran Guthikonda, MD, PhD, Dartmouth-Hitchcock Medical Center.</div><div id=\"graphicVersion\">Graphic 113969 Version 1.0</div></div></div>"},"113970":{"type":"graphic_figure","displayName":"Diagram of glomerular anatomy","title":"Diagram of glomerular anatomy","html":"<div class=\"graphic\"><div style=\"width: 762px\" class=\"figure\"><div class=\"ttl\">Diagram of glomerular anatomy</div><div class=\"cntnt\"><img style=\"width:742px; height:489px;\" src=\"images/NEPH/113970_Diagramglomerularanatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The glomerular basement membrane (GBM; shown in green) is a thin sheet of extracellular matrix protein that surrounds the capillary and provides support and a barrier.<br />(A) Renal corpuscle and juxtaglomerular apparatus.<br />(B) Peripheral portion of a glomerular lobule.</div><div class=\"graphic_reference\">Reproduced from: Kriz W, Elger M. Renal Anatomy. In: Comprehensive Clinical Nephrology, 5th ed, Johnson RJ, Feehally J, Floege J (Eds), Elsevier 2014. Illustrations used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113970 Version 1.0</div></div></div>"},"113972":{"type":"graphic_table","displayName":"Inhalation anesthetic agents","title":"Inhalation anesthetic agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Inhalation anesthetic agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Generic name</strong></td> <td>Nitrous oxide</td> <td>Halothane</td> <td>Isoflurane</td> <td>Sevoflurane</td> <td>Desflurane</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Brand name</strong></td> <td>N/A</td> <td>Fluothane</td> <td>Forane</td> <td>Ultane</td> <td>Suprane</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Chemical formula</strong></td> <td>N<sub>2</sub>O</td> <td>C<sub>2</sub>HBrClF<sub>3</sub></td> <td>C<sub>3</sub>H<sub>2</sub>ClF<sub>5</sub>O</td> <td>C<sub>4</sub>H<sub>3</sub>F<sub>7</sub>O</td> <td>C<sub>3</sub>H<sub>2</sub>F<sub>6</sub>O</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Odor</strong></td> <td>Slightly sweet</td> <td>Sweet</td> <td>Sweet</td> <td>Sweet</td> <td>Sweet</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Color</strong></td> <td>Colorless</td> <td>Colorless</td> <td>Colorless</td> <td>Colorless</td> <td>Colorless</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pungency</strong></td> <td>None</td> <td>Moderate</td> <td>High</td> <td>Low</td> <td>Very high</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Solubility:blood:gas partition coefficient</strong></td> <td>Very low: 0.46</td> <td>Very high: 2.40</td> <td>Moderately high: 1.40</td> <td>Low: 0.65</td> <td>Very low: 0.45</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Redistribution:brain:blood partition coefficient</strong></td> <td>1.1</td> <td>1.9</td> <td>1.6</td> <td>1.7</td> <td>1.3</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Potency:oil:gas partition coefficient</strong></td> <td>Very low: 1.4</td> <td>Very high: 224.0</td> <td>High: 97.0</td> <td>Moderately high: 42.0</td> <td>Low: 18.7</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Minimum alveolar concentration<br /> (MAC) = ED<sub>50</sub> for response to surgery</strong></td> <td>105.0%</td> <td>0.8%</td> <td>1.2%</td> <td>2.0%</td> <td>6.0%</td> </tr> <tr class=\"divider_bottom\"> <td><strong>MAC-awake/MAC-aware = ED<sub>50</sub> for response to voice/touch</strong></td> <td>68.0%</td> <td>0.4%</td> <td>0.5%</td> <td>0.6%</td> <td>2.5%</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Blood pressure effect</strong></td> <td>Negligible</td> <td>Dose-dependent hypotension</td> <td>Dose-dependent hypotension</td> <td>Dose-dependent hypotension</td> <td>Dose-dependent hypotension</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Vascular effect</strong></td> <td>Negligible</td> <td>Negligible</td> <td>Vasodilation</td> <td>Vasodilation</td> <td>Initial vasoconstriction, later vasodilation</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Inotropic effect</strong></td> <td>Negligible</td> <td>Negative</td> <td>Slightly negative</td> <td>Slightly negative</td> <td>Initial positive, later negative</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Chronotropic effect</strong></td> <td>Negligible</td> <td>Bradycardia</td> <td>Tachycardia</td> <td>Tachycardia &#62;1 MAC</td> <td>Tachycardia</td> </tr> <tr class=\"divider_bottom\"> <td><strong>How supplied</strong></td> <td>Pressurized bottled gas</td> <td>Bottled liquid</td> <td>Bottled liquid</td> <td>Bottled liquid</td> <td>Bottled liquid</td> </tr> <tr class=\"divider_bottom\"> <td><strong>How delivered</strong></td> <td>Flowmeter</td> <td>Vaporizer</td> <td>Vaporizer</td> <td>Vaporizer</td> <td>Electric heated vaporizer</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Fire risk</strong></td> <td>Supports combustion</td> <td>Non-flammable</td> <td>Non-flammable</td> <td>Non-flammable</td> <td>Non-flammable</td> </tr> <tr> <td><strong>Notes</strong></td> <td>Nausea/emesis</td> <td>Nausea/emesis; bradycardia/asystole; inhalational induction; no longer used in US</td> <td>Nausea/emesis; potentially significant tachycardia</td> <td>Nausea/emesis; inhalational induction</td> <td>Nausea/emesis; airway irritation; initial sympathomimetic</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">N/A: not applicable.</div><div id=\"graphicVersion\">Graphic 113972 Version 1.0</div></div></div>"},"113973":{"type":"graphic_table","displayName":"ASA Physical Status classes","title":"American Society of Anesthesiologists (ASA) Physical Status Classification System","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Society of Anesthesiologists (ASA) Physical Status Classification System</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Classification</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td class=\"centered\">ASA 1</td> <td>A normal healthy patient.</td> </tr> <tr> <td class=\"centered\">ASA 2</td> <td>A patient with mild systemic disease.</td> </tr> <tr> <td class=\"centered\">ASA 3</td> <td>A patient with severe systemic disease.</td> </tr> <tr> <td class=\"centered\">ASA 4</td> <td>A patient with severe systemic disease that is a constant threat to life.</td> </tr> <tr> <td class=\"centered\">ASA 5</td> <td>A moribund patient who is not expected to survive without the operation.</td> </tr> <tr> <td class=\"centered\">ASA 6</td> <td>A declared brain-dead patient whose organs are being removed for donor purposes.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">ASA Physical Status Classification System is reprinted with permission of the American Society of Anesthesiologists, 520 N. Northwest Highway, Park Ridge, Illinois 60068-2573.</div><div id=\"graphicVersion\">Graphic 113973 Version 1.0</div></div></div>"},"113974":{"type":"graphic_figure","displayName":"Mortality vs ASA classification and procedure risk","title":"Mortality versus ASA classification and procedure risk","html":"<div class=\"graphic\"><div style=\"width: 654px\" class=\"figure\"><div class=\"ttl\">Mortality versus ASA classification and procedure risk</div><div class=\"cntnt\"><img style=\"width:634px; height:405px;\" src=\"images/ANEST/113974_Mortality_vs_ASA_risk.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The observed mortality rate as a function of American Society of Anesthesiologists' physical status and surgery-specific risk.</div><div class=\"graphic_footnotes\">ASA: American Society of Anesthesiologists.</div><div class=\"graphic_reference\">From: Glance L, Lustik SJ, Hannan EL, et al. The surgical mortality probability model derivation and validation of a simple risk prediction rule for noncardiac surgery. Ann Surg 2012; 255:696. DOI: <A href=\"http://journals.lww.com/annalsofsurgery/Abstract/2012/04000/The_Surgical_Mortality_Probability_Model_.13.aspx\" target=_blank>10.1097/SLA.0b013e31824b45af</A>. Copyright © 2012. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113974 Version 1.0</div></div></div>"},"113975":{"type":"graphic_figure","displayName":"ACS risk calculator report","title":"ACS NSQIP surgical risk calculator report","html":"<div class=\"graphic\"><div style=\"width: 704px\" class=\"figure\"><div class=\"ttl\">ACS NSQIP surgical risk calculator report</div><div class=\"cntnt\"><img style=\"width:684px; height:864px;\" src=\"images/ANEST/113975_ACS_risk_calculator_report.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graphic shows an example of the type of report that would be generated after entering patient data into the ACS NSQIP calculator, based on a fictitious patient. The actual report would reflect the individual patient data.</div><div class=\"graphic_footnotes\">ACS: American College of Surgeons; NSQIP: National Surgical Quality Improvement Program.</div><div class=\"graphic_reference\">Reproduced with permission from the American College of Surgeons National Surgical Quality Improvement Program. Copyright © 2007 - 2016. All rights reserved.</div><div id=\"graphicVersion\">Graphic 113975 Version 2.0</div></div></div>"},"113976":{"type":"graphic_table","displayName":"Surgical mortality probability model","title":"Surgical mortality probability model for predicting risk of 30-day mortality after noncardiac surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Surgical mortality probability model for predicting risk of 30-day mortality after noncardiac surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Risk factor</td> <td class=\"subtitle1\">Points assigned</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">ASA physical status</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">I</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">II</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">III</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">IV</td> <td class=\"centered\">5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">V</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Procedure risk</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Low risk</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Intermediate risk</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">High risk</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Emergency</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Nonemergent</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">Emergency surgery</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Point total</td> <td class=\"subtitle1\">Mortality</td> </tr> <tr> <td class=\"centered\">I</td> <td class=\"centered\">0 to 4</td> <td class=\"centered\">&#60;0.50%</td> </tr> <tr> <td class=\"centered\">II</td> <td class=\"centered\">5 to 6</td> <td class=\"centered\">1.5 to 4.0%</td> </tr> <tr> <td class=\"centered\">III</td> <td class=\"centered\">7 to 9</td> <td class=\"centered\">&#62;10%</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Glance L, Lustik SJ, Hannan EL, et al. The surgical mortality probability model derivation and validation of a simple risk prediction rule for noncardiac surgery. Ann Surg 2012; 255:696. DOI: <A href=\"http://journals.lww.com/annalsofsurgery/Abstract/2012/04000/The_Surgical_Mortality_Probability_Model_.13.aspx\" target=_blank>10.1097/SLA.0b013e31824b45af</A>. Copyright © 2012. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 113976 Version 1.0</div></div></div>"},"113978":{"type":"graphic_table","displayName":"Gait observation checklist","title":"Gait observation checklist","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gait observation checklist</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\"> <ol class=\"numbers_to_nine\"> <li>Observe upper extremity swing: </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Is arm swing symmetrical? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Is any joint positioned abnormally? </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Are the hands relaxed? </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\"> <ol class=\"numbers_to_nine\" start=\"2\"> <li>Observe head and trunk position and motion: </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Are the head and trunk midline? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Is there smooth motion and vertical excursion of head? </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Does motion of the trunk appear smooth and equal? </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\"> <ol class=\"numbers_to_nine\" start=\"3\"> <li>Observe the position of the pelvis: </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Does the pelvis appear level? </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Is there equal anterior to posterior rotation of the pelvis on each side? </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\"> <ol class=\"numbers_to_nine\" start=\"4\"> <li>Observe hip motion: </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Does hip flexion and extension appear equal on each side? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Is there any observable shift on either side? </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Is there any lateral excursion from the hip during the swing phase of gait? </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\"> <ol class=\"numbers_to_nine\" start=\"5\"> <li>Observe knee position and motion: </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Is there genu valgus or varus at rest? If so, is it unilateral or bilateral? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Is there horizontal motion at the knee during gait (eg, valgus or varus thrust)? </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Does knee flexion and extension appear equal on each side? </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\"> <ol class=\"numbers_to_nine\" start=\"6\"> <li>Observe ankle and foot motion: </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Are ankle plantar and dorsi-flexion symmetric? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Is ankle alignment normal when observed in frontal plane? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Is the foot position normal, symmetric? In-toed or out-toed? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Does either foot demonstrate excessive pronation or supination? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Is push off/toe off equal on each side? </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Is there calcaneal varus or valgus? </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\"> <ol class=\"numbers_to_nine\" start=\"7\"> <li>Observe overall gait dynamics: </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Is the stride length normal? Is step length symmetric? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Is the stride frequency normal or slowed? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Is there appropriate counterbalanced movement of the contralateral limb? </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 113978 Version 1.0</div></div></div>"},"113979":{"type":"graphic_table","displayName":"Pediatric sedation state scale","title":"Pediatric sedation state scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric sedation state scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">State</td> <td class=\"subtitle1\">Behavior</td> </tr> <tr> <td class=\"centered\">5</td> <td>Patient is moving (purposefully or nonpurposefully) in a manner that impedes the proceduralist and requires forceful immobilization. This includes crying or shouting during the procedure, but vocalization is not required. Score is based on movement.</td> </tr> <tr> <td class=\"centered\">4</td> <td>Moving during the procedure (awake or sedated) that requires gentle immobilization for positioning. May verbalize some discomfort or stress, but there is no crying or shouting that expresses stress or objection.</td> </tr> <tr> <td class=\"centered\">3</td> <td>Expression of pain or anxiety on face (may verbalize discomfort), but not moving or impeding completion of the procedure. May require help positioning (as with a lumbar puncture) but does not require restraint to stop movement during the procedure.</td> </tr> <tr> <td class=\"centered\">2</td> <td>Quiet (asleep or awake), not moving during procedure, and no frown (or brow furrow) indicating pain or anxiety. No verbalization of any complaint.</td> </tr> <tr> <td class=\"centered\">1</td> <td>Deeply asleep with normal vital signs, but requiring airway intervention and/or assistance (eg, central or obstructive apnea, etc).</td> </tr> <tr> <td class=\"centered\">0</td> <td>Sedation associated with abnormal physiologic parameters that require acute intervention (ie, oxygen saturation &#60;90%, blood pressure is 30% lower than baseline, bradycardia receiving therapy).</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 139, p. e20162897, Copyright © 2017 by the AAP.</div><div id=\"graphicVersion\">Graphic 113979 Version 1.0</div></div></div>"},"113983":{"type":"graphic_table","displayName":"Epidural local anesthetic onset time and duration of action","title":"Epidural local anesthetic onset time and duration of action","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epidural local anesthetic onset time and duration of action</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug</td> <td class=\"subtitle1\" rowspan=\"2\">Concentration (%)</td> <td class=\"subtitle1\" rowspan=\"2\">Onset (minutes)</td> <td class=\"subtitle1\" colspan=\"2\">Duration of anesthesia (minutes)</td> </tr> <tr> <td class=\"subtitle2\">Plain</td> <td class=\"subtitle2\">Plus epinephrine</td> </tr> <tr> <td>Bupivacaine</td> <td class=\"centered\">0.25 to 0.75</td> <td class=\"centered\">20</td> <td class=\"centered\">165 to 225</td> <td class=\"centered\">180 to 240</td> </tr> <tr> <td>Lidocaine</td> <td class=\"centered\">1 to 2</td> <td class=\"centered\">15</td> <td class=\"centered\">60 to 90</td> <td class=\"centered\">90 to 120</td> </tr> <tr> <td>Ropivacaine</td> <td class=\"centered\">0.2 to 1.0</td> <td class=\"centered\">15 to 20</td> <td class=\"centered\">90 to 180</td> <td class=\"centered\">150 to 200</td> </tr> <tr> <td>Levobupivacaine</td> <td class=\"centered\">0.25 to 0.75</td> <td class=\"centered\">15 to 20</td> <td class=\"centered\">150 to 225</td> <td class=\"centered\">150 to 240</td> </tr> <tr> <td>2-Chloroprocaine</td> <td class=\"centered\">2 to 3</td> <td class=\"centered\">10 to 15</td> <td class=\"centered\">45 to 60</td> <td class=\"centered\">60 to 90</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table shows commonly used concentrations of local anesthetics for epidural anesthesia, onset time, and duration of action, based on published studies and clinical experience.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Cousins MJ, Bromage PR. Epidural neural blockage. In: Neural blockade in clinical anesthesia and management of pain, Cousins MJ, Bridenbaugh PO (Eds), JB Lippincott, Philadelphia 1988. p.255.</LI>&#xD;&#xA;<LI>Veering BT, Cousins MJ. Epidural neural blockade. In: Cousins &amp; Bridenbaugh's Neural Blockade in Clinical Anesthesia and Pain Medicine, 4th ed, Cousins MJ, Carr DB, Horlocker TT, Bridenbaugh PO (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009.</LI>&#xD;&#xA;<LI>Berde CB, Strichartz GR. Local anesthetics. In: Miller's Anesthesia, 8th ed, Miller RD (Ed), Elsevier, Philadelphia 2015.</LI></OL></div><div id=\"graphicVersion\">Graphic 113983 Version 1.0</div></div></div>"},"113987":{"type":"graphic_algorithm","displayName":"Screening and management of acute malnutrition","title":"Screening and management of acute malnutrition in children 6 to 59 months old","html":"<div class=\"graphic\"><div style=\"width: 675px\" class=\"figure\"><div class=\"ttl\">Screening and management of acute malnutrition in children 6 to 59 months old</div><div class=\"cntnt\"><img style=\"width:655px; height:839px;\" src=\"images/PEDS/113987_Screeng_mgmt_acute_malntrtn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MUAC: mid-upper arm circumference; WHZ: weight-for-height Z-score (standard deviation score); RUTF: ready-to-use therapeutic food; F-75: therapeutic milk formula providing 75 kcal/100 mL, designed by the World Health Organization (WHO); IV: intravenous; HIV: human immunodeficiency virus.<br />* This algorithm applies to children with acute malnutrition, with or without underlying chronic malnutrition. Acute malnutrition is defined by wasting (determined by MUAC or WHZ), and/or pitting edema. Chronic malnutrition is generally manifested as stunting (impaired linear growth) and/or underweight for age.<br />&para; Indications for inpatient treatment include poor appetite; medical complications (sepsis, diarrhea with dehydration, significant skin breakdown with open ulceration); untreated HIV or tuberculosis infection; challenging psychosocial situations that preclude effective outpatient care; or failure of a prior trial of outpatient treatment.<br />&Delta; Selection and progression of feeds depends on the results of serial appetite tests using RUTF. For details on inpatient management, refer to UpToDate content on management of complicated severe acute malnutrition.<br /><span class=\"lozenge\">&loz;</span> Oral antibiotics are not needed if the child has completed a course of empiric IV antibiotics as an inpatient.</div><div class=\"graphic_reference\">From: Trehan I, Manary MJ. Management of severe acute malnutrition in low-income and middle-income countries. Arch Dis Child 2015; 100:283. Modified with permission from BMJ Publishing Group Ltd. Copyright &copy; 2015.</div><div id=\"graphicVersion\">Graphic 113987 Version 2.0</div></div></div>"},"113988":{"type":"graphic_algorithm","displayName":"Therapeutic feeding regimens for severe acute malnutrition","title":"Therapeutic feeding regimens for inpatient treatment of complicated severe acute malnutrition in children 6 to 59 months old","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Therapeutic feeding regimens for inpatient treatment of complicated severe acute malnutrition in children 6 to 59 months old</div><div class=\"cntnt\"><img style=\"width:447px; height:849px;\" src=\"images/PEDS/113988_Thptc_fd_rgm_svr_act_mlntrn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RUTF: ready-to-use therapeutic food; F-75: therapeutic milk formula providing 75 kcal/100 mL, designed by the World Health Organization (WHO); F-100: therapeutic milk formula providing 100 kcal/100 mL, designed by the WHO.<br />* For the appetite test, the child is offered RUTF in a calm setting; the child passes the test if he or she consumes approximately 30 grams of RUTF without vomiting or significant distress.<br />¶ Goal for RUTF feeds is 150 to 200 kcal/kg/day.</div><div class=\"graphic_reference\">Adapted with permission from original algorithm by Diana Culbertson, MS, MMSc, PA-C.</div><div id=\"graphicVersion\">Graphic 113988 Version 2.0</div></div></div>"},"113993":{"type":"graphic_algorithm","displayName":"Management of melanoma brain metastases","title":"Management of melanoma brain metastases","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Management of melanoma brain metastases</div><div class=\"cntnt\"><img style=\"width:583px; height:382px;\" src=\"images/ONC/113993_Melanoma_brain_metastases2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CNS: central nervous system; SRS: stereotactic radiosurgery; RT: radiation therapy; MRI: magnetic resonance imaging.<br />* Contrast-enhanced MRI to assess the extent of intracranial disease burden and associated edema.<br />¶ Immediate systemic therapy with deferred definitive treatment may be considered as an alternative to surgery or SRS in carefully selected patients, based upon significant intracranial activity seen in phase II trials. Close monitoring with imaging is required if initial treatment with systemic therapy is utilized.<br />Δ SRS is an alternative for patients with a lesion that is surgically inaccessible or in an eloquent region, or who are not candidates for surgery.<br /><FONT class=lozenge>◊</FONT> Postoperative SRS to the resection cavity should be discouraged, except in situations where there is an isolated CNS metastasis with no systemic disease and/or no systemic treatment options. The risks of disease recurrence must be balanced against the risk of delayed radiation necrosis.<br />§ Options include checkpoint inhibitor immunotherapy (ipilimumab plus nivolumab) or targeted therapy (combined BRAF plus MEK inhibition) in patients with&nbsp;V600 <EM>BRAF</EM> mutation. RT toxicity may be enhanced when BRAF inhibitors are administered concurrently with RT.<br />¥ Corticosteroids and/or anticonvulsants as clinically indicated.</div><div id=\"graphicVersion\">Graphic 113993 Version 1.0</div></div></div>"},"113994":{"type":"graphic_figure","displayName":"Transvenous ICD shock lead configurations","title":"Transvenous ICD shock lead configurations","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Transvenous ICD shock lead configurations</div><div class=\"cntnt\"><img style=\"width:533px; height:362px;\" src=\"images/CARD/113994_TransvenousICDshockleadconfigurations.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the active can electrode, current flows between the coil(s)&nbsp;right ventricular (RV) electrode and the housing (active can) of the pulse generator. For transvenous leads with two coils, current also&nbsp;flows between two transvenous coils (RV and superior vena cava).</div><div class=\"graphic_footnotes\">ICD: implantable cardioverter-defibrillator.</div><div id=\"graphicVersion\">Graphic 113994 Version 1.0</div></div></div>"},"113995":{"type":"graphic_table","displayName":"Potential indications for postop CRT rectal cancer no preop RT","title":"ESMO guidelines: Potential indications for postoperative chemoradiotherapy in rectal cancer if preoperative chemoradiotherapy not given","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ESMO guidelines: Potential indications for postoperative chemoradiotherapy in rectal cancer if preoperative chemoradiotherapy not given</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Sufficient and necessary</td> </tr> <tr> <td class=\"indent1\">CRM &#8804;1 mm</td> </tr> <tr> <td class=\"indent1\">pT4b</td> </tr> <tr> <td class=\"indent1\">pN2 extracapsular spread close to MRF</td> </tr> <tr> <td class=\"indent1\">Extranodal deposits (N1c)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">pN2 if poor mesorectal quality/defects</td> </tr> <tr> <td class=\"subtitle1_single\">Sufficient</td> </tr> <tr> <td class=\"indent1\">pN2 low tumors within 4 cm of anal verge (risk of involved LPLN)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Extensive extramural vascular invasion/perineural invasion close to MRF</td> </tr> <tr> <td class=\"subtitle1_single\">Borderline sufficient</td> </tr> <tr> <td class=\"indent1\">pN2 in mid/upper rectum if good mesorectal quality</td> </tr> <tr> <td class=\"indent1\">CRM 1 to 2 mm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Circumferential obstructing tumours</td> </tr> <tr> <td class=\"subtitle1_single\">Insufficient and unnecessary</td> </tr> <tr> <td class=\"indent1\">pT1/pT2</td> </tr> <tr> <td class=\"indent1\">pT3</td> </tr> <tr> <td class=\"indent1\">CRM &#62;2 mm</td> </tr> <tr> <td class=\"indent1\">pT4a above peritoneal reflection</td> </tr> <tr> <td class=\"indent1\">pN1</td> </tr> <tr> <td class=\"indent1\">If good-quality smooth intact mesorectum</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ESMO: European Society for Medical Oncology; CRM: circumferential resection margin; MRF: mesorectal fascia; LPLN: lateral pelvic lymph node.</div><div class=\"graphic_reference\">Reproduced from: Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28(4 suppl):iv22-iv40, by permission of Oxford University Press on behalf of the European Society for Medical Oncology. Copyright © 2017 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.esmo.org/\" target=_blank>www.esmo.org/</A>.</div><div id=\"graphicVersion\">Graphic 113995 Version 2.0</div></div></div>"},"113996":{"type":"graphic_algorithm","displayName":"Beta thalassemia management","title":"Overview of the management of beta thalassemia","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Overview of the management of beta thalassemia</div><div class=\"cntnt\"><img style=\"width:564px; height:502px;\" src=\"images/HEME/113996_Beta_thalassemia_management.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm applies to individuals with significant clinical manifestations from beta thalassemia. Refer to UpToDate for additional details as well as for the care of individuals with alpha thalassemia and less severe forms of beta thalassemia such as beta thalassemia minor. All individuals with significant hemolysis are treated with daily folic acid.</div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen; MRI: magnetic resonance imaging; GVHD: graft-versus-host disease.<br />&para; Includes those with anemia, which may require transfusions (periodic or regular); as well as other clinical manifestations as discussed in UpToDate. Does not include thalassemia trait.<br />&Delta; Refer to UpToDate for considerations in the decision to pursue hematopoietic cell transplantation and for details such as donor selection, stem cell source (bone marrow, peripheral blood, or umbilical cord blood), conditioning regimen, and GVHD prophylaxis.<br /><span class=\"lozenge\">&loz;</span> Refer to UpToDate for monitoring schedule and methods for measuring liver and cardiac iron.</div><div id=\"graphicVersion\">Graphic 113996 Version 1.0</div></div></div>"}};